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1.1 DOPAMINE AND ITS FUNCTION IN THE CENTRAL NERVOUS 
SYSTEM 
The nervous system is divided into the central nervous system (CNS) and the peripheral 
nervous system. Neurotransmission between nerve cells is realized by generation of action 
potentials. This generally results in a release of a chemical neurotransmitter which 
stimulates or inhibits another cell. An example of such a chemical neurotransmitter is 
dopamine (DA).1 DA (2-(3,4-dihydroxyphenyl)ethylamine) is a catecholamine 
neurotransmitter found in neurons of both the CNS and peripheral nervous system. 
Although DAergic neurons correspond to less than 1% of the total number of brain neurons, 
they play a significant role in brain functions, such as motivation, working memory and 
motor behavior. A high concentration of the DA is found in the striatum, which forms an 
important part of the extrapyramidal system and is known to control motor activity.2, 3 The 
DA neurons in this pathway play an important role in the pathophysiology and treatment of 
Parkinson’s disease. 
DA is formed from its precursor L-DOPA (3,4-dihydroxy-L-phenylalanine) by aromatic-L-
amino-acid decarboxylase (AAAD) (Scheme 1.1). The clearance of DA occurs by re-uptake 
into the presynaptic neuron, or by metabolic inactivation by monoamine oxidase B (MAO-
B) as well as catechol-O-methyltransferase (COMT).4 Homovanillic acid (HVA, 4-
hydroxy-3-methoxyphenylacetic acid) is the final and main metabolic break-down product 
of DA in the human brain. Most of the brain DA is first attacked by MAO-B to give 3,4-
dihydroxyphenylacetic acid (DOPAC) and subsequently attacked by COMT to form HVA. 
Another route occurs via initial O-methylation by COMT to give 3-methoxytyramine (3-
MT) followed by oxidative deamination by MAO-B to give HVA.5 
 




1.2 ANATOMY OF THE DOPAMINE SYSTEM 
Techniques to detect DA neurons and localize DA receptors have identified distinct DA 
pathways in the brain of which the nigrostriatal, mesolimbic, mesocortical and 
tuberoinfundibular are the major pathways (Figure 1.1).4, 6  
The highly organized nigrostriatal pathway is the major DA pathway of the brain and 
originates from the substantia nigra pars compacta (SNc) projecting to the corpus striatum 
of the basal nuclei, whose function is to produce a smooth coordination in movement. A 
second prominent DA pathway is the mesolimbic pathway, which has cell bodies in the 
ventral tegmental area and sends axons to the limbic system, whose primary responsibility 
is the regulation of reward and related emotion-based behaviour.1, 3, 6, 7 The mesocortical 
pathway has DAergic projections to the prefrontal cortex and modulates cognitive 
behaviour7, learning and memory.8 The tuberoinfundibular pathway has its cell bodies in 
the hypothalamus and projects toward the pituitary gland.9 
 




1.3 DOPAMINE RECEPTORS 
DA exerts its action by binding to specific membrane DA receptors. Five distinct DA 
receptors have been subdivided into two subfamilies, D1- and D2-like, on the basis of their 
biochemical and pharmacological properties.8 The D1 and D5 receptors are classified as 
“D1-like” and the D2, D3 and D4 receptors are considered to be “D2-like”.10 
1.3.1 G protein-coupled receptor structure 
The DA receptor subtypes belong to the large G protein-coupled receptor (GPCR) family. 
The receptors are characterized structurally by the presence of 7 transmembrane domains 
which form the DA binding site.4, 10 Members of the same DA subfamily share considerable 
homology in their transmembrane domains (Figure 1.2).11 
 
Figure 1.2 DA receptor structure.11 
1.3.2 Second messenger pathways 
The best-described effects mediated by DA are the activation or inhibition of the cyclic 
adenosine monophosphate (cAMP) pathway via adenylate cyclase (AC), and modulation of 
Ca2+ signalling.8 Two distinct guanosine triphosphate(GTP)-binding proteins regulate 
cAMP formation: one is specific for stimulation of AC (Gs), and the other is specific for its 
inhibition (Gi).1, 4, 8, 9, 12 All D1-like receptors stimulate cAMP accumulation10 and the D2-
like receptors inhibit the activity of AC.8, 10, 11, 13, 14 
1.3.3 Distribution of the dopamine receptor families in the brain 
D1- and D2-like receptors have similar regional distributions in rat, monkey, and human 
brain, with the highest concentrations in striatum, olfactory bulb, and substantia nigra (SN). 




(GABA, γ-aminobutyric acid) neurons: the DA D1 receptors are located in striatonigral 
neurons coexpressing substance P and dynorphin, and the DA D2 receptors are located in 
striatopallidal neurons coexpressing enkephalin.13 The relative abundance of the DA 
receptors in the rat CNS would be D1>D2>D3>D5>D4.10 Both rat D1 and D2 mRNA 
(messenger ribonucleic acid) are each found in about 45% of striatal neurons.13 The D3 
receptor mRNA is mainly detected in telencephalic areas receiving DAergic inputs from the 
A10 cell group15, the D4 receptor mRNA appears to have a cortical, limbic and 
hypothalamic distribution, and D5 mRNA was localized in the hippocampus and in the 
parafascicular nucleus of the thalamus.16 
1.3.4 Pharmacology 
Although DA antagonism plays an important role in treating diseases of the CNS, the scope 
of this thesis mainly concern DA D1 and DA D2 agonism and its clinical applications. 
Therefore, DA antagonists will not be discussed. The interest we have in DA D1 and DA D2 
receptor agonists is related to the function of these receptors in the brain and their 
involvement in Parkinson's disease. 
LS-186899 (dihydrexidine) and its polycyclic analogues A-86929, DAR 201 (dinapsoline), 
dinoxyline and doxanthrine are examples of selective DA D1 receptor agonists.17 The di-N-
substituted phenethylamines RU 24926 and RU 24213, the di-N-substituted 5-hydroxy-2-
aminotetralins N-0434 and N-0437, and the partial ergoline LY 171555 (Quinpirole), 
selectively stimulate the DA D2 receptor.13 A classical DA agonist such as apomorphine is 
considered to be a mixed agonist at the D1 and D2 receptor (Figure 1.3).8 
 
Figure 1.3 Selective DA D1 and D2 receptor agonists and the mixed DA D1/D2 receptor agonist 




1.3.5 Dopamine autoreceptor 
DA autoreceptors located on nerve endings and somatodendritic sites of nigrostriatal 
DAergic neurons can modulate the synthesis and release of DA. Stimulation of these 
autoreceptors depresses spontaneous electrical activity and inhibits the synthesis and 
release of DA.13 Although these DA autoreceptors appear to be very similar to the post-
synaptic D2 receptor, many agonists display substantially greater affinity at the former 
site.15, 19, 20 This could be explained by a large receptor reserve of the DA autoreceptor.21 
1.3.6 Interaction between dopamine D1 and D2 receptors 
The different effects of DA on the neurons of the two major output systems of the striatum 
to the SN and the globus pallidus (GP) are mediated by their specific expression of D1 and 
D2 DA receptor subtypes, respectively. Moreover, simultaneously administered D1 and D2 
agonists suggest a synergistic interaction between D1 and D2 DA receptors.22 Several lines 
of evidence have led to the conceptualization of D1/D2 interaction15, 22-24 and to the 
hypothesis that concurrent DA D1 and D2 receptor stimulation is necessary for the full 
expression of postsynaptic receptor-mediated effects of DA and DA agonists in the basal 
ganglia.24, 25 Murray et al. suggested that there may be at least two forms of functional 
interaction between D1 and D2 systems: one co-operative and the other oppositional.26 
Moreover, behavioral and biochemical effects of selective receptor blockade are 
significantly altered by concurrent stimulation or inhibition of the complementary receptor 
subtype.27  
1.4 PARKINSON’S DISEASE 
Parkinson's disease was first described by James Parkinson in 1817.28 Parkinson's disease is 
classically defined as a progressive, idiopathic, neurodegenerative disease associated with 
four fundamental motoric signs: akinesia/bradykinesia, rest tremor, cogwheel rigidity and 
postural instability. A resting tremor is the first symptom in 70% of Parkinson's disease 
patients.29-31  
The prevalence of Parkinson's disease in industrialised countries is estimated at 0.3% of the 
general population and about 1.8% of the population older than age 65 years.32, 33 People of 
all ethnic origins are affected, and men are slightly more prone to the disorder.34, 35 Young-
onset Parkinson's disease affects 5-10% of patients.36 
Parkinson's disease is probably a result of multiple factors acting together, including 
ageing, genetic susceptibility, and environmental exposures. 1-Methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) is the only toxic agent that has been directly linked to 
development of parkinsonism. Pesticide exposure, living in rural areas (in industrialised 
countries), and drinking well water have all been linked to Parkinson's disease. Conversely, 




cigarette smoking and the intake of caffeine.31 Five genes have been identified that are 
important in autosomal dominant and autosomal recessive forms of Parkinson's disease.37 
1.4.1 Neuropathology 
Most striatal neurons are GABAergic neurons that receive glutamatergic inputs from 
terminals that originate in the cortex and thalamus. A common feature of cortical-
subcortical loops is their projection from the motor cortices to the basal ganglia with entry 
via striatal areas and outflow through the internal globus pallidus (GPi) or the SNr. Each 
loop contains ‘direct’ and ‘indirect’ pathways, the former projecting directly from striatum 
to GPi/SNr and the latter through the external globus pallidus (GPe) and the subthalamic 
nucleus (STN) to reach GPi/SNr (Figure 1.4). SNc DA neurons differentially influence the 
striatopallidal neuronal activity. DA facilitates activity in D1-bearing neurons, which have 
an inhibitory effect on the GPi (direct pathway). DA inhibits activity in D2-bearing neurons, 
which lead to excitation of the GPe (indirect pathway). Outflow from both pathways rejoin 
and then project directly back to the originating cortical structure via the thalamus. 
Movement facilitation is associated with increased activity in the direct pathway and 
reduced activity in the indirect pathway.29, 30, 38, 39  
 
Figure 1.4 Simplified diagram of the circuitry and neurotransmitters of the basal ganglia-
thalamocortical circuitry, indicating the parallel 'direct' and 'indirect' pathways from the striatum to 
the basal ganglia output nuclei in a normal situation. Inhibitory neurons are shown as filled symbols, 
excitatory neurons are open symbols. Abbreviations: DA, dopamine; D1, dopamine D1 receptor; D2, 
dopamine D2 receptor; enk, enkephalin; GABA, γ-aminobutyric acid; GPe, external segment of 
globus pallidus; GPi, internal segment of globus pallidus; glu, glutamate; SNc, substantia nigra pars 





The loss of neurons in the nigrostriatal DA-containing pathway is a principal feature of 
Parkinson's disease, and may initially be compensated for by downregulation of the DA 
transporter, heightened postsynaptic receptor sensitivity, and changes in STN and GPi 
firing. However, compensatory mechanisms eventually fail and D2-bearing neurons become 
overactive whereas D1-bearing neurons become hypoactive. These changes eventually lead 
to an excessive inhibition of thalamocortical and brainstem motor neurons, and the 
development of parkinsonian features.29, 30, 38, 39, 43 Although striatal deficiency constitutes 
the bulk of parkinsonian abnormalities, other neuronal systems are also affected.30, 44, 45 
DAergic neurons continue to be lost throughout the course of Parkinson's disease. 
Regression analysis indicates that parkinsonian symptoms are seen only after DAergic 
neuronal loss has reached a certain threshold.44 Neurodegeneration could be related to 
mitochondrial dysfunction, oxidative stress, apoptosis, misfolding and aggregation of 
proteins, excitotoxicity, and inflammation. The presence of Lewy bodies in addition to loss 
of pigmented neurons in the SN, is accepted as neuropathological confirmation of the 
diagnosis Parkinson's disease.30, 31, 38, 44, 46, 47  
1.4.2 Animal models used to study dopamine receptor ligands 
One of the Parkinson's disease models results from the administration of the neurotoxic 
MPTP to primates (including humans) which causes irreversible and severe parkinsonian 
symptoms and includes degeneration of nigral DA neurons.48 After systemic administration 
MPTP crosses the blood-brain barrier (BBB), and once in the brain MPTP is metabolized to 
MPP+ (1-methyl-4-phenylpyridinium) by MAO-B which is taken up into DA neurons and 
subsequently blocks complex I within mitochondria (Figure 1.5).46 
 
Figure 1.5 Structures of MPTP and MPP+.46 
6-Hydroxydopamine (6-OH-DA) is a commonly used neurotoxin to create Parkinson's 
disease models of hemiparkinsonian rats.49 A particular model results from the 6-OH-DA-
induced destruction of the DAergic nigrostriatal pathway but sparing of the DAergic 
mesolimbic pathway, which parallels the MPTP-induced hemiparkinsonian model in 
primates.50 An alternative  6-OH-DA model causes slow partial lesion of DAergic neurons 






Figure 1.6 Schematic representation of a microdialysis probe. The dialysis membrane is constantly 
perfused with artificial cerebrospinal fluid (CSF) by a microinfusion pump and molecules are 
exchanged with the brain extracellular fluid (ECF) by diffusion in both directions. After 
transportation of the microdialysate through the silica capilary outlet tube, it is collected and the 
neurotransmitter or drug of interest could be subjected to analysis.51, 52 
In this thesis the microdialysis technique was used to monitor DA release in the 
extracellular fluid of the anesthetized rat. This method is based on the dialysis principle in 
which a membrane, permeable to water and small molecules, separates two fluid 
compartments. A schematic representation of a microdialysis probe is shown in Figure 1.6.  
Advantages of brain solute extraction by microdialysis are:52-55 
 
1 Microdialysis can be performed in living, awake and freely moving animals and a 
significant amount of data can be obtained from each animal experiment. 
2 Microdialysis detects the free drug and/or neurotransmitter at a specific region within 
the brain.  
3 Microdialysis offers the advantage of protein-free sample fluids that can directly be 
analyzed by high-performance liquid chromatography (HPLC) or liquid 
chromatography–mass spectrometry (HPLC-MS). 
4 In the freely moving “conscious” animal central neurochemical activity can be 




5 Microdialysis during anesthesia is easier to use than microdialysis in the freely moving 
animal, and anesthesia eliminates sensory or behavioural influences on the 
neurotransmitter systems of interest. 
6 Microdialysis can both introduce and remove molecules into and from the brain, 
respectively. 
1.4.4 Treatment of Parkinson’s disease 
The current treatment for Parkinson's disease is largely symptomatic rather than preventive. 
Pharmacological treatment is based on restoring the DA deficiency and may be classified 
into two main categories. The first category is a strategy that uses drugs to increase DA 
concentrations at the synaptic junction. The second approach is the use of drugs that mimic 
the action of DA (Figure 1.7).56 
 
Figure 1.7 Sites of action of Parkinson's disease drugs.56 
1.4.4.1 L-dopa and drugs that increase dopamine concentrations 
The most effective pharmacologic treatment for Parkinson's disease is L-DOPA.31 In 
contrast to DA which is unable to cross the BBB, the precursor L-DOPA is transported 
actively into the brain where it is converted to DA. Initially, all motoric features of 
Parkinson's disease have benefit from this pharmacologic treatment.30 L-DOPA acts on both 
DA D1 and D2 receptor families57 and since there are equal numbers of these receptors in 
the human striatum, simultaneous activation may be one of the explanations for the superior 
effects of L-DOPA.58 
L-DOPA is combined with carbidopa or benserazide, which are AAAD inhibitors, to 
prevent systemic adverse effects related to the peripheral metabolism of L-DOPA.59 L-




and therefore COMT inhibitors, e.g. entacapone and tolcapone, are given to extend the half-
life of L-DOPA.61 Selegiline and rasagiline which are MAO-B inhibitors selectively reduce 
the metabolism of L-DOPA and DA in the brain (Figure 1.8).59, 62  
Side-effects of DA receptor stimulation are nausea, vomiting, dyskinesias, hallucinations, 
delusions, and sexual function enhancement.63 
 
Figure 1.8 Drugs that increase DA concentrations.61 
1.4.4.2 Motor complications involved with long-term L-DOPA 
treatment: motor fluctuations and dyskinesia 
Long-term L-DOPA treatment is an important risk factor for the development of motor 
complications, i.e. motor fluctuations and dyskinesia.64 The motor complications could be 
related to abnormal intermittent or pulsatile stimulation of DA receptors, dysregulation of 
downstream genes and proteins, and the induction of abnormal neuronal firing patterns in 
basal ganglia output neurons.65 With advancing disease, there is a progressive loss of 
striatal DAergic terminals and a reduction in their buffering capacity. Consequently, striatal 
DA becomes totally dependent on peripheral L-DOPA availability and striatal DA receptors 
are exposed to alternating high and low levels of DA with the risk of ensuing motor 
complications.60, 64 The motor fluctuations may be  predictable, termed wearing-off or end-
of-dose fluctuations, but they can become unpredictable, referred to as on-off phenomena. 
About a quarter to half of patients taking L-DOPA develop motor fluctuations after 5 




1.4.4.3 Delay or prevention of motor complications by continuous 
dopaminergic stimulation 
In practice the early use of continuous release L-DOPA formulations induced the same rate 
of motor complications as the standard L-DOPA therapy. Because motor complications are 
clearly related to L-DOPA, DA agonists could be interesting drugs to use for continuous 
DAergic stimulation (CDS).67-70 DA agonists are however less well tolerated than L-DOPA 
in early Parkinson's disease71, and the antiparkinsonian benefits of DA agonists are less 
than that of L-DOPA.72 Nevertheless, evidence shows that motor complications might be 
prevented, delayed or even reversed by delivering DAergic therapy by CDS.38, 60  
1.4.4.4 Treatment of motor fluctuations 
A large body of scientific and clinical information supports the idea that discontinuous or 
pulsatile stimulation of striatal DA receptors contributes to the development of L-DOPA -
induced motor complications and favours the use of CDS-based therapies.39 Therefore, 
treatment of motor fluctuations focuses on improvement of L-DOPA absorption and 
alteration in timing of doses. The addition of DA agonists to pharmacotherapy is also 
considered to reduce motor fluctuations.31, 65, 67 The application of L-DOPA/carbidopa-gel 
suspension directly in the duodenum (Duodopa®) permits a continuous delivery by a 
portable pump, resulting in less variability in L-DOPA concentrations, and thereby in less 
motor fluctuations compared to oral L-DOPA administration.73 
1.4.4.5 Treatment of dyskinesias 
The first strategy for reducing dyskinesia is to reduce antiparkinsonian medications that are 
adjunctive therapy and may contribute to dyskinesia, e.g. selegiline, L-DOPA controlled 
release preparations, and DA agonists. Although the latter rarely cause dyskinesias by 
themselves, when added to L-DOPA they may augment dyskinesia. Low-dose L-DOPA 
treatment appears to have a slightly lower incidence of drug-induced dyskinesias74 and 
therefore also L-DOPA itself may be reduced. A second strategy is to add drugs. 
Amantadine (Figure 1.9) may have antidyskinetic effects perhaps through antagonism of 
the N-methyl-D-aspartate (NMDA) glutamate receptor31, and addition of DA agonists in 
combination with a reduced dosis or stop of L-DOPA may be very effective.67, 75  
 




CDS via subcutaneous DA agonist infusions may eventually control dyskinesias75, and 
Duodopa® treatment resulted in reduced time and intensity of dyskinesia.73 A third 
strategy, for severe, disabling dyskinesia is through brain surgery, e.g. by pallidotomy67, 
which is gradually being replaced by deep brain stimulation.76 
1.4.4.6 Dopamine agonists 
DA agonist monotherapy is usually sufficient to control parkinsonism for the first couple of 
years, and DA agonists are also prescribed as adjuncts to L-DOPA to improve response and 
reduce motor complications.31, 66, 77 The effect of DA agonists on non-motor domains like 
mood or cognition is now acknowledged as a key factor in fully addressing patients’ 
needs.77, 78 Furthermore, DA receptor agonists have been shown to produce neuroprotective 
activities in experimental models, although no drug has been unequivocally proven to be 
neuroprotective in the parkinsonian patient.79  
 
Figure 1.10 DA receptor agonists.80 
The older, "first generation" agonists are ergot-containing drugs including bromocriptine 
(Parlodel®), pergolide (Permax®) and lisuride.59 Two of the "second generation" most 
commonly prescribed DA agonists are the non-ergoline drugs pramipexole (Mirapex®) and 
ropinirole (Requip®).59, 80, 81 Pramipexole is currently also being investigated for its 
potential to modify disease progression by neuroprotection82 and its action on mood in 
Parkinson's disease.83, 84 Ropinirole, cabergoline and rotigotine (N-0923) are DA receptor 
agonists which have been approved for the treatment of Parkinson's disease66, 80, and the 
latter is used for continuous transdermal administration (Neupro®).59, 60 At present, 
intermittent subcutaneous apomorphine is the only acute treatment for “off” episodes in 
Parkinson's disease.85 Apomorphine is a short-acting DA D1/D2 receptor agonist62 and the 





1.4.4.7 Anticholinergics and amantadine 
Anticholinergics are benztropine, biperiden, orphenadrine, procyclidine, and 
trihexyphenidyl and can be used in young patients in whom tremor is the major symptom.31, 
59, 68 Elderly patients seem to be more susceptible to the peripheral (e.g. urinary retention, 
blurred vision, constipration, tachycardia) and centrally-mediated (e.g. mental confusion) 
adverse effects of anticholinergic agents, which limit their usefulness in older patients.86 
Amantadine, which has weak antiparkinson actions, is sometimes used for initial therapy 
(Figure 1.9).31 
1.4.4.8 Surgery 
There has been resurgence in the use of surgical techniques for the treatment of Parkinson's 
disease such as pallidotomy, thalamotomy, and more specifically deep brain stimulation 
(DBS),47 where electrodes are placed in the brain which stimulate the GPi, STN or 
thalamus. DBS causes less irreversible brain trauma than ablative surgery. Furthermore, the 
functional lesion induced by high frequency stimulation can be easily adjusted.87-89 
Nevertheless, akinesia can not be alleviated, mechanical defects and infection are a risk, 
DBS can not slow down disease progression, it's is expensive, and expertise in several 
fields is required. All these factors limit the widespread applicability of DBS.90 
1.5 MEDICINAL CHEMISTRY OF CENTRALLY ACTING DOPAMINE 
D2 AND D1/D2 RECEPTOR AGONISTS 
1.5.1 Structure-activity relationships of dopamine receptor agonists: 
rotameric conformation 
Giesecke showed by X-ray diffractometric analysis that the trans conformation of DA 
hydrochloride is favoured as compared to the cis conformation (Figure 1.11).91 Cannon 
defined α- and β-rotamers of the trans conformation of DA, in which the catechol ring is 
coplanar with the plane of the ethylamine side chain, and proposed that these are significant 
in agonist-receptor interactions.92 
 




McDermed et al. observed that for DA agonists which are α-rotamers, the S-enantiomer is 
more active, while for compounds which are β-rotamers the R-enantiomer is the more 
active form. If the structure of (S)-5-Hydroxy-2-(N,N-di-n-propylamino)tetralin ((S)-5-OH-
DPAT) is rotated and is superimposed over the structure of (R)-7-Hydroxy-2-(N,N,-di-n-
propylamino)tetralin ((R)-7-OH-DPAT) to obtain a similar orientation of the amino group 
and the meta alcohol groups, the amine moieties are pointing in the same direction (Figure 
1.12).93, 94  
 
Figure 1.12 Superimposition of (S)-5-OH-DPAT and (R)-7-OH-DPAT.93, 94 
In an extended model by Wikström et al. using monohydroxylated 3-phenylpiperidines and 
octahydrobenzo[f[quinolines a relationship was found between the absolute configuration, 
the ring position of the alcohol group and the size of the N-alkyl substituents, named 
“upwards” and “downwards”.95, 96 α- and β-rotamers of benzo[f[quinolines and 
benzo[g]quinolines have been investigated and all α-rotameric conformations appeared to 
be more potent than the β-conformations.97, 98 Nevertheless, it is not yet clear which of the 
two rotamers the DA receptor actually prefers.98-100 
1.5.2 5-OH-DPAT and N-0437 
5-Hydroxy-2-(N,N-di-n-propylamino)tetralin (5-OH-DPAT) is a DA receptor agonist with a 
higher selectivity for D2- over D1-receptors and the agonist potency resides in the (S)-
enantiomer (Figure 1.13).101, 102 A derivative, 5-hydroxy-2-(N-propyl-N-2-
thienylethylamino)tetralin (N-0437) was found to be an even more potent DA agonist than 
(S)-5-OH-DPAT102, and showed a long duration of action.103 The differential actions of 
(R)- and (S)-N-0437 gave rise to mutual antagonism, thus providing a strong argument for 
using the enantiomers instead of the racemate in clinical situations.18, 104  
Structure-activity studies with series of tetralins showed the effect of chemical differences 
on the biological activity. 5-OH-DPAT is more potent than its 6- and 7-hydroxy analogs 
and apomorphine, but less so than its 5,6-dihydroxy analog.93 6-Hydroxy-2-(N,N-di-n-
propylamino)tetralin (6-OH-DPAT) lost most of the DAergic potency whereas 7-OH-
DPAT is also a potent DA receptor ligand. In contrast, 8-OH-DPAT is a potent and 
selective serotonergic 5-HT1A-receptor agonist.101, 102 Hacksell et al. investigated an 
extensive series of N-alkylated 2-aminotetralins and concluded that an n-propyl group on 




(methylthio)propyl derivatives of 5-hydroxy-2-aminotetralins also showed high DAergic 
activities.110 
 
Figure 1.13 5-OH-DPAT and derivatives, N-0437, 8-OH-DPAC, 5,6-(OH)2-DPAT and 5,6-(OH)2-
MPAT.93, 102, 102, 105-108  
1.5.3 8-OH-DPAC 
8-Hydroxy-3,4-dihydro-3-(N,N-di-n-propylamino)-2H-1-benzopyran (8-OH-DPAC) has 
been shown to be a potent, centrally acting agonist at DA D2 receptors.18, 111 In fact, it 
shows enhanced selectivity for the presynaptic DA D2 receptors. 8-OH-DPAC was found to 
be a more potent DA agonist than apomorphine and its carbon analogue 5-OH-DPAT in 
vitro, and the (-)-enantiomer shows higher affinity and selectivity for DA D2 receptors than 
the (+)-enantiomer (the absolute stereochemistry of the enantiomers of 8-OH-DPAC has 
not been found in literature).105, 112-114 Then again, 8-OH-DPAC was shown to be less potent 
than 5-OH-DPAT in vivo112, which is probably due to rapid metabolic degradation.113  
1.5.4 5,6-(OH)2-DPAT 
Potent central DAergic-like activity can also be found in molecules where a free catechol 
group resides in the proper spatial relationship to the nitrogen atom, as in apomorphine.115 
The catechol 5,6-dihydroxy-2-(N,N-di-n-propylamino)tetralin (5,6-(OH)2-DPAT) was 
found to be a potent mixed DA D1/D2 receptor agonist.97, 116, 117 Experiments showed a 
higher DAergic binding and in vivo effect for the (-)-enantiomer.118 Moreover, 5,6-(OH)2-




showed low ED50 values for inhibition of locomotion and induction of stereotypy119, and 
were more potent than apomorphine as an emetic.116 
1.5.5 Metabolism of monophenolic and catecholic dopamine agonists 
Due to the fact that most of the potent DA receptor agonists contain aromatic hydroxyl 
functionalities, they have poor pharmacokinetic properties. Although both monophenolic 
and catecholic aromatic compounds are metabolically labile, the first are chemically and 
metabolically more stable than the latter.109 Phenols and catechols are likely to be 
conjugated on their first passage through the liver after p.o. or i.p. administration, the so-
called first-pass metabolism. Therefore, the central activity of catecholic drugs was mostly 
studied by using the peripheral subcutaneous route of administration.106, 116, 120 In addition, 
an electronically activated aromatic nucleus such as a phenol is susceptible to aromatic 
hydroxylation by the cytochrome P-450 enzyme system and catechols are degraded by the 
enzyme COMT.18, 121  
1.6 BLOOD BRAIN BARRIER 
The brain is separated from direct contact with blood by the presence of two barriers: the 
BBB and the blood-cerebrospinal fluid barrier (BCSFB). The first and largest barrier is the 
BBB, which contains tight junctions between the cells, restricting the passage of mainly 
hydrophilic drugs. The second barrier is the BCSFB. Its barrier function is provided by 
tight junctions between cells which contact the cerebrospinal fluid. The tight junctions are 
slightly more permeable than those of the BBB. 
Molecules can cross the BBB both by passive and active transport. Passive transport 
(diffusion) depends on size, charge and lipid solubility of the drug. Lipophilic, small, and 
non-charged drugs diffuse transcellularly easier than do hydrophilic, large and charged 
drugs. The capillaries of the BBB express proteins involved in active transport, i.e. uptake 
and excretion (e.g. P-glycoprotein). These proteins are also responsible for the degradation 
of proteins, peptides, neurotransmitters and drugs, forming a significant metabolic barrier. 
As the “gatekeeper” to the brain, the BBB determines the ability of drugs to gain entrance 
to brain extracellular fluid and reach therapeutic concentrations within the CNS.53, 55, 122 
Overall, more than 98% of all small-molecule drugs and approximately 100% of large-






Major barriers could exist in the pharmacokinetic phase of a drug which may limit its 
usefulness, i.e. incomplete absorption, incomplete systemic bioavailability due to first-pass 
metabolism, too rapid absorption or excretion, toxicity problems, and poor site-specificity 
of the drug.101 In order to circumvent these barriers a drug might be converted to a prodrug 
with improved delivery properties over the parent drug molecule. A prodrug is a 
pharmacologically inactive derivative of a parent drug molecule that requires chemical or 
enzymatic biotransformation in order to release the active drug, i.e bioactivation (Figure 
1.14).124 
 
Figure 1.14 Schematic illustration of the prodrug concept.101, 124 
Several criteria should be considered in the design of a prodrug101:  
1 The functional groups on the parent drug molecule which are amenable to chemical 
derivatization. 
2 The mechanisms and systems available in the organism for the required bioactivation. 
3 Synthesis and purification of the prodrug should be relatively simple.  
4 The prodrug should be chemically stable in bulk form. 
Examples of noteworthy blockbuster prodrugs are omeprazole, simvastatin, enalapril, and 
acyclovir (Figure 1.15).125 
From toxicological view, prodrugs must be considered new drugs126 and preferably pro-
moieties that are known to be nontoxic should be used.125 Many drugs contain hydroxyl or 
carboxyl functional groups and the popularity of using esters as a prodrug type for these 




hydrolyzing esters. In addition, by appropriate esterification it is possible to obtain 
derivatives with almost any desirable hydrophilicity or lipophilicity as well as in vivo 
lability.124 Other examples of functional groups which could be utilized in prodrugs are 
ethers, carbonates, phosphates and amides. 
 
Figure 1.15 Structures of noteworthy blockbuster prodrugs, the ester prodrug of morphine, the 
prodrug of MGS0039, and amonafide and mitonafide N-oxide prodrugs. The prodrug moieties of the 
drugs are indicated by a box.125, 127-129 
Common prodrug strategies are: prolongated drug delivery, improved cell permeation, 
carrier-mediated transport, site-directed drug delivery, site-specific drug release, and 
antibody-directed enzyme prodrug therapy (ADEPT). 
Prolonging the duration of action of a drug can be accomplished by the prodrug approach in 
two principal ways101: 
1 through sustained delivery of the prodrug form to the systemic circulation, e.g. lipid 
emulsions of morphine and its ester prodrugs (Figure 1.15)130, 
2 through design of prodrugs possessing a slow conversion to the parent drug in the 
organism, e.g. phosphoramidate monoesters of zidovudine (AZT)131, 132, and polymeric 
prodrugs of ketoprofen and naproxen.128 
Drugs that are too hydrophilic frequently have low bioavailabilities. The absorption could 
be improved by derivatization with a more lipophilic moiety.101, 125 Eligible drugs for this 
strategy are e.g. amino alcoholic β-blocking agents133, drugs with an ionic phosphate 
moiety124, and carboxylic acids such as the active acid of enalapril and MGS0039 (Figure 




by usage of intestinal peptide transporters.125 Site-directed drug delivery is a strategy that 
affords increased or selective transport of the parent drug to the site of action, e.g. 
simvastatin which undergoes predominant uptake by the liver. A drug that is released site-
specifically can be distributed everywhere but is activated at a specific site, e.g. acyclovir, 
omeprazole101, prophalan134, and the N-oxide amonafide and mitonafide prodrugs (Figure 
1.15).129 In ADEPT monoclonal antibody-enzyme conjugates are targeted to antigens 
present on tumor cell surfaces where they could activate anticancer prodrugs site-
selectively.135 
In the following paragraphs we will discuss several topics in regard of prodrug design. 
Because the prodrugs in this thesis are based on phenolic DA agonists, i.e. 5-OH-DPAT 
and 8-OH-DPAC, we will mainly focus on the derivatization of alcoholic drugs. 
Table 1.1 Prodrugs of Leu-enkephalin, acyclovir, indomethacin, and theophylline.  
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1.7.2 Chemical stability 
The stability of a prodrug plays an important role in drug bioavailability, formulation and 
storage. Ideal water soluble prodrug design requires an in vitro/in vivo stability ratio of 
nearly 106 and this may be readily achievable if the bioactivation is enzyme dependent. 
Besides usage of the various enzyme systems of the body to carry out the necessary 
activation of prodrugs, the buffered and relatively constant value of the physiological pH 
(7.4) may be useful in triggering the release of a drug from a prodrug.124, 126 When purely 
chemical prodrug activation is chosen, interspecies variability, genetic polymorphisms, and 
drug-drug interaction problems are no concern.125 
1.7.2.1 Alkyl ester prodrugs 
Since chemical ester hydrolysis is both specific acid and base catalyzed, ester hydrolysis 
rates are pH-dependent. Since the hydroxide ion catalyzed rate constant, kOH- is generally 
much larger than the hydronium-catalyzed rate constant, kH+, the pH of optimum stability of 
most alkyl esters is typically between 3.5 and 5.126 Examples of alkyl esters are the acetyl, 
propionyl and pivaloyl ester prodrugs of a leu-enkephalin analogue (Table 1.1).136  
1.7.2.2 Amino acid ester prodrugs 
The diverse properties of the various amino acid residues, combined with the fact that 
usually they are nontoxic, give esterification with these moieties wide applicability in 
prodrug design. Especially to increase solubility and bioavailability, e.g. the L-valine ester 
of acyclovir (Table 1.1).124 However, the introduction of ionizable functionalities, i.e. an 
amino or carboxylic acid group, is often associated with decreased stability.140 The major 
reason for the low stability of α-amino and short-chained aliphatic amino acid esters in 
aqueous solution at pH values affording their favourable water-solubility (i.e. pH 3-5) is 
due to the strongly electron-withdrawing effect of the protonated amino group which 
activates the ester linkage toward hydroxide ion attack. Another reason for the facilitated 
ester hydrolysis is intramolecular catalysis or assistance by the neighbouring amino group. 
The mechanisms involved include intramolecular nucleophilic catalysis, intramolecular 
general-base catalysis or general-acid specicific base catalysis as depicted in Figure 1.17.101 
Relatively stable amino acid esters under both acid- and base-catalyzed hydrolytic 
conditions are esters of cyclopropane amino acids as seen with acyclovir prodrugs (Table 
1.1).137 
1.7.2.2 Prodrugs with other pro-moieties 
Amide prodrugs, e.g. the prodrug of indomethacin, are in general more chemically stable 




prodrugs of theophylline, are relatively considerably slower than the rates of the N-
alkylcarbonyl prodrugs (Table 1.1).139 
 
Figure 1.17.Mechanisms of amino acid ester hydrolysis: (a) intramolecular nucleophilic catalysis, (b) 
intramolecular general-base catalysis or (c) general-acid specicific base catalysis.101 
1.7.3 Enzymatic stability 
Enzymes are classified according to function into six major groups: oxidoreductases, 
transferases, hydrolases, lyases, isomerases, and ligases.124 While prodrug activation 
through bioconversion as a time- and tissue-controlled process has a clear benefit, the inter- 
and intraspecies variability, genetic polymorphism, and the potential for drug-drug 
interactions pose significant challenges for such a prodrug strategy.125 In this thesis we 
describe the synthesis and study of ester prodrugs and we will therefore focus on esterases, 
a subgroup of the hydrolases. Esterases hydrolyze ester functional groups and are 
distributed widely in vertebrate tissues and blood.124 
 




1.7.3.1 The influence of amino acids on enzymatic stability 
As discussed in Section 1.7.2.2, amino acid prodrugs have wide applicability in prodrug 
design. The susceptibility of amino acid esters to undergo enzymatic hydrolysis could be 
affected by the structure of the amino functionality and size of the acyl moiety.142 
Enzymatic hydrolysis studies with prodrug esters of methylprednisolone suggest that 
derivatives having an anionic moiety are not hydrolyzed in serum, while compounds having 
a cationic moiety are hyrolyzed rapidly by serum esterases (Figure 1.18).141 
1.7.3.2 Protection against first-pass metabolism 
Drugs containing phenolic groups, e.g. 5-OH-DPAT and N-0437, undergo extensive first-
pass metabolism (Section 1.5.5). Nonetheless, several prodrug approaches are available to 
prevent this:101 
1 Mask the metabolizable moiety, e.g. derivatization with an acid to yield an ester 
prodrug; 
2 Design of an ester with a built-in esterase inhibiting function, e.g. bambuterol which 
exhibits esterase-inhibiting properties; 
3 To derivatize the susceptible drug molecule at some other position in the molecule so 
that the prodrug obtained is no longer a substrate for the presystemic metabolizing 
enzyme. 
1.7.4 Increased solubility of prodrugs 
Two physico-chemical strategies can be employed to increase the aqueous solubility of a 
drug: (i) derivatization of the drug in order to decrease the melting point and (ii) 
introduction of an ionic or ionisable group by a pro-moiety. The most commonly used 
esters for increasing aqueous solubility of alcoholic drugs are amino acid esters142-152, 
dicarboxylic acid esters144, 147, phosphates150, 153-155, sulphates144 and polyols156 (Table 1.2). 
For a drug or prodrug having ionizable functional groups, salt formation can also be a 
powerful tool in improving the formulation properties. The salt form of a drug is known to 
influence a number of physicochemical properties of the parent compound, including 
solubility and dissolution rate, stability and hygroscopicity.124, 126 
Another strategy to increase water solubility is the use of micellar prodrugs, as was shown 
in a series of PEG-paclitaxel conjugate prodrugs.157 Besides being highly water soluble, 
micelles have additional advantages: they solubilize poorly soluble degradation products 
which may otherwise precipitate and they are self-stabilizing due to protection of the 








Table 1.2 Examples of water-soluble prodrugs. 
Name parent drug Prodrug structure R group 
Metronidazole145, 149 
 
Amino acid ester 
Acyclovir147 
 
Amino acid ester, 
dicarboxylic acid ester 
3-(Hydroxymethyl)-phenytoin150 
 






Amino acid ester, 
dicarboxylic acid ester, or 




1.7.5 Prodrugs aimed at oligopeptide and glucose transporters 
The oral bioavailability of poorly absorbed drugs can be enhanced by targeting them to 
oligopeptide transporters159, 160 such as the peptide transporter 1 (PEPT1) which actively 
transports small peptides.161 Oligopeptide transporters are highly expressed in the intestine 
and are also enriched in some cancer epithelial cells and can be used for delivery of 




Table 1.3 Structures of amino acid ester prodrugs aimed at oligopeptide transporters. 
Name parent drug Prodrug structurea R group 
Floxuridine164-166 
 
Val, Phe, Pro, Asp, Lys, Leu, 
Ile, or Gly 
BDCRB167, 168 
 
Val, Phe, Pro, Asp, Lys, or Ile 
PMEA169 
 
Val, Phe, Ile, Gly, or Ala 
Zidovudine170 
 
Phe, Lys, Ile, Tyr, or Gln 
a n = 1 or 2, X = O or S. 
In this section several examples of amino acid ester prodrugs of antiviral and antitumor 
agents are presented (Table 1.3). Floxuridine prodrug strategies offer great potential, not 
only for increased drug absorption by targeting the PEPT1 transporter, but as well for 
improved tumor selectivity and drug efficacy.164, 166, 171, 172 Amino acid prodrugs of 
gemcitabine173, 2-bromo-5,6-dichloro-1-(β-D-ribofuranosyl)benzimidazole (BDCRB)167, 168, 
9-[2-(phosphonomethoxy)-ethyl] adenine (PMEA)169 also exhibited enhanced transport or 
affinity for PEPT1. Additionally, amino acid prodrugs could  increase drug activity, evasion 
of metabolizing enzymes, bioavailability, and reduce toxicity. The enhanced uptake by 
HIV-1 infected cells of amino acid prodrugs of AZT170 and the increased nasal uptake of 
amino acid prodrugs of acyclovir174 probably also involves an active transport system. 
In addition to targeting an active amino acid transport system, incorporation of glycosyl or 
polyhydric pro-moieties could increase the affinity for sugar active transport systems in 
order to increase absorption, e.g. a lonidamine prodrug which targets the glucose 




1.7.6 Dipeptide ester prodrugs 
The dipeptide prodrug strategy can be applied to increase solubility, optimize chemical and 
enzymatic stability, improve active transport by membrane peptide transporters, increase 
bioavailability, enhance pharmacological activity, and decrease toxicity. Examples are 
dipeptide ester prodrugs of ganciclovir175, lopinavir176, LY354740177 (Table 1.4), 
acyclovir178, 179, and floxuridine172.  According to Nashed and Mitra both geometrical 
isomerism and hydrogen bonding of dipeptide ester prodrugs might enhance the stability 
compared to the mono amino acid ester prodrugs.180 The stabilizing effect of the 
substituents of alkyl dipeptides has the following order: isobutyl ≥ isopropyl > ethyl > 
methyl > H, which indicates that steric hindrance influences the chemical stability.181 This 
stability relationship was also found for dipeptide ester prodrugs. A valine residue linked to 
the parent drug in dipeptide prodrugs is of outmost importance to improve chemical 
stability, while the N-terminal residue can be used for further fine tuning of the prodrug’s 
properties.182 Moreover, incorporation of D-valine in a dipeptide did not abolish its affinity 
towards peptide transporters, though it enhanced the enzymatic stability of the prodrug to a 
certain extent.183 
Table 1.4 Structures of dipeptide ester prodrugs. 






Val-Tyr-, or Gly-Tyr- 
Lopinavir176 
 
Gly-Val-, or Val-Val 
LY354740177 
 
R1 or R2 = Ala, Leu, Phe, 
Val, Gly, Met, Pro, Ile, Tyr, 
Lys, or Ser 
Besides basic hydrolysis of the ester bond, the chemical release of the parent drug of 
dipeptide esters can also follow another pathway, i.e. cyclization-activation. In this pathway 
dipeptide esters are degraded to the parent drug and corresponding 2,5-diketopiperazines by 
intramolecular activation (Figure 1.19).184, 185 The development of prodrugs that can 
regenerate the parent drug through non-enzymatic pathways has emerged as an alternative 




variability that affects enzymatic activity. Furthermore, intramolecular pathways have a key 
role in a more refined two-step prodrug activation, where an initial enzymatic cleavage step 
is followed by a cyclization-elimination reaction that releases the active drug.186, 187 
 
Figure 1.19 Formation of diketopiperazines from a dipeptide prodrug of paracetamol.184 
1.7.7 Prodrugs for delivery to the central nervous system 
The major neurological diseases affecting the brain may be categorized as 
neurodegenerative, cerebrovascular, inflammatory (infectious and autoimmune) and 
cancerous.188 The vascular route would be very promising in drug delivery for targeting the 
brain, if the BBB could be passed. In general, polar hydrophilic drugs are not easily 
transported across the BBB (Section 1.6). Fortunately, lipidization through prodrugs offers 
a possibility for an efficient CNS delivery of polar drugs.189, 190 Although the brain tissue 
activity of non specific esterases is unfavourable for utility of esterase activated prodrugs, a 
variety of oxidative enzymes could be utilized as biotransformation system in the 
conversion of drugs unable to cross BBB.188 
In the absence of lipid-mediated mechanisms, circulating molecules can penetrate into the 
CNS by interaction with endogenous transport systems.188 Several carriers are targets for 
this approach, e.g. the L-amino acid transporter LAT1 and the glucose transporter 
GLUT1.191 The use of L-DOPA for the brain targeting of DA which does not cross the 
BBB, is a classical example of modification of the drug structure, with the aim of obtaining 
a prodrug as a “pseudonutrient” substrate for LAT1.188 The crucial role played by 
glutathione in the pathogenesis of Parkinson's disease and the presence of its influx 
transporters at the basolateral membrane of the BBB served as the basis for an anti-
Parkinson glutathione-based prodrug design.192 
1.7.8 Dopaminergic prodrugs 
Several strategies are available to increase the brain uptake, absorption and bioavailability 
of DA and DAergic compounds. Glycosyl prodrugs of DA have been developed to increase 
brain uptake by targeting the GLUT1 transporter.193 Also the lipophilic phenyl-




advantage of this strategy is that upon delivery into the brain dopimid prodrugs are cleaved 
to the active L-DOPA (or DA) and phenyl-imidazopyridine moieties, of which the latter 
could improve the antiparkinsonian therapeutic effect.194 Improvement of solubility offers 
potential for more rapid and consistent absorption, and a higher bioavailability as seen with 
the L-DOPA methyl ester.195-198  
Because phenolic and catecholic functional groups are sensitive to oxidation, these groups 
can be protected against first-pass metabolism by esterification, e.g. the L-DOPA pivaloyl 
ester prodrug NB-355199, apomorphine diester produgs200-203, and ABT-431 which is the 
diester prodrug of the potent and selective DA D1 receptor agonist A-86929.204 
Furthermore, dimeric prodrugs of L-DOPA were synthesized to protect multiple functional 
groups against metabolism and to improve physicochemical properties (Table 1.5).205, 206 
Table 1.5 DAergic prodrugs. 
Prodrug Structure Advantage over parent drug 
Glycosyl DA derivatives193 
 
Interaction with GLUT1 carrier 




1) serves as a lipophilic carrier 
for DA and L-DOPA to penetrate 
the BBB 
2) influences DAergic neurons 
through the GABA-
benzodiazepine receptor complex 





Protection of the catechol against 




Protection of the catechol against 
first-pass metabolism by di-
esterification. 
Diamides of (O,O-diacetyl)- L-
DOPA-methyl ester205, 206 
 
1) Protection of multiple 
functional groups against 
enzymatic degradation 





(S)-PD148903 is an orally active prodrug with enone structure which is converted by an 
oxidative bioactivation mechanism to the corresponding catechol and is delivered 
enantioselectively into the CNS.207, 208 Though less potent than the parent drug, the oxime 
derivative of PD148903 was also orally active.209 With a potency comparable to that of 
apomorphine, the enone prodrug GMC-6650 can potentially compete with L-DOPA and 
apomorphine in the treatment of Parkinson's disease.210 TL-334, the active form of GMC-
6650 showed an extremely potent DAergic activity, however, the bioavailability was low 
due to rapid metabolization of the catechol moiety (Figure 1.20).211 
 
Figure 1.20 Structure of PD148903 and the in vivo bioactivation of GMC-6650 into TL-334.210, 211  
1.8 TRANSDERMAL DRUG DELIVERY 
1.8.1 Skin and routes of skin penetration 
The skin’s barrier function is accomplished by the stratum corneum (SC) which prevents 
the flux of toxins into the body and minimizes water loss.212, 213 The SC is an extremely thin 
layer that is formed by a laminate of compressed keratin-filled corneocytes anchored in a 
lipophilic matrix.214, 215 The next consecutive layers are the epidermis and the dermis. At 
epidermal-dermal junction exists an efficient blood supply which provides a mechanism for 
eliminating drugs from the local area.124, 216 A skin penetrant has three potential pathways to 
the viable tissue, i.e. via sweat ducts, across the SC between the appendages, or through 
hair follicles with associated sebaceous glands (Figure 1.21).217 
1.8.2 Passive transdermal drug delivery 
The transdermal mode offers several advantages: (1) the skin presents a relatively large 
surface area for absorption; (2) the application is a non-invasive procedure; (3) the potential 
for sustained release and (4) controlled input kinetics218; (5) circumvention of the first-pass 
effect; (6) potential for self-administration; and (7) the production of the systems is 
generally inexpensive.219 Ideally, a transdermal drug must possess both good lipoidal and 
aqueous solubilities.218 All drugs presently administered across skin have an adequate high 
lipophilicity and low molecular mass (<500 Da).212 Other factors that influence the passive 




point.221 Presently available transdermal patches for passive delivery can be classified into 
two categories on the basis of their design: reservoir-type patches and matrix-type 
patches.212 The worldwide transdermal market consists of eight FDA-approved active 
agents: scopolamine, nitroglycerin, clonidine, oestradiol, fentanyl, nicotine, testosterone 
and norethisterone.218 In addition,  rotigotine (N-0437) is available formulated in a patch 
against symptoms of Parkinson's disease and restless legs syndrome.222, 223 
 
Figure 1.21 Simplified diagram of skin structure and possible routes for drug penetration: (1) via the 
sweat ducts; (2) across the stratum corneum or (3) through the hair follicles with their associated 
sebaceous glands.217 
1.8.3 Prodrugs for passive transdermal drug delivery 
Prodrugs which enhance the passive transdermal delivery are presented in Table 1.6 The 
blood circulation contains many enzymes which are capable of releasing a drug from the 
prodrug after transdermal delivery. Also the epidermis contains many non-specific enzymes 
capable of metabolizing prodrugs224, and because of stereoselective enzymatic degradation 
chiral prodrugs may be transported stereoselective through the skin.225 For these reasons the 
transdermal delivery of prodrugs has considerable potency for therapeutic applications.124 
Both good aqueous and lipid solubility is an important factor for the passive transdermal 
flux139, and several pro-moieties are available to achieve this good biphasic solubility. 
Increase of lipophilicity by alkylcarbonate formation219 or esterification with an alkylgroup 
improves penetration through the skin and displays profound therapeutic effects as 
observed for prodrugs of nalbuphine, temozolomide, and captopril.226, 232, 233 Other pro-
moieties that were developed to improve the passive transdermal flux are N-alkyl-N-
alkyloxycarbonylaminomethyl groups227, acyloxyalkyl esters231, aminocarbonyloxymethyl 
esters228, aminoacyloxyalkyl esters230 and methylpiperazinylacyloxyalkyl ester229 (Table 




Table 1.6 Structures of prodrugs suitable for passive transdermal delivery and their passive 
transdermal flux in vitro. 






































The essential components of an iontophoresis system are the current source, the anode 
reservoir system and the cathode reservoir system. The principle of iontophoresis is to 
transport the drug out of the reservoir into or through the skin, with eventual absorption of 
the drug by the vasculature for distribution throughout the body (Figure 1.22).234 Ions prefer 
skin entry via the pores, such as hair follicles and sweat ducts235, but ions can also be 
delivered via the intercellular route.236 Binding within the skin may form a barrier for drug 
absorption.237 
Three main mechanisms enhance molecular transport in iontophoresis: (a) charged species 
are driven primarily by electro-repulsion from the driving electrode; (b) the flow of electric 




uncharged molecules and large polar peptides.217 The electro-repulsive effect produces the 
largest enhancement to the flux of small lipophilic cations238, and the fraction of current 
carried by each type of ion is called the transference number.239 A linear relationship has 
been observed between the apparent flux and the applied current for several compounds.240 
Enhancement by electro-osmosis involves the delivery of molecules that are dragged by 
electrically induced solvent flow212, and its impact increases with the size of the ion.235  At 
the physiological pH of 7.4 the transport of positively charged solutes by iontophoresis is 
facilitated by the negatively charged proteins in the SC.241 
 
Figure 1.22 Schematic of an iontophoretic device. D+ is a cationic drug, D- is an anionic drug.218 
Many factors have been shown to affect the results of iontophoresis. These include the 
current strength, physicochemical properties of the compound, drug formulation, equipment 
used, biological variations, skin temperature and duration of iontophoresis.235 Drug 
concentration and drug charge are important factors affecting the iontophoretic process. An 
increase in concentration increases flux upto a point, after which the flux becomes 
independent of the donor concentration.240 Although the drug charge is an important 
physicochemical property which governs iontophoretic transport, the influence of drug 
charge on iontophoresis is not yet unambiguously clarified.212, 234, 235 The optimal 
application sites of an iontophoretic device are the upper outer arm or chest. Bodyweight 
and race do not affect the pharmacokinetics.242 Examples of iontophoretic delivery systems 
are the fentanyl HCl iontophoresis transdermal system (fentanyl ITS; IONSYS™, Ortho-
McNeil, Inc, Raritan, NJ)243, Lidosite®,  Iomed Phoresor® II, and Ocuphor™.240 
1.8.4.1 Advantages and limitations of iontophoresis 
Transdermal iontophoresis not only provides the usual benefits of transdermal drug delivery 
(Section 1.8.2) but it has several additional advantages: 
1 Iontophoresis can be used for programmed and controlled delivery by adjusting the 
current to the patient's needs, as the transdermal flux of the drug is proportional to the 




2 Iontophoresis can be used for constant drug delivery. The peaks and valleys of blood 
concentration that are inherent for oral and systemic administration can be avoided 
simply by maintaining the current at a level known to provide the desired serum 
level.234 Electronic controllers are used to keep the current output constant resulting in 
a constant drug delivery rate.244 
3 Iontophoresis may provide overall improved drug delivery when the currently available 
dosage form provides very limited bioavailability.234 
The main limitations of iontophoresis are: 
1 The impossibility to achieve a high transference number with some drugs.234 
2 If the molecule cannot be formulated as an ion, the prospects of its moving through the 
skin in sufficient quantity in order to be therapeutically effective are poor. Furthermore, 
it must exist in ionic form over the variable pH range of the skin of about 4.0 to 7.3.234 
3 Iontophoresis does not affect the delivery of macromolecules or vaccines, unless used 
in combination with other methods that increase skin permeability.219 
4 The vulnerability of the skin limits the amount of current that can safely pass through 
the skin.234 
1.8.4.2 Drugs suitable for iontophoretic drug delivery 
Iontophoresis was used clinically to rapidly deliver lidocaine for local anesthesia.219, 245 
Pilocarpine can be adminstered by transdermal iontophoresis to induce sweating as part of a 
cystic fibrosis diagnostic test.219 The fentanyl ITS was approved as a iontophoretic patch 
which enables patients to periodically activate the patch by administering a bolus of 
fentanyl based on their need for pain relief.243, 246 Also glipizide247 and venlafaxine 
hydrochloride are considered promising candidates for transdermal iontophoretic delivery 
(Figure 1.25).248 
 




1.8.4.3 Prodrugs suitable for iontophoretic drug delivery 
Prodrug design based upon a charged precursor of an active drug to be delivered by 
iontophoresis is a promising strategy to deliver drugs transdermally. The different enzymes 
present in the skin may be utilized by the prodrugs to regenerate the active parent drug.220 
Examples of prodrugs which were investigated for transdermal iontophoretic delivery are 
prodrugs of dexamethasone249, 5-aminolevulinic acid250-252, desglymidodrine253, 
acyclovir254, dehydroepiandrosterone255, nalbuphine226, and atenolol256 (Table 1.1, Table 1.6 
and Table 1.7). 
Table 1.7 Structures of prodrugs suitable for transdermal iontophoretic delivery and their transdermal 
iontophoretic flux in vitro. Also the skin type, electrical current strength and the drug concentration in 
the donor phase are presented. 
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1.8.5 Other methods for transdermal drug delivery 
Besides iontophoresis several other penetration enhancing techniques are available. The 




diminish the skin’s barrier. Also ultrasound or skin electroporation are techniques to 
temporarily decrease the skin’s barrier function.217, 218 Needles of micron dimensions can 
pierce into the skin surface to create holes large enough for molecules to enter212 and 
because the SC usually provides the permeation barrier, ablation may also be considered.217 
Furthermore, combinations of penetration enhancers are often more effective and reduce 
the required ‘dose’ of each enhancer.212 Examples are the combination of gel with 
iontophoresis for the delivery of triamcinolone acetonide acetate257 and the combination of 
iontophoresis with microneedles in the case of methotrexate (Figure 1.26).258 
 
Figure 1.24 Structures of triamcinolone acetonide acetate and methotrexate. 
1.8.6 Transdermal drug delivery, iontophoresis and Parkinson’s disease 
In addition to investigation of the passive transdermal drug delivery of potent DAergic 
drugs such as (-)-N-0437259, 260 and (+)-PHNO261, 262, also the iontophoretic transdermal 
drug delivery has been explored in the field of antiparkinsonian drugs (Table 1.8). The 
iontophoretic delivery of apomorphine can be controlled and manipulated accurately by the 
applied current263, 264 and may be an attractive tool in future clinical pharmacological 
investigations in patients with Parkinson's disease (Table 1.8).265 Besides the current, also 
secondary effects such as convective flow and electro-osmosis may contribute to the 
delivery of apomorphine.266 A chip-controlled iontophoretic system, which is able to 
directly measure a patient's physical symptoms of Parkinson's disease and accordingly 
regulate the drug input, seems to be a promising technique.267  
Iontophoretic delivery of ropinirole was not proportional to drug concentration in vitro268, 
nevertheless iontophoresis was able to deliver therapeutic amounts of ropinirole 
hydrochloride in vivo.271 For the iontophoretic delivery of rotigotine the electro-repulsion 
was the main mechanism of the iontophoretic transport and crucial factors were: pH and 
NaCl concentration of the donor phase272, drug concentration, current density, and skin 
thickness.269 The iontophoretic transport of 5-OH-DPAT in vitro was found to increase 
linearly with concentration and current density, providing a convenient way to manage dose 




DAergic effect in vivo, indicating that therapeutically effective concentrations were 
achieved.273  
Table 1.8 Structures of DA agonists suitable for transdermal iontophoretic delivery and their 
transdermal iontophoretic flux in vitro. Also the skin type, electrical current strength and the drug 
concentration in the donor phase are presented. 
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1.9 AIM OF THIS THESIS 
Nugroho had determined the optimal conditions for the iontophoretic transport of 5-OH-
DPAT across human skin in vitro.270 Moreover, he investigated the iontophoretic delivery 
of 5-OH-DPAT in vivo and concluded that the DA agonist was successfully delivered in 
sufficients amounts into the striatum to achieve a strong DAergic effect.274 In succession of 
Nugroho’s research, the iontophoretic delivery of 5-OH-DPAT needs further investigation 
in order to obtain a drug or prodrug which is applicable for administration to patients with 
Parkinson's disease. The main aim of this study is the development of prodrugs and 
derivatives of 5-OH-DPAT with optimized physicochemical properties for transdermal 
delivery by iontophoresis. The main challenges to overcome were the limited solubility of 
the hydrobromide salt of 5-OH-DPAT, and the stability issues that appear when a prodrug 




To achieve an improved iontophoretic profile of newly designed prodrugs or derivatives of 
5-OH-DPAT, in vitro and in vivo studies are necessary. The results of the iontophoretic in 
vitro studies may lead to the selection of the optimal candidate for in vivo experiments 
which include: 1) the validation of a rat model for the iontophoretic delivery of 5-OH-
DPAT in combination with microdialysis using an alternative anaesthetic method compared 
to the one used by Nugroho; and 2) the investigation of the iontophoretic transdermal 
delivery of  a prodrug or derivative of 5-OH-DPAT with enhanced physico-chemical 
properties. 
In this thesis we studied amino acid ester prodrugs of 5-OH-DPAT, dipeptide ester 
prodrugs of 5-OH-DPAT, and amino acid ester prodrugs of 8-OH-DPAC.  
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Synthesis of a series of prodrugs of the 
potent dopamine (DA) D2 agonist 5-
hydroxy-2-(N,N,-di-n-propylamino)tetralin 
(5-OH-DPAT), compounds designed for 





The administration of 5-OH-DPAT by transdermal iontophoretic transdermal delivery is 
promising, but further optimization for human administration is necessary. A prodrug 
strategy with amino acid pro-moieties would be ideal to improve the physicochemical 
properties of 5-OH-DPAT for iontophoresis as well as for its formulation. By tailoring the 
pro-moieties we aimed to improve the chemical stability while maintaining high enzymatic 
instability for blood and skin esterases. In conclusion, a series of amino acid ester prodrugs 
of 5-OH-DPAT was synthesized ready to be examined in stability and iontophoretic 
experiments in vitro and in vivo. 
2.1 INTRODUCTION 
5-Hydroxy-2-(N,N-di-n-propylamino)tetralin (5-OH-DPAT, 2.12, Figure 2.1) is a potent 
DA D2 receptor agonist and a potential candidate for iontophoretic delivery in the treatment 
of patients with Parkinson’s disease.1-4 The in vitro and in vivo iontophoretic administration 
of 5-OH-DPAT and other dopamine (DA) agonists has been thoroughly investigated.5-12 
These studies show that the administration of DA agonists is promising, but further 
optimization for human administration is necessary. A prodrug strategy would be ideal to 
improve the physicochemical properties of 5-OH-DPAT for iontophoresis and its 
formulation. 
 
Figure 2.1 Structures of 5-OH-DPAT.HBr and rotigotine.HCl. 
First, higher hydrophilicity proved beneficial for the iontophoretic flux.13 Second, for 5-
OH-DPAT and rotigotine (Figure 2.1) it has been demonstrated that the drug concentration 
is positively correlated to the transdermal flux.7, 9 Third, iontophoretic flux is negatively 
correlated to the molecular weight.14 It would therefore be convenient to improve the 
hydrophilicity and aqueous solubility of 5-OH-DPAT by introduction of a small 
hydrophilic functional group, e.g. an amino or alcoholic group, preferably in a water 
soluble salt form. An amino acid, a widely used pro-moiety, especially for carrier-mediated 
absorption, would be suitable for this purpose.15 The application for transdermal 
iontophoresis of cationic amino acid ester prodrugs of several non-ionic drugs has been 
investigated before. Valacyclovir hydrochloride (Figure 2.2), the L-valine ester prodrug of 
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acyclovir, showed superior iontophoresis over the parent molecule.16 Also the amino acid 
ester prodrugs of dehydroepiandrosteron (DHEA) resulted in an improved iontophoretic 
flux, together with a decreased drug lipophilicity and an increased aqueous solubility.17 In 
the case of the cationic molecule 5-OH-DPAT hydrobromide, a second chargeable group 
may be beneficial for the iontophoretic flux and aqueous solubility.18 In addition, an 
increase in flux would also allow a reduction of the electrical current strength, which may 
lessen skin irritation.19 And the increased solubility could result in a patient-friendly 
advantage, i.e. minimization of the patch size. 
 
Figure 2.2 Structures of the parent drugs and amino acid ester prodrugs of acyclovir and 
dehydroepiandrosterone (DHEA). 
Several studies have been performed concerning the synthesis of prodrugs of DAergic 
agonists. These phenolic or catecholic DA receptor agonists were esterified into mono- or 
diesters.20 The chemical and enzymatic stability are important properties of a prodrug, and 
the finding of a good ratio between these properties could pose a challenge.21, 22 Previous 
investigations show that this can also be achieved when amino acid ester prodrugs are 
utilized. Various water-soluble amino acid ester prodrugs of aliphatic alcohols have been 
synthesized of which the L-valine, L-isoleucine, 1-aminocyclopropane carboxylic acid and 
the β-amino acids ester prodrugs were chemically the most stable, while they showed 
sufficient enzymatic lability.23-30 In general, the chemical and enzymatic stability of amino 
acid ester prodrugs of aromatic alcohols e.g. 5-OH-DPAT, are expected to be lower in 
comparison to amino acid esters of aliphatic alcohols.31-33 Although some non-endogenous 
bulky N-alkylated amino acid ester prodrugs showed high chemical stability and solubility, 
natural amino acids are preferred.34 
In this chapter the synthesis of a series of amino acid ester prodrugs of the phenolic 5-OH-
DPAT is described. With several analogous prodrug series in hands we can roughly explore 
the influence of alcoholic, basic and bulky side chains, alkylation of the amino group, and 
chain elongation on the chemical stability of the phenolic ester. By tailoring the amino acid 
pro-moieties we aim to improve the chemical stability of the prodrug while maintaining 
high enzymatic lability for blood and skin esterases. These prodrugs and the results of the 
stability tests could be a useful tool for the development of prodrugs of other phenolic drugs 
which need higher aqueous solubility, an amino acid moiety for peptide carrier-mediated 




and physico-chemical properties for transdermal iontophoresis will be used for further 
investigation. 
2.2 CHEMISTRY 
2.2.1 Synthesis of (S) and (R)-5-hydroxy-2-(N,N-di-n-propyl-
amino)tetralin ((S)-2.12) and (R)-2.12) 
1,6-Dimethoxynaphthalene (2.7) was prepared by methylation of 1,6-dihydroxynaphthalene 
with dimethyl sulfate under basic aqueous conditions with a yield of 83%. Subsequently, 
the naphthalene ether 2.7 was reduced to the enol ether intermediate followed by acid 
hydrolysis to 5-methoxy-tetralone 2.8 with a yield of 89%.35 After the condensation with 
benzylamine, subsequent catalytic hydrogenation of the imine and treatment with hydrogen 
chloride, 2-(benzylamino)-5-methoxytetralin was obtained as the hydrochloride salt with a 
yield of 56%. Our initial attempt of resolution by fractional recrystallization of the 
mandelates of 2.9 from ether yielded no crystals, but instead an oily precipitation.2 
Eventually, the (S)- and (R)-enantiomers of 2.9 were resolved in moderate yields by a more 
convenient fractional recrystallization of the diastereomeric (-)- and (+)-di-p-
toluoyltartrates, respectively, from 96% ethanol (Scheme 2.1).36 
 
Scheme 2.1 Synthesis and resolution of (±)-2-(benzylamino)-5-methoxytetralin (2.9). Reagents and 
conditions: a) (CH3)2SO4, 2N NaOH, reflux; b) Na, EtOH; 2N HCl (aq), reflux; c) benzylamine, p-
toluenesulfonic acid, 3.5 bar H2, PtO2 in EtOH, RT, overnight; d) fractional recrystallization with (-)-
di-p-toluoyl-L-tartaric acid in 96% EtOH; e) fractional recrystallization with (+)-di-p-toluoyl-D-
tartaric acid in 96% EtOH. 
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The enantiomers (S)-2.9 and (R)-2.9 were debenzylated by hydrogenolysis with 10% 
palladium on carbon to give amines (S)-2.10 and (R)-2.10 with yields of 94% and 80%, 
respectively. These primary amines were propylated with 4 equivalents of 1-iodopropane to 
the tertiary amines (S)-2.11 and (R)-2.11, with yields of 64% and 54%, respectively.  
Finally, the phenolic enantiomers of 5-OH-DPAT ((S)-2.12 and (R)-2.12) were obtained 
after demethylation by refluxing in 48% hydrobromic acid (Scheme 2.2).1, 2, 36 
 
Scheme 2.2 Synthesis of (S)-5-OH-DPAT ((S)-2.12) and (R)-5-OH-DPAT ((R)-2.12). Reagents and 
conditions: f) 3.5 bar H2,10% Pd/C in EtOH, 40 °C; g) 1-iodopropane (4 eq), K2CO3 in acetonitrile, 
reflux; h) 48% HBr, reflux. 
During the synthesis of (S)-2.11 a side-product was observed with a yield of 19% when 8 
equivalents of 1-iodopropane were used instead of 4 equivalents. This side product was the 
propylated quaternary amine, which could be removed from (S)-2.11 by column 
chromatography (Scheme 2.3). 
 
Scheme 2.3 Synthesis of (S)-5-hydroxy-2-(N,N,N-tri-n-propyl-ammonium)tetralin iodide-salt. 
Reagents and conditions: a) 1-iodopropane (8 eq), K2CO3 in acetonitrile, reflux. 
2.2.2 Protection of amino acids 
The N-tert-butoxycarbonyl(Boc)-protected L-alanine (2.1), L-proline (2.2), N-
methylglycine (2.3), γ-aminobutyric acid (2.4) and 5-aminovaleric acid (2.5) were 
successfully prepared from their respective amino acids and di-tert-butyl dicarbonate in 
yields between 34% and 77% (Scheme 2.4). The other N-protected amino acids were 





Scheme 2.4 N-Boc-protection of L-alanine, N-methylglycine, L-proline, γ-aminobutyric acid and 5-
aminovaleric acid. Reagents and conditions: a) Boc2O, NaHCO3, H2O/THF (1:1), RT. 
2.2.3 Preparation of amino acid esters of 5-OH-DPAT 
The hydroxy moiety of (S)-5-OH-DPAT ((S)-2.12) was esterified with the N-protected 
amino acids according to Scheme 2.5 and Scheme 2.6. As coupling reagent N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide (EDC) was used. To suppress racemization 
and catalyze the coupling 1-hydroxybenzotriazole (HOBt) was added. According to this 
method, the N-Boc-protected esters of (S)-5-OH-DPAT with glycine (2.13), L-alanine 
(2.14), 1-amino-cyclopropanecarboxylic acid (2.15),  L-valine (2.16), D-valine, (2.17) L-
isoleucine (2.18),  L-phenylalanine (2.20), L-lysine (2.21) and L-proline (2.23) were 
synthesized with yields between 49% and 77%. 
 
Scheme 2.5 Synthesis of glycine (2.28), L-alanine (2.29), L-valine (2.31), L-isoleucine (2.33), L-
phenylalanine (2.35) and L-lysine (2.36) (S)-2-(di-n-propyl-amino)tetralin-5-yl esters as 2HCl salts 
(2.36=3HCl salt). Reagents and conditions: a) EDC, N-tert-Boc-amino acid, HOBt hydrate, 0 °C-RT; 
b) 4N HCl in dioxane, RT. 
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The deprotection of the Boc-protected compounds 2.13-2.18, 2.20, 2.21 and 2.23 was 
carried out with a solution of hydrogen chloride in dioxane.37 After reaction completion, 
decantation of the solvent and drying in vacuo, the solid hygroscopic foams were 
reprecipitated from dry methanol with dry ether to remove excess dioxane. The 
hydrochloride salts 2.28-2.33, 2.35-2.37 were obtained with yields between 80% and 100%. 
Only the D-valine (2.32) and L-lysine (2.36) (S)-5-OH-DPAT esters gave lower yields, 
32% and 10%, respectively. 
 
Scheme 2.6 Synthesis of 1-aminocyclopropane-1-carboxylic acid (2.30), D-valine (2.32), L-proline 
(2.37) (S)-2-(di-n-propyl-amino)tetralin-5-yl esters as 2HCl salts. Reagents and conditions: a) EDC, 
N-tert-Boc-amino acid, HOBt hydrate, 0 °C-RT; b) 4N HCl in dioxane, RT. 
The esterification of (R)-5-OH-DPAT ((R)-2.12)  with di-protected N-tert-Boc-O-benzyl-L-
serine was also established by carbodiimide coupling, and yielded the L-serine ester of (R)-
5-OH-DPAT (2.19). The debenzylation of compound 2.19 was performed by 
hydrogenolysis in ethanol at 45oC and 3 bar hydrogen atmosphere to obtain compound 2.42 
with a yield of 47%. Subsequently, the deprotected alcohol 2.42 was treated with hydrogen 
chloride in dioxane to remove the Boc group. The product 2.34 was reprecipitated from dry 






Scheme 2.7 Synthesis of L-serine (R)-2-(di-n-propyl-amino)tetralin-5-yl ester 2HCl salt (2.34). 
Reagents and conditions: a) EDC, N-tert-Boc-O-benzyl-L-serine, HOBt hydrate, 0 °C-RT; b) ~3 bar 
H2, 10% Pd/C in EtOH, 45 °C; c) 4N HCl in dioxane, RT. 
A special case was the synthesis of the L-arginine ester of (S)-5-OH-DPAT (Scheme 2.8). 
First, L-arginine was protected with three carbobenzyloxy groups (Cbz) by a one-pot 
synthetic method as described by Jetten et al.38 Although the N-urethane formation was 
facilitated by prior silylation of the amine groups, a reasonable amount (>50% ) of the di-
Cbz-L-arginine side-product was found after mass spectrometry analysis, but could be 
removed by column chromatography followed by recrystallization. The overall yield of the 
synthesis of Nα, Nδ, Nω-tri-Cbz-L-arginine (2.6) was 36%. The Nα, Nδ, Nω-tri-Cbz-L-
arginine (S)-5-OH-DPAT ester (2.22) was formed by the same coupling method as 
described before and was subsequently debenzylated by hydrogenolysis with 10% 
palladium on carbon as catalyst in a solution of hydrogen chloride in dry methanol. The L-
arginine (S)-5-OH-DPAT ester (2.43) was precipitated with dry ether and was obtained as 
the tetra-hydrochloride salt with a yield of 79%. 
 
Scheme 2.8 Synthesis of L-arginine (S)-2-(di-n-propyl-amino)tetralin-5-yl ester 4HCl salt (2.43). 
Reagents and conditions: a) EDC, HOBt hydrate, 0 °C-RT; b) ~1 bar H2, 10% Pd/C, 0.3N HCl in 
MeOH, RT; c) i) TMS-Cl, DIPEA, 45°C in 1,2-dichloroethane, ii) benzylchloroformate, 0 °C-RT. 
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The N-Boc-N-methylglycine (S)-5-OH-DPAT ester (2.24) and the dimethylglycine (R)-5-
OH-DPAT ester (2.44) were synthesized by the coupling of N-tert-Boc-N-methylglycine 
and N,N-dimethylglycine respectively to the corresponding enantiomers of 5-OH-DPAT. 
Compound 2.44 was converted to the dihydrochloride salt with hydrogen chloride in 
methanol and the yields for 2.24 and 2.44 were 45% and 57%, respectively. Finally, 
compound 2.24 was deprotected with hydrogen chloride in dioxane to give the 
dihydrochloride salt of 2.38 with a yield of 92% (Scheme 2.9). 
 
Scheme 2.9 Synthesis of N,N-dimethylglycine (R)-2-(di-n-propyl-amino)tetralin-5-yl ester 2HCl salt 
(2.44) and N-methylglycine (S)-2-(di-n-propyl-amino)tetralin-5-yl ester 2HCl salt (2.38). Reagents 
and conditions: a) EDC, N-tert-Boc-N-methylglycine (2.24) / N,N-dimethylglycine (2.44), HOBt 
hydrate, 0 °C-RT; b) 4N HCl in dioxane, RT. 
After the formation of the acid chloride of N,N,N-trimethylglycine with thionyl chloride at 
reflux temperature, the N,N,N-trimethylglycine (R)-5-OH-DPAT ester (2.46) was 
synthesized by nucleophilic substitution of the acid chloride with (R)-5-OH-DPAT 
(Scheme 2.10).39 
 
Scheme 2.10 Synthesis of N,N,N-trimethylglycine (R)-2-(di-n-propyl-amino)tetralin-5-yl ester 
Cl.HCl salt (2.46). Reagents and conditions: a) pyridine, CH2Cl2, 0 °C; b) SOCl2, 70 °C. 
The N-Boc-β-alanine (2.25), N-Boc-γ-aminobutyric acid (2.26) and N-Boc-5-aminovaleric 
acid (2.27) esters of 5-OH-DPAT were synthesized from the corresponding N-Boc 




reagent EDC and HOBt, of which the latter is added to catalyze the coupling reaction. The 
final compounds 2.39-2.41 were obtained as dihydrochloride salts after Boc-deprotection 
with hydrogen chloride in dioxane with yields between 85% and 89% (Scheme 2.11). 
 
Scheme 2.11 Synthesis of β-alanine (2.39), γ-aminobutyric acid (2.40), 5-aminovaleric acid (2.41) 5-
OH-DPAT esters as 2HCl salts. Reagents and conditions: a) EDC, N-tert-Boc-amino acid, HOBt 
hydrate, 0 °C-RT; b) 4N HCl in dioxane, RT. 
2.3 DISCUSSION 
The enantiomers of intermediate 2.9 were successfully resolved by fractional 
recrystallization with the corresponding enantiomers of di-p-toluoyltartaric acid. The oil 
precipitation instead of crystal formation that was observed during resolution with mandelic 
acid may have been caused by the presence of impurities which interfered with this 
particular recrystallization method. The synthesized enantiomerically pure enantiomers of 
2.12 were used in the follow-up synthesis of the amino acid ester prodrugs. In vivo data of 
(S)-2.12 are presented in Chapter 5. 
Initial use of the carbodiimide coupling reagent N,N'-dicyclohexylcarbodiimide (DCC) for 
the synthesis of the amino acid 5-OH-DPAT ester prodrugs gave fair yields, but the ureas 
which were generated during the reaction were difficult to remove. The side-product ureas 
of reaction with EDC were water soluble and easily removed from the organic layer by 
washing with water.40 EDC was used for all couplings and gave yields between 38% and 
90%. 
Unfortunately, in contrast to the serine analog 2.19, the N-tert-Boc-O-benzyl-L-threonine 
ester could not be debenzylated by catalytic hydrogenolysis and for this reason the 
synthesis of the L-threonine ester of 5-OH-DPAT was abandoned. N-Boc deprotection for 
the synthesis of amino acid ester prodrugs is typically carried out in a mixture of 
trifluoroacetic acid and dichloromethane.17, 23, 26, 27, 29  
Although the deprotection with trifluoroacetic acid was feasible, in our case the reaction 
with hydrogen chloride in dioxane and the resulting products as hydrochloride salts offered 
some advantages: 
 The product precipitated as an oil which indicated reaction progress. 
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 The precipitated product could be readily isolated from the solvent by decantation, 
thereby circumventing the needs for evaporation in vacuo which would lead to major 
hydrolysis.  
 The acidic environment protected the ester against hydrolysis.  
 Chloride atoms are necessary for the electrochemical process of iontophoresis at the 
anode. 
 Addition of extra sodium chloride in the iontophoretic donor compartment could be 
minimized and thus less sodium cations would be present to compete with the cationic 
drug molecules during iontophoretic transport.  
Deprotection with hydrogen chloride in methanol or tetrahydrofuran also gave good yields, 
but lacked the reaction progress indication and facile isolation, because the product did not 
precipitate. A disadvantage of the hydrochloride salt form of the prodrugs was 
hygroscopicity, which impeded easy handling and storage. Alternative salt forms were 
considered. It has been reported that different salt forms have different specific 
conductivities and that conductivity experiments will provide information concerning the 
general suitability of a drug for iontophoresis.41 Salt combinations with monocarboxylic 
acids are less soluble in water, while those of dicarboxylic acids confer water solubility if 
one carboxylic acid is left free.42 If stability is a problem, and the salt is hygroscopic it 
would seem more reasonable to select a less polar acid, e.g. carboxylic.43 Based on these 
arguments it would be interesting to convert the hygroscopic hydrochloride salts to 
dicarboxylic acid salts (e.g. maleate or fumarate) and determine the conductivities and 
aqueous solubility in future experiments. 
To form alternative salts, the hydrochloride salts should be converted to the free amine. The 
following conversion methods were performed with the glycine analog 2.28: 1) washing a 
solution of the prodrug in an organic solvent with an aqueous basic solution; 2) reaction of 
the prodrug with solid inorganic base (NaHCO3, Na2CO3) in dry organic solvent; 3) 
reaction of the prodrug with 1 equivalent of triethylamine to precipitate the triethylamine 
hydrochloride salt from the solution. None of these methods prevented the hydrolysis of the 
glycine prodrug during conversion to the free amine or during the evaporation of the 
prodrug solution. Interestingly, in contrast to the other synthesized 5-OH-DPAT esters, the 
N,N-dimethylglycine prodrug 2.44 (free amine) and the N,N,N-trimethylglycine prodrug 
2.46 (chloride salt) could be purified by column chromatography without occurrence of 
hydrolysis. Prodrug 2.44 which appeared to be stable in its free amine form could be a 
candidate for an alternative salt form. Nevertheless, the suitability of 2.44 for iontophoresis 
should first be examined in chemical stability studies. 
Conformational isomers were observed for the N-Boc-N-methylglycine compounds in both 
proton and carbon NMR spectra. This may be explained by different isomers of the amide 




we also found chemical shifts for two conformational isomers, which may also be 
explained by isomerism of the amide bond. 
Table 2.1 Overall yields and purities (HPLC) of the synthesis of 5-OH-DPAT (2.12) from 1,6-
dihydroxynaphthalene, and the synthesis of prodrugs 2.28-2.41, 2.43, 2.44 and 2.46 from 5-OH-
DPAT. 
Compound Prodrug Moiety Yield (%) Purity (%) 
(S)-2.12 - 11 100a 
(R)-2.12 - 6 99a 
2.28 Glycine 50 98 
2.29 L-Alanine 47 100 
2.30 1-Aminocyclopropane-1-carboxylic acid 40 100 
2.31 L-Valine 60 96 
2.32 D-Valine 19 100 
2.33 L-Isoleucine 69 100 
2.34 L-Serine 5 98 
2.35 L-Phenylalanine 52 100 
2.36 L-Lysine 6 99 
2.43 L-Arginine 47 99 
2.37 L-Proline 42 100 
2.38 N-Methylglycine 41 98 
2.44 N,N-Dimethylglycine 57 100 
2.46 N,N,N-Trimethylglycine 74 100 
2.39 β-Alanine 77 99 
2.40 γ-Aminobutyric acid 59 >95 
2.41 5-Aminovaleric acid 32 96 
a Purity determined on gas chromatography–mass spectrometry (GCMS)  
The influence on iontophoretic flux of additional charges could be negative or positive, 
which depends on the interaction of the molecules with charged sites in the stratum 
corneum, the hydrated molecular volume of the ions and the charge/molecular weight 
ratio.45-47 The novelty of this series of prodrugs is that they contain at least two chargeable 
amino groups which may lead to increased iontophoretic transport. Additionally, prodrugs 
2.28-2.33, 2.35 and 2.37 contain sterically hindered groups which could increase stability 
against chemical and enzymatic hydrolysis. Prodrugs 2.34, 2.36 and 2.43 have polar side 
chain groups, i.e. alcohol and amino groups, which may increase aqueous solubility. In 
addition, prodrugs 2.36 and 2.43 could change iontophoretic flux by introduction of a third 
chargeable group in the molecule. Compounds 2.37, 2.38, 2.44 and 2.46 vary in degree of 
alkylation of the α-amino group, and therefore also vary in degree of protonation. Prodrug 
2.46 is even permanently protonated and is independent to pH changes in the skin during 
transport, as long as the prodrug remains intact. Prodrugs 2.39-2.41 differ in the number of 
methylene groups between the amino and carboxylic acid functional group. 
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In conclusion, amino acid ester prodrugs of 5-OH-DPAT were synthesized (Table 2.1) with 
structural differences in order to control chemical and enzymatic stability, increase aqueous 
solubility and improve iontophoretic transport. The chemical and enzymatic stability should 
be determined in order to select candidates for in vitro and in vivo experiments. 
2.4. EXPERIMENTAL 
2.4.1 General 
Thin-layer chromatography (TLC) was performed on aluminium sheets of silica gel 60 F254 or 
aluminium oxide F254 neutral, the spots were observed under ultraviolet light (254 nm) or visualized 
with I2 vapour or KMnO4 solution. The chemical purity of the final compounds 2.29, 2.35, 2.37, 2.38, 
2.40, 2.43 and 2.44 were analyzed isocratically on HPLC system (A), which consisted of an ISCO 
Model 2360 Gradient Programmer, a Waters 510 HPLC Pump, a Waters 486 Tunable Absorbance 
Detector and a HP 3396 Series II Integrator. Prodrugs 2.28, 2.30, 2.31, 2.32, 2.33, 2.34, 2.36, 2.39, 
2.41 and 2.46 were analyzed isocratically on a Hewlett Packard Series 1100 HPLC system (B) 
connected to a Tray-Cooling Marathon Basic+ Autosampler and a Hewlett Packard HP3395 
Integrator. All samples were injected onto a Supelco Discovery C18 reversed-phase column (5 μm, 
250 x 4.6 mm I.D.). The mobile phase consisted of a mixture of 23% acetonitrile and 77% water with 
0.1% trifluoroacetic acid added. The flow rate was set at 1.0 mL/min and the analysis was performed 
at room temperature. The compounds were detected by UV at λ =217 nm. The e.e. of compound (S)-
2.9 was determined with HPLC system A at λ =254 nm on a Chiralpak AD column (250 x 10 mm) 
with an eluent mixture of 96% hexane and 4% isopropanol with 0.1% triethylamine added and at a 
flow rate of 4.0 ml/min. The e.e. of compounds (S)-2.12 and (R)-2.12 was determined with HPLC 
system A at λ =275 nm on a Chiralcel OD column (250 x 10 mm) with an eluent mixture of 98.4% 
hexane and 1.6% isopropanol with 0.1% triethylamine added and at a flow rate of 4.0 ml/min. IR 
spectra were obtained on a ATI Mattson Genesis series FTIR™. Optical rotations were determined on 
a Perkin-Elmer polarimeter 241 (Na, 589 nm). Chromatography was performed using MP Ecochrom 
silica gel 32-63, 60 Å. Electron ionization (EI) mass spectra were obtained on a Shimadzu GCMS-
QP5000 fitted with a CP-Sil 5 CB Lowbleed/MS column (15 m, 0.25mm, filmthickness 0.10μm). 
Electrospray ionization (ESI) mass spectra were recorded by the Mass Spectrometry Core Facility 
unit of the University of Groningen on a SCIEX API3000 triple quadrupole mass spectrometer 
(Applied Biosystems/MDS SCIEX) equipped with a Turbo Ion Spray interface and operated in the 
positive ion mode. High-resolution mass spectrometry (HR-MS) was performed by the mass 
spectrometry unit of the University of Groningen using a flow injection method on a LTQ-Orbitrap 
XL mass spectrometer (Thermo Electron, Bremen, Germany) operating in positive ion mode with a 
resolution of 60000 at m/z 400. 1H NMR spectra were recorded on a Varian Gemini 200 (at 200 
MHz), a Varian VXR 300 (at 300 MHz) and a Varian Mercuri Plus 400 (at 400 MHz) spectrometer. 
13C NMR spectra were recorded at 50.3 MHz on a Varian Gemini 200 spectrometer. The chemical 
shifts are reported as part per million (δ). The splitting patterns are designated as follows: s (singlet), 
br s (broad singlet), d (doublet), dd (double doublet), br d (broad doublet), t (triplet), q (quartet), m 
(multiplet). The coupling constants (J) are reported in hertz (Hz). In case of two isomers, the chemical 
shift of only one of the isomers was notated in the list of chemical shifts. Elemental analysis was 




elemental analyzer (Eurovector) for C,H,N, on a CHN-O-Rapid (Heraeus) for O, and Cl was 
determined potentiometrically with the use of a 665 Dosimat and a 713 pH meter. The measured 
values were within 0.4% of the theoretical values, except where noted. All reagents were 
commercially available from Sigma Aldrich and Acros Organics and were used without purification. 
CH2Cl2 was dried by Al2O3/molecular sieves 4Å, Et2O was dried with Na wire, and MeOH was 
distilled from Mg/I2 and dried over molecular sieves 3Å. 
2.4.2 General procedure for the protection of amino acids 2.1-2.5 
Di-tert-butyl-dicarbonate (38.5 mmol) was added to a suspension of the amino acid (35.0 mmol) and 
NaHCO3 (175 mmol) in 85 mL H2O/THF (1:1). The reaction mixture was stirred overnight. The 
organic solvent was removed under reduced pressure and the remaining suspension was acidified with 
4N HCl (aq, 40 mL) while cooled in ice. The aqueous mixture was extracted with EtOAc (2x150 mL) 
and the combined organic layers were washed with brine, dried on MgSO4 and evaporated in vacuo. 
After recrystallization from EtOAc/Hexane, the Boc-protected amino acid was obtained as white 
needles. 
N-tert-Boc-L-alanine (2.1). Yield: 35%; IR (KBr, cm-1) νmax 3383, 2987, 1739, 1691; 1H NMR (200 
MHz, CD3OD): δ 4.10 (q, J=7 Hz, 1H, CH), 1.43 (s, 9H, OC(CH3)3), 1.34 (d, 
J=7.4 hz, 3H, CH3); 13C NMR (50 MHz, CD3OD): δ 175.6, 79.2, 49.2, 27.5, 
16.7. 
N-tert-Boc-L-proline (2.2). Yield: 77%; IR (KBr, cm-1) νmax 2967, 1739. 
 
N-tert-Boc-N-methylglycine (2.3). Yield: 67%; IR (KBr, cm-1) νmax 2976, 1693; 1H NMR (200 MHz, 
CDCl3) of rotamer A δ 4.00 (s, 2H, CH2), 2.91 (s, 3H, CH3), 1.44 (s, 9H, 
OC(CH3)3), rotamer B δ 3.91 (s, 2H, CH2), 2.91 (s, 3H, CH3), 1.40 (s, 9H, 
OC(CH3)3); 13C NMR (50 MHz, CDCl3) of rotamer A δ 175.3, 156.6, 80.9, 
50.9, 35.8, 28.5, rotamer B δ 175.3, 155.8, 80.9, 50.3, 35.7, 28.4. 
N-tert-Boc-γ-aminobutyric acid (2.4). Yield: 75%; IR (NaCl, cm-1) νmax 3344 (br), 2977, 1712, 
1527. 
 
N-tert-Boc-5-aminovaleric acid (2.5). Yield: 70%; IR (KBr, cm-1) νmax 3373, 2984, 1713, 1685, 
1523; 1H NMR (200 MHz, CD3OD): δ 3.04 (t, J=6.6 Hz, 2H, δ-CH2), 
2.30 (t, J=7.1 Hz, 2H, α-CH2), 1.73-1.38 (m, 4H, β-CH2, γ-CH2), 1.43 (s, 
9H, OC(CH3)3); 13C NMR (50 MHz, CD3OD): δ 176.2, 135.7, 78.7, 
39.8, 33.3, 29.3, 27.6, 22.1. 
2.4.3 Nα, Nδ, Nω-tri-benzyloxycarbonyl-L-arginine (2.6).38 Suspend L-arginine (5.0 g, 28.7 mmol) 
in a mixture of dry 1,2-dichloroethane (50 mL) and DIPEA (38 mL, 229 mmol) under nitrogen 
atmosphere. Slowly TMS-Cl (29 mL, 227 mmol) was added and the reaction mixture was heated at 
45 °C for 2 hours. The mixture was cooled down to 5 °C and another portion of DIPEA (19 mL, 115 
mmol) was added. Benzylchloroformate (16 mL, 113 mmol) was added to the ice-cooled suspension 
and the mixture was allowed to attain room temperature. After addition of another portion of 1,2-
dichloroethane (50 mL) the reaction mixture was stirred for 1 hour. 1N HCl (aq, 34 mL) was added, 
the reaction mixture was partitioned between H2O (50 mL) and CH2Cl2 (50 mL), and extracted with 
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CH2Cl2 (2x100 mL). The combined organic layers were 
evaporated in vacuo and the orange oil was purified by 
column chromatography (SiO2, CH2Cl2/MeOH) and 
recrystallized from MeOH/H2O (4:1) to yield 2.6 as white 
crystals (6.0 g, 36%). IR (KBr, cm-1) νmax 3384, 1721, 1688; 
1H NMR (200 MHz, CDCl3): δ 7.47-7.21 (m, 15H, 
CH2C6H5), 5.76 (br d, J=7.9 Hz, 1H, NH), 5.20 (s, 2H, 
OCH2C6H5), 5.09 (s, 2H, OCH2C6H5), 5.05 (s, 2H, 
OCH2C6H5), 4.43-4.25 (m, 1H, α-CH), 4.06-3.83 (m, 2H, δ-
CH2), 1.90-1.42 (m, 4H, β-CH2, γ-CH2); 13C NMR (50 MHz, 
CDCl3): δ 176.0, 163.8, 160.7, 156.6, 156.0, 137.0, 136.4, 134.8, 129.1, 129.0, 128.7, 128.6, 128.5, 
128.4, 128.3, 128.1, 69.2, 67.3, 67.2, 54.0, 44.4, 29.0, 25.0; ESI-MS m/z 577.2 (M+H)+. 
2.4.4 Synthesis of (S)– and (R)-5-hydroxy-2-(di-n-propyl-amino)tetralin 
1,6-dimethoxynaphthalene (2.7).35 1,6-dihydroxynaphthalene (150 g, 0.94 mol) was dissolved in 2N 
NaOH (800 mL) and dimethyl sulphate (250 mL, 2.6 mol) was added while stirring 
vigorously. The temperature of the reaction mixture increased to 62 oC and the 
solution became acidic (pH 2). A second portion of 2N NaOH (500 mL) and 
dimethyl sulphate (50 mL, 0.52 mol) was added respectively and the warm solution 
was stirred vigorously for 1 hour. 4N NaOH (100 mL) was added and the reaction 
mixture was refluxed for 4 hours. After attaining r.t. the H2O layer was extracted with CH2Cl2 (3 x 
250 mL), washed with 2N NaOH (3 x 350 mL) and brine (400 mL), and dried on Na2SO4. After 
filtration and evaporation in vacuo the obtained brown oil was purified by column chromatography 
(Al2O3, CH2Cl2) resulting in compound 2.1 as a light yellow oil which solidified on standing (146 g, 
83%). Purity: 100% (GCMS); IR (KBr, cm-1) νmax 2965, 1627, 1581, 1450, 1370, 1222; 1H NMR 
(200 MHz, CDCl3 ): δ 8.26-8.10 (m, 1H, ArH), 7.42-7.28 (m, 2H, ArH), 7.18-7.05 (m, 2H, ArH, 
6.78-6.63 (m, 1H, ArH),  3.99 (s, 3H, OCH3), 3.93 (s, 3H, OCH3); 13C NMR (50 MHz, CDCl3): δ 
158.4, 155.9, 136.2, 126.9, 124.0, 121.0, 119.5, 117.8, 106.0, 102.3, 55.7, 55.5; EI-MS m/z 188 (M)+. 
5-methoxy-2-tetralone (2.8).35 A solution of 1,6-dimethoxynaphthalene (63.77 g, 0.339 mol) in 
absolute EtOH (585 mL) was heated to reflux. Sodium (40.2 g, 1.75 mol) cut in 
small pieces was added to the nitrogen-flushed reaction mixture as rapidly as 
possible. Another portion of absolute EtOH (160 mL) was added and the reaction 
mixture was refluxed for 1.5 hours until all sodium had reacted. After cooling down 
in ice the mixture was acidified with aqueous 1N HCl (850 mL) and subsequently 
with aqueous 4N HCl (570 mL) to pH 2.5 and the colour changed from white to yellow. After 
refluxing for 1 hour, yellow oil precipitated, was collected separately from the reaction mixture. The 
EtOH was evaporated in vacuo from the H2O/EtOH layer, until mostly H2O was left. The H2O layer 
was extracted with Et2O (3 x 500 mL). The separately collected yellow oil was added to the 
extractions and the Et2O layer was washed with brine, dried on Na2SO4, filtrated and evaporated in 
vacuo to afford the crude product as an orange oil (59 g). The oil was purified by vacuum distillation 
to yield compound 2.2 as a light yellow oil which solidified on standing (53 g, 89%). Bp 94-98 oC 
(0.13 mbar); Purity: 98% (GCMS); IR (NaCl, cm-1) νmax 2937, 1717, 1587; 1H NMR (200 MHz, 
CDCl3): δ 7,19 (m, 1H, ArH), 6,76 (m, 2H, ArH), 3,86 (s, 3H, OCH3), 3,57 (s, 2H, ArCH2CO), 3.09 
(t, J = 7 Hz, 2H, ArCH2), 2.53 (t, J = 7 Hz, 2H, CH2CO ); 13C NMR (50 MHz, CDCl3): δ 209.4, 
154.7, 133.5, 126.0, 123.5, 118.9, 106.9, 53.9, 43.2, 36.4, 19.4; EI-MS m/z 176 (M)+. 
(±)-2-(benzylamino)-5-methoxytetralin HCl-salt ((±)-2.9).2 Benzylamine (94 mL, 0.86 mol) and p-
toluenesulfonic acid monohydrate (4 g, 0.02 mol) were added to a solution of 
5-methoxy-2-tetralone (120 g, 0.68 mol) in toluene (500 mL) under nitrogen 
atmosphere. The reaction mixture was refluxed for 2 hours with continuous 
removal of water via a Dean-Stark water trap. After completion of the 
reaction, the solvent was evaporated in vacuo, absolute EtOH (150 mL) was 
added and the solution was transferred to a Parr flask. After addition of PtO2 




suspension was filtrated, evaporated in vacuo and the crude product was obtained as a brown oil (183 
g). The free amine was converted to the HCl salt and recrystallized from MeOH/EtOAc which yielded 
compound 2.3 as pink crystals (116 g, 56%). Purity: 97.8%; IR (KBr, cm-1) νmax 2932, 2768, 2640, 
1585; 1H NMR (200 MHz, d6-DMSO): δ 9.78 (br s, 1H, NH), 7.78-7.60 (m, 2H, ArH), 7.49-7.31 (m, 
3H, ArH), 7.10 (t, J=7.93 Hz, 1H, ArH), 6.76 Hz (d, J=7.93 Hz, 1H, ArH), 6.69 (d, J=7.34 Hz, 1H, 
ArH), 4.23 (s, 2H, CH2C6H5), 3.73 (s, 3H, OCH3), 3.48-3.02 (m, 3H, H1ax, H1eq, H2ax), 2.96-2.76 (m, 
1H, H4eq), 2.55-2.30 (m, 2H, H3eq, H4ax), 1.99-1.71 (m, 1H, H3ax); 13C NMR (50 MHz, d6-DMSO): δ 
157.4, 134.6, 133.0, 130.9, 129.4, 129.2, 127.4, 124.0, 121.7, 108.5, 55.9, 53.7, 47.9, 31.9, 25.3, 22.3; 
EI-MS m/z 267 (M)+. 
(S)-2-(benzylamino)-5-methoxytetralin HCl-salt ((S)-2.9).36 (-)-Di-p-toluoyl-L-tartaric acid (131.0 
g, 0.34 mol) and racemic 2-(benzylamino)-5-methoxytetralin (90.6 g, 0.34 
mol) were added together and were recrystallized 3 times from 96% EtOH 
(7.9 L, 5.8 L, 4.8 L). The tartrate-salt was converted to HCl-salt and 
recrystallized from MeOH-Et2O and yielded (S)-2.3 as white solid crystals 
(25.9 g, 25%). Purity: 100% (GCMS);     MeOH0.27, c 64.0α 21D  ; 
e.e.>98% (HPLC); 1H NMR (200 MHz, DMSO): δ 7.70-7.55 (m, 2H, ArH), 
7.46-7.29 (m, 3H, ArH), 7.10 (t, J=7.94 Hz, 1H, ArH), 6.75 Hz (d, J=7.93 Hz, 1H, ArH), 6.69 (d, 
J=7.64 Hz, 1H, ArH), 4.18 (s, 2H, CH2C6H5), 3.73 (s, 3H, OCH3), 3.34-2.97 (m, 3H, H1ax, H1eq, H2ax), 
2.96-2.73 (m, 1H, H4eq), 2.58-2.26 (m, 2H, H3eq, H4ax), 1.95-1.67 (m, 1H, H3ax); 13C NMR (50 MHz, 
DMSO): δ 157.4, 134.9, 133.8, 130.7, 129.2, 127.4, 124.1, 121.7, 108.4, 55.9, 53.6, 48.1, 32.3, 25.7, 
22.3; EI-MS m/z 267 (M)+. 
(R)-2-(benzylamino)-5-methoxytetralin HCl-salt ((R)-2.9).36 The motherliquors of the 
recrystallizations of compound (S)-2.3 were collected, evaporated in vacuo 
and converted to the free amine. (+)-Di-p-toluoyl-D-tartaric acid (80.4 g, 0.21 
mol) was added to the resultant oil (55.7 g, 0.21 mol) and the mixture was 
recrystallized 3 times from 96% EtOH (4.9 L, 4.5 L, 3.9 L). The tartrate-salt 
was converted to HCl-salt and recrystallized from MeOH-Et2O and yielded 
(R)-2.3 as white solid crystals (23.7 g, 23%). 
(S)-2-amino-5-methoxytetralin ((S)-2.10).36 The HCl-salt of (S)-2.9 was converted to the free amine 
(21.8 g, 0.08 mol), dissolved in EtOH 100% (300 mL) and Pd/C 10% (15 g) was 
added under nitrogen atmosphere. The solution was transferred to a Parr flask and 
hydrogenolyzed at 40 °C under 3.5 bar H2 atmosphere. After completion of the 
reaction the mixture was filtrated and evaporated in vacuo to yield the free amine of 
(S)-2.10 as an oil (14.0 g, 94%). IR (KBr, cm-1) νmax 2953, 2629, 1587. 
(R)-2-amino-5-methoxytetralin ((R)-2.10).36 Similar to the procedure described for the synthesis of 
(S)-2.10. Compound (R)-2.10 was obtained as an oil (10.8 g, 80%). 
 
 (S)-5-methoxy-2-(N,N-di-n-propylamino)-tetralin ((S)-2.11).2 A solution of 1-iodopropane (30 
mL, 0.31 mol) and (S)-2.10 (13.9 g, 0.079 mol) in acetonitrile (200 mL) was 
refluxed with 100 mL of K2CO3 (aq, sat) for 2.5 hours. After separation of the 
organic layer, evaporation in vacuo and purification on column chromatography 
(SiO2, EtOAc/Hexane=1:4) compound (S)-2.11 was yielded as a yellow oil (13.2 g, 
64%). Purity: 100% (GCMS); 1H NMR (300 MHz, CDCl3): δ 7.10 (t, J=7.9 Hz, 1H, 
ArH), 6.73 (d, J=7.6 Hz, 1H, ArH), 6.66 (d, J=7.9 Hz, 1H, ArH), 3.82 (s, 3H, 
OCH3), 3.11-2.64 (m, 4H, H1ax, H1eq, H2ax, H4eq), 2.63-2.40 (m, 5H, H4ax, N(CH2CH2CH3)2), 2.16-2.00 
(m, 1H, H3eq), 1.70-1.39 (m,  5H, H3ax, N(CH2CH2CH3)2), 0.91 (t, J=7.3 Hz, 6H, N(CH2CH2CH3)2); 
13C NMR (50 MHz, CDCl3): δ 157.4, 138.5, 126.3, 125.6, 121.9, 107.0, 56.7, 55.4, 52.9, 32.5, 25.9, 
24.2, 22.4, 12.2; EI-MS m/z 261 (M)+. 
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(R)-5-methoxy-2-(N,N-di-n-propylamino)-tetralin ((R)-2.11).2 Similar to the procedure described 
for the synthesis of (S)-2.11. Compound (R)-2.11 was obtained as a yellow oil (8.6 
g, 54%). Purity: 100% (GCMS); IR (NaCl, cm-1) νmax 2953, 1585, 1468, 1259, 
1095; 1H NMR (200 MHz, CDCl3): δ 7.12 (t, J=7.9 Hz, 1H, ArH), 6.76 (d, J=7.6 
Hz, 1H, ArH), 6.68 (d, J=8.2 Hz, 1H, ArH), 3.84 (s, 3H, OCH3), 3.14-2.73 (m, 4H, 
H1ax, H1eq, H2ax, H4eq), 2.71-2.40 (m, 5H, H4ax, N(CH2CH2CH3)2), 2.18-2.02 (m, 1H, 
H3eq), 1.72-1.49 (m,  1H, H3ax), 1.48-1.39 (m, 4H, N(CH2CH2CH3)2), 0.94 (t, J=7.4 
Hz, 6H, N(CH2CH2CH3)2); 13C NMR (50 MHz, CDCl3): δ 157.5, 138.5, 126.3, 125.6, 121.9, 107.0, 
56.7, 55.4, 52.9, 32.5, 25.9, 24.2, 22.5, 12.2; EI-MS m/z 261 (M)+. 
(S)-5-hydroxy-2-(N,N-di-n-propyl-amino)tetralin HBr-salt((S)-2.12).1 A mixture of freshly 
distilled 48% HBr (40 mL) and (S)-2.11 (13.2 g, 0.05 mol) was refluxed for 1.5 
hours under nitrogen atmosphere. After cooling down, the reaction mixture was 
evaporated in vacuo and the resultant pink solid material was recrystallized from 
100% EtOH to afford (S)-2.12 as white crystals (14.5 g, 87%). Purity: 100% 
(GCMS);    MeOH ,00.1 c 7.6623D  ; e.e.=100% (HPLC); IR (KBr, cm-1) νmax 
3243, 2931, 2690,2639, 2515, 1590,1465. 1276; 1H NMR (200 MHz, CD3OD): δ 
6.96 (t, J=7.8 Hz, 1H, ArH), 6.64 (d, J=7.6 Hz, 1H, ArH), 6.63 (d, J=8.2 Hz, 1H, ArH), 3.78-3.55 (m, 
1H, H2ax), 3.40-2.94 (m, 7H, H1ax, H1eq, N(CH2CH2CH3)2, H4eq), 2.78-2.49 (m, 1H, H4ax), 2.44-2.26 
(m, 1H, H3eq), 2.02-1.69 (m, 5H, H3ax, N(CH2CH2CH3)2), 1.05 (t, J=7.3 Hz, 6H, N(CH2CH2CH3)2); 
13C NMR (50 MHz, CD3OD): δ 154.9, 133.7, 126.8, 121.9, 120.1, 112.3, 60.6, 52.5, 29.6, 23.7, 22.5, 
18.7, 10.2; ESI-MS m/z 248.1 (M+H)+. 
(R)-5-hydroxy-2-(N,N-di-n-propyl-amino)tetralin HBr-salt ((R)-2.12).1 A mixture of freshly 
distilled 48% HBr (25 mL) and (R)-2.11 (8.6 g, 0.03 mol) was refluxed for 4 hours 
under nitrogen atmosphere. After cooling down, the reaction mixture was 
evaporated in vacuo and the resultant pink solid material was recrystallized from 
100% EtOH to afford (R)-2.12 as white crystals (7.4 g, 69%). Purity: 99% 
(GCMS);    MeOHcD  ,00.1  3.6520  ; e.e.>99% (HPLC); IR (KBr, cm-1) νmax 
3243, 2933, 2690, 2652,1590, 1465, 1277; 1H NMR (200 MHz, CD3OD): δ 6.96 (t, 
J=7.8 Hz, 1H, ArH), 6.64 (d, J=7.6 Hz, 1H, ArH), 6.63 (d, J=7.9 Hz, 1H, ArH), 3.83-3.58 (m, 1H, 
H2ax), 3.39-2.97 (m, 7H, H1ax, H1eq, N(CH2CH2CH3)2, H4eq), 2.75-2.52 (m, 1H, H4ax), 2.44-2.27 (m, 
1H, H3eq), 2.01-1.68 (m, 5H, H3ax, N(CH2CH2CH3)2), 1.05 (t, J=7.2 Hz, 6H, N(CH2CH2CH3)2); 13C 
NMR (50 MHz, CD3OD): δ 154.9, 133.7, 126.8, 121.9, 120.1, 112.3, 60.6, 52.5, 29.6, 23.7, 22.5, 
18.7, 10.2; EI-MS m/z 247 (M)+. 
(S)-5-hydroxy-2-(N,N,N-tri-n-propyl-ammonium)tetralin iodide salt ((S)-2.47). A solution of 1-
iodopropane (81 mL, 0.83 mol) and (S)-2.10 (18.4 g, 0.10 mol) in acetonitrile 
(450 mL) was refluxed with 150 mL of K2CO3 (aq, sat) overnight. After 
separation of the organic layer, evaporation in vacuo and purification on column 
chromatography (SiO2, CH2Cl2) the iodide salt of compound (S)-2.47 was 
yielded as a white solid (8 g, 19%).  1H NMR (300 MHz, CDCl3): δ 7.12 (t, 
J=7.9 Hz, 1H, ArH), 6.80 (d, J=7.6 Hz, 1H, ArH), 6.68 (d, J=8.2 Hz, 1H, ArH), 
3.81 (s, 3H, OCH3), 3.82-3.64 (m, 1H, H2), 3.63-3.37 (m, 6H, (CH2CH2CH3)3), 3.36-3.02 (m, 3H, H1, 
H4), 2.77-2.50 (m, 2H, H3, H4), 2.03-1.67 (m, 7H, H3, N(CH2CH2CH3)3), 1.08 (t, J=7.6 Hz, 6H, CH3); 
13C NMR (50 MHz, CDCl3): δ 157.3, 133.2, 127.6, 123.3, 121.6, 108.3, 69.5, 61.0, 55.6, 30.9, 24.6, 
24.2, 17.8, 11.6. 
2.4.5 General procedure for preparation of protected amino acid (S)-2-(N,N-di-n-propyl-
amino)tetralin-5-yl esters 2.13-2.18 and 2.20-2.26, N-tert-Boc-O-benzyl-L-serine (R)-2-(N,N-di-
n-propyl-amino)tetralin-5-yl ester (2.19) and N-tert-Boc-5-aminovaleric acid (R)-2-(N,N-di-n-
propyl-amino)tetralin-5-yl ester (2.27). 
The protected amino acid (0.88 mmol) and HOBt hydrate (0.96 mmol) were suspended in 5 mL 




the reaction mixture was stirred for 15 minutes. After all solid material dissolved, the free amine of 5-
OH-DPAT (0.80 mmol) in 1 mL anhydrous CH2Cl2 was slowly added to the yellow suspension. The 
solution was allowed to attain room temperature and was stirred for 2 hours until the reaction was 
complete. CH2Cl2 (100 mL) was added and the reaction mixture was washed with aqueous 0.1 N HCl 
(10 mL), 1.0 N NaOH (20 mL) and brine (10 mL). The organic layer was dried over MgSO4 and 
evaporated in vacuo; the resultant yellow oil was purified by column chromatography (CH2Cl2/MeOH 
= 20:1) to afford the pure compounds 2.13-2.27 as colourless oils. 
N-tert-Boc-glycine (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester (2.13). Yield: 59%; IR (KBr, 
cm-1) νmax 3381 (br), 2957, 1773, 1716, 1514; 1H NMR (200 MHz, 
CDCl3): δ 7.12 (t, J=7.6 Hz, 1H, ArH), 6.99 (d, J=7.3 Hz, 1H, ArH), 6.84 
(d, J=7.3 Hz, 1H, ArH), 5.09 (br s, 1H, NH), 4.17 (d, J=5.6 Hz, 2H, α-
CH2), 3.06-2.63 (m, 4H, H1ax, H1eq, H2ax, H4eq), 2.61-2.24 (m, 5H, H4ax, 
N(CH2CH2CH3)2), 2.13-1.94 (m, 1H, H3eq), 1.68-1.28 (m, 5H, H3ax, 
N(CH2CH2CH3)2), 1.47 (s, 9H, OC(CH3)3), 0.88 (t, J=7.4 Hz, 6H, CH3); 
13C NMR (50 MHz, CDCl3): δ 167.1, 154.1, 147.0, 137.7, 127.3, 126.0, 
124.8, 117.2, 78.7, 54.7, 51.1, 40.9, 30.6, 26.8, 23.6, 22.5, 20.5, 10.4; HR-MS m/z Calcd. for 
C23H37N2O4 405.2747 (M+1)+, found 405.2767 (M+1)+. 
N-tert-Boc-L-alanine (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester (2.14). Yield: 56%; IR 
(KBr, cm-1) νmax 3357, 2975, 1746, 1706, 1525; 1H NMR (200 MHz, 
CDCl3): δ 7.12 (t, J=8 Hz, 1H, ArH), 6.99 (d, J=7 Hz, 1H, ArH), 6.83 
(d, J=8 Hz, 1H, ArH), 5.10 (br d, J=7.1 Hz, 1H, NH), 4.69-4.36 (m, 
1H, α-CH), 3.04-2.61 (m, 4H, H1ax, H1eq, H2ax, H4eq), 2.60-2.27 (m, 5H, 
H4ax, N(CH2CH2CH3)2), 2.11-1.90 (m, 1H, H3eq), 1.83-1.32 (m, 5H, 
H3ax, N(CH2CH2CH3)2), 1.56 (d, J=7.3 Hz, 3H, β-CH3), 1.46 (s, 9H, 
OC(CH3)3), 0.88 (t, J=7.4 Hz, 6H, CH3); 13C NMR (50 MHz, CDCl3): δ 170.2, 153.5, 147.0, 137.6, 127.3, 126.0, 124.8, 117.2, 78.5, 54.6, 
51.1, 47.9, 30.7, 26.8, 23.6, 22.5, 20.6, 17.2, 10.4; HR-MS m/z Calcd. for C24H39N2O4 419.2904 
(M+1)+, found 419.2913 (M+1)+.  
N-tert-Boc-1-aminocyclopropane-1-carboxylic acid (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl 
ester (2.15). Yield: 49%; IR (NaCl, cm-1) νmax 3377 (br), 2957, 1746, 
1729, 1713, 1503, 1461, 1366, 1247, 1169, 1140; 1H NMR (300 MHz, 
CDCl3): δ 7.10 (t, J=7.9 Hz, 1H, ArH), 6.97 (d, J=7.3 Hz, 1H, ArH), 
6.82 (d, J=7.7 Hz, 1H, ArH), 5.12 (br s, 1H, NH), 3.03-2.67 (m, 4H, 
H1ax, H1eq, H2ax, H4eq), 2.61-2.39 (m, 1H, H4ax), 2.47 (t, J=7.5 Hz, 4H, 
N(CH2CH2CH3)2), 2.10-1.94 (m, 1H, H3eq), 1.76-1.64 (m, 2H, β-CH2), 
1.46 (s, 9H, OC(CH3)3), 1.63-1.37 (m, 5H, H3ax, N(CH2CH2CH3)2), 1.36-
1.20 (m, 2H, β-CH2), 0.88 (t, J=7.3 Hz, 6H, CH3); 13C NMR (50 MHz, CDCl3): δ 171.8, 156.1, 149.1, 
139.1, 129.1, 127.5, 126.5, 119.1, 56.5, 52.8, 32.3, 28.5, 25.3, 24.2, 22.1, 18.6, 12.1; HR-MS m/z 
Calcd. for C25H39N2O4 431.29043 (M+H)+, found 431.28940 (M+H)+. 
N-tert-Boc-L-valine (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester (2.16). Yield: 66%; IR (KBr, 
cm-1) νmax 3363, 2956, 1738, 1706, 1521; 1H NMR (200 MHz, CDCl3): δ 
7.11 (t, J=8 Hz, 1H, ArH), 6.99 (d, J=7 Hz, 1H, ArH), 6.82 (d, J=8 Hz, 
1H, ArH), 5.06 (br d, J=9.1 Hz, 1H, NH), 4.47 (dd, J=9 Hz, 4 Hz, 1H, α-
CH), 3.04-2.62 (m, 4H, H1ax, H1eq, H2ax, H4eq), 2.61-2.20 (m, 6H, H4ax, 
N(CH2CH2CH3)2, β-CH), 2.10-1.93 (m, 1H, H3eq), 1.68-1.31 (m,  5H, 
H3ax, N(CH2CH2CH3)2), 1.47 (s, 9H, OC(CH3)3), 1.09 (d, J=6.8 Hz, 3H, γ-CH3), 1.02 (d, J=7.0 Hz, 3H, γ-CH3), 0.88 (t, J=7 Hz, 6H, CH3); 13C 
NMR (50 MHz, CDCl3): δ 169.3, 154.2, 147.1, 137.7, 127.3, 125.9, 
124.7, 117.3, 78.4, 57.2, 54.6, 51.1, 30.7, 29.7, 26.8, 23.6, 22.7, 20.6, 17.9, 16.0, 10.4; HR-MS m/z 
Calcd. for C26H43N2O4 447.3217 (M+1)+, found 447.3197 (M+1)+. 
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N-tert-Boc-D-valine (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester (2.17). Yield: 60%; IR 
(NaCl, cm-1) νmax 3365 (br), 2959, 1759, 1715, 1499; 1H NMR (200 
MHz, CDCl3): δ 7.12 (t, J=7.8 Hz, 1H, ArH), 6.99 (d, J=7.3 Hz, 1H, 
ArH), 6.81 (d, J=7.4 Hz, 1H, ArH), 5.06 (br d, J=9.1 Hz, 1H, NH), 
4.46 (dd, J=9.4 Hz, 4.7 Hz, 1H, α-CH), 3.05-2.63 (m, 4H, H1ax, H1eq, 
H2ax, H4eq), 2.62-2.18 (m, 6H, H4ax, N(CH2CH2CH3)2, β-CH), 2.13-
1.90 (m, 1H, H3eq), 1.70-1.30 (m, 5H, H3ax, N(CH2CH2CH3)2), 1.47 (s, 
9H, OC(CH3)3), 1.09 (d, J=6.8 Hz, 3H, γ-CH3), 1.02 (d, J=7.1 Hz, 3H, γ-CH3), 0.88 (t, J=7.3 Hz, 6H, CH3); 13C NMR (50 MHz, CDCl3): δ 171.2, 156.0, 148.9, 139.1, 129.1, 
127.7, 126.5, 119.0, 80.2, 58.9, 56.5, 52.8, 32.2, 31.5, 28.6, 25.3, 24.4, 22.2, 19.5, 17.8, 12.1; EI-MS 
m/z 446 (M+H)+. 
N-tert-Boc-L-isoleucine (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester (2.18). Yield: 77%; IR 
(NaCl, cm-1) νmax 3342 (br), 2960, 1759, 1715, 1503; 1H NMR (200 
MHz, CDCl3): δ 7.12 (t, J=8 Hz, 1H, ArH), 6.99 (d, J=7 Hz, 1H, ArH), 
6.82 (d, J=8 Hz, 1H, ArH), 5.07 (br d, J=8.8 Hz, 1H, NH), 4.51 (dd, 
J=9.2 Hz, 4.5 Hz, 1H, α-CH), 3.06-2.65 (m, 4H, H1ax, H1eq, H2ax, H4eq), 
2.64-2.30 (m, 5H, H4ax, N(CH2CH2CH3)2), 2.15-1.90 (m, 2H, H3eq, β-
CH), 1.70-1.12 (m, 7H, H3ax, N(CH2CH2CH3)2, γ-CH2), 1.46 (s, 9H, 
OC(CH3)3), 1.07 (d, J=6.8 Hz, 3H, β1-CH3), 0.98 (t, J=7.4 Hz, 3H, δ-
CH3), 0.88 (t, J=7.4 Hz, 6H, CH3); 13C NMR (50 MHz, CDCl3): δ 171.2, 
155.9, 148.8, 128.9, 127.7, 126.6, 119.1, 105.0, 80.2, 58.5, 56.5, 52.8, 38.2, 32.2, 28.6, 25.3, 25.2, 
24.4, 22.1, 16.1, 12.1, 11.9; HR-MS m/z Calcd. for C27H45N2O4 461.3373 (M+1)+, found 461.3388 
(M+1)+. 
N-tert-Boc-O-benzyl-L-serine (R)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester (2.19). Yield: 
43%; IR (NaCl, cm-1) νmax 3453, 2956, 1767, 1720, 1501; 1H NMR 
(400 MHz, CDCl3): δ 7.40-7.22 (m, 5H, ArH), 7.10 (t, J=7.9 Hz, 1H, 
ArH), 6.98 (d, J=7.3 Hz, 1H, ArH), 6.80 (d, J=7.7 Hz, 1H, ArH), 5.51 
(d, J=8.8 Hz, 1H, NH), 4.70 (d, J=8.8 Hz, 1H, α-CH), 4.60 and 4.57 
(AB-system, JAB=11.7 Hz, 2H, ArCH2), 3.82 and 4.11 (dd, J=9.3 Hz, 
J=2.9 Hz, 2H, CH2O), 3.01-2.67 (m, 4H, H1ax, H1eq, H2ax, H4eq), 2.55-
2.34 (m, 5H, H4ax, N(CH2CH2CH3)2), 1.96-1.83 (m, 1H, H3eq), 1.57-
1.33 (m, 5H, H3ax, N(CH2CH2CH3)2), 1.47 (s, 9H, OC(CH3)3), 0.89 (t, J=7.3 Hz, 6H, CH3); 13C NMR 
(50 MHz, CDCl3): δ 169.5, 155.7, 148.9, 139.1, 137.6, 120.1, 128.7, 128.1, 127.9, 127.7, 126.5, 
119.1, 80.4, 73.8, 70.6, 56.6, 54.5, 52.8, 32.2, 28.6, 25.2, 24.1, 22.0, 12.1; HR-MS m/z Calcd. for 
C31H45N2O5 525.3323 (M+H)+, found 525.33179 (M+H)+. 
N-tert-Boc-L-phenylalanine (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester (2.20). Yield: 67%; 
IR (NaCl, cm-1) νmax 3401 (br), 2958, 1762, 1715, 1495; 1H NMR (200 
MHz, CDCl3): δ 7.45-7.12 (m, 5H, ArH), 7.10 (t, J=7.6 Hz, 1H, ArH), 
6.98 (d, J=7.3 Hz, 1H, ArH), 6.73 (d, J=7.6 Hz, 1H, ArH), 5.13-4.96 
(m, 2H, NH), 4.91-4.71 (m, 1H, α-CH),  3.40-3.08 (m, 2H, 
CHCH2C6H5), 3.03-2.55 (m, 4H, H1ax, H1eq, H2ax, H4eq), 2.54-2.28 (m, 
5H, H4ax, N(CH2CH2CH3)2), 2.07-1.89 (m, 1H, H3eq), 1.65-1.27 (m, 5H, 
H3ax, N(CH2CH2CH3)2), 1.43 (s, 9H, OC(CH3)3), 0.88 (t, J=7 Hz, 6H, 
CH3); 13C NMR (50 MHz, CDCl3): δ 167.0, 153.6, 147.0, 137.7, 134.3, 
128.0, 127.2, 125.9, 124.7, 117.2, 78.6, 54.7, 53.1, 51.1, 36.8, 30.6, 26.8, 23.6, 22.5, 20.6, 10.4; HR-
MS m/z Calcd. for C30H43N2O4 495.3217 (M+1)+, found 495.3232 (M+1)+. 
 
Nα,Nε-di-tert-Boc-L-lysine (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester (2.21). Yield: 57%; 
IR (NaCl, cm-1) νmax 3353 (br), 2956, 1761, 1712, 1695, 1515; 1H NMR (200 MHz, CDCl3): δ 7.12 (t, 
J=7.8 Hz, 1H, ArH), 6.99 (d, J=7.1 Hz, 1H, ArH), 6.81 (d, J=7.4 Hz, 1H, ArH), 5.18 (br d, J=7.3 Hz, 




H1ax, H1eq, H2ax, H4eq), 2.61-2.37 (m, 5H, H4ax, N(CH2CH2CH3)2), 
2.14-1.68 (m, 3H, H3eq, β-CH2), 1.67-1.34 (m, 9H, H3ax, 
N(CH2CH2CH3)2, γ-CH2, δ-CH2), 1.46 (s, 9H, OC(CH3)3), 1.44 (s, 
9H, OC(CH3)3) 0.88 (t, J=7.4 Hz, 6H, CH3); 13C NMR (50 MHz, 
CDCl3): δ 171.6, 155.8, 148.8, 139.1, 128.9, 127.7, 126.6, 119.1, 
80.3, 56.5, 53.8, 52.7, 40.2, 32.4, 32.2, 29.9, 28.7, 28.6, 25.2, 24.3, 
22.9, 22.1, 12.1. 
 
Nα, Nδ, Nω-tri-benzyloxycarbonyl-L-arginine (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester 
(2.22). Yield: 60%; IR (KBr, cm-1) νmax 3388, 2957, 1760, 1720, 
1691, 1608, 1509; 1H NMR (200 MHz, CDCl3): δ 9.46 (br s, 1H, 
NH), 9.28 (br s, 1H, NH), 7.47-7.20 (m, 15H, CH2C6H5), 7.09 (t, 
J=8 Hz, 1H, ArH), 6.98 (d, J=7 Hz, 1H, ArH), 6.77 (d, J=8 Hz, 1H, 
ArH), 5.74 (br d, J=8.5 Hz, 1H, NH), 5.23 (s, 2H, OCH2C6H5), 
5.09 (s, 4H, OCH2C6H5), 4.74-4.54 (m, 1H, α-CH), 4.19-3.88 (m, 
2H, δ-CH2), 3.04-2.63 (m, 4H, H1ax, H1eq, H2ax, H4eq), 2.58-2.19 (m, 
5H, H4ax, N(CH2CH2CH3)2), 2.08-1.67 (m, 5H, H3eq, β-CH2, γ-
CH2), 1.66-1.34 (m, 5H, H3ax, N(CH2CH2CH3)2), 0.89 (t, J=7.3 Hz, 
6H, CH3); 13C NMR (50 MHz, CDCl3): δ 171.0, 164.0, 160.8, 
156.4, 156.0, 148.7, 137.1, 136.5, 134.8, 129.14, 129.07, 128.82, 
128.75, 128.59, 128.56, 128.4, 128.3, 128.0, 127.8, 126.6, 119.0, 
69.2, 67.2, 56.5, 54.2, 52.7, 44.3, 32.3, 29.2, 25.3, 24.2, 22.1, 12.1; HR-MS m/z Calcd. for 
C46H56N5O8 806.4123 (M+1)+, found 806.4139 (M+1)+. 
N-tert-Boc-L-proline (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester (2.23). Yield: 51%; IR 
(NaCl, cm-1) νmax 2959, 1767, 1706; 1H NMR (200 MHz, CDCl3): δ 
7.20-7.03 (m, 1H, ArH), 7.02-6.91 (m, 1H, ArH), 6.90-6.75 (m, 1H, 
ArH), 4.62-4.43 (m, 1H, α-CH), 3.72-3.34 (m, 2H, δ-CH2), 3.03-2.64 (m, 
4H, H1ax, H1eq, H2ax, H4eq), 2.63-1.87 (m, 10H, H4ax, N(CH2CH2CH3)2, β-
CH2, γ-CH2, H3eq), 1.68-1.30 (m, 5H, H3ax, N(CH2CH2CH3)2), 1.47 (s, 
9H, OC(CH3)3), 0.88 (t, J=7.4 Hz, 6H, CH3); 13C NMR (50 MHz, 
CDCl3): δ 169.5, 152.1, 137.6, 131.6, 127.1, 125.7, 124.7, 117.0, 78.4, 
57.5, 54.6, 51.0, 44.9, 30.5, 29.7, 28.6, 26.9, 23.7, 22.6, 22.1, 20.6, 10.4; 
HR-MS m/z Calcd. for C26H41N2O4 445.3060 (M+1)+, found 445.3055 (M+1)+. 
N-tert-Boc-sarcosine (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester (2.24). Yield: 45%; IR 
(NaCl, cm-1) νmax 2959, 1770, 1703; 1H NMR (200 MHz, CDCl3): δ 7.12 
(t, J=8 Hz, 1H, ArH), 6.99 (d, J=8 Hz, 1H, ArH), 6.84 (d, J=6 Hz, 1H, 
ArH), 4.20 (d, J=12.6, 2H, α-CH2), 3.01 (d, J=4.4 Hz, 3H, NCH3), 2.97-
2.64 (m, 4H, H1ax, H1eq, H2ax, H4eq), 2.63-2.35 (m, 5H, H4ax, 
N(CH2CH2CH3)2), 2.11-1.93 (m, 1H, H3eq), 1.68-1.31 (m, 5H, H3ax, 
N(CH2CH2CH3)2), 1.47 (s, 9H, OC(CH3)3), 0.88 (t, J=7.3 Hz, 6H, CH3); 
13C NMR (50 MHz, CDCl3): δ 166.7, 147.0, 137.6, 127.2, 126.0, 125.8, 
124.8, 117.4, 117.1, 78.9, 54.7, 51.1, 49.4, 48.9, 34.2, 30.6, 30.4, 26.8, 23.7, 22.7, 20.6, 10.4; HR-MS 
m/z Calcd. for C24H39N2O4 419.2904 (M+1)+, found 419.2906 (M+1)+. 
 
N-tert-Boc-β-alanine (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester (2.25). Yield: 90%; IR 
(NaCl, cm-1) νmax 3367 (br), 2954, 1754, 1715, 1504; 1H NMR (200 
MHz, CDCl3): δ 7.12 (t, J=7.6 Hz, 1H, ArH), 6.99 (d, J=7.3 Hz, 1H, 
ArH), 6.82 (d, J=7.9 Hz, 1H, ArH), 5.04 (br s, 1H, NH), 3.50 (q, 
J=6.2 Hz, 2H, β-CH2), 3.05-2.67 (m, 4H, H1ax, H1eq, H2ax, H4eq), 2.80 
(t, J=6.2 Hz, 2H, α-CH2), 2.63-2.17 (m, 5H, H4ax, N(CH2CH2CH3)2), 
2.12-1.95 (m, 1H, H3eq), 1.70-1.33 (m, 5H, H3ax, N(CH2CH2CH3)2), 
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1.45 (s, 9H, OC(CH3)3), 0.88 (t, J=7.3 Hz, 6H, CH3); 13C NMR (50 MHz, CDCl3): δ 169.3, 154.3, 
147.1, 137.7, 127.2, 125.9, 124.8, 117.4, 78.0, 54.6, 51.1, 34.7, 33.0, 30.6, 26.9, 23.7, 22.6, 20.6, 
10.4; HR-MS m/z Calcd. for C24H39N2O4 419.2904 (M+1)+, found 419.2912 (M+1)+. 
N-tert-Boc-γ-aminobutyric acid (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester (2.26). Yield: 
66%; IR (NaCl, cm-1) νmax 3388 (br), 2962, 1758, 1714, 1515; 1H 
NMR (200 MHz, CDCl3): δ 7.11 (t, J=7.6 Hz, 1H, ArH), 6.98 (d, 
J=7.3 Hz, 1H, ArH), 6.82 (d, J=7.6 Hz, 1H, ArH), 4.67 (br s, 1H, 
NH), 3.25 (q, J=6.5, 2H, γ-CH2), 3.04-2.69 (m, 4H, H1ax, H1eq, H2ax, 
H4eq), 2.61 (t, J=7.3 Hz, 2H, α-CH2), 2.51-2.38 (m, 5H, H4ax, 
N(CH2CH2CH3)2), 2.11-1.71 (m, 1H, H3eq), 1.94 (quintet, J=7.1 Hz, 
2H, β-CH2), 1.70-1.31 (m, 5H, H3ax, N(CH2CH2CH3)2), 1.45 (s, 9H, 
OC(CH3)3), 0.88 (t, J=7 Hz, 6H, CH3); 13C NMR (50 MHz, CDCl3): δ 170.1, 154.5, 147.3, 137.6, 127.3, 125.8, 124.7, 117.4, 54.7, 51.1, 38.4, 30.6, 30.0, 26.9, 23.9, 23.7, 
22.6, 20.6, 10.4; HR-MS m/z Calcd. for C25H41N2O4 433.3060 (M+1)+, found 433.3054 (M+1)+. 
N-tert-Boc-5-aminovaleric acid (R)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester (2.27). Yield: 
38%; IR (NaCl, cm-1) νmax 3362 (br), 2956, 1757, 1713, 1517, 
1461, 1365, 1247, 1172; 1H NMR (200 MHz, CDCl3): δ 7.12 (t, 
J=7.6 Hz, 1H, ArH), 6.98 (d, J=7.6 Hz, 1H, ArH), 6.80 (d, J=7.6 
Hz, 1H, ArH), 4.60 (br s, 1H, NH), 3.17 (q, J=6.5, 2H, δ-CH2), 
3.05-2.65 (m, 4H, H1ax, H1eq, H2ax, H4eq), 2.59 (t, J=7.2 Hz, 2H, α-
CH2), 2.53-2.37 (m, 5H, H4ax, N(CH2CH2CH3)2), 2.14-1.97 (m, 1H, 
H3eq), 1.88-1.68 (m, 2H, γ-CH2), 1.67-1.54 (m, 2H, β-CH2), 1.53-
1.33 (m, 5H, H3ax, N(CH2CH2CH3)2), 1.44 (s, 9H, OC(CH3)3), 0.88 (t, J=7.3 Hz, 6H, CH3); 13C NMR 
(50 MHz, CDCl3): δ 172.0, 156.2, 149.0, 139.0, 129.9, 127.5, 126.6, 119.3, 79.4, 56.5, 52.8, 40.3, 
33.9, 32.2, 29.8, 28.6, 25.3, 24.3, 22.3, 22.1, 12.1; HR-MS m/z Calcd. for C26H43N2O4 447.32173 
(M+H)+, found 447.32062 (M+H)+. 
2.4.6 General deprotection procedure for the preparation of the amino acid (S)-2-(N,N-di-n-
propyl-amino)tetralin-5-yl ester hydrochlorides 2.28-2.33 and 2.35-2.41 and L-Serine (R)-2-
(N,N-di-n-propyl-amino)tetralin-5-yl ester 2HCl salt (2.34) 
The N-tert-Boc-amino acid 2-(di-n-propyl-amino)tetralin-5-yl ester (0.40 mmol) was dissolved in 4 N 
HCl in dioxane (5 mL) under nitrogen atmosphere. The solution was stirred for 15 minutes at r.t. until 
a colourless oil precipitated. The solvent was carefully removed, the remaining oil was triturated with 
dry Et2O and the solvent was evaporated in vacuo to afford a white solid foam. The solid material was 
dissolved in dry MeOH (2 mL) under N2 atmosphere. After the solution was cooled in ice, the product 
was precipitated with dry Et2O (50 mL) to afford an oil. The solvent was removed, the remaining oil 
was evaporated in vacuo and dried on the oil pump overnight to afford the hydrochloric acid salts of 
2.28-2.41 as hygroscopic white solid foams. 
Glycine (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester 2HCl salt (2.28). Yield: 85%; Purity: 
98% (HPLC); IR (KBr, cm-1) νmax 3413 (br), 2952, 2623, 1772; 1H NMR 
(400 MHz, CD3OD):δ 7.25 (t, J=7.7 Hz, 1H, ArH), 7.18 (d, J=7.3 Hz, 1H, 
ArH), 7.04 (d, J=7.7 Hz, 1H, ArH), 4.22 (s, 2H, α-CH2), 3.81-3.76 (m, 1H, 
H2ax), 3.37-3.08 (m, 6H, H1ax, H1eq, N(CH2CH2CH3)2), 3.07-2.95 (m, 1H, 
H4eq), 2.79-2.64 (m, 1H, H4ax), 2.45-2.33 (m, 1H, H3eq), 2.03-1.89 (m, 1H, 
H3ax), 1.88-1.74 (m, 4H, N(CH2CH2CH3)2), 1.05 (t, J=7.3 Hz, 6H, 
N(CH2CH2CH3)2); 13C NMR (50 MHz, CD3OD): δ 166.1, 148.3, 135.1, 
127.7, 127.5, 127.2, 119.9, 59.9, 52.6, 40.0, 29.2, 23.2, 22.7, 18.5, 10.2; 
HR-MS m/z Calcd. for C18H29N2O2 305.22235 (M)+, found 305.22238 (M)+. 
L-Alanine (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester 2HCl salt (2.29). Yield: 84%; Purity: 
100% (HPLC); IR (KBr, cm-1) νmax 3436 (br), 2967, 2644, 1768; 1H NMR (400 MHz, CD3OD):δ 7.26 
(t, J=8 Hz, 1H, ArH), 7.18 (d, J=7.3 Hz, 1H, ArH), 7.02 (d, J=7.7 Hz, 1H, ArH), 4.47 (q, J=7.3 Hz, 




1H, H4eq), 2.76-2.64 (m, 1H, H4ax), 2.44-2.34 (m, 1H, H3eq), 2.05-1.90 (m, 
1H, H3ax), 1.89-1.77 (m, 4H, N(CH2CH2CH3)2), 1.75 (d, J=7.3 Hz, 3H, 
CHCH3) 1.05 (t, J=7.3 Hz, 6H, N(CH2CH2CH3)2); 13C NMR (50 MHz, 
CD3OD): δ 168.6, 148.3, 135.1, 127.8, 127.4, 127.2, 119.8, 59.8, 52.5, 
29.2, 27.5, 23.2, 22.7, 18.6, 15.2, 10.2; HR-MS m/z Calcd. for C19H31N2O2 
319.23801 (M+H)+, found 319.23792 (M+H)+. 
 
1-Aminocyclopropane-1-carboxylic acid (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester 2HCl 
salt (2.30). Yield: 81%; Purity: 100% (HPLC); IR (KBr, cm-1) νmax 3431 (br), 2969, 2659, 1753, 
1460, 1173; 1H NMR (400 MHz, CD3OD): δ 7.25 (t, J=7.7 Hz, 1H, ArH), 
7.18 (d, J=7.7 Hz, 1H, ArH), 7.01 (d, J=7.7 Hz, 1H, ArH), 3.83-3.70 (m, 
1H, H2ax), 3.38-3.08 (m, 6H, H1ax, H1eq, N(CH2CH2CH3)2), 2.97 (dd, J=7.2 
Hz, 3.3 Hz, 1H, H4eq), 2.78-2.64 (m, 1H, H4ax), 2.47-2.36 (m, 1H, H3eq), 
2.02-1.74 (m, 7H, H3ax, β-CH2), N(CH2CH2CH3)2), 1.68-1.58 (m, 2H, β-
CH2), 1.05 (t, J=7.3 Hz, 6H, CH3); 13C NMR (50 MHz, CDCl3): δ 168.2, 
148.3, 135.2, 127.8, 127.6, 127.2, 119.8, 59.8, 52.5, 34.3, 29.2, 23.2, 22.7, 
18.5, 13.9, 10.2; HR-MS m/z Calcd. for C20H31N2O2 331.23801 (M+H)+, found 331.23816 (M+H)+. 
L-Valine (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester 2HCl salt (2.31). Yield: 90%; Purity: 
96% (HPLC); IR (KBr, cm-1) νmax 3416 (br), 2969, 2622, 1762; 1H NMR 
(200 MHz, CD3OD): δ 7.28 (t, J=7.8 Hz, 1H, ArH), 7.20 (d, J=6.6 Hz, 1H, 
ArH), 7.02 (d, J=7.6 Hz, 1H, ArH), 4.33 (d, J=4.1 Hz, 1H, α-CH), 3.88-3.68 
(m, 1H, H2ax), 3.39-2.93 (m, 7H, H1ax, H1eq, N(CH2CH2CH3)2, H4eq), 2.85-
2.67 (m, 1H, H4ax), 2.62-2.45 (m, 1H,  β-CH), 2.45-2.29 (m, 1H, H3eq), 2.06-
1.70 (m, 5H, H3ax, N(CH2CH2CH3)2), 1.22 (dd, J=7.1 Hz, J=3.5 Hz, 6H, γ-
CH3), 1.05 (t, J=7.3 Hz, 6H, N(CH2CH2CH3)2); 13C NMR (50 MHz, 
CD3OD): δ 167.6, 148.4, 135.3, 127.8, 127.4, 127.2, 119.8, 59.8, 58.4, 52.5, 
29.9, 29.3, 23.2, 23.0, 18.5, 17.5, 17.2, 10.2; HR-MS m/z Calcd. for C21H35N2O2 347.26931 (M+H)+, 
found 347.26828 (M+H)+. 
D-valine (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester 2HCl salt (2.32). Yield: 32%. Purity: 
100% (HPLC); IR (KBr, cm-1) νmax 3418 (br), 2966, 2637, 1763, 1462, 1186; 1H NMR (400 MHz, 
CD3OD): δ 7.27 (t, J=7.9 Hz, 1H, ArH), 7.19 (d, J=7.3 Hz, 1H, ArH), 7.02 (d, J=7.7 Hz, 1H, ArH), 
4.34 (d, J=4.4 Hz, 1H, α-CH), 3.84-3.71 (m, 1H, H2ax), 3.42-2.95 (m, 7H, 
H1ax, H1eq, N(CH2CH2CH3)2, H4eq), 2.82-2.67 (m, 1H, H4ax), 2.60-2.48 (m, 
1H, β-CH), 2.47-2.35 (m, 1H, H3eq), 2.04-1.75 (m, 5H, H3ax, 
N(CH2CH2CH3)2), 1.22 (dd, J=7.0 Hz, J=1.8 Hz, 6H, γ-CH3), 1.05 (t, J=7.3 
Hz, 6H, N(CH2CH2CH3)2); 13C NMR (50 MHz, CD3OD): δ 167.5, 148.4, 
135.3, 127.9, 127.5, 127.2, 119.7, 59.8, 58.3, 52.6, 29.9, 29.2, 23.2, 23.0, 
18.5, 17.4, 17.3, 10.2; HR-MS m/z Calcd. for C21H35N2O2 347.26931 
(M+H)+, found 347.2692 (M+H)+. 
L-Isoleucine (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester 2HCl salt (2.33). Yield: 89%; 
Purity: 100% (HPLC); IR (KBr, cm-1) νmax 3451 {br), 2967, 2641, 1763; 1H 
NMR (400 MHz, CD3OD): δ 7.26 (t, J=7.9 Hz, 1H, ArH), 7.19 (d, J=7.3 Hz, 
1H, ArH), 7.02 (d, J=7.7 Hz, 1H, ArH), 4.41 (d, J=3.7 Hz, 1H, α-CH), 3.85-
3.73 (m, 1H, H2ax), 3.42-2.96 (m, 7H, H1ax, H1eq, N(CH2CH2CH3)2, H4eq), 
2.84-2.67 (m, 1H, H4ax),  2.48-2.38 (m, 1H, H3eq), 2.29-2.16 (m, 1H, β-CH), 
2.05-1.77 (m, 5H, H3ax, N(CH2CH2CH3)2), 1.76-1.63 (m, 1H, γ-CH2), 1.59-
1.43 (m, 1H, γ-CH2) 1.20 (d, J=7.0 Hz, 3H, β-CHCH3), 1.09 (t, J=7.3 Hz, 3H, δ-CH3), 1.05 (t, J=7.3 Hz, 6H, N(CH2CH2CH3)2); 13C NMR (50 MHz, CD3OD): δ 167.5, 147.8, 
135.3, 127.9, 127.4, 127.2, 119.8, 59.8, 57.4, 52.5, 36.7, 29.2, 25.6, 23.2, 23.1, 18.4, 14.1, 11.0, 10.2; 
HR-MS m/z Calcd. for C22H37N2O2 361.28496 (M+H)+, found 361.28506 (M+H)+. 
SYNTHESIS OF A SERIES OF PRODRUGS OF 5-OH-DPAT 
 
 83 
L-Serine (R)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester 2HCl salt (2.34). Yield: 26%; Purity: 
98%; 1H NMR (200 MHz, CD3OD): δ 7.32-7.09 (m, 2H, ArH), 7.04 (d, 
J=7.1 Hz, 1H, ArH), 4.53 (s, 1H, α-CH), 4.04 and 4.35 (AB-system, 
JAB=9.4 Hz, 2H, CH2OH), 3.87-3.68 (m, 1H, H2ax), 3.39-2.92 (m, 7H, H1ax, 
H1eq, N(CH2CH2CH3)2, H4eq), 2.87-2.58 (m, 1H, H4ax), 2.51-2.29 (m, 1H, 
H3eq), 2.07-1.68 (m, 5H, H3ax, N(CH2CH2CH3)2), 1.05 (t, J=7.1 Hz, 6H, 
N(CH2CH2CH3)2); 13C NMR (50 MHz, CD3OD): δ 166.6, 148.4, 135.5, 
127.8, 127.6, 127.2, 119.9, 67.0, 59.9, 55.0, 53.0, 29.2, 23.2, 22.7, 18.6, 
10.2. 
L-Phenylalanine (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester 2HCl salt (2.35). Yield: 78%; 
Purity: 100% (HPLC); IR (KBr, cm-1) νmax 3415 (br), 2967, 2641, 1763; 
1H NMR (400 MHz, CD3OD):δ 7.52-7.31 (m, 5H, C6H5), 7.23 (t, J=8 Hz, 
1H, ArH), 7.16 (d, J=7.7 Hz, 1H, ArH), 6.93 (d, J=7.7 Hz, 1H, ArH), 4.72 
(t, J=7 Hz, 1H, α-CH), 3.83-3.68 (m, 1H, H2ax), 3.55-3.34 (m, 2H, β-CH2), 
3.33-3.05 (m, 6H, H1ax, H1eq, N(CH2CH2CH3)2), 2.89-2.73 (m, 1H, H4eq), 
2.63-2.48 (m, 1H, H4ax), 2.39-2.28 (m, 1H, H3eq), 1.97-1.73 (m, 5H, H3ax, 
N(CH2CH2CH3)2), 1.05 (t, J=7.3 Hz, 6H, N(CH2CH2CH3)2); 13C NMR 
(50 MHz, CD3OD): δ 167.7, 148.3, 135.1, 134.1, 129.5, 129.1, 128.0, 127.8, 127.3, 127.1, 119.7, 
59.8, 54.0, 52.5, 36.5, 29.1, 23.1, 22.6, 18.6, 10.1; HR-MS m/z Calcd. for C25H35N2O2 395.26931 
(M+H)+, found 395.2688 (M+H)+. 
L-Lysine (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester 3HCl salt (2.36). Yield: 10%; Purity: 
99% (HPLC); IR (KBr, cm-1) νmax 3398 (br), 2968, 2660, 1765, 1461, 1200, 
1182; 1H NMR (200 MHz, CD3OD):δ 7.33-7.15 (m, 2H, ArH), 7.10-6.98 (m, 
1H, ArH), 4.46 (t, J=6.4 Hz, 1H, α-CH), 3.88-3.64 (m, 1H, H2ax), 3.40-2.90 
(m, 9H, H1ax, H1eq, H4eq, ε-CH2, N(CH2CH2CH3)2), 2.85-2.61 (m, 1H, H4ax), 
2.53-2.37 (m, 1H, H3eq), 2.36-2.02 (m, 2H, β-CH2), 2.01-1.51 (m, 9H, H3ax, γ-CH2, δ-CH2, N(CH2CH2CH3)2), 1.05 (t, J=7.3 Hz, 6H, N(CH2CH2CH3)2); 
13C NMR (50 MHz, CD3OD): δ 148.3, 135.2, 127.8, 127.4, 127.2, 59.9, 52.9, 
52.7, 52.5, 49.1, 39.1, 29.9, 26.9, 23.2, 22.9, 18.6, 10.2; HR-MS m/z Calcd. 
for C22H38N3O2 376.2959 (M+H)+, found 376.2959 (M+H)+. 
L-Proline (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester 2HCl salt (2.37). Yield: 82%; Purity: 
100% (HPLC); IR (KBr, cm-1) νmax 3441 (br), 2966, 2637, 1762; 1H NMR 
(400 MHz, CD3OD): δ 7.26 (t, J=8 Hz, 1H, ArH), 7.19 (d, J=7.7 Hz, 1H, 
ArH), 7.07 (d, J=7.7 Hz, 1H, ArH), 4.80 (t, J=8 Hz, 1H, α-CH), 3.82-3.70 
(m, 1H, H2ax), 3.54-3.42 (m, 2H, δ-CH2), 3.36-3.09 (m, 6H, H1ax, H1eq, 
N(CH2CH2CH3)2), 3.08-2.98 (m, 1H, H4eq), 2.78-2.57 (m, 2H, Hβ-CH2, H4ax), 
2.45-2.33 (m, 2H, Hβ-CH2, H3eq), 2.24-2.12 (m, 2H, γ-CH2), 2.04-1.84 (m, 1H, 
H3ax), 1.83-1.75 (m, 4H, N(CH2CH2CH3)2), 1.05 (t, J=7.3 Hz, 6H, 
N(CH2CH2CH3)2); 13C NMR (50 MHz, CD3OD): δ 167.6, 148.3, 135.1, 
127.9, 127.4, 127.2, 119.8, 59.8, 59.7, 52.5, 46.1, 29.2, 28.5, 23.5, 23.1, 22.7, 18.6, 10.1; HR-MS m/z 
Calcd. for C21H33N2O2 345.25366 (M+H)+, found 345.25357 (M+H)+. 
N-Methylglycine (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester 2HCl salt (2.38). Yield: 92%; 
Purity: 98% (HPLC); IR (KBr, cm-1) νmax 3442 (br), 2951, 2649, 1771; 1H 
NMR (400 MHz, CD3OD):δ 7.25 (t, J=7.9 Hz 1H, ArH), 7.18 (d, J=7.3 Hz, 
1H, ArH), 7.05 (d, J=7.3 Hz, 1H, ArH), 4.87 (s, 2H, α-CH2), 3.83-3.70 (m, 
1H, H2ax), 3.38-2.95 (m, 7H, H1ax, H1eq, H4eq, N(CH2CH2CH3)2), 2.84 (s, 3H, 
NCH3), 2.78-2.63 (m, 1H, H4ax), 2.47-2.34 (m, 1H, H3eq), 2.03-1.74 (m, 5H, 
H3ax, N(CH2CH2CH3)2), 1.05 (t, J=7.1 Hz, 6H, CH3) ; 13C NMR (50 MHz, 
CD3OD): δ 165.3, 152.1, 135.2, 127.8, 127.2, 127.1, 119.9, 59.9, 52.9, 52.5, 





β-Alanine (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester 2HCl salt (2.39). Yield: 86%; Purity: 
99% (HPLC); IR (KBr, cm-1) νmax 3399 (br), 2968, 2653, 1753; 1H NMR 
(400 MHz, CD3OD):δ 7.23 (t, J=8 Hz, 1H, ArH), 7.14 (d, J=7.7 Hz, 1H, 
ArH), 7.00 (d, J=8.1 Hz, 1H, ArH), 3.83-3.68 (m, 1H, H2ax), 3.38-3.11 
(m, 8H, H1ax, H1eq, β-CH2, N(CH2CH2CH3)2), 3.09 (t, J=6.6 Hz, 2H, α-
CH2), 3.05-2.91 (m, 1H, H4eq), 2.77-2.64 (m, 1H, H4ax), 2.44-2.31 (m, 
1H, H3eq), 2.04-1.90 (m, 1H, H3ax), 1.89-1.70 (m, 4H, N(CH2CH2CH3)2), 
1.05 (t, J=7.3 Hz, 6H, N(CH2CH2CH3)2); 13C NMR (50 MHz, CD3OD): δ 169.4, 148.8, 134.8, 127.6, 127.3, 127.0, 120.1, 59.9, 35.0, 31.0, 29.2, 
23.2, 22.7, 18.6, 10.1; HR-MS m/z Calcd. for C19H31N2O2 319.23801 (M+H)+, found 319.23788 
(M+H)+. 
γ-Aminobutyric acid (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester 2HCl salt (2.40). Yield: 
89%; Purity: >95% (HPLC); IR (KBr, cm-1) νmax 3430 (br), 2959, 
2641, 1752; 1H NMR (400 MHz, CD3OD):δ 7.22 (t, J=7.7 Hz, 1H, 
ArH), 7.13 (d, J=7.7 Hz, 1H, ArH), 6.95 (d, J=7.7 Hz, 1H, ArH), 
3.83-3.69 (m, 1H, H2ax), 3.37-3.09 (m, 6H, H1ax, H1eq, 
N(CH2CH2CH3)2), 3.07 (t, J=7.7 Hz, 2H, γ-CH2), 3.02-2.91 (m, 1H, 
H4eq), 2.81 (t, J=7 Hz, 2H, α-CH2), 2.74-2.60 (m, 1H, H4ax), 2.43-2.33 
(m, 1H, H3eq), 2.07 (p, J=7.5 Hz, 2H, β-CH2), 2.00-1.89 (m, 1H, H3ax), 
1.88-1.73 (m, 4H, N(CH2CH2CH3)2), 1.05 (t, J=7 Hz, 6H, 
N(CH2CH2CH3)2); 13C NMR (50 MHz, CD3OD): δ 171.2, 149.0, 134.7, 127.6, 127.1, 127.0, 120.2, 
59.9, 52.5, 38.8, 30.3, 29.2, 23.3, 22.8, 22.6, 18.6, 10.1; HR-MS m/z Calcd. for C20H33N2O2 
333.25366 (M+H)+, found 333.25357 (M+H)+. 
5-Aminovaleric acid (R)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester 2HCl salt (2.41). Yield: 
85%; Purity: 96% (HPLC); IR (KBr, cm-1) νmax 3428 (br), 2929, 
2634, 1751, 1463, 1137; 1H NMR (400 MHz, CD3OD):δ 7.21 (t, 
J=7.7 Hz, 1H, ArH), 7.12 (d, J=7.3 Hz, 1H, ArH), 6.93 (d, J=7.7 
Hz, 1H, ArH), 3.80-3.68 (m, 1H, H2ax), 3.37-3.05 (m, 6H, H1ax, 
H1eq, N(CH2CH2CH3)2), 3.04-2.87 (m, 3H, H4eq, δ-CH2), 2.78-2.60 
(m, 3H, H4ax, α-CH2), 2.44-2.32 (m, 1H, H3eq), 2.00-1.70 (m, 9H, 
H3ax, β-CH2, γ-CH2, N(CH2CH2CH3)2), 1.05 (t, J=7.1 Hz, 6H, 
N(CH2CH2CH3)2); 13C NMR (50 MHz, CD3OD): δ 171.8, 149.1, 
134.7, 127.6, 127.0, 120.2, 60.0, 39.3, 32.9, 29.2, 26.8, 23.3, 22.8, 21.6, 18.6, 18.4, 10.2; HR-MS m/z 
Calcd. for C21H35N2O2 347.26931 (M+H)+, found 347.26932 (M+H)+. 
2.4.7 N-tert-Boc-L-serine (R)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester (2.42). To a solution of 
2.19 (75 mg, 0.14 mmol) in 7 mL absolute EtOH was added Pd-C 10% (30 mg). The suspension was 
shaken under H2 (3 bar) atmosphere at 45 oC for 4 hours. The black 
suspension was filtered and evaporated in vacuo. The resultant light 
yellow oil was purified by column chromatography (CH2Cl2/MeOH = 
20 : 1) to afford 2.42 (29 mg, 47%) as a colourless oil. IR (KBr, cm-1) 
νmax 3348 (br), 2973, 2640, 1772, 1709, 1459, 1154; HR-MS m/z 
Calcd. for C39H24N2O5 435.2854 (M+H)+, found 435.2851 (M+H)+. 
 
2.4.8 L-Arginine (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester 4HCl salt (2.43).  The N-
benzyloxy protected L-arginine ester 2.22 (0.23 g, 0.28 mmol) was 
dissolved in a mixture of dry MeOH (30 mL) and 2N HCl in dry 
MeOH (5 mL) under N2 atmosphere. Pd-C 10% (50 mg) was added and 
the mixture was stirred vigorously for 1.5 hours under H2 (1 bar) 
atmosphere at r.t. until gas formation ceased. The black suspension was 
filtered and the colourless solution was cooled to 0 oC in ice and 
precipitated with dry Et2O to obtain white solid material. The solvent 
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was removed and the white solid material was dried in vacuo to afford the tetrahydrochloric acid salt 
of compound 2.43 (0.12 g, 79%) as a hygroscopic white powder. Purity: 99% (HPLC); IR (KBr, cm-1) 
νmax 3411, 3171, 2951, 1762, 1667; 1H NMR (300 MHz, CD3OD): δ 7.34-7.11 (m, 2H, ArH), 7.06 (d, 
J=7.3 Hz, 1H, ArH), 4.55-4.42 (m, 1H, α-CH), 3.89-3.67 (m, 1H, H2ax), 3.44-2.91 (m, 9H, H1ax, H1eq, δ-CH2, N(CH2CH2CH3)2, H4eq), 2.87-2.63 (m, 1H, H4ax), 2.54-2.37 (m, 1H,  β-CH), 2.36-2.08 (m, 2H, 
H3eq, β-CH), 2.07-2.65 (m, 7H, H3ax, N(CH2CH2CH3)2), γ-CH2), 1.05 (t, J=6.4 Hz, 6H, 
N(CH2CH2CH3)2); 13C NMR (50 MHz, CD3OD): δ 172.8, 157.5, 136.5, 135.2, 127.9, 127.3, 127.2, 
119.9, 59.9, 52.6, 50.3, 47.5, 40.6, 23.3, 23.0, 18.7, 18.5, 10.2; HR-MS m/z Calcd. for C22H38N5O2 
404.302 (M+H)+, found 404.30206 (M+H)+; Anal. Calcd for C22H41N5O2Cl4: C, 48.10; H, 7.52; N, 
12.75. Found: C, 48.37; H, 7.72; N, 12.91. 
2.4.9 N,N-Dimethylglycine (R)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester 2HCl salt (2.44). 
Dimethylglycine.HCl (0.63 g, 4.5 mmol) and DMAP (1.08 g, 8.9 mmol) 
were suspended in 10 mL anhydrous CH2Cl2 under nitrogen atmosphere and 
cooled to 0 oC. EDC (0.86 mL, 4.9 mmol) was added and the reaction 
mixture was stirred for 15 minutes. 5-OH-DPAT (1.0 g, 4.0 mmol) in 3 mL 
anhydrous CH2Cl2 was slowly added to the cloudy suspension. The clear 
light orange solution was allowed to attain room temperature and was stirred 
for 2 hours until the reaction was complete. CH2Cl2 (50 mL) was added and 
the reaction mixture was washed with H2O (3 x 10 mL) and brine (10 mL). 
The organic layer was dried over Na2SO4 and evaporated in vacuo; the resultant light pink-orange 
solid material was purified by column chromatography (CH2Cl2/MeOH = 10:1) to afford the free 
amine of compound 2.44 as a colourless oil (0.97 g). The free amine was dissolved in 3 mL 2N HCl 
in dry MeOH and cooled to 0 oC in ice under N2. The hydrochloride salt was precipitated as white 
solid material with dry Et2O. The solvent was removed and the salt was reprecipitated from dry 
MeOH with dry Et2O. The solvent was removed and the precipitate was evaporated in vacuo to afford 
3m as a hygroscopic white powder (0.14 g, 57%). Purity: 100% (HPLC); IR (KBr, cm-1) νmax 3424 
(br), 2935, 2482, 2368, 1768, 1461, 1365, 1205; 1H NMR (200 MHz, CD3OD):δ 7.26 (t, J=7.6 Hz 
1H, ArH), 7.19 (d, J=6.5 Hz, 1H, ArH), 7.09 (d, J=7.4 Hz, 1H, ArH), 4.57 (s, 2H, α-CH2), 3.86-3.67 
(m, 1H, H2ax), 3.39-2.95 (m, 7H, H1ax, H1eq, H4eq, N(CH2CH2CH3)2), 3.06 (s, 6H, N(CH3)2), 2.83-2.63 
(m, 1H, H4ax), 2.51-2.34 (m, 1H, H3eq), 2.03-1.74 (m, 5H, H3ax, N(CH2CH2CH3)2), 1.05 (t, J=7.2 Hz, 
6H, CH3); 13C NMR (50 MHz, CD3OD): δ 164.9, 148.2, 135.2, 127.9, 127.5, 127.2, 119.9, 59.9, 56.7, 
52.7, 43.5, 29.2, 23.2, 22.8, 18.5, 10.2; HR-MS m/z Calcd. for C20H33N2O2 333.25366 (M+1)+, found 
333.25345 (M+1)+.. 
2.4.10 N-2-Chlorocarbonylmethyl-N,N,N-trimethylammoniumchloride (2.45). Oven-dried N,N,N-
trimethylglycine.HCl (6.2 g, 40 mmol) was suspended in SOCl2 (7.9 mL, 109 mmol) 
under nitrogen atmosphere. The suspension was stirred vigorously and heated at 70 oC 
for 2 hours until gas formation ceased. The yellow solution was evaporated in vacuo 
and the resultant yellow-white solid material was washed with dry CH2Cl2. After 
filtration and drying in vacuo, compound 2.45 was afforded as a white solid material (5.8 g, 82%). IR 
(KBr, cm-1) νmax 2830, 2480, 1742, 1179. 1H NMR (400 MHz, d6-DMSO): δ 4.47 (s, 2H, α-CH2), 
3.26 (s, 9H, N(CH3)3+). 
2.4.11 N,N,N-Trimethylglycine (R)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester Cl.HCl salt 
(2.46). (R)-5-OH-DPAT (135 mg, 0.54 mmol) was dissolved in 1 mL dry CH2Cl2 under a nitrogen 
atmosphere. The solution was cooled in ice to 0 oC and pyridine (176 μL, 
2.2 mmol) was added. A suspension of the betaïne acid chloride 2.45 
(476 mg, 2.7 mmol) in 1.5 mL dry CH2Cl2 was dropwise added and the 
reaction mixture was stirred for 30 minutes. After filtration the solution 
was evaporated in vacuo and gave an orange-brown oil. The crude 
product was purified by column chromatography (CH2Cl2/MeOH, 
gradient = 4:1 to 2:1) to afford the chloride-hydrochloride salt 2.46 as a 
white hygroscopic powder (169 mg, 74%). Purity: 100% (HPLC); IR 
(KBr, cm-1) νmax 3436 (br), 2967, 2640, 1764, 1460, 1179; 1H NMR (400 MHz, CD3OD):δ 7.26 (t, 




2H, α-CH2), 3.82-3.70 (m, 1H, H2ax), 3.45 (s, 9H, N(CH3)3+), 3.40-3.10 (m, 6H, H1ax, H1eq, 
N(CH2CH2CH3)2), 3.09-2.98 (m, 1H, H4eq), 2.80-2.67 (m, 1H, H4ax), 2.49-2.37 (m, 1H, H3eq), 2.04-
1.92 (m, 1H, H3ax), 1.91-1.75 (m, 4H, N(CH2CH2CH3)2), 1.05 (t, J=7.3 Hz, 6H, N(CH2CH2CH3)2); 
13C NMR (50 MHz, CD3OD): δ 163.6, 147.9, 135.3, 127.9, 127.5, 127.2, 119.9, 62.8, 59.8, 53.5, 
52.5, 29.2, 23.1, 22.8, 18.4, 10.2; HR-MS m/z Calcd. for C21H35N2O2 347.2693 (M)+, found 347.2692 
(M)+. 
2.5 ACKNOWLEDGMENTS.  
We thank the Mass spectrometry unit of the University of Groningen (head: Dr Andries 
Bruins) for the analysis of our final compounds. 
2.6 REFERENCES 
1.     Hacksell, U.; Svensson, U.; Nilsson, J. L. G.; Hjorth, S.; Carlsson, A.; Wikstrom, H.; Lindberg, 
P.; Sanchez, D. N-Alkylated 2-Aminotetralins - Central Dopamine-Receptor Stimulating Activity. J. 
Med. Chem. 1979, 22, 1469-1475.  
2.     McDermed, J. D.; McKenzie, G. M.; Freeman, H. S. Synthesis and Dopaminergic Activity of 
(+/-)-1,2,3,4-Tetrahydronaphthalene, (+)-1,2,3,4-Tetrahydronaphthalene, and (-)-2-Dipropylamino-5-
Hydroxy-1,2,3,4-Tetrahydronaphthalene. J. Med. Chem. 1976, 19, 547-549.  
3.     vanVliet, L. A.; Tepper, P. G.; Dijkstra, D.; Damsma, G.; Wikstrom, H.; Pugsley, T. A.; Akunne, 
H. C.; Heffner, T. G.; Glase, S. A.; Wise, L. D. Affinity for dopamine D-2, D-3, and D-4 receptors of 
2-aminotetralins. Relevance of D-2 agonist binding for determination of receptor subtype selectivity. 
J. Med. Chem. 1996, 39, 4233-4237.  
4.     Wikstrom, H.; Andersson, B.; Sanchez, D.; Lindberg, P.; Arvidsson, L. E.; Johansson, A. M.; 
Nilsson, J. L. G.; Svensson, K.; Hjorth, S.; Carlsson, A. Resolved Monophenolic 2-Aminotetralins 
and 1,2,3,4,4A,5,6,10B-Octahydrobenzo[F]Quinolines - Structural and Stereochemical 
Considerations for Centrally Acting Presynaptic and Postsynaptic Dopamine-Receptor Agonists. J. 
Med. Chem. 1985, 28, 215-225.  
5.     van der Geest, R.; Danhof, M.; Bodde, H. E. Iontophoretic delivery of apomorphine I: In vitro 
optimization and validation. Pharm. Res. 1997, 14, 1798-1803.  
6.     Luzardo-Alvarez, A.; Delgado-Charro, M. B.; Blanco-Mendez, J. Iontophoretic delivery of 
ropinirole hydrochloride: effect of current density and vehicle formulation. Pharm. Res. 2001, 18, 
1714-20.  
7.     Nugroho, A. K.; Li, G. L.; Grossklaus, A.; Danhof, M.; Bouwstra, J. A. Transdermal 
iontophoresis of rotigotine: influence of concentration, temperature and current density in human skin 
in vitro. J. Controlled Release 2004, 96, 159-167.  
8.     Nugroho, A. K.; Li, G. L.; Danhof, M.; Bouwstra, J. A. Transdermal iontophoresis of rotigotine 
across human stratum corneum in vitro: Influence of pH and NaCl concentration. Pharm. Res. 2004, 
21, 844-850.  
9.     Nugroho, A. K.; Li, L.; Dijkstra, D.; Wikstrom, H.; Danhof, M.; Bouwstra, J. A. Transdermal 
iontophoresis of the dopamine agonist 5-OH-DPAT in human skin in vitro. J. Controlled Release 
2005, 103, 393-403.  
10.     Nugroho, A. K.; Romeijn, S. G.; Zwier, R.; De Vries, J. B.; Dijkstra, D.; Wikstrom, H.; la-
Pasqua, O.; Danhof, M.; Bouwstra, J. A. Pharmacokinetics and pharmacodynamics analysis of 
transdermal iontophoresis of 5-OH-DPAT in rats: In vitro-in vivo correlation. J. Pharm. Sci. 2006, 
95, 1570-1585.  
11.     Luzardo-Alvarez, A.; Delgado-Charro, M. B.; Blanco-Mendez, J. In vivo iontophoretic 
administration of ropinirole hydrochloride. J. Pharm. Sci. 2003, 92, 2441-8.  
SYNTHESIS OF A SERIES OF PRODRUGS OF 5-OH-DPAT 
 
 87 
12.     van der Geest, R.; van Laar, T.; Gubbens-Stibbe, J. M.; Bodde, H. E.; Danhof, M. Iontophoretic 
delivery of apomorphine II: An in vivo study in patients with Parkinson's disease. Pharm. Res. 1997, 
14, 1804-1810.  
13.     Sung, K. C.; Fang, J. Y.; Hu, O. Y. P. Delivery of nalbuphine and its prodrugs across skin by 
passive diffusion and iontophoresis. J. Controlled Release 2000, 67, 1-8.  
14.     Yoshida, N. H.; Roberts, M. S. Structure Transport Relationships in Transdermal Iontophoresis. 
Adv. Drug Delivery Rev. 1992, 9, 239-264.  
15.     Rautio, J.; Kumpulainen, H.; Heimbach, T.; Oliyai, R.; Oh, D.; Jarvinen, T.; Savolainen, J. 
Prodrugs: design and clinical applications. Nat. Rev. Drug Discov. 2008, 7, 255-70.  
16.     Abla, N.; Naik, A.; Guy, R. H.; Kalia, Y. N. Topical iontophoresis of valaciclovir 
hydrochloride improves cutaneous aciclovir delivery. Pharm. Res. 2006, 23, 1842-1849.  
17.     Laneri, S.; Sacchi, A.; di Frassello, E. A.; Luraschi, E.; Colombo, P.; Santi, P. Ionized prodrugs 
of dehydroepiandrosterone for transdermal iontophoretic delivery. Pharm. Res. 1999, 16, 1818-1824.  
18.     Prausnitz, M. R.; Mitragotri, S.; Langer, R. Current status and future potential of transdermal 
drug delivery. Nat. Rev. Drug Discov. 2004, 3, 115-124.  
19.     Anigbogu, A.; Patil, S.; Singh, P.; Liu, P.; Dinh, S.; Maibach, H. An in vivo investigation of the 
rabbit skin responses to transdermal iontophoresis. Int. J. Pharm. 2000, 200, 195-206.  
20.     Di Stefano, A.; Sozio, P.; Cerasa, L. S. Antiparkinson Prodrugs. Molecules 2008, 13, 46-68.  
21.     Bundgaard, H. Design of prodrugs; Elsevier: Amsterdam etc., 1985; , pp VII, 360.  
22.     Roche, E. B. Bioreversible carriers in drug design : theory and applications; Pergamon Press: 
New York etc., 1987; , pp VIII, 292.  
23.     Aggarwal, S. K.; Gogu, S. R.; Rangan, S. R. S.; Agrawal, K. C. Synthesis and Biological 
Evaluation of Prodrugs of Zidovudine. J. Med. Chem. 1990, 33, 1505-1510.  
24.     Bender, D. M.; Peterson, J. A.; McCarthy, J. R.; Gunaydin, H.; Takano, Y.; Houk, K. N. 
Cyclopropanecarboxylic acid esters as potential prodrugs with enhanced hydrolytic stability. Org. 
Lett. 2008, 10, 509-511.  
25.     Bundgaard, H.; Larsen, C.; Thorbek, P. Prodrugs as Drug Delivery Systems .26. Preparation 
and Enzymatic-Hydrolysis of Various Water-Soluble Amino-Acid Esters of Metronidazole. Int. J. 
Pharm. 1984, 18, 67-77.  
26.     Landowski, C. P.; Song, X. Q.; Lorenzi, P. L.; Hilfinger, J. M.; Amidon, G. L. Floxuridine 
amino acid ester prodrugs: Enhancing Caco-2 permeability and resistance to glycosidic bond 
metabolism. Pharm. Res. 2005, 22, 1510-1518.  
27.     Song, X.; Lorenzi, P. L.; Landowski, C. P.; Vig, B. S.; Hilfinger, J. M.; Amidon, G. L. Amino 
acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic 
bioevasion, and hPEPT1-mediated transport. Mol. Pharmaceutics 2005, 2, 157-167.  
28.     Takata, J.; Karube, Y.; Nagata, Y.; Matsushima, Y. Prodrugs of Vitamin-e .1. Preparation and 
Enzymatic-Hydrolysis of Aminoalkanecarboxylic Acid-Esters of D-Alpha-Tocopherol. J. Pharm. Sci. 
1995, 84, 96-100.  
29.     Vig, B. S.; Lorenzi, P. J.; Mittal, S.; Landowski, C. P.; Shin, H. C.; Mosberg, H. I.; Hilfinger, J. 
M.; Amidon, G. L. Amino acid ester prodrugs of floxuridine: Synthesis and effects of structure, 
stereochemistry, and site of esterification on the rate of hydrolysis. Pharm. Res. 2003, 20, 1381-1388.  
30.     Colla, L.; De Clercq, E.; Busson, R.; Vanderhaeghe, H. Synthesis and antiviral activity of 
water-soluble esters of acyclovir [9-[(2-hydroxyethoxy)methyl]guanine]. J. Med. Chem. 1983, 26, 
602-4.  
31.     Altomare, C.; Trapani, G.; Latrofa, A.; Serra, M.; Sanna, E.; Biggio, G.; Liso, G. Highly water-
soluble derivatives of the anesthetic agent propofol: in vitro and in vivo evaluation of cyclic amino 
acid esters. Eur. J. Pharm. Sci. 2003, 20, 17-26.  
32.     Anderson, A.; Belelli, D.; Bennett, D. J.; Buchanan, K. I.; Casula, A.; Cooke, A.; Feilden, H.; 
Gemmell, D. K.; Hamilton, N. M.; Hutchinson, E. J.; Lambert, J. J.; Maidment, M. S.; McGuire, R.; 
McPhail, P.; Miller, S.; Muntoni, A.; Peters, J. A.; Sansbury, F. H.; Stevenson, D.; Sundaram, H. 
Alpha-amino acid phenolic ester derivatives: novel water-soluble general anesthetic agents which 




33.     Kovach, I. M.; Pitman, I. H.; Higuchi, T. Amino acid esters of phenols as prodrugs: synthesis 
and stability of glycine, beta-aspartic acid, and alpha-aspartic acid esters of p-acetamidophenol. J. 
Pharm. Sci. 1981, 70, 881-5.  
34.     Mahfouz, N. M.; Hassan, M. A. Synthesis, chemical and enzymatic hydrolysis, and 
bioavailability evaluation in rabbits of metronidazole amino acid ester prodrugs with enhanced water 
solubility. J. Pharm. Pharmacol. 2001, 53, 841-848.  
35.     Copinga, S.; Tepper, P. G.; Grol, C. J.; Horn, A. S.; Dubocovich, M. L. 2-Amido-8-
Methoxytetralins - A Series of Nonindolic Melatonin-Like Agents. J. Med. Chem. 1993, 36, 2891-
2898.  
36.     Karlsson, A.; Bjork, L.; Pettersson, C.; Anden, N. E.; Hacksell, U. (R)-5-Hydroxy-2-
(Dipropylamino)Tetralin and (S)-5-Hydroxy-2-(Dipropylamino)Tetralin (5-Oh Dpat) - Assessment of 
Optical Purities and Dopaminergic Activities. Chirality 1990, 2, 90-95.  
37.     Matta, M. S.; Andracki, M. E. Rate-Controlling Step of Oxazolinone Formation - Secondary 
and Solvent Kinetic Isotope Effects. J. Am. Chem. Soc. 1985, 107, 6036-6039.  
38.     Jetten, M.; Peters, C. A. M.; Vannispen, J. W. F. M.; Ottenheijm, H. C. J. A One-Pot N-
Protection of L-Arginine. Tetrahedron Lett. 1991, 32, 6025-6028.  
39.     Linch, A. L. US2359863, 1944.  
40.     Marder, O.; Albericio, F. Industrial application of coupling reagents in peptides. Chim. Oggi 
2003, 21, 35-40.  
41.     Gangarosa, L. P.; Park, N. H.; Fong, B. C.; Scott, D. F.; Hill, J. M. Conductivity of drugs used 
for iontophoresis. J. Pharm. Sci. 1978, 67, 1439-43.  
42.     Berge, S. M.; Bighley, L. D.; Monkhouse, D. C. Pharmaceutical Salts. J. Pharm. Sci. 1977, 66, 
1-19.  
43.     Gould, P. L. Salt Selection for Basic Drugs. Int. J. Pharm. 1986, 33, 201-217.  
44.     Quintanilla-Licea, R.; Colunga-Valladares, J. F.; Caballero-Quintero, A.; Rodríguez-Padilla, 
C.; Tamez-Guerra, R.; Gómez-Flores, R.; Waksman, N. NMR Detection of Isomers Arising from 
Restricted Rotation of the C-N Amide Bond of N-Formyl-o-toluidine and N,N’-bis-Formyl-o-tolidine. 
Molecules 2002, 7, 662-673; 662.  
45.     Lai, P. M.; Roberts, M. S. An analysis of solute structure-human epidermal transport 
relationships in epidermal iontophoresis using the ionic mobility: pore model. J. Controlled Release 
1999, 58, 323-33.  
46.     Abla, N.; Naik, A.; Guy, R. H.; Kalia, Y. N. Effect of charge and molecular weight on 
transdermal peptide delivery by iontophoresis. Pharm. Res. 2005, 22, 2069-78.  
47.     Phipps, J. B.; Padmanabhan, R. V.; Lattin, G. A. Iontophoretic delivery of model inorganic and 
drug ions. J. Pharm. Sci. 1989, 78, 365-9.  
 
   
   
 
   
3 
 
Chemical stability and enzymatic 
hydrolysis of a series of amino acid 






The ratio between chemical (in vitro) and enzymatic (in vivo) stability determines the 
suitability of prodrugs for iontophoresis and other routes of administration. To select 5-
OH-DPAT prodrugs for transdermal iontophoretic delivery based on optimal in vitro/in 
vivo ratios, the hydrolysis rates were determined in the donor phase of the iontophoretic 
device and in human blood plasma. Chemical stability studies in citrate buffer at pH 5 
indicated that the L-valine and β-alanine prodrugs of (S)-5-OH-DPAT showed sufficient 
stability in vitro. Enzymatic stability studies in 80% human blood plasma indicated that 
these prodrugs are rapidly converted to the parent drug in vivo. In conlusion, L-valine and 
β-alanine prodrugs of 5-OH-DPAT may meet the requisites for improved transport across 
the skin by iontophoresis. 
3.1. INTRODUCTION 
Iontophoretic delivery has attracted attention because it represents a localized, non-
invasive, convenient and rapid method to deliver water soluble, ionized medication into the 
skin. Iontophoretic drug delivery avoids the hepatic first-pass metabolism. In addition, it 
also reduces the chance of fluctuating plasma levels by providing programmed delivery of 
the drug. It also provides a rapid way to terminate the delivery by turning off the current.1 
Because of the many advantages there is growing interest in iontophoretic drug delivery. 
Besides the applied electrical current strength, drug concentration is one of the most 
important factors affecting the iontophoretic process. High aqueous solubility of drugs or 
prodrugs is therefore favourable for iontophoresis. Effects of concentration have been 
studied for a number of drugs e.g. metoprolol and the dopamine (DA) agonists 5-OH DPAT 
and rotigotine.2-4 All these drugs showed with an increase in concentration a proportional 
increase in flux. The pH of the donor compartment is also an important factor in 
iontophoretic drug delivery. The optimum pH for iontophoretic delivery of a compound is 
one where it exist predominantly in its ionized form.5 However, the pH and more 
specifically the ion competition between the hydrogen ion and the drug ion to carry the 
current, also influences the iontophoretic flux. The optimum acidity in the donor phase for 
the transdermal iontophoretic delivery of 5-OH-DPAT was determined pH 5.3 
Hydroxylated 2-aminotetralins exhibited low oral bioavailability in rats and humans. One 
of the primary reasons for this low bioavailability is probably an extensive first-pass 
metabolism. Various prodrug strategies have been employed to improve the oral absorption 
or passive transdermal administration of hydroxylated 2-aminotetralins by esterification 
with aliphatic and aromatic moieties.6, 7 To overcome absorption barriers, prodrugs can also 
be designed by coupling e.g. amino acids to the phenol moiety. Because of the presence of 
high esterase activity these ester prodrugs will be cleaved to regenerate the parent 
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compound in the blood.8 Amino acid prodrugs offer an additional advantage by producing 
non-toxic by-products in vivo during their bioactivation.9 
Esterases, hydrolases which split ester bonds, hydrolyse a number of compounds used as 
drugs in humans and are important for the bioactivation of prodrugs. Cholinesterases are 
primarily involved in drug hydrolysis in plasma, and arylesterases in the plasma and red 
blood cells.10 The low barrier H-bond between the amino acids Glu336 and His450 facilitates 
nucleophilic attack by the β-OH group of Ser203 on the carbonyl group of the substrate by 
carboxylesterases.11 Apart from the blood, prodrugs can also be activated by esterases 
present within the skin.12  
Human serum albumin (HSA) is an abundant plasma protein with ascribed ligand-binding 
and transport properties, and enzymatic activities. These enzymatic properties could benefit 
the release of parent drugs from its prodrug form. Although the enzymatic activity of a 
single HSA molecule is low, the concentration of this protein in the circulation is very high. 
Therefore this kind of prodrug activation is believed to be clinically relevant.13 The activity 
of HSA on ester hydrolysis depends on the substrate, e.g. the prodrug isosorbide 
diaspirinate is hydrolyzed relatively slow by HSA compared to hydrolysis in human blood 
plasma (HBP).14 Hydrolysis of a substrate by HSA occurs probably by acylation due to 
nucleophilic attack by Tyr411 or Lys199, followed by hydrolysis.15, 16 It is of interest to 
examine the contribution of HSA to enzymatic hydrolysis of 5-OH-DPAT prodrugs in 
HBP. 
The ratio between chemical and enzymatic stability, i.e. the in vitro/in vivo stability ratio of 
prodrugs, determines their suitability for administration and is preferably around 106.17 In 
this chapter the chemical and enzymatic stabilities of a series of amino acid ester prodrugs 
introduced in chapter 2 are evaluated. The chemical stability was tested under the same 
conditions used for in vitro and in vivo studies.3, 18 That is, the chemical hydrolysis of the 
prodrugs was followed in citrate buffer pH 5 which is the acidity of the donor phase of the 
utilized iontophoretic system. To guarantee the rapid hydrolysis of 5-OH-DPAT ester 
prodrugs in blood after skin absorption, the enzymatic stability was determined in human 
blood plasma. 
3.2 RESULTS 
3.2.1 Influence of the prodrug concentration on hydrolysis half-life 
The chemical hydrolysis of the 5-OH-DPAT prodrugs was studied in citrate buffer pH 5 
(5mM) at 32 °C, representing the mean skin temperature. This particular buffer was chosen 
because of its optimal properties for iontophoretic experiments with 5-OH-DPAT in vitro 
as well as in vivo.3, 18. At appropriate intervals samples were withdrawn and the observed 




plotting the logarithm of the remaining prodrug concentration as a function of time. The 
first experiments with the newly synthesized prodrugs were conducted at a prodrug 
concentration of 0.31 mM (compounds 2.29, 2.35, 2.37, 2.38, 2.40, 2.43 and 2.44). Because 
of limited availability of the parent drug 5-OH-DPAT, we determined the optimal prodrug 
concentration. The glycine prodrug 2.28, as representative for all 5-OH-DPAT prodrugs 
described in this chapter, was studied at concentrations of 0.05, 0.25 and 0.31 mM (Table 
3.1). The estimated half-life of 2.28 at all three prodrug concentrations was around 20 hours 
and statistically not different. Similar results were shown for experiments with the L-valine 
prodrug 2.31 (data not shown). Based on these results the next stability experiments were 
conducted at a concentration of 0.05 mM (compounds 2.30-2.34, 2.36, 2.39, 2.41 and 2.46). 
Table 3.1 Effect of concentration (n=3) on mean half-lives (± SEM) during hydrolysis of the glycine 
ester of 5-OH-DPAT (2.28) in 0.005 M citrate buffer (pH 5) 




3.2.2 Non-enzymatic hydrolysis in citrate buffer 
We have divided the prodrugs in five groups based on the side chain of the pro-moieties: 
prodrugs with bulky side chains, prodrugs with weakly basic side chains, prodrugs with 
alkylated α-amino groups, a homologous series and prodrugs with an alcoholic or aromatic 
side chain. The hydrolysis profiles of the 5-OH-DPAT prodrugs in citrate buffer pH 5 are 
plotted in Figure 3.1 and are based on the estimated half-lives presented in Table 3.2. The 
decrease in 5-OH-DPAT ester concentration was quantitatively accompanied by 
corresponding increase in 5-OH-DPAT concentration (data not shown). 
A) Influence of bulky side chains on the chemical hydrolysis of 5-OH-DPAT prodrugs. 
The pseudo first-order hydrolysis rate plots for the chemical hydrolysis of prodrugs 2.28-
2.33 are shown in Figure 3.1 A. This group of prodrugs consists of esterified amino acids 
which contain closely related aliphatic substituents in the side chain. The 1-
aminocyclopropanecarboxylic acid prodrug 2.30 was chemically the most stable prodrug 
with a half-life of 150 hours. The glycine (2.28) and L-alanine (2.29) esters of 5-OH-DPAT 
were the least stable with half-lives of 21 and 16 hours, respectively. The L- and D-valine 
prodrugs 2.31 and 2.32 with comparable half-lives of 53 en 49 hours, respectively, were 
more stable than prodrug 2.28. The L-isoleucine 5-OH-DPAT ester (2.33) was fairly stable 
with a half-life of 73 hours. Pairwise multiple comparisons of the half-lives of compounds 
2.28-2.33 showed that the mean half-lives differed significantly (p < 0.005). Two 
exceptional cases were the glycine prodrug 2.28 versus the L-alanine prodrug 2.29 and the 
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diastereomeric pair: the L-valine prodrug 2.31 versus the D-valine prodrug 2.32. The half-
lives of these pairs did not differ significantly and thus showed similar chemical stability 
under the slight acidic conditions. 
Figure 3.1 Pseudo first-order hydrolysis rate plots of 5-OH-DPAT prodrugs in citrate buffer pH 5 at 
32°C, based on the estimated half-lives presented in Table 3.2. The prodrugs are listed per group in 
sequence of descending half-life. A) prodrugs with a bulky side chain; B) prodrugs with a weakly 
basic side chain; C) prodrugs with an alkylated α-amino group; D) homologous series. 
B) Influence of a weakly basic side chain on the chemical hydrolysis of 5-OH-DPAT 




(2.28), L-lysine (2.36), L-arginine (2.43) and 5-aminovaleric acid (2.41) prodrugs. This 
group of prodrugs contains weakly basic amino groups in the side chain. The half-lives of 
2.36, 2.41 and 2.43 were compared pairwise to each other and showed statistical significant 
differences (p < 0.05). The half-lives found for the prodrugs 2.36 and 2.43 were 10 and 0.3 
hours, respectively, and prodrug 2.41 exhibited a half-life of 1.6 hours. 
Table 3.2 Estimated half-lives (t1/2) of prodrugs 2.28-2.41, 2.43, 2.44 and 2.46 during hydrolysis in 
5 mM citrate buffer, pH 5 at 32 ºC (n=3, exceptions are 2.28 (n=9), 2.30-2.33 and 2.39 (n=6). 
Compound 5-OH-DPAT ester 
Estimated t1/2 ± SEM 
(Hours) 
5 mM Citrate Buffer (pH 5) 
t1/2 ratio prodrug 
compared to 
prodrug 2.28 
A Bulky Side Chain   
2.28 Glycine 20.7±0.3a 1 
2.29 L-Alanine 16.2±0.3a 0.8 
2.30 1-Aminocyclopropane-1-carboxylic acid 149.7±3.2 7.7 
2.31 L-Valine 53.1±1.6b 2.6 
2.32 D-Valine 48.7±6.9b 2.4 
2.33 L-Isoleucine 72.7±2.8 3.5 
B  Basic Side Chain   
2.36 L-Lysine 9.6±0.2 0.5 
2.43 L-Arginine 0.3±0.004 0.01 
C Alkylated α-amino group   
2.37 L-Proline 6.6±0.2 0.3 
2.38 N-Methylglycine 13.7±0.6 0.7 
2.44 N,N-Dimethylglycine 31.8±0.1 1.5 
2.46 N,N,N-Trimethylglycine 36.0±0.5 1.7 
D Homologous Series   
2.39 β-Alanine 117.0±5.3 5.7 
2.40 γ-Aminobutyric acid 6.6±0.1 0.3 
2.41 5-Aminovaleric acid 1.6±0.01 0.08 
E Alcoholic and Aromatic Side Chain   
2.34 L-Serine 18.6±0.5 0.9 
2.35 L-Phenylalanine 17.1±0.3 0.8 
a, b: Statistically no difference in mean t1/2 after pairwise one-way ANOVA with post-hoc Tukey’s test 
within the group of compounds 2.28-2.33 (p < 0.05). 
C) Influence of alkylation of the α-amino group on the chemical hydrolysis of 5-OH-
DPAT prodrugs. The pseudo first-order hydrolysis rate plots of the glycine (2.28), L-
proline (2.37), N-methylglycine (2.38), N,N-dimethylglycine (2.44) and N,N,N-
trimethylglycine (2.46) 5-OH-DPAT prodrugs are presented in Figure 3.1 C. The half-lives 
were evaluated pairwise against each other and were shown to differ significantly (p < 
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0.001). This group includes a series of prodrugs with primary, secondary, tertiary and 
quaternary alkylated amine groups of the pro-moiety. The half-lives of 2.37, 2.38, 2.44, 
2.46 were 7, 14, 32, 36 hours, respectively. 
D) Influence of increasing chain length on the chemical hydrolysis of 5-OH-DPAT 
prodrugs. In Figure 3.1 D the pseudo first-order hydrolysis rate plots are shown of glycine 
(2.28), β-alanine (2.39), γ-aminobutyric acid (2.40) and 5-aminovaleric acid (2.41) 5-OH-
DPAT ester prodrugs. The half-life values of compounds 2.28 and 2.39-2.41 were 
evaluated pairwise versus each other and were shown to differ significantly (p < 0.001). 
This group of prodrugs is characterized by a variable chain length between the ester and 
amino group, i.e. a homologous series. This range varies between one and four methylene 
groups. The half-lives of the prodrugs 2.39, 2.40 and 2.41 are 117, 7 and 1.6 hours, 
respectively. 
E) Influence of alcoholic and aromatic side chains on the chemical hydrolysis of 5-OH-
DPAT prodrugs. In contrast to the prodrugs with L-serine (2.34) and L-phenylalanine  
(2.35) pro-moieties, the glycine prodrug contains no alcoholic or phenylic amino acid side 
chain. Although comparison of the half-lives of compounds 2.34 and 2.35 versus 2.28 
showed significant differences (p < 0.05), the half-lives differed only 2 and 4 hours from 
the half-life of 2.28, respectively. Therefore, the hydrolysis rate plots of 2.34 and 2.35 5-
OH-DPAT prodrugs were omitted from Figure 3.1. 
3.2.3 Non-enzymatic hydrolysis in phosphate buffered saline 
The 1-aminocyclopropanecarboxylic acid (2.30), L-valine (2.31), D-valine (2.32), L-
isoleucine (2.33) and β-alanine (2.39) esters of 5-OH-DPAT were shown to be the most 
chemically stable prodrugs in citrate buffer pH 5 (Section 3.2.2). To further investigate the 
applicability of these prodrugs for iontophoretic delivery, the hydrolysis in human blood 
plasma was determined. First, the non-enzymatic hydrolysis of these prodrugs and 
compound 2.28 was determined at pH 7.4. The hydrolysis rate constants (kobs) and half-
lives (t1/2) were obtained by measuring the initial rate of 5-OH-DPAT formation in triplicate 
during hydrolysis experiments in 9.5 mM phosphate buffered saline (PBS), pH 7.4. The 
hydrolysis rate plots of these experiments are presented in Figure 3.2 and are based on the 




Figure 3.2 Pseudo first-order rate plots of 5-OH-DPAT formation during prodrug hydrolysis of 
prodrugs 2.28, 2.30-2.33 and 2.39 at 37 °C with an initial concentration of 100 µM in: A) 9.5 mM 
phosphate buffered saline (PBS) pH 7.4; B) 4% w/v human serum albumin (HSA) in PBS; C) 80% 
v/v human blood plasma (HBP) in PBS. The plots are based on the estimated half-lives presented in 
Table 3.3 and the prodrugs are listed per group in sequence of ascending half-life. 
The 1-aminocyclopropane-1-carboxylic acid prodrug 2.30 was very stable compared to the 
other tested prodrugs, and we found a half-life of 1438 minutes (24 hours) (p < 0.025). This 
finding resembled relatively the highest chemical stability determined from hydrolysis 
experiments in citrate buffer pH 5. The half-lives of the other prodrugs were ranked in the 
following order: β-alanine (2.39, 57 min) > glycine (2.28, 25 min) > L-isoleucine (2.33, 19 
min) ≥ D-valine (2.32, 17 min) ≥ L-valine (2.31, 13 min) (p < 0.025). 
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3.2.4 Enzymatic hydrolysis in human serum albumin and human blood 
plasma 
According to the similar method described in section 3.2.3, the half-lives of compounds 
2.28, 2.30-2.33 and 2.39 were estimated when hydrolyzed in human serum albumin (HSA, 
4% w/v) and human blood plasma (HBP, 80% v/v). The plots for the enzymatic hydrolysis 
rates for these compounds are presented in Figure 3.2 and are based on the estimated half-
lives presented in Table 3.3. 
A concentration of 4% HSA per 100 mL PBS at pH 7.4 resembles an 80% dilution of the 
mean normal albumin concentration of the general population (4.5±1.0 g /100 mL).19 Table 
3.3 shows the following stability trend under influence of HSA: β-alanine (2.39, 10 min) ≈ 
L-isoleucine (2.33, 10 min) > L-valine (2.31, 7 min) ≈ D-valine (2.32, 5 min) > 1-
aminocyclopropane-1-carboxylic acid (2.30, 1.6 min) ≈ glycine (2.28, 0.7 min). The highest 
enzymatic stability in 4% HSA was found for prodrugs 2.33 and 2.39. The half-lives of 
compounds 2.31 and 2.32 were not significantly different. Compared to the half-lives 
determined from hydrolysis experiments in PBS (Section 3.2.3), the half-lives of 2.31 and 
2.32 decreased by a factor 1.8 and 3.2, respectively. The half-lives of prodrugs 2.28 and 
2.30 were considerably decreased, namely with a factor 35 and 899, respectively. 
Table 3.3 Estimated half-lives (t1/2) of the hydrolysis of prodrugs 2.28-2.41, 2.43, 2.44 and 2.46 at 
37 °C (n=3) with an initial concentration of 100 µM in PBS, HSA and HBP. 
  Estimated t1/2 ± SEM (Minutes) 
Comp. 5-OH-
DPAT ester 




























 1438.3±52  1.6±0.1c 0.001  0.18±0.007g, h 0.0001 0.11 
2.31 L-Valine  12.6±1.2a  7.1±0.01d 0.6  0.22±0.02g, i 0.02 0.03 
2.32 D-Valine  16.8±0.2a, b  5.2±0.8d 0.3  0.15±0.01f, g 0.009 0.03 
2.33 L-Isoleucine  18.8±0.9b  9.7±0.6e 0.5  0.41±0.02 0.02 0.04 
2.39 β-Alanine  56.7±6.0  10.2±0.1e 0.2  0.24±0.01h, i 0.004 0.02 
a-i: Statistically no difference in mean t1/2 after pairwise one-way ANOVA with post-hoc Tukey’s test 
within the group of compounds  tested in PBS, HSA and HBP (p < 0.025). 
Table 3.3 shows the following enzymatic stability trend in HBP (80%): L-isoleucine (2.33, 
0.41 min) > β-alanine (2.39, 0.24 min) ≈ L-valine (2.31, 0.22 min) ≈ 1-aminocyclopropane-
1-carboxylic acid (2.30, 0.18 min) ≈ D-valine (2.32, 0.15 min) ≈ glycine (2.28, 0.09 min). 
Prodrug 2.33 with the L-isoleucine pro-moiety is enzymatically the most stable prodrug, 
while the glycine prodrug 2.28 is the most labile prodrug. The L-valine and D-valine 




2.39 show moderate half-lives between 0.15 and 0.24 minutes. Although small differences 
are observed between the half-lives of the prodrugs during hydrolysis in HBP, in general all 
prodrugs are enzymatically highly instable compared to their chemical stability. 
3.3 DISCUSSION 
Based on previous investigations on hydrolysis rates of several amino acid esters at various 
pH values and corrected for hydrolysis by the buffer concentration, the following general 
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 k  k     (Equation 3.1) 
where the rate constant k0 refers to the pH-independent hydrolysis of the protonated form of 
the ester prodrug. kOH and k'OH represent the second-order rate constants for the attack of 
the hydroxide ion on the protonated and unprotonated forms of the esters, respectively. 
These rate constants are based on several mechanisms of intramolecular catalysis, namely 
(a) intramolecular nucleophilic catalysis, (b) intramolecular general-base catalysis, (c) 
intramolecular general-acid specific base catalysis, and (d) electrostatic facilitation (Figure 
3.3).23 The factors aH/(aH + Ka) and Ka/(aH + Ka) represent the fractions of the protonated 
and unprotonated forms of the total ester prodrug concentration, respectively. aH and aOH 
refer to the hydrogen ion and hydroxide ion activity and Ka is the ionization constant of the 
amino group in the amino acid ester prodrug. 
 
Figure 3.3 Mechanisms available to the neighbouring amino group for facilitation of ester hydrolysis. 
We hypothesize that the pH-hydrolysis rate profile of the series of 5-OH-DPAT ester 
prodrugs follows equation 3.1. Most of the α-amino acid ester prodrugs that were 
investigated have calculated pKa values of about 8, and at pH 5 the α-amino functional 
groups will be largely protonated.24 Therefore the α-amino group is strongly electron-
withdrawing and activates the ester function to hydrolysis. The mechanisms of the 
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hydrolysis of amino acid esters depend mainly on the pH range in which the hydrolysis 
takes place: 
1 At pH values < 4, the primary reaction, k0, involves water attack on the protonated 
amino acid ester. 
2 At pH values between pH 5 and the pKa value, the primary reaction is probably 
hydroxide ion attack on the protonated amino acid ester or attack of water on the 
unprotonated amino acid ester. 
3 At pH > pKa, the major reaction is probably hydroxide attack on the unprotonated 
amino acid ester.22 
Thus, at low pH the observed hydrolysis rate will be solely dependent on k0 and the 
hydrolysis rate will be low. Therefore we use acidification with TFA to stop the hydrolysis 
in our experiments. Because a low buffer concentration was used consistently for all 
experiments, its intermolecular catalytic influence may be negligible.22 Differences in kobs 
are assumed to arise only from differences in pH (or aOH), pKa (or Ka) and intramolecular 
catalysis of the amino group of the pro-moiety defined as the rate constants k0, kOH and 
k'OH. Equation 3.1 and the mechanisms shown in Figure 3.3 will be used for the explanation 
of the differences in chemical hydrolysis found for the amino acid ester prodrugs of 5-OH-
DPAT. 
3.3.1 Influence of the prodrug concentration on hydrolysis half-life 
We found no differences in hydrolysis rate for the experiments with different initial prodrug 
concentrations. The intermolecular catalysis of the prodrugs and thus the influence of the 
prodrug concentrations on the hydrolysis half-life appears to be negligible in our 
experiments. Therefore, the chemical hydrolysis rate constants of all prodrugs were 
determined at initial concentrations of 0.05 or 0.31 mM and were statistically compared 
among each other in groups of analogous series. 
3.3.2 Non-enzymatic hydrolysis in citrate buffer 
A) Influence of bulky groups on the chemical hydrolysis of 5-OH-DPAT prodrugs. 
The increasing steric hindrance from the glycine (2.28) and L-alanine (2.29) to the  L-valine 
(2.31) and D-valine (2.32) to ultimately the L-isoleucine (2.33) 5-OH-DPAT esters was 
reflected in the increased chemical stability. Although the half-life of the L-alanine prodrug 
2.29 according to the increased steric effect was expected to be higher than the half-life of 
the glycine prodrug 2.28, it did not differ significantly. The experimental pKa value of the 
amino functional group of L-alanine is 9.69, while this pKa value for glycine is 9.60.25, 26  If 
the negative effect on the hydrolysis rate by the increased steric hindrance of the methyl 
group side chain of 2.29 is balanced by the positive effect by the increased pKa, this could 
be a reason for similar stability found for the L-alanine and glycine ester prodrugs. 




to the extent of prodrugs 2.31, 2.32 and 2.33, it was chemically the most stable prodrug in 
this series. Bender et al hypothesized that this increased chemical stability is caused by 
hyperconjugative stabilization of the carbonyl group by the cyclopropane ring.27 
B) Influence of a weakly basic side chain on the chemical hydrolysis of 5-OH-DPAT 
prodrugs. Reference glycine ester prodrug 2.28 has an α-amino group with a calculated 
pKa of 8.0.24 In addition to an α-amino group with a pKa of 8.1, L-lysine ester prodrug 2.36 
has an extra amino group on the ε–position (pKa 10) and L-arginine ester prodrug 2.43 has a 
guanidino group on the δ-position (pKa 14). The amino group of 5-aminovaleric acid ester 
prodrug 2.41 is located on the δ-position of the amino acid and has a calculated pKa of 10. 
The decreased chemical stability of this group of prodrugs may be explained by the 
introduction of an (additional) amino group with a higher pKa value. Therefore these 
prodrugs have an increased intramolecular catalysis of hydrolysis. The lengthy chains of 
this group of prodrugs may cause various spatial conformations during intramolecular 
catalysis (Figure 3.3) which consist of 7 to 9-membered rings. 
C) Influence of alkylation of the α-amino group on the chemical hydrolysis of 5-OH-
DPAT prodrugs. The L-proline (2.37, pKa 8.5) and N-methylglycine (2.38, pKa 8.3) 
prodrugs are hydrolyzed faster than the reference glycine prodrug (2.28, pKa 8.0). The 
positive effect on the hydrolysis of the greater pKa values of prodrugs 2.37 and 2.38 
compared to prodrug 2.28 may be explained by the corresponding greater fraction of 
protonated amino acid ester. This larger protonation gives a stimulation of intramolecular 
catalysis and an increased electron-withdrawing effect of the protonated amine on the 
carbonyl group making it more sensitive for hydrolysis. The N,N-dimethylglycine (2.44) 
and N,N,N-trimethylglycine (2.46) prodrugs are hydrolyzed slower than prodrug 2.28. The 
higher half-lives compared to prodrug 2.28 can be explained by the lower calculated pKa 
value of prodrug 2.44 (pKa 7.0) and the absence of a pKa value for the quaternary prodrug 
2.46. The hydrolysis of prodrug 2.46 is probably catalyzed by electrostatic facilitation 
(Figure 3.3). 
D) Influence of increasing chain length on the chemical hydrolysis of 5-OH-DPAT 
prodrugs. The β-alanine (2.39, pKa 8.8), γ-aminobutyric acid (2.40, pKa 9.8), and 5-
aminovaleric acid (2.41, pKa 10.2) prodrugs all have higher calculated pKa values than 
reference prodrug 2.28 (pKa 8.0). With the exception of the β-alanine prodrug, the higher 
pKa values of the prodrugs with an increased chain length gave shorter half-lives as 
expected from equation 3.1. Although the electron-withdrawing effect will decline with 
increasing chain length between the amino group and the carbonyl, the intramolecular 
catalytic influence of the amino group will remain pronounced. Interestingly, the β-alanine 
2.39 is extremely stable in contrast to the chemically unstable prodrugs 2.40 and 2.41. The 
stabilizing effect of β-alanine on chemical hydrolysis has previously been determined for 
metronidazole and d-α-tocopherol prodrugs.28, 29 Moreover, Nam et al. found that folding 
effects of the terminal amino group might play an important role towards the amide 
STABILITY STUDIES OF A SERIES OF AMINO ACID ESTER PRODRUGS OF 5-OH-DPAT 
 
 103 
hydrolysis of prodrugs. The formation of the more stable five-membered ring intermediate 
during the amino mediated intramolecular cyclative cleavage of the γ-amino butyric acid 
prodrug was more favourable, compared to the constrained four-membered ring 
intermediate of the β-alanine prodrug.30 The same reason could explain the chemical 
stability of the β-alanine ester prodrug of 5-OH-DPAT compared to the γ-aminobutyric acid 
and 5-aminovaleric acid ester prodrugs of 5-OH-DPAT. 
E) Influence of alcoholic and aromatic side chains on the chemical hydrolysis of 5-OH-
DPAT prodrugs. On the one hand, the calculated pKa values of the L-serine prodrug 2.34 
(pKa 7.3) and the L-phenylalanine prodrug 2.35 (pKa 7.74) are lower than the pKa value of 
the glycine prodrug 2.28 (pKa 8.08). As described in equation 3.1, a smaller pKa results in a 
smaller protonated fraction of the amino functional groups. Thus both the electron-
withdrawing effect and the intramolecular catalysis are decreased and consequently the 
ester is stabilized. Also the steric hindrance of prodrugs 2.34 and 2.35 is greater than the 
steric hindrance of 2.28, which causes a stabilization of the ester group against hydrolysis. 
On the other hand, the predominant electron-withdrawing properties of the alcoholic and 
aromatic groups, could make the ester more susceptible to hydrolysis.31 The corresponding 
half-lives found in this group of prodrugs may thus be explained by opposing effects of 
pKa, steric hindrance and electron-withdrawing properties. 
3.3.3 Non-enzymatic hydrolysis in phosphate buffered saline 
Compounds 2.30, 2.31, 2.32, 2.33 and 2.39 were selected as suitable candidates for further 
development because of their sufficient stability in citrate buffer. In general, the half-lives 
of the hydrolysis in PBS at pH 7.4 were considerably lower than the half-lives found for the 
hydrolysis in citrate buffer at pH 5. Thus, a higher pH has a destabilizing influence on the 
chemical hydrolysis of the 5-OH-DPAT prodrugs. This can be explained from equation 3.1, 
because a higher pH gives an increase of aOH and therefore a higher hydrolysis rate. In 
contrast to the hydrolysis experiments performed in citrate buffer pH 5 at 32 °C, the glycine 
ester of 5-OH-DPAT 2.28 was chemically slightly more stable than the more bulky 
compounds 2.31-2.33 when hydrolyzed at pH 7.4 in PBS at 37 °C. Apparently, the role of 
steric hindrance on chemical stability at pH 7 has become smaller compared to its role on 
stability at pH 5. Both prodrugs 2.39 and 2.30 were the most stable prodrugs in PBS and 
these results resembled our previous data obtained from the chemical hydrolysis in citrate 
buffer. 
3.3.4 Enzymatic hydrolysis in human serum albumin 
L-isoleucine (2.33) and β-alanine (2.39) esters were showing the highest enzymatic stability 
in 4% HSA. The presence of HSA decreased the half-lives by a factor varying between 2 
for the L-valine (2.31) and 1000 for the 1-aminocyclopropanecarboxylic acid (2.30) 




of HSA on hydrolysis was less pronounced for the steric hindered L-valine (2.31, factor 2), 
D-valine (2.32, factor 3) and L-isoleucine (2.33, factor 2) prodrugs, but was more distinct 
for the glycine (2.28, factor 33) and 1-aminocyclopropane-1-carboxylic acid (2.30, factor 
1000) prodrugs which lacked branched aliphatic side chains. Thus, for the examined 5-OH-
DPAT prodrugs the influence of HSA on the hydrolysis depended mostly on the substrate 
structure, especially steric hindrance played a crucial role in this. Even though, a 
contamination by a genuine hydrolase (mainly pseudo-cholinesterase) cannot be 
excluded.32, 33  
Moreover, HSA is able to bind stereoselective a great number of various endogenous and 
exogenous compounds.34 The catalytic activity of HSA on the L-alanine ester of p-
nitrophenol was twice as high as the activity of HSA on the D-alanine ester. In contrast, the 
enzymatic activity on the L- and D-phenylalanine esters of p-nitrophenol was similar.35 
Reversible binding of prodrugs to HSA in combination with regeneration of parent drug by 
the esterase-like properties of HSA could lead to sustained release.36 However, in our case 
the sustained release factor is already covered by controlled iontophoresis. Moreover, our 
studies showed that the prodrugs were hydrolyzed rapidly in HBP, which prevents 
sustained release in the blood stream. Based on the similar half-lives found for L- and D-
valine (S)-5-OH-DPAT in 4% HSA we can conclude that HSA does not catalyse the 
hydrolysis of these prodrugs diastereoselectively. 
3.3.5 Enzymatic hydrolysis in human blood plasma 
Many examples have shown very rapid biotransformation rates for prodrugs in rodents, 
which could lead to an underestimation of the stability of the prodrugs in humans.8 
Therefore, we have chosen to determine the enzymatic hydrolysis of the 5-OH-DPAT 
prodrugs in HBP. The observed half-lives in HBP of all investigated prodrugs were less 
than 1 minute (Table 3.3). The ratios comparing the hydrolysis rates in HBP to HSA 
showed that influence of other hydrolyzing components found in HBP, like esterases, was 
more pronounced for the L-valine (2.31, factor 33), D-valine (2.32, factor 33) and L-
isoleucine (2.33, factor 25) prodrugs with steric hindering side chains than for the glycine 
(2.28, factor 8) and 1-aminocyclopropane-1-carboxylic acid (2.30, factor 9) prodrugs. This 
observation was vice versa to the influence of HSA on the hydrolysis rate (vide supra). An 
exception was the β-alanine prodrug 2.39, which was moderately affected by the HSA 
enzymatic acitivity, but was extremely labile to other hydrolyzing components in HBP, i.e. 
esterases. In addition to e.g. cholinesterase and arylesterase, human valacyclovirase could 
be responsible for the increased hydrolysis in HBP. Human valacyclovirase has a unique 
binding mode and specificity for amino acid esters.37 In general, the amino acid prodrugs of 
5-OH-DPAT are immediately hydrolysed in HBP pH 7.4 at 37 °C. 
The hydrolysis of butyryl propranolol was non-stereoselective in plasma.38 In addition, 
Udata et al. found that the disappearance of four diastereomeric phenylbutyryl propranolol 
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ester prodrugs in rat plasma was stereoselective.39 Since esterase recognition typically 
favors L-amino acids over D-amino acids, the presence of L-amino acid residues makes the 
peptides better substrates for these enzymes.8 With the aim to manipulate the enzymatic 
hydrolysis rate in HBP diastereomeric esters of L- and D-valine with (S)-5-OH-DPAT were 
synthesized and tested. Unfortunately, their half-lives showed no significant difference for 
hydrolysis in HBP. Thus, HBP does not catalyse the hydrolysis of the L- and D-valine (S)-
5-OH-DPAT prodrugs diastereoselectively. 
3.3.6 Selection of Prodrugs for further investigation 
The 1-aminocyclopropane-1-carboxylic acid (2.30), L-valine (2.31), D-valine (2.32), L-
isoleucine (2.33) and β-alanine (2.39) prodrugs are chemically stable at pH 5 which is the 
acidity in the donor compartment of iontophoretic experiments with 5-OH-DPAT. 
Moreover, these prodrugs will be rapidly hydrolyzed on arrival in the blood stream after 
transdermal delivery by iontophoresis. Because the valine prodrugs 2.31 and 2.32 show 
similar stabilities in HBP, the natural amino acid L-valine is preferred over the non-
physiological amino acid D-valine. The L-isoleucine ester of 5-OH-DPAT (2.33) has a high 
lipophilicity which may have an adverse effect on transdermal iontophoretic delivery.40 
Therefore, the 1-aminocyclopropane-1-carboxylic acid (2.30), L-valine (2.31) and β-alanine 
(2.39) 5-OH-DPAT esters are promising candidates for further experiments. Nevertheless, 
the non-proteinogenic amino acids of compounds 2.30 and 2.39 have biological activities of 
their own. 1-Aminocyclopropane-1-carboxylic acid is a non-physiological partial agonist 
on the glycine modulatory site of the NDMA receptor.41 And β-alanine occurs naturally in 
the CNS and has several recognized receptor sites, namely at the NDMA, glycine and 
GABA receptors.42  Thus, in principle both amino acids could lead to side effects. 
Nevertheless, the β-alanine prodrug 2.39 is preferred because it  has been used orally and 
topically, and is tolerated fairly well.42 
 In conclusion, in a series of novel amino acid ester prodrugs of 5-OH-DPAT we have 
identified some promising candidates for iontophoretic delivery. The stability is highly 
dependent on the side chain, and the prodrugs were completely hydrolysed instantaneously 
in 80% HBP at 37 °C. The L-valine (2.31)and β-alanine (2.39) prodrugs were acceptably 
stable in the iontophoresis donor phase at pH 5, and showed a 4-fold and 14-fold increase in 
solubility compared to 5-OH-DPAT itself (Chapter 5).43 These prodrugs are suitable 
candidates for further in vitro and in vivo iontophoretic experiments. 
3.4 EXPERIMENTAL SECTION 
3.4.1 Materials 
Trifluoroacetic acid (Fluka), citric acid trisodium salt (anhydrous, Sigma), citric acid (Aldrich), 




serum albumin (96%-99% agarose gel electrophoresis, Sigma), screw top 2 mL amber vials 
(Supelco), black top closures with silicone septa (Supelco), inserts for 2 mL standard opening vial 
with 4.6 mm I.D. (Supelco) were purchased from Sigma-Aldrich. Sodium chloride (Merck) and 
potassium chloride (Merck) were purchased from VWR International (Amsterdam, The Netherlands). 
Pooled human plasma with lithium heparin as anticoagulant (6 individual mixed gender donors) was 
purchased from Sera Laboratories International (Bolney, United Kingdom).  Acetonitrile HPLC-S 
(gradient grade) was obtained from Biosolve (Valkenswaard, The Netherlands). Ultrapure water was 
obtained after purification with an Arium 611 VF system fitted with a Sartopore 2 150 filter with a 
resistivity of 18.2 MΩ (Sartorius Stedim Biotech S.A., Aubagne, France). The handling of the 
hygroscopic prodrugs was performed in an Aldrich AtmosBag (Aldrich) under nitrogen atmosphere. 
The 70 mM NaCl 5mM citrate buffer was prepared by dissolving 0.818 gram citric acid trisodium 
salt, 0.352 gram citric acid and 4.091 gram sodium chloride in 1.0 L ultrapure water and adjusting the 
pH to 5.00 with 0.1 N sodium hydroxide or 0.1 N hydrochloric acid if necessary. The phosphate 
buffered saline 0.0095 M was prepared by dissolving 1.135 gram sodium phosphate dibasic 
anhydrous, 0.200 gram potassium phosphate monobasic, 8.125 gram sodium chloride and 0.1875 
gram potassium chloride in 1.0 L ultrapure water and adjusting the pH to 7.4 with 0.1 M phosphoric 
acid or 0.1 N sodium hydroxide if necessary. The 4% (w/v) solution of human serum albumin was 
prepared by dissolving 5.0 grams human serum albumin in 125 mL phosphate buffered saline and 
adjusting the pH to 7.4 with 0.1 N NaOH. 80% (v/v) human blood plasma was prepared by diluting 
39 mL human blood plasma to a total volume of 48.75 mL with phosphate buffered saline pH 7.4. 
3.4.2 Hydrolysis of prodrugs in citrate buffer pH 5 
The initial concentration used for compounds 2.29, 2.35, 2.37, 2.38, 2.40, 2.43 and 2.44 was 0.31 
mM. Prodrugs 2.30-2.34, 2.36, 2.39, 2.41 and 2.46 were tested at initial prodrug concentrations of 
0.05 mM. 
The initial rates of hydrolysis were used to obtain the observed first-order rate constants (kobs) and to 
calculate the half-lives (t1/2). Least-square equations, derived by correlating areas in HPLC 
chromatograms to known concentrations of prodrug were used for calculation of the residual prodrug 
concentration in the studied samples. The correlation coefficients of the standard curves were 0.99.  
The observed first-order hydrolysis rate constants of the 5-OH-DPAT prodrugs were determined by 
plotting the logarithm of the remaining prodrug concentration as a function of time. The linear 
regression slopes of these plots (r2 ≥ 0.95) are related to the observed rate constant, kobs, and are given 
by:  time) vsC (log slope 
e log




ln2t  . In order to study the relationship between the chemical stabilities, the results 
were grouped in four series of related compounds and are presented in separate pseudo first-order rate 
plots in Figure 3.1 A-D. The half-lives are presented in Table 3.1. Statistical significance was 
evaluated with SigmaPlot for Windows v. 10 by performing one-way ANOVA with post-hoc Tukey’s 
test to compare means within each separate group (n=3-9). 
For the experiments with prodrugs 2.28, 2.29, 2.35, 2.37, 2.38, 2.40, 2.43 and 2.44 the chemical 
hydrolysis was initiated by adding 20 μl of a 62.5 mM stock solution in eluent to 3.98 mL 5 mM 
citrate buffer (pH 5) preheated at 32 °C. The final concentration of the resulting solutions was about 
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313 μM. The test solutions of the compounds were vortexed and maintained in a Lab-Line Orbit 
Shaker (model 310, J-KEM scientific, J-KEM 3300) at a constant temperature of 32±0.2 °C. At 
appropriate intervals samples of 20 μL were withdrawn and in order to inhibit further hydrolysis were 
diluted with 230 μL eluent giving a concentration of 25 μM. The samples were stored in the freezer 
until they were analyzed by HPLC. For the experiments with prodrugs 2.28, 2.31, 2.39 the chemical 
hydrolysis was initiated by adding 20 μl of a 25 mM stock solution in 5 mM citrate buffer (pH 5) to 
1.98 mL 5 mM citrate buffer (pH 5) preheated at 32 °C. The final concentration of the resulting 
solutions was about 250 μM. The test solutions of the compounds were vortexed and maintained in a 
Lab-Line Orbit Shaker at a constant temperature of 32±0.2 °C. At appropriate intervals samples of 
100 μL were withdrawn and diluted with 900 μL H2O/ACN/TFA (2.9/1/0.004) giving a concentration 
of 25 μM. The samples were stored in the freezer until they were analyzed by HPLC. For the 
experiments with prodrugs 2.28, 2.30, 2.31, 2.32, 2.33, 2.34, 2.36, 2.39, 2.41 and 2.46 the chemical 
hydrolysis was initiated by adding 6 μl of a 25 mM stock solution in 5 mM citrate buffer (pH 5) to 
2.994 mL 5 mM citrate buffer (pH 5) preheated at 32 °C. The final concentration of the resulting 
solutions was about 50 μM. The test solutions of the compounds were vortexed and maintained in a 
Lab-Line Orbit Shaker at a constant temperature of 32±0.2 °C. At appropriate intervals samples of 
100 μL were withdrawn and diluted with 100 μL H2O/ACN/TFA (1.2/1/0.004) giving a concentration 
of 25 μM. The samples were stored in the freezer until they were analyzed by HPLC. The compounds 
were estimated by measuring the peak areas or peak heights in relation to those of standards which 
were prepared by serial dilution of known concentrations (0.5, 5, 10 and 25 μM) and 
chromatographed under the same conditions. 
3.4.3 Hydrolysis of prodrugs in phosphate buffered saline pH 7.4 
The formation of 5-OH-DPAT during prodrug hydrolysis followed pseudo-first-order kinetics and is 
described by: )e(1DPAT]-OH-[5DPAT]-OH-[5 ktmaxformed
 . The observed first-order 
hydrolysis rate constants of the 5-OH-DPAT formation from the selected prodrugs were determined 





formed  as a function of time. The linear regression 
slopes of these plots (r2 ≥ 0.95) are related to the observed rate constant, kobs, and are given by: 
 time) vsC (log slope 
loge
1kobs  . The half-lives (t1/2) can be estimated by the equation: k
ln2t1/2  .  
For the experiments with prodrugs 2.28, 2.30, 2.31, 2.32, 2.33 and 2.39 the chemical hydrolysis was 
initiated by adding 8 μl of a 25 mM stock solution in citrate buffer (pH 5) to 1.992 mL phosphate 
buffered saline (pH 7.4) preheated at 37 °C. The final concentration of the resulting solutions was 
about 100 μM. The test solutions of the compounds were vortexed and maintained in a Lab-Line 
Orbit Shaker at a constant temperature of 37±0.2 °C. At appropriate intervals samples of 100 μL were 
withdrawn and diluted with 100 μL H2O/ACN/TFA (1.2/1/0.004) giving a concentration of 50 μM. 
100 μL of the samples was further diluted with 100 μL eluent to give a concentration of 25 μM. The 
samples were stored in the freezer until they were analyzed by HPLC. The compounds were estimated 
by measuring the peak areas or peak heights in relation to those of standards which were prepared by 





3.4.4 Hydrolysis of prodrugs in human blood plasma (80% v/v) 
The rates of enzymatic hydrolysis for prodrugs 2.28, 2.30, 2.31, 2.32, 2.33 and 2.39 were studied in 
human blood plasma (80% (v/v) in phosphate buffered saline of pH 7.4) at 37°C. The formation of 5-
OH-DPAT which was measured during prodrug hydrolysis followed pseudo-first-order kinetics as 
described in 3.4.3 and the recovery of 5-OH-DPAT was 61%. The incubations were initiated by 
adding 8 μl of a 25 mM stock solution in citrate buffer (pH 5) to 1.992 mL human blood plasma 
(80%) preheated at 37 °C. The final concentration of the resulting solutions was about 100 μM. The 
test solutions of the compounds were vortexed and maintained in a Lab-Line Orbit Shaker at a 
constant temperature of 37±0.2 °C. At appropriate intervals samples of 100 μL were withdrawn and 
added to 100 μL cold 10% TFA in order to precipitate protein from the blood plasma. The samples 
were centrifuged for 10 minutes at 14,000 rpm and 100 μL of the resultant supernatant was then 
diluted with 100 μL H2O/ACN (1.2/1). The samples were stored in the freezer until they were 
analyzed by HPLC. The compounds were estimated by measuring the peak areas or peak heights in 
relation to those of standards which were prepared by serial dilution of known concentrations (0.5, 5, 
10 and 25 μM) and chromatographed under the same conditions.  
3.4.5 Hydrolysis of prodrugs in a 4% (w/v) solution of human serum 
albumin in phosphate buffered saline pH 7.4 
The rates of enzymatic hydrolysis for prodrugs 2.28, 2.30, 2.31, 2.32, 2.33 and 2.39 were studied in a 
solution of human serum albumin (4% (w/v) in phosphate buffered saline of pH 7.4) at 37°C. The 
formation of 5-OH-DPAT which was measured during prodrug hydrolysis followed pseudo-first-
order kinetics as described in 3.4.3 and the recovery of 5-OH-DPAT was 66%. The method was 
similar to the procedure described for the enzymatic hydrolysis experiments in section 3.6.4. 
3.4.6 HPLC analysis 
Chemical Stability: samples of prodrugs 2.29, 2.35, 2.37, 2.38, 2.40, 2.43 and 2.44 were analyzed 
isocratically on a HPLC system which consisted of an ISCO Model 2360 Gradient Programmer, a 
Waters 510 HPLC Pump, a Waters 486 Tunable Absorbance Detector and a HP 3396 Series II 
Integrator. Prodrugs 2.28, 2.30, 2.31, 2.32, 2.33, 2.34, 2.36, 2.39, 2.41 and 2.46 were analyzed 
isocratically on a Hewlett Packard Series 1100 HPLC system connected to a Tray-Cooling Marathon 
Basic+ Autosampler and a Hewlett Packard HP3395 Integrator. The samples were injected onto a 
Supelco Discovery C18 reversed-phase column (5 μm, 250 x 4.6 mm I.D.). The mobile phase 
consisted of a mixture of 23% acetonitrile and 77% water with 0.1% trifluoroacetic acid added. The 
flow was set at 1.0 mL/min and the analysis was performed at room temperature. The injection 
volume was 20 μL and the compounds were detected by UV at 217 nm. The run time was 12 minutes, 
except for compound 2.35 which had a run time of 20 minutes. The retention times of 5-OH-DPAT 
and the amino acid 5-OH-DPAT esters were: 9.57 min (2.12), 4.70 min (2.28), 4.85 min (2.29), 5.26 
min (2.30), 7.31 min (2.31), 7.70 min (2.32), 10.92 min (2.33), 4.58 min (2.34), 15.34 min (2.35), 
3.96 min (2.36), 5.25 min (2.37), 4.79 min (2.38), 5.14 min (2.39), 6.02 min (2.40), 6.68 min (2.41), 
4.09 min (2.43), 4.97 min (2.44), 5.46 min (2.46).  
Enzymatic Stability: samples of the prodrugs were analyzed according to a similar method described 
for the chemical stability on the Hewlett Packard Series 1100 HPLC system. The mobile phase 
consisted of a mixture of 21% acetonitrile and 79% water with 0.1% trifluoroacetic acid added. The 
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run time for the 80% (v/v) human blood plasma and 4% (w/v) human serum albumin experiments was 
18 minutes and the retention time of 5-OH-DPAT was 11.65 minutes. The run time for the phosphate 
buffered saline pH 7.4 experiments was 14 minutes and the retention time of 5-OH-DPAT was 9.50 
minutes.  
3.4.7 Data analysis 
All hydrolysis experiments were carried out in triplicate. The pseudo-first-order chemical hydrolysis 
rate constants (k) from the experiments conducted in citrate buffer were calculated from the linear 
slopes of plots of the logarithm of the remaining prodrug concentration against time (t). The pseudo-
first-order enzymatic hydrolysis rate constants and the pseudo-first-order chemical hydrolysis rate 
constants from experiments conducted in phosphate buffered saline were calculated from the linear 
slopes of plots of the logarithm of the formed 5-OH-DPAT concentration against time. The slopes of 
these plots are related to the rate constant, k, and given by k = 2.303 x slope (log C vs time). On the 
one hand the hydrolysis of the prodrug follows pseudo-first-order kinetics described by the formula: 
kt
0 e[Prodrug][Prodrug]
 . On the other hand, the formation of 5-OH-DPAT during prodrug 
hydrolysis also follow pseudo-first-order kinetics, but is described by another formula, i.e.: 
)e(1DPAT]-OH-[5DPAT]-OH-[5 ktmax
 . The half-lives (t1/2) can be estimated by the 
equation: 
k
ln2t1/2  .  
Statistical significance was evaluated with SigmaPlot for Windows Version 11.0 by performing one-
way analysis of variance with post-hoc Tukey’s test to compare means. 
3.4.8 pKa calculation 
The pKa values of the amino acid ester prodrugs were calculated with Pallas 1.2 of CompuDrug 
Chemistry Ltd.Copyright©1994. 
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The pharmacokinetic (PK) and pharmacodynamic (PD) properties of the active (S)-
enantiomer of the potent dopamine (DA) agonist 5-OH-DPAT were investigated in a novel 
anesthetized animal model. First, the relationship between current density, in vivo 
transport and plasma profile was characterized. Second, the effect of the anesthetic 
mixture, transdermal iontophoresis and blood sampling on the striatal DA release (PD 
endpoint) was investigated. Third, the PK-PD relationship following transdermal 
iontophoresis was investigated during a controlled and reversible pharmacological 
response. Given that the striatal DA levels are unaltered during experimental procedures, 
this rat model can be used to investigate the PK-PD relationship. The in vivo flux was 
found to be linearly correlated with the current density. Following both transdermal 
iontophoresis and IV infusion, a strong and reversible PD effect was observed. 
Compartmental modeling showed that the relationship between drug plasma concentration 
and biomarker response can be best characterized by an effect compartment, rather than 
an indirect response model. In addition, covariate analysis suggested that the delivery rate 
can affect the pharmacodynamic efficiency. Finally, simultaneous PK-PD analysis revealed 
that steady delivery rates are translated into continuous DAergic stimulation. This can be 
of great benefit for reducing side effects in the symptomatic treatment of Parkinson’s 
disease with 5-OH-DPAT. 
4.1 INTRODUCTION 
Transdermal iontophoresis is a well established physical method to facilitate the 
percutaneous penetration of molecules.1 By application of a small electrical current across 
the skin iontophoresis enhances the transdermal delivery of therapeutic agents. An 
important advantage of transdermal delivery is the circumvention of the hepatic first-pass 
metabolism, making it an interesting non-invasive alternative for oral drug delivery. A 
particular advantage of iontophoresis is the possibility to tailor the delivery to the patient’s 
needs by adjusting the current density. This may allow for better therapeutic efficacy and 
reduction in overdosing and subsequent side effects. These properties make iontophoresis 
an excellent method for the transdermal delivery of drug molecules for the symptomatic 
treatment of Parkinson’s disease. 
Parkinson’s disease is a neurodegenerative disorder, which is characterized by tremor, 
akinesia, rigidity and postural instability.2 Up to today orally dosed levodopa is still the 
most effective symptomatic treatment, but chronic use eventually leads to severe long-term 
side-effects, i.e. dyskinesia and the on-off phenomenon.3, 4 Current strategy to prevent or 
delay the onset of these side-effects is to administer therapeutics in a constant and 
controlled manner.5 Therefore, the transdermal iontophoretic delivery of the DAergic 
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agonists (R)-apomorphine, ropinirole and 5-OH-DPAT were investigated in vivo for their 
application in symptomatic treatment of Parkinson’s disease.6-9 
Besides a constant and controlled delivery, another attractive property of iontophoresis is 
the possibility to develop a feedback system. In this approach, the concentration of a 
relevant biomarker, extracted for instance with reverse iontophoresis, can be used to titrate 
the transdermal iontophoretic delivery of the drug molecule. Preferably, a 
pharmacodynamic endpoint instead of the drug plasma concentration should be chosen to 
monitor the drug effect. Under experimental conditions, striatal DA concentration, 
measured by microdialysis, has been shown to be a biomarker for DAergic activity.10, 11 
In the current investigation, we have therefore characterized pharmacokinetic-
pharmacodynamic (PK-PD) relationships of the DA agonist following transdermal 
iontophoresis using DA as a measure of the pharmacological effect. In order to optimize the 
feedback system, we have also performed an integrated evaluation of relationship between 
the pharmacodynamics, pharmacokinetics and the delivery rates of the compound. In a 
previous study, the PK-PD of 5-OH-DPAT as assessed, however a ceiling effect was 
observed, with DAergic levels not altering throughout the time frame of the experiments.7 
The aims of this study were three-fold. First, to examine the relationship between the 
current density, the in vivo iontophoretic transport and the (S)-5-OH-DPAT plasma profile. 
Given the requirement for the use of anaesthesia to conduct transdermal iontophoresis, 
second, to examine the effect of the anesthetic mixture, transdermal iontophoresis and 
blood sampling on the striatal DA release. Third, to assess the PK-PD relationship 
following transdermal iontophoresis of (S)-5-OH-DPAT, ensuring the induction of a 
controlled and reversible effect.7 
 
Figure 4.1 The molecular structures of (S)-5-hydroxy-2-(N,N-di-n-propylamino-tetralin ((S)-5-OH-
DPAT) and (R)-5-hydroxy-2-(N-n-propyl-N-α,α-dideutero-propylamino)-tetralin ((R)-d2-5-OH-
DPAT) 
A comprehensive approach based on non-linear mixed effects modeling was used that 
allows us to characterize and predict the time course of drug action. Furthermore this 
approach enables to combine data from different experiments to obtain individual and 




characterize the pharmacodynamic effect. The PK model to describe the plasma 
concentration was adapted from literature.7 Given that a delay is observed between plasma 
concentrations and the onset of the pharmacological response, two PD models are 
compared to describe the DA release: the effect compartment model13 vs the indirect 
response type I model14. The results of this comparison add value to the efforts in the 
optimization of drug delivery. We ultimately illustrate how PK-PD relationships can be 
used to design a delivery system for symptomatic treatment of Parkinson’s disease. 
4.2 CHEMISTRY 
For the analysis of the in vivo samples an internal standard was required. We have 
synthesized the deuterated form of 5-OH-DPAT. The first applied route (Scheme 4.1) to 
obtain deuterated compound 4.3 was deuteration of 5-methoxy-2-(N,N-diallylamino)tetralin 
(4.1) with deuterium gas and a catalyst. However, 5-methoxy-2-(N,N-di-(β,γ-
dideutero)propylamino)-tetralin (4.2) was not the only deuterated product obtained. Due to 
hydrogen-deuterium scrambling, compound 4.2 was not only exclusively deuterated on the 
allyl bond but also on other positions in the molecule.15, 16 Lower deuterium pressure or 
alternative catalysts may reduce this phenomenon. We obtained a series of related 
deuterated products with molecular weights of 263, 267 and 269 m/z, meaning that up to 
eight positions were deuterated. 
 
Scheme 4.1 Synthesis of 5-methoxy-2-(N,N-di-(β,γ-dideutero)propylamino)tetralin (4.3). Conditions 
and reagents: a) 1 bar D2, PtO2 or PdO in CD3OD, RT, 30 min; b) 48% HBr, reflux. 
An alternative deuteration strategy was employed (Scheme 4.2). (R)-5-Methoxy-2-(N-n-
propylamino)tetralin ((R)-4.4) was converted to the propionamide (R)-4.5. Subsequently, 
(R)-4.5 was reduced to compound (R)-4.6 with lithium aluminium deuteride and only the 
amide moiety was deuterated. After demethylation with 48% hydrobromic acid, the final 
compound (R)-5-hydroxy-2-(N-propyl-N-α,α-dideutero-propylamino)tetralin ((R)-4.7) was 
obtained with an overall  yield of 13%. 




Scheme 4.2 Synthesis of (R)-5-hydroxy-2-(N-n-propyl-N-α,α-dideutero-propylamino)-tetralin HBr 
salt ((R)-4.7). Reagents and conditions: a) 1.25 M NaOH, propionylchloride, CH2Cl2, RT; b) LiAlD4, 




The materials and analysis methods for the chemistry are described in section 2.4.1 
4.3.1.2 Preparation of (R)-5-hydroxy-2-(N-n-propyl-N-α,α-dideuterio-
propylamino)-tetralin HBr salt (Internal Standard) 
(R)-5-methoxy-2-(N-propylpropionamido)-tetralin ((R)-4.5).17 (R)-5-Methoxy-2-(N-n-propyl-
amino)-tetralin (prepared from (R)-2.9 according to similar procedures 
as for the synthesis of 8.14, 1.0 g, 4.6 mmol) was dissolved in a mixture 
of CH2Cl2 (50 mL) and 1.25 M NaOH (50 mL). Slowly 
propionylchloride (1.0 mL, 11.5 mmol) was added and the reaction 
mixture was stirred for 20 minutes at r.t. CH2Cl2 (100 mL) was added 
and the organic layer was separated, dried on Na2SO4, filtrated and 
evaporated in vacuo to afford crude (R)-4.5 as an oil (1.0 g, 79%). 
Purity: 96% (GCMS); EI-MS m/z 275 (M)+. 
(R)-5-methoxy-2-(N-propyl-N-(α,α-dideuterio-propyl)amino)-tetralin ((R)-4.6). Under nitrogen 
atmosphere a solution of (R)-4.5 (0.84 g, 3.1 mmol) in dry THF (10 
mL) was added to a suspension of LiAlD4 (0.19 g, 4.5 mmol) in dry 
THF (20 mL) and the mixture was stirred for 30 minutes at r.t. After 
addition of EtOAc (10 mL), diluted H2SO4 (2 mL) was added until 
precipitation at pH 4. The mixture was filtrated, basified with 2N 
NaOH (2 mL) and extracted with EtOAc (2x100 mL). The combined 
organic layers were washed with brine, dried on Na2SO4, evaporated in 
vacuo and purified on column chromatography (SiO2 (NH3), 
Hexane/EtOAc=8:1) to yield (R)-4.6 as an oil (0.80 g, 77%). 
(R)-5-hydroxy-2-(N-propyl-N-α,α-dideuterio-propylamino)-tetralin HBr salt ((R)-4.7). A 
mixture of freshly distilled 48% HBr (10 mL) and (R)-4.6 (0.41 g, 1.6 mmol) was refluxed for 2 




recrystallized from MeOH/EtOAc to afford the HBr-salt of (R)-4.7 as 
white crystals (0.11 g, 21%). Purity>95% (GCMS); 1H NMR (200 MHz, 
CD3OD):δ 6.97 (t, J=7.6 Hz 1H, ArH), 6.75-6.55 (m, 2H, ArH), 3.82-3.77 
(m, 1H, H2ax), 3.43-2.88 (m, 5H, H1ax, H1eq, H4eq, N(CH2CH2CH3)), 2.78-
2.50 (m, 1H, H4ax), 2.46-2.23 (m, 1H, H3eq), 2.03-1.63 (m, 5H, H3ax, 
N(CH2CH2CH3)2), 1.05 (t, J=7.3 Hz, 6H, CH3) ; 13C NMR (50 MHz, 
CD3OD): δ 154.9, 133.7, 126.8, 121.9, 120.1, 112.3, 60.6, 52.7, 29.6, 
23.7, 22.5, 18.6, 10.2; EI-MS m/z 249 (M)+. 
4.3.2 Materials 
Silver and silver chloride (puritiy >99.99%) were obtained from Sigma-Aldrich (Zwijndrecht, the 
Netherlands). Acetonitrile (LC-MS grade), ammonium acetate (LC-MS grade), acetic acid (LC-MS 
grade) and methanol (LC-MS grade) were purchased from Biosolve (Valkenswaard, the Netherlands). 
Ammonium hydroxide (25% w/v; analytical grade) was obtained from Baker (Deventer, the 
Netherlands). NaCl 0.9% was purchased from the hospital pharmacy of LUMC (Leiden, the 
Netherlands). EDTA was obtained from Merck (Merck KGaA, Darmstadt, Germany). All solutions 
were prepared in Millipore water with a resistivity of more than 18 MΩ.cm. 
4.3.3 Iontophoresis patches 
A detailed description of the iontophoresis patches, used for the transdermal iontophoresis studies can 
be found elsewhere.7 Briefly, the iontophoresis patches were prepared by the Fine Mechanical 
Department of Leiden University from elastic silicon materials (silicon: Smooth-Sil 920; Smooth-on 
Inc., Easton, PA, USA). The volume of the patches was 2.3 ml and the active area was 2.5 cm². The 
patch was fixed on wound dressing film (Opsite Flexigrid, Smith&Nephew, Hoofdorp, The 
Netherlands), which can be attached to the skin during the experiment. Ag/AgCl was used as driver 
electrode pair. 
4.3.4 Animals 
Animal procedures were conducted in accordance with guidelines published in the NIH guide for the 
care and use of laboratory animals and all protocols were approved by the Institutional Animal Care 
and Use Committee of the University of Groningen and Leiden University. The pharmacokinetic (PK) 
and the pharmacokinetic-pharmacodynamic (PK-PD) studies were performed in albino male Wistar 
rats (280-340 g) obtained from Charles River (Maastricht, the Netherlands) and Harlan (Horst, the 
Netherlands), respectively. Prior to surgery the animals were housed at least 1 week in Plexiglas 
cages, maximum 6 animals per cage with free access to water and standard laboratory chow. The 
cages were placed in a room with a controlled temperature at 21 °C and controlled humidity between 
60-65% and a light-dark cycle of 12 h. 
4.3.5 Pharmacokinetic (PK) studies 
In these studies the relationship between the current density and the plasma concentration profile of 
(S)-5-OH-DPAT following transdermal iontophoresis was investigated. (S)-5-OH-DPAT was 
administered by transdermal iontophoresis and intravenous (IV) infusion to the same animals with a 
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one week interval between treatments. The use of both routes of administration allowed improved 
pharmacokinetic parameter estimation. A detailed description of the experiments is given below. 
4.3.5.1 Surgical procedures 
Prior to surgery the animals were anaesthetized with a combination of Dormicum® (midazolam, 5 
mg.ml-1, Roche Nederland, Mijdrecht, the Netherlands) and Hypnorm® (fentanyl citrate 0.315 mg.ml-
1 + fluanizone 10 mg.ml-1, Janssen Pharmaceutica, Beerse, Belgium) at a dose of 0.5 mL.kg-1 rat 
weight. The permanent cannulation was performed using Polethene tubings (Rubler BV, Hilversum, 
the Netherlands) with the diameter of 0.58 mm (I.D.) – 0.96 mm (O.D.) and 0.28 mm (I.D.) – 0.61 
mm (O.D.), respectively for femoral vein and artery cannulation. After surgery the animals were 
housed individually and were allowed to recover during one week. 
4.3.5.2 Experimental procedures 
In the first part of the study (S)-5-OH-DPAT was administered by transdermal iontophoresis. First, 
the animals were anesthetized with Hypnorm® and Dormicum® (0.5 mL.kg-1) and the hair of the back 
was removed using an electrical clipper and a scalpel. A pair of patches was attached to the skin 
surface. After 15 min the patches were filled with (S)-5-OH-DPAT (3.9 mM) at pH 5 (citric buffer, 5 
mM) and with PBS pH 7.4 (NaCl: 8 g.L-1, Na2HPO4: 2.86 g.L-1, KH2PO4: 0.2 g.L-1, KCl: 0.19 g.L-
1) at the anodal and the cathodal side, respectively. The following protocol was used for the 
iontophoresis studies: 15 min passive diffusion + 120 min 75 μA.cm-2 + 120 min 150 μA.cm-2. At 
time=255 min, the patches were removed and the skin was wiped using a tissue paper. Blood samples 
were taken at regular time intervals during the current application and after removal of the patch: 0, 
15, 45, 75, 105, 135, 165, 195, 225, 255, 270, 285, 315, 345, 390, 435 min. Blood samples (0.2 ml) 
were collected using lithium-heparin containing tubes (Microvette® 200 Plasma/Lithium Heparin, 
Sarsted BV, Etten-Leur, the Netherlands). Plasma was then separated by centrifugation at a speed of 
6000 rpm during 10 min. The samples were kept at -20 °C prior to analysis with LC-MS-MS. 
After 1 week of recovery in individualized housing, animals received a total dose of 29 nmol (S)-5-
OH-DPAT, dissolved in 0.9% NaCl, during 15-min IV infusion. At regular time intervals blood 
samples were taken from the femoral artery cannula: 0, 15, 20, 30, 45, 60, 75, 90, 105, 120, 150, 180 
min. The samples were prepared in the same way as described above following iontophoretic delivery 
(see above). In all experiments the animals were kept in an anaesthetized condition during the 
experiment using Hypnorm® and Dormicum®. 
4.3.6 On-line microdialysis studies (PK-PD studies)  
This series of experiments consisted of three parts. First, the influence of anesthesia and iontophoresis 
on the striatal DA release (PD end point) was determined with on-line microdialysis. Second, the 
pharmacokinetic (PK) and pharmacodynamic (PD) properties following transdermal iontophoretic 
delivery were examined. Third, to explore the implications of differences in delivery rate on the PK 
and PD parameters, (S)-5-OH-DPAT was administered with IV infusion. In all experiments the 
striatal DA level and the striatal 5-OH-DPAT concentration were monitored by microdialysis with 
simultaneous blood sampling for the analysis of (S)-5-OH-DPAT plasma concentrations. A detailed 




4.3.6.1 Surgical procedures 
Prior to surgery the rats were anaesthetized with Isofluran 2% in N2O/O2 (2/1). The permanent 
cannulations were performed using silicone catheters (inner diameter (I.D.): 0.5 mm; outer diameter 
(O.D.): 0.9 mm) (UNO BV, Zevenaar, The Netherlands). The catheters were inserted approximately 2 
cm inside the vessels. The catheters were tunneled subcutaneously, externalized at the back of the 
head. After the cannulation the rats were kept under anaesthetized condition and mounted into a 
stereotaxic frame for the implementation of microdialysis probes in left and right striatum according 
to a method described previously.10, 11 After exposing and anesthetizing the skull with 0.5% marcaine-
adrenaline, the holes for probe insertion were drilled. A Y-shaped dialysis probe was used for the 
experiments, with an exposed tip length of 3 mm. The dialysis canulla (I.D.: 0.24 mm; O.D.: 0.34 
mm) was prepared from polyacrylonitrile/sodium methallyl sulfonate copolymer (AN 69, Hospal, 
Bologna, Italy). The microdialysis canulla was implanted in the striatum. The following coordinates 
were used according to the atlas of Paxinos and Watson18: AP +0.9, LM ± 3.0 relative to bregma, and 
Vd – 6.0 below dura. Before insertion into the brain, the dialysis probe was perfused successively 
with 70% ethanol, ultrapure water and Ringer solution (140 mM NaCl, 3.0 mM KCl, 1.2 mM CaCl2, 
1.0 mM MgCl2). The dialysis probe was positioned in the burr hole under stereotaxic guidance. The 
probe was cemented in this position with dental cement. Thereafter the rats were housed solitary. 
4.3.6.2 Experimental procedures 
The PK-PD experiments were performed 15-20 h after cannulation and implementation of the probes. 
The rats were anaesthetized prior to and kept under anesthetized condition during the experiment with 
Hypnorm® and Dormicum® at a starting dose of 0.5 mL.kg-1 and subsequently with hourly doses of 
0.17 mL.kg-1.  
First, to dismiss the potential confounding effects of anaesthesia, an iontophoretic control experiment 
was conducted administering only citric buffer (pH 5.0, 5 mM), as this is the donor phase used for 
transdermal iontophoresis, without (S)-5-OH-DPAT. Before the start of the experiment, the hair of 
the back of the anesthetized rat was removed with an electrical clipper and scalpel. 15 min after 
attaching the patches to the skin surface, the cathodal patch was filled with PBS pH 7.4 and the 
anodal patch was filled with donor solution. The protocol for iontophoresis was: 15 min passive 
diffusion + 90 min current application (250 μA.cm-2). The patch was removed and the skin was 
wiped using tissue paper. To include the influence of blood sampling on the DA level, blood samples 
were taken at regular time intervals: 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 165, 195, 225, 255, and 
285. Blood sampling and subsequent preparation of the samples were identical to the procedures used 
for the PK studies following transdermal iontophoresis (cf. supra).  
Second, a PK-PD microdialysis study following transdermal iontophoretic delivery of (S)-5-OH-
DPAT was performed. The donor solution consisted of (S)-5-OH-DPAT (3.9 mM), buffered with a 
citric buffer (pH 5, 5 mM). All the experimental procedures were identical to the control experiment, 
as described in the previous paragraph. Third, a PK-PD microdialysis study was performed with a 
total dose of 113 nmol 5-OH-DPAT, dissolved in NaCl 0.9%, administered as a 10-min IV infusion. 
Blood sampling and subsequent preparation of the samples were identical to the procedures used for 
the PK studies following IV infusion (cf. supra).  
In all the PK-PD studies the DA level and the 5-OH-DPAT concentration were monitored in the left 
and right striatum, respectively, with microdialysis. The microdialysis probes in the striata were 
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perfused with Ringer solution at a flow of 2 μL.min-1 (CMA/102 Microdialysis Pump, Sweden). 
Every 15 min a sample was collected for analysis with a total volume of 30 μl. The analysis of the 
microdialysate samples is described below (Section 4.3.7.2). 
4.3.7 Sample analysis 
4.3.7.1 Blood samples of (S)-5-OH-DPAT 
The blood samples of 5-OH-DPAT were analyzed with an on-line solid-phase extraction-liquid-
chromatography-mass spectrometry/mass spectrometry (SPE-LC-MS/MS) method. 5 μl of the 
internal standard (d2-5-OH-DPAT; 5 ng.ml-1) was added to 35 μl of the collected plasma and 350 μl 
acetonitrile was added to precipitate the proteins. The mixture was vortexed and centrifuged at a 
speed of 8000 rpm during 10 min at 10 °C. The supernatant was dried and redissolved in 50 μl MilliQ 
and 3 μl was injected on to the SPE cartridge. An external binary HPLC pump (Gynkotek, Munich, 
Germany) and an external Agilent 1200, 2/6 switch valve (Agilent Technology, Santa Clara. CA, 
USA) were used for the SPE sample trapping. The samples were trapped in a Hysphere Resin C8, 
endcapped, 10 x 4 mm, 10 μm SPE cartridge (Spark Holland B.V, The Netherland). Prior to injection, 
the SPE cartridge was conditioned with 50mM ammonium acetate buffer pH 9, after the injection the 
sample was trapped with 10mM ammonium acetate buffer pH 9/ACN (4:1 v/v) during 1 min with a 
flow of 0.4 ml.min-1. Subsequently, the valve was switched placing the SPE cartridge in-line with the 
LC system for elution onto the analytical column. Elution of 5-OH-DPAT and its internal standard 
was accomplished by flushing the SPE column with H2O/ACN (1:9 v/v) during 4 min with a flow of 
0.05 ml.min-1 and 1 min with 1 ml.min-1. Finally, the cartridge was switched off-line again and re-
conditioned using a 50mM ammonium acetate buffer at pH 9 during 2 min with a flow of 1 ml.min-1. 
To analyze the extracted sample an Agilent 1200 HPLC system with autosampler (Agilent 
Technology, Santa Clara. CA, USA) was coupled online with an Agilent 6460 Triple Quadrupole 
mass spectrometer (Agilent Technology, Santa Clara. CA, USA). The samples were analyzed by 
μPLC-MS/MS using an Altima HP C18 column (150X 1.0 mm; 5 μm) (Grace Davison Discovery 
Sciences, Lokeren, Belgium). The mobile phase consisted of 10 mM ammonium acetate buffer pH 
3.7: Acetonitril (2.3:1 v/v) was used. The total analysis time was 11 min, the flow-rate was 100 
μl.min-1, the temperature of the autosample tray was set to 4 ºC and the column temperature was set 
to room temperature. The detection was performed with a triple quadrupole mass spectrometer in the 
positive-ion electrospray mode and all analytes were monitored with Multiple Reaction Monitoring 
(MRM). 5-OH-DPAT and the internal standard d2-5-OH-DPAT were ionized to produce the 
protonated molecules at m/z 248 and m/z 250, respectively. Upon collision (collision energy 15 eV; 
fragmentor enenergy 120 V) the pre-cursor ions of both 5-OH-DPAT and d2-5-OH-DPAT produced 
the same product-ion at m/z 147, corresponding to 5-hydroxy-aminotetraline. System operation and 
handling the acquired data was performed using Agilent MassHunter data acquisition software 
(version, B.02.00; Agilent). Calibration curves showed a linear response when using concentrations of 
compounds between 0.2 and 50 ng.mL-1 (R2>0.999). The recovery, limit of detection (LOD) and 





4.3.7.2 Microdialysate samples of (S)-5-OH-DPAT 
To analyze the striatal 5-OH-DPAT concentration the dialysate from the probe in the right striatum 
was collected every 15 min, resulting in a total volume of 30 μL per sample. Subsequently, 70 μL of a 
7.15 nM solution of (R)- d2-5-OH-DPAT as internal standard was added to yield final concentrations 
of 5 nM internal standard in a 100 μL mixture of water + 0.1% formic acid and Ringer (1:1). The 
solution was analyzed using LC-MS/MS. The HPLC system consisted of a Shimadzu LC 20 AD 
binary system with a Shimadzu SIL 20AC autosampler. The samples were injected on a Grace 
Alltech Alltima HP C18 EPS reverse-phased column (3 μm, length 150 x 2.1 mm I.D.) (Grace 
Alltech, Lokeren, Belgium). The mobile phase consisted of a mixture of 0.1% formic acid in water 
(solvent A) and 0.1% formic acid in acetonitrile (solvent B). The gradient was programmed as 
follows: 1 minute isocratically at 15% B, increase in 7.5 min to 95% B, 2.5 min isocratically at 95% 
B, decrease in 1 minute to 15% B and isocratically for 5 min at 15% B. The total runtime was 17 min. 
The flow was set at 0.4 mL.min-1 and the analysis was performed at room temperature. The injection 
volume was 20 μL (partial loop fill) and the compounds were detected on a SCIEX API3000 triple 
quadrupole mass spectrometer (Applied Biosystems/MDS SCIEX, Foster City, CA, USA) equipped 
with a Turbo Ion Spray interface. The mass spectrometer was operated in the positive ion mode with 
MRM, quantifying transition pairs of m/z 248.2/147.1 and 250.2/147.1 for 5-OH-DPAT and d2-5-
OH-DPAT, respectively. Instrument parameters were as follows: Ion spray voltage 5000 V, nebulizer 
gas 13, curtain gas 13, TIST (Turbo Ion Spray Temperature) 500 °C, CAD gas 4, declustering 
potential (DP)=35 V, focusing potential (FP)=130 V, entrance potential (EP)=10 V. The detection 
limit of 5-OH-DPAT was 1 fmol which is 0.25 pg (5 x 10-11 M, 20 μL injection volume). 
4.3.7.3 Striatal concentration of dopamine and metabolites 
The dialysate contents of DA and its metabolites were quantified from the probe implanted at the left 
striatum by an on-line HPLC with electrochemical detection with the detection limit of 1 
fmol/sample. A HPLC pump (LC-10AD vp, Shimadzu, Japan) was used in conjunction with an 
analytical cell (5011A, ESA, Chelmsford, MA, USA) and a electrochemical detector (Coulochem II, 
ESA, Chelmsford, MA, USA) working at +300 mV for DOPAC and HIAA and -300 mV for DA. The 
analytical column was a Supelco Supelcosil™ LC-18-DB column (150 mm x 4.6 mm, 3 μm) (Sigma-
Aldrich Chemie B.V., Zwijndrecht, The Netherlands). The mobile phase consisted of a mixture of 4.1 
g.L-1 sodium acetate (Merck), 215 mg.L-1 octane sulphonic acid, 186 mg.L-1 EDTA, 7% methanol and 
ultrapure water (pH=4.2 with glacial acetic acid). Data were converted into percentage of basal levels. 
The basal levels were determined from four consecutive samples (less than 20% variation), and set to 
100%. After the experiments the rats were sacrificed and the brains were removed. The removed 
brains were kept in 4% paraformaldehyde solution until they were sectioned to control the location of 
the dialysis probes. 
4.3.8 Data Analysis 
A non-linear mixed effects modeling approach was used to describe the pharmacokinetics of (S)-5-
OH-DPAT in plasma and the DA levels (PD end-point) in the striatum. The in vivo data following 
transdermal and IV infusion were combined for analysis. 
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4.3.8.1 PK model 
A detailed description of the pharmacokinetic model for (S)-5-OH-DPAT has been reported 
elsewhere.7 Briefly, the PK model is based on compartmental mass transfer to describe the 
iontophoretic transport in vivo. Data fitting was performed according to the ordinary differential 















3                                                                                    (3) 
With 
dt
)t(dXi as the rate of change in the amount of the drug in compartment i, Xi as the amount of the 
drug in compartment i, which refers to the skin compartment (i=1), the plasma compartment (i=2) and 
the peripheral compartment (i=3). I0 is defined as the zero order mass input during iontophoresis, KR 
as the first order release rate constant from skin to plasma, k as the first order elimination rate 
constant, k23 and k32 as the first order distribution rate constants from plasma to tissue and tissue to 
plasma, respectively. N is a flag in the model to indicate that the input rate I0 is only valid during the 
iontophoresis period.  
Following intravenous administration, data was modeled using equation 4, which describes the rate of 





2                                (4) 
With Rate as the zero order intravenous infusion rate and M as a flag to indicate that the Rate only 
applies during the duration of the infusion. Equation 3 was used to describe the rate of change in the 
peripheral compartment. 
4.3.8.2 PD model 
Two PD models were compared to fit the data of the DA release in the striatum during and after 
transdermal iontophoresis and intravenous infusion. The first model was the indirect response (IDR) 
type I model in analogy to the model proposed by Nugroho et al.7 The levels of 5-OH-DPAT in the 
plasma (Cp) were directly linked to the DAergic effect. The equations of the model to describe the 
rate of change in the DA concentration 
dt
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With Imax as the maximum inhibition of the DA production, IC50 is the plasma concentration of 5-OH-




k0in is the zero order rate constant for the production of response, kout is the first order rate constant for 
the loss of response, CDA(0) is the baseline values of DA (i.e., DA concentration prior to the inhibiting 
effect of 5-OH-DPAT). 
In the second model, an extra hypothetic compartment was introduced to account for the delay 
between plasma concentration and the response, i.e. the effect compartment. The rate of change of 
drug concentration 
dt
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With ke0 as the first order distribution rate constant from plasma to effect compartment and the 
elimination rate constant from the effect compartment. The effect is described by the sigmoid Imax 
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With Ce as the drug concentration in the effect compartment. 
4.3.8.3 Model parameters 
A detailed description of the  PK and PD modeling steps is presented elsewhere.7 In short, the data 
analysis was performed using NONMEM version VI (NONMEM project group, University of 
California, San Francisco, USA) with ADVAN6 TRANS1 TOL=5 from PREDPP as subroutines. The 
fixed effect parameters (θ) included: I0, KR, clearance (CL), inter compartmental clearance (Q), 
volume of central compartment (V2), volume of peripheral compartment (V3), kout, Imax, and IC50 and 
ke0. Variability in pharmacokinetic parameters was assumed to be log-normally distributed in the 
population. Inter-individual variability was modeled by an exponential error model as written in 
Equation 9: 
)exp(.P ii                                                                                                                                        (9) 
in which θ is the population value for the fixed effect parameter P, Pi is the individual estimate and ηi 
is the normally distributed interindividual random variable with mean zero and variance ω2. The 
coefficient of variation (CV %) of the structural model parameters is expressed as percentage of the 
root mean square of the interindividual variability term. The residual error was modeled by a 
proportional error model as written in Equation 10: 
)1.(CC 1,ijij,predij,ob                                                                                                                      (10) 
where Cobs,ij is the jth observed concentration in the ith individual, Cpred,ij is the predicted 
concentration, and εij is the normally distributed residual random variable with mean zero and 
variance σ2. 
The estimation of the final population parameters was performed using the conventional first order 
estimation method (FOCE). The PK model parameters were estimated independently and 
subsequently used as input for the PD analysis. During model building, goodness-of-fit was based on 
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statistical and graphical diagnostic data. Model selection and identification was based on the 
likelihood ratio test, coefficient of variation of parameter estimates, parameter correlations and 
goodness-of-fit plots. For the likelihood ratio test, the significance level for the inclusion of one 
parameter was set at p<0.05, which corresponds with a decrease of 3.84 points in the minimum value 
of the objective function (MVOF) under the assumption that the difference in MVOF between two 
nested models is χ2 distributed. Non-nested models are evaluated using the Aikaike Information 
Criterion (AIC), which is the MVOF plus two times the number of parameters. The following 
goodness-of-fit plots were subjected to visual inspection to detect systemic deviations from the model 
fits: individual observed versus population and individual predicted values. Finally, the performance 
of the population PK and PK-PD models were assessed by simulating 100 data sets with the final 
model parameter estimates. The evaluation of model performance also included visual predictive 
check (VPC), as implemented in Xpose 4 (R version 2.7.0, R-foundation).19 
4.4 RESULTS 
Three series of in vivo experiments were conducted to investigate the controllability of 
transdermal iontophoresis and to explore the potential impact of delivery rate on the PK-PD 
relationship of (S)-5-OH-DPAT. In the first study, the influence of the current density on 
drug pharmacokinetics in plasma profile was assessed. Two current densities were applied 
consecutively for 2h (75 and 150 μA.cm-2). In addition, (S)-5-OH-DPAT was administered 
as an IV infusion to the same animals to discriminate delivery-related properties from 
intrinsic pharmacokinetic properties. The crossover design also allowed higher precision of 
the parameter estimates. In the second study, the influence of the anesthetics, iontophoresis 
and blood sampling on the striatal DA level (PD endpoint) was investigated as a validation 
procedure for this experimental model. In the third study, the PK-PD relationship was 
investigated across a range of exposures, with maximum effects being attained for a short 
period followed by return of DA levels back to baseline conditions. For this reason, 
transdermal iontophoresis (250 μA.cm-2) was applied up to 1.5h. In analogy to the first 
study presented above, (S)-5-OH-DPAT was also administered with IV infusion to enable 
separation of delivery-related properties from intrinsic pharmacokinetic properties. 
4.4.1 PK properties following iontophoresis and IV infusion 
In these studies two different current densities (75 and 150 μA.cm-2) were applied 
consecutively during 2 h to investigate the impact of flux on plasma profiles. Moreover it 
was of interest to determine the time to reach steady state conditions. The results of the 
pharmacokinetic studies are depicted in Figure 4.2. After 15 min of passive diffusion prior 
to iontophoresis no detectable amount was transported into the plasma (data not shown). In 
contrast, drug plasma level increase immediately when switching on the current. In almost 
all the animals steady state plasma levels were achieved after 2 h of 75 μA.cm-2 current 
application, with an average plasma concentration (Cp) of 4.1 ± 1.9 ng.ml-1. By further 




approximately. In parallel, following IV infusion, Cp reached a maximum of 5.3 ± 0.5 
ng.ml-1 after 15 min (data not shown). After the discontinuation of infusion or upon 
termination of the current application, the Cp declined according to a 2-compartment 
disposition model. 
 
Figure 4.2 The observed data (filled circles) of the plasma concentration (Cp) of the individual rats 
during and after transdermal iontophoretic delivery of (S)-5-OH-DPAT (3.9 mM) together with the 
population model prediction (solid line) and the individual model prediction (dashed line). The 
following protocol was used: 120 min current density of 75 µA.cm-²+120 min current density of 150 
µA.cm-2. The patch was removed after 240 minutes. 




Figure 4.3 A: (S)-5-OH-DPAT concentration-time profiles in blood plasma following transdermal 
iontophoresis of (S)-5-OH-DPAT (3.9 mM). Depicted are the observed data (filled circles) together 
with simulated median (50%, solid line) and the upper and lower limit of the model-simulated 
interquantile concentration range (97.5%-5%, dashed lines).  
B: (S)-5-OH-DPAT concentration-time profiles in striatum following transdermal iontophoresis of 
(S)-5-OH-DPAT (3.9 mM). Depicted are the observed data together with the mean. 
4.4.2 Validation of the rat model to investigate the PD effect 
The potential effects of anaesthesia (fentanyl+fluanisone and midazolam), of blood 
sampling and of transdermal iontophoresis on the striatal levels of DA (PD end-point) were 
investigated. The results of this control experiment are presented in Figure 4.4A. DA levels 
remained stable in the period immediately before attaching the patch (-60 to -15 min) and in 
the 15 minute period of passive diffusion before iontophoresis (-15 to 0 min). The DA 
levels, which were set to 100% showed a non-significant small increase from 97 ± 3% to 
100 ± 4% during iontophoresis, followed by a stronger increase to 114 ± 6% during 115 
min after the end of iontophoresis. These results indicate the suitability of the anesthetized 
rat model for monitoring of DA levels to evaluate the properties of transdermal 
iontophoretic delivery or IV infusion of (S)-5-OH-DPAT. 
4.4.3 PK-PD relationships following iontophoresis and IV infusion 
The pharmacokinetics and pharmacodynamics of (S)-5-OH-DPAT were assessed following 
transdermal iontophoresis and IV infusion. With regard to the PK, no detectable plasma 
concentration could be observed after 15 min passive diffusion (data not shown). When 
starting the current application (250 μA.cm-2) the plasma concentration increased 
immediately and tended towards steady state after 90 min of current application (Fig.4.3A). 
The average concentration after 90 min of iontophoresis was 20.4 ± 3.7 ng.ml-1. Following 
IV infusion, Cp reached a maximum of 29.9 ± 2.4 ng.ml-1 after 10 min (data not shown). 
The decline in plasma concentration post (S)-5-OH-DPAT administration was best 
described by a 2-compartment disposition model. Following transdermal iontophoresis the 




4.3B, 5-OH-DPAT concentrations increased to 0.96 ± 0.18 ng.ml-1 during current 
application, but this effect occured after a small delay (between 7.5 and 22.5 min) in 
relation to the beginning of iontophoresis. The concentrations decreased again with the 
same delay upon discontinuation of the iontophoretic current. 
 
Figure 4.4 The DA release, expressed as % of baseline vs time: A: transdermal iontophoresis of only 
buffer (control experiment) B, D: transdermal iontophoresis of (S)-5-OH-DPAT  (3.9 mM). C,E: IV 
infusion of (S)-5-OH-DPAT (113 µM). 
A: depicted is the mean ± S.D. B-E: depicted are the observations (filled circles) together with the 
model simulated interquantile DA% range (2.5 %-97.5%, dashed lines) and the simulated median 
(50%, solid line). A number of 100 samples were simulated based on the final parameter estimates. 
B,C: the visual predictive check without including a covariate of route of administration on IC50. D,E: 
the visual predictive check including a covariate of route of administration on IC50. In all panels the 
average DA release of 4 consecutive points prior to administration (time=-60 to -15 min) was set to 
100%. 
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4.4.4 PK-PD analysis following transdermal iontophoretic delivery and 
IV infusion 
The striatal DA release (PD endpoint) was monitored on-line simultaneously with plasma 
and striatal concentration of (S)-5-OH-DPAT. These results are presented in Figure 4.4. 
Firstly, the pharmacodynamic effect was monitored following iontophoresis (15 min 
passive diffusion + 90 min of iontophoresis 250 μA.cm-2) (Fig. 4.4B). During passive 
diffusion (-15 to 0 min) no change in DA levels were observed. Subsequently, DA levels 
gradually decreased to a minimum of 48.8 ± 5.1% of basal values within 94.5 ± 16.4 min 
after the start of the iontophoresis. DA levels returned to baseline values 79.4 ± 11.3 min 
after the end of iontophoresis. In contrast, IV infusion of (S)-5-OH-DPAT resulted in an 
immediate decrease in the DA level. Maximum inhibition of 38.3 ± 8.4 % relative to 
baseline values was achieved after 42.1 ± 2.5 min (tmax) after start of IV infusion (Fig. 
4.4C). DA levels returned to baseline values within 120.4 ± 20.5 min after the end of 
infusion. A slight rebound effect was observed at the end of the experiment. DA level 
further increased to 119 ± 22 and 120 ± 23% relative to baseline after transdermal delivery 
and IV infusion, respectively. 
The pharmacokinetic data following transdermal iontophoresis analyzed simultaneously 
with the PK data following intravenous infusion. The objective of the integrated analysis 
was to facilitate discrimination between delivery-specific parameters (I0, KR) and drug-
specific parameters (V2, V3, CL, Q). The larger sample size also allowed for more precise 
estimation of model parameters. The resulting parameters are provided in Table 4.1. The 
low relative standard error (RSE) for all the fixed effect parameters (RSE ≤ 30%) indicates 
high precision of estimates. Moreover, as observed in Figure 4.2 and in Figure 4.5A, the 
model accurately describes the time course of plasma concentration during and after current 
application.  
An integrated approach was also applied to the PK-PD experiments. The analysis of the 
PK-PD data following IV administration and iontophoresis was performed simultaneously. 
In analogy to the PK study, the plasma concentration profile could be described by the 
proposed compartment model. In Figure 4.3A, the VPC depicts the goodness of fit, with 
observed data randomly distributed within the 95% confidence interval (C.I.). In addition, 
the diagnostic plots (Figure 4.5B) show a good correlation between the observed and 





Figure 4.5 Diagnostic plots of the plasma and striatum analysis using the integrated PK-PD model. 
A: Analysis of plasma concentration (Cp) of (S)-5-OH-DPAT following IV infusion and 
iontophoresis during the PK study. B: Analysis of plasma concentration (Cp) of (S)-5-OH-DPAT 
following IV infusion and iontophoresis during the microdialysis study. C: Analysis of DA release in 
striatum, expressed as % of baseline values, following IV infusion and iontophoresis. In every panel 
the population prediction (left graph) and individual prediction (right graph) vs the measured value is 
displayed. 
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Table 4.1 The population estimates obtained from fitting the plasma profile and/or the 
pharmacological response following transdermal iontophoresis. During the PK study, two different 
current densities (75 and 150 µA.cm-2) were applied consecutively for 2h. During the PK-PD study, a 
current density of 250 µA.cm-2 was applied for 1.5h. 
  PK study  PK-PD study 
  Estimate Between 
animal 
variabity 
 Estimate Between 
animal 
variabity 








V2 L 0.5 6    0.5 18 0.100 71 
V3 L 1.7 16 0.189 46  0.7 16 0.109 42 
CL L.h-1 2.6 13 0.194 45  2.0 6 0.027 29 
Q L.h-1 2.5 9    1.9 23 0.218 44 
Jss 75 nmol.cm-2.h-1 24.7 29        
Jss 150 nmol.cm-2.h-1 51.3 30        
Jss 250 nmol.cm-2.h-1      87.3 8 0.000  / 
KR h-1 2.2 21    5.5 26 0.000  / 
           
ke0 h-1      3.9 10 0.192  77 
IC50 
IONTO 
ng.ml-1      4.4 13 0.162 50 
IC50 IV ng.ml-1      1.9 11   
N       3.2 10 0.000  / 
IMAX DA%      41.6 8 0.045 36 
           
Sigma  PK  0.037 12    0.0246 20   
Sigma PD       0.0120 22   
 
The effect of (S)-5-OH-DPAT (striatal DA release) was assessed by two pharmacodynamic 
models. The first model consisted of a turnover model, i.e. with indirect response type I14, 
and the second model consisted of an effect compartment and a sigmoid Imax model.13 The 
AIC of the effect compartment was lower than the turnover model. In addition, an 
improved distribution of the observations in the 95% C.I. of the VPC and a lower residual 
standard error (RSE) of the parameter estimates were observed when fitting the data with 
the effect compartment model (comparison not shown). Therefore the effect compartment 
model was selected for further evaluation of the PK-PD relationship of (S)-5-OH-DPAT. 
Given the small bias observed in the simulated median profiles of DA (Figure 4.4B and 
4.4C), a covariate analysis was performed, which revealed differences in IC50 depending 
upon the administration route. Incorporation of the route of administration as covariate into 
the model improved the VPC (Figure 4.4D and 4.4E) and the objective function decreased 




and PD parameters were estimated with good precision, as indicated by a relatively low 
RSE of the parameters (≤26%). 
Figure 4.4D and 4.4E depict the 95 C.I. together with the simulated  median response when 
including route of administration as covariate in the model. It can be observed that the 
model slightly under- and overpredicts the median of the DA release following transdermal 
iontophoresis and IV infusion, respectively. Nonetheless, 95% of the observations can be 
found within the boundaries of the confidence interval. Finally, goodness-of-fit plots for the 
DA release (Figure 4.5C) show that the model accurately predicts the observed DA release 
for both administration routes. 
4.5 DISCUSSION 
The present study provides novel information on the pharmacokinetic and 
pharmacodynamic properties of the active enantiomer of the potent DA agonist (S)-5-OH-
DPAT. Specifically, the present investigation focused on the controllability of the 
transdermal iontophoretic delivery of this compound with regard to the plasma 
concentration and the DAergic activity in the striatum. 
4.5.1 Relationship between current density and plasma profile 
With regard to the controllability of the plasma concentration, the relationship between the 
applied current density and the corresponding plasma profile was investigated. Three 
different current densities (75, 150 and 250 μA.cm-2) were applied in 2 different studies. A 
comparison of the pharmacokinetic parameters however of the PK-study (using two current 
densities 75, 150 μA.cm-2) and the PK-PD study (applying 250 μA.cm-2) revealed a 
difference in peripheral volume of distribution (V3), central (Cl) and peripheral clearance 
(Q). The difference in these pharmacokinetic parameters can be attributed to the difference 
in recovery period after surgery of the animals in the two studies, rather than due to 
differences in transport/delivery. For the PK-studies, the animals were allowed to recover 
for at least 1 week, whereas the PK-PD studies were executed 15-20h post surgery. Similar 
results were found by Torres-Molina and co-workers, who demonstrated that the placement 
of a permanent cannula in the jugular vein influences the PK parameters of amoxycilin and 
antipyrin in rats. The PK parameters depended on the time of execution of the experiment 
after placement of the cannula.20 This should be taken into account when designing new 
experiments, especially with a cross-over design.  
Despite the difference in PK parameters between the two studies, a clear linear dependency 
(R2=0.999) was observed (Figure 4.6) between the applied current density and the in vivo 
steady state flux, calculated from the zero order mass input using the following equation21:  
S
IFlux 0SS                                                                           (11) 
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In literature similar results were reported for the iontophoretic delivery in vivo of 
hydromorphone and ropinirole.6, 22 Moreover, Patel et al. recently demonstrated the 
controllability of the plasma concentration profiles by the current density for zolmitriptan.23 
These results show that, despite differences in PK properties, the drug input into the skin 
can be controlled very carefully by adjusting the current density. This can be very useful in 
initiating therapeutic treatment with DA agonist, adjusting the dose to the demand of the 
individual patient.  
Based on this relationship between the in vivo flux and the current density, the in vivo flux, 
applying a current density of 500 µA.cm-2, was estimated at 174.9 nmol.cm-2.h-1. Despite 
the interspecies differences, this value differs only 21% from the in vitro flux across human 
stratum corneum (211.9±11.1 nmol.cm-2.h-1), when applying a current density of 500 
µA.cm-2.24 This indicates that in vitro transport parameters can be used to predict drug 
delivery properties in vivo, even across species. Regarding the rat skin, iontophoretic 
transport is frequently comparable with human skin, in which iontophoresis may diminish 
interspecies variations in in vitro skin permeation studies.25, 26 
Our findings suggest the possibility of further refinement of future experiments for the 
evaluation of drug delivery by iontophoresis. In fact, a model-based approach can be used 
to provide guidance for optimal sampling and dose selection as well as by allowing a more 
quantitative assessment of safety margins. This is one of the reasons why PK-PD modeling 
is gaining a more prominent place in the different stages of drug development.27 
4.5.2 PK-PD relationship 
Next to a controlled plasma concentration the second aim of our investigation was to 
characterize the PK-PD relationship of (S)-5-OH-DPAT. A previous study showed that 5-
OH-DPAT, administered with transdermal iontophoresis can cause a very strong 
pharmacodynamic effect. However it was observed that even after 3 h post-iontophoresis 
the DA level (PD end-point) did not recover to its initial state.7 In addition, during these 
studies choral hydrate was used as anesthetic.7 Chloral hydrate is not considered the 
optimal choice for anesthesia of small animals, like rodents. Moreover several studies 
showed that choral hydrate influences the striatal DA turnover28-30 and enhances the 
suppressive effects of several DA agonists.31 Therefore our studies were performed 
following IV infusion and iontophoresis to explore the implications and validate the use of 
new anesthetic procedures in conjunction with on-line brain microdialysis.10, 11 In addition, 
we assessed the PK-PD relationship under a wider range of exposures, ensuring 





Figure 4.6 In vivo flux vs current density. Each data point presents the parameter estimate, 
determined with compartmental modeling, with the standard error of the parameter estimate. In each 
experiment 4-6 rats were used. 
A mixture of fentanyl, fluanisone and midazolam was chosen to anesthetize the animals. 
However, it has been reported in literature that these anesthetics individually also can affect 
the striatal DA metabolism. Fentanyl and fluanisone can increase the DA turnover in the 
striatum32-34, while midazolam has been reported to decrease the DA levels in a dose 
dependent manner.35 Besides the effect of the combination of anesthetics, the effect of 
iontophoresis and blood sampling on the DA level was also investigated. As shown in 
Figure 4.4A, the stimulating effect of fentanyl and fluanisone and the inhibiting effect of 
midazolam on the DA release were balanced during iontophoresis. After iontophoresis the 
DA release increased slightly, which could indicate a dominating effect of fentanyl. 
Nonetheless a rat model was established with stable DA release levels during anesthesia, 
which enables us to investigate the DAergic effect of (S)-5-OH-DPAT following 
intravenous infusion and transdermal iontophoresis.  
For both administration routes a decrease in striatal DA level can be observed which returns 
to baseline within 2 h after ending the administration. This demonstrates that a controlled 
reversible effect can be obtained. Moreover, DA levels seem to reach steady state following 
transdermal iontophoresis, in parallel to time course of concentrations in plasma. These 
results suggest that steady state concentrations of (S)-5-OH-DPAT translate into a steady 
state decrease of the DA level. Given that DA synthesis is indirectly controlled by 
presynaptic DA receptors, these findings suggest a continuous stimulation of the DA 
receptors.36, 37 Likewise, it has been shown that stable plasma levels of rotigotine, another 
potent 2-aminotetralin, also result into continuous DAergic stimulation.38 This could be of 
great benefit for symptomatic treatment of Parkinson’s disease. It is generally believed that 
continuous DAergic stimulation is currently the best strategy to reduce motor complications 
after long-term use of DAergic agents.5 However, further investigations are required 
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applying current for a longer time period with different doses to confirm the applicability of 
transdermal iontophoresis of DA agonists like (S)-5-OH-DPAT. 
4.5.3 PK-PD modeling 
The plasma profile and the DA release following IV infusion and transdermal iontophoresis 
were analyzed using compartmental modeling. Plotting the DA release vs the plasma 
concentration showed a counter clock-wise hysteresis (data not shown). This indicates a 
time delay between the plasma concentration and the pharmacological response. To account 
for this delay an effect compartment model  was compared with an indirect response model 
type I.14 In the present study, it is shown that the DA release is best described by an effect 
compartment in conjunction with the sigmoidal Imax model. This suggests that the delay 
between plasma concentration and pharmacological response is attributed to the distribution 
from plasma to site of action, rather than because of a slow onset of the effect. This is 
further supported by the delayed increase in striatal 5-OH-DPAT concentration following 
transdermal iontophoresis in Figure 4.3B. These findings shed light into the mechanisms 
underlying delay reported by Nugroho et al., who described the DA release, following 
transdermal iontophoresis of 5-OH-DPAT with an indirect response model type I.7 
As observed in Table 4.1, the IC50 is approximately 2.3 times lower when administering 
(S)-5-OH-DPAT with IV infusion compared to the IC50 with transdermal administration. 
This raises an important question regarding the role of the delivery rate: Do differences in 
delivery rate alter the response profiles of (S)-5-OH-DPAT? This question can be addressed 
by estimating the pharmacodynamic efficiency (EFF), defined as the pharmacological 
response per unit of concentration, as shown in the following equation: 
AUC
AAECEFF                                                                                                    (12) 
Where AUC (ng.ml-1.min) is the area under the plasma 5-OH-DPAT concentration curve 
and AAEC (DA%.min) is the area above the effect curve (normalized for baseline DA 
levels). For the IV infusion EFF was 9.2 ± 2.3 ml.ng-1, which is approximately 1.9 ± 0.8 
times higher than the EFF following transdermal iontophoresis, estimated at 4.8 ± 1.7 
ml.ng-1. Given that the delivery rate during IV infusion was approximately 3.5 times higher 
than during transdermal iontophoresis, these observations suggest that a high delivery rate 
may improve the pharmacodynamic efficiency. In this respect, transdermal iontophoresis 
can be a suitable delivery technique, since the delivery rate can easily be adjusted using 
different current densities (Figure 4.6). For instance a loading dose, by applying a higher 
current density at the start of the iontophoretic delivery, can be combined with a 
maintenance dose, by gradually decreasing the current density to a certain level. Follow-up 
studies based on drug administration with different delivery rates should be performed to 




The use of an integrated PK-PD approach, simultaneously monitoring drug concentrations 
in plasma and pharmacodynamic effects, has several benefits over experimental designs in 
which Cp or the PD effect are evaluated independently. First, it was shown that a steady 
state plasma concentration may result in a continuous stimulation of the DA receptor. 
Second, PK-PD modeling contributes to further understanding of the mechanisms and time 
course of drug action. Third, PK-PD model parameters can be used to support the design of 
future experiments. Furthermore, the assessment of PK-PD relationships enables 
discrimination between delivery-specific and drug-specific parameters. This distinction is 
critical in drug delivery research, in that it warrants the identification of the factors which 
may ultimately determine treatment response in vivo.  
In conclusion, these studies demonstrate that transdermal iontophoresis can be an excellent 
delivery route for continuous controlled administration of (S)-5-OH-DPAT and other potent 
DA agonists for the symptomatic treatment of Parkinson’s disease. PK-PD modeling 
suggests that target distribution causes the delay between plasma concentration and drug 
effect. In addition, modulation of the delivery rate seems to have a direct impact on the 
pharmacodynamics. These results are very important for understanding of the mechanisms 
underlying drug transport and disposition following transdermal iontophoresis. This 
information will be crucial for designing a self-controlled delivery device, guided by a 
feedback system.  
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The feasibility of transdermal iontophoretic transport of 4 novel ester prodrugs of 5-OH-
DPAT (glycine-, proline-, valine- and β-alanine-5-OH-DPAT) was investigated in vitro and 
in vivo. Based on the chemical stability of the prodrugs, the best candidates were selected 
for in vitro transport studies across human skin. The pharmacokinetics and 
pharmacodynamic effect of the prodrug with highest transport efficiency, was investigated 
in a rat model. The in vitro transport, plasma profile and pharmacological response were 
analyzed with compartmental modeling. Valine- and β-alanine-5-OH-DPAT were 
acceptably stable in the donor phase and showed a 4-fold and 14-fold increase in solubility 
compared to 5-OH-DPAT. Compared to 5-OH-DPAT, valine- and β-alanine-5-OH-DPAT 
were transported less and more efficiently across human skin, respectively. Despite a 
higher in vitro transport, lower plasma concentrations were observed following 1.5 h 
current application (250 μA.cm-2) of β-alanine-(S)-5-OH-DPAT in comparison to (S)-5-
OH-DPAT. However the prodrug showed higher plasma concentrations post-iontophoresis, 
explained by a delayed release due to hydrolysis and skin depot formation. This resulted in 
a pharmacological effect with the same maximum as 5-OH-DPAT, but the effect lasted for a 
longer time. The current findings suggest that β-alanine-5-OH-DPAT is a promising 
prodrug, with a good balance between stability, transport efficiency and enzymatic 
conversion. 
5.1 INTRODUCTION 
Transdermal delivery has been explored thoroughly as an alternative for oral delivery and 
injections. However, the main hurdle for transdermal delivery is the barrier function of the 
skin located in the outermost layer of the skin, the stratum corneum. An attractive approach 
to overcome this main barrier for drug delivery is iontophoresis. By applying a small 
current across the skin it is possible to enhance the transport of low molecular weight 
molecules across the skin. One of the interesting properties of this technique is the 
possibility to modulate the transport rate into and through the skin. This is an important 
advantage for drugs with a narrow therapeutic window, such as dopamine (DA) agonists 
(e.g. rotigotine, apomorphine, pergolide, 5-OH-DPAT). Most of the DA agonists are 
considered moderate lipophillic and have a relative low solubility in aqueous solutions.1-3 
For this reason, besides a low efficiency in iontophoretic transport, the low solubility of DA 
agonists can be a limitation for application with transdermal iontophoresis. Increasing the 
maximum solubility in the donor phase can be achieved by adjusting the donor phase (co-
solvent, surfactant, source of Cl--ions) or by changing the salt form. Another approach is 
the use of prodrugs with the desired physicochemical properties to overcome the problem 
of solubility and increase the efficiency in iontophoretic transport.4 The principle goal of 
synthesizing prodrugs is to chemically modify an existing pharmacologically active drug in 
a form that can be reversed to the parent drug in vivo, with the aim to change the 
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physicochemical and/or pharmacokinetic properties. Moreover for transdermal delivery a 
prodrug should be enzymatically metabolized in a controllable and predictable manner once 
it has penetrated the main barrier, the stratum corneum.5-7 
 
Figure 5.1 Molecular structures of (S)-5-OH-DPAT ((S)-2.12) and the 4 synthesized prodrugs, 
glycine-(S)-5-OH-DPAT (2.28), L-proline-(S)-5-OH-DPAT (2.37), L-valine-(S)-5-OH-DPAT (2.31) 
and β-alanine-S-5-OHDPAT (2.39). 
The main focus of the present study is to identify a prodrug that is transported efficiently 
with transdermal iontophoresis and is hydrolyzed during transport through the skin. This 
implies a good balance between the transport rate and the rate of enzymatic conversion of 
the prodrug. Previous studies showed that transdermal iontophoretic delivery of 5-OH-
DPAT resulted in a strong pharmacological response, which is believed to meet the 
requirements for symptomatic therapy with a reasonable patch size and acceptable current 
density. However, further improving the iontophoretic delivery could merely enhance the 
clinical applicability of this DA agonist by reduction of the patch size and more importantly 
minimization of the current density. Therefore 5-OH-DPAT, a DA agonist with limited 
aqueous solubility, was esterified with 4 different natural occurring amino acids (Figure 
5.1). These amino acids contain an extra chargeable aminogroup, providing the possibility 
to investigate the influence of an additional charge on the iontophoretic delivery of 5-OH-
DPAT. The stability of these 4 prodrugs is investigated and the most stable compounds are 
selected for transdermal iontophoretic transport. Depending on the iontophoretic transport 
efficiency of the selected prodrugs in vitro across human stratum corneum and dermatomed 




The plasma profile and the pharmacodynamic effect are monitored simultaneously in an 
animal model under anaesthetized conditions. Both in vitro and in vivo transport profiles 
are analyzed using compartmental modeling. Taking the hydrolysis of the prodrug into 
account, an adaptation to existing kinetic models is made to describe the transdermal 
iontophoretic delivery in vivo.8, 9 
5.2 MATERIALS AND METHODS 
5.2.1 General synthesis of the glycine, L-proline, β-alanine and L-valine 
esters of 5-OH-DPAT 
The full description of the synthesis of the 4 prodrugs of 5-OH-DPAT is described in Chapter 2.10 
Briefly 5-OH-DPAT was esterified to the N-protected amino acid with the carbodiimide coupling 
reagent N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide (EDC). 1-Hydroxybenzotriazole (HOBt) 
was added to suppress racemisation. The deprotection of the Boc-protected compound was carried out 
in 4N HCl in dioxane. After removal of the solvent and evaporation in vacuo, the solid hygroscopic 
foams were reprecipitated from dry methanol with dry ether to remove excess dioxane. The prodrugs 
were obtained as white hygroscopic di-HCl salts with a purity of >95% (HPLC). 
5.2.2 Materials 
5-OH-DPAT and 5-hydroxy-2-(N-n-propyl-N-α,α-dideutero-propylamino)-tetralin (d2-5-OH-DPAT) 
(HBr salts, purity > 8%) were synthesized at the Department of Medicinal Chemistry of the 
University of Groningen, Groningen, the Netherlands. Silver, silver chloride (purity >99.99%), 
trypsin (Type III from bovine pancreas) and trypsin inhibitor (Type II-S from soybean) were obtained 
from Sigma-Aldrich (Zwijndrecht, The Netherlands). Acetaminophen was purchased from Brocacef 
BV (Maarssen, the Netherlands) and D-Mannitol was obtained from BDH Laboratory supplies 
(Poole, UK). Spectra/Por® RC dialysis membrane disks (cut off value of 6000-8000 Da) were 
purchased from Spectrum laboratories, Inc (Rancho Dominquez, Ca, USA). Tetrahydrofuran (THF, 
stabilized, purity >99.8%) was obtained from Biosolve (Valkenswaard, the Netherlands). 
Triethylamine (TEA, purity >99%) was obtained from Acros Organics (Geel, Belgium). All other 
chemicals and solvents were of analytical grade. All solutions were prepared in Millipore water with a 
resistance of more than 18 MΩ.cm. 
5.2.3 Stability of glycine-, proline-, valine- and β-alanine-5-OH-DPAT 
The stability of the prodrugs was investigated under various conditions. At the starting point 1 mg.ml-
1 of proline- and glycine-5-OH-DPAT and 0.02 mg.ml-1 of valine- and β-alanine-5-OH-DPAT were 
dissolved in the buffer solution. The buffer solution was citric buffer (5 mM, pH 5.0 + 4 g.L-1 NaCl+ 
23.1 g.L-1 D-mannitol), PBS pH 6.2 (NaCl: 8 g.l-1, KCl: 0.19 g.l-1, Na2HPO4.2H2O: 0.43 g.l-1, 
KH2PO4: 0.97 g.l-1) or PBS pH 7.4 (NaCl: 8 g.l-1, Na2HPO4: 2.86 g.l-1, KH2PO4: 0.2 g.l-1, KCl:0.19 
g.l-1). The solutions were continuously stirred and kept constant at the desired temperature, using a 
thermostat controlled water bath. If required a circular sheet of human stratum corneum (HSC) (ø=18 
mm) was added to the solution and a current of 320 μA was applied. At regular time intervals samples 
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were taken from the solution and diluted in Millipore water, containing 0.1% trifluoroacetic acid  to 
stop the degradation. Both the amount of remaining prodrug and the parent drug 5-OH-DPAT were 
quantified by RP-HPLC. The amount of remaining prodrug was plotted as a function of time to 
calculate the first order rate constant, k and the corresponding half life. 
5.2.4 Maximum solubility of valine-5-OH-DPAT and β-alanine-5-OH-
DPAT 
The solubility studies of the different compounds were carried out as described elsewhere.2 Briefly, 
each compound was solubilized in citric buffer 5 mM, pH 5 + 4 g.L-1 NaCl + 23.1 g.L-1 D-mannitol. 
Subsequently the pH in each test tube was adjusted to pH 5.0 with 1M NaOH or 1M HCl under 
continuous shaking. Each solution was shaken for 48 h, after which the solution was centrifuged and 
filtered. The concentration in each solution was determined with HPLC. Due to the limited 
availability of the compound and the relative high solubility, this assay was performed in monoplicate 
(n=1). 
5.2.5 in vitro transport studies  
The preparation of dermatomed human skin (DHS) and human stratum corneum was performed 
according to the method described previously.11 All transport experiments were carried out as 
described elsewhere.11 The donor formulation (citric buffer 5 mM, pH 5.0, NaCl: 4 g.L-1, D-mannitol: 
23.1 g.L-1), containing the solute, was added to the anodal chamber. The cathodal chamber was filled 
with PBS pH 7.4. Unless described differently, the acceptor phase, maintained at 32°C, was 
continuously perfused with PBS pH 7.4 at a flow rate of 7.0 ml.h-1. The following protocol was used: 
6 h passive diffusion + 9 h iontophoresis (500 μA.cm-2) + 5 h passive diffusion. Samples were 
collected every hour with an automatic fraction collector (ISCO Retriever IV, Beun De Ronde BV, 
Abcoude, The Netherlands). To stop the hydrolysis after transport through the skin and before 
analysis TFA (0.1% v/v) was added to each sample. The specific conditions of the individual 
transport studies are described below. 
5.2.5.1 Iontophoretic delivery of valine-OH-DPAT and β-alanine-5-OH-
DPAT 
The iontophoretic delivery of valine-5-OH-DPAT across HSC and DHS was studied at a 
concentration of 3.9 mM.  
Iontophoretic delivery of β-alanine-5-OH-DPAT across HSC was studied at 3 different concentrations 
(1.5 mM, 3.9 mM or 7.0 mM). For the transport study with 1.5 mM as donor phase the current was 
only applied for 7 h, after which the experiment was stopped. Transport studies across DHS were 
performed with a donor concentration of 3.9 mM. For all experiments PBS pH 7.4 was used as 
acceptor phase. 
5.2.5.2 Electroosmotic flux across HSC 
The electroosmotic flux across HSC was investigated during iontophoretic transport of valine- and β-
alanine-5-OH-DPAT (3.9 mM), buffered at pH 5.0. Acetaminophen (15 mM) was added to the donor 




5.2.6 Hydrolysis after transport across HSC and DHS 
The prodrugs valine-5-OH-DPAT and β-alanine-5-OH-DPAT are expected to hydrolyze during 
transdermal transport. Although stratum corneum is considered as the main barrier of the skin, the 
majority of the enzymes, such as esterases can be found in the epidermis.12 Therefore the hydrolysis 
of the prodrugs (donor conc: 3.9 mM) was determined during iontophoresis across HSC and DHS. In 
case of valine-5-OH-DPAT, PBS pH 6.2 was used as acceptor phase and for β-alanine-5-OH-DPAT 
PBS pH 7.4 was used. The remaining prodrug was determined in the acceptor phase every hour after 
transport, taking the degradation in the donor phase and acceptor phase into account. 
5.2.7 PK-PD studies 
In the following studies the pharmacokinetic (PK) and pharmacodynamic (PD) properties of ß-ala-
(S)-5-OH-DPAT following transdermal iontophoretic delivery were determined simultaneously by 
taking blood samples (PK) and using on-line microdialysis (PD). For these studies, the active 
enantiomer (S)-5-OH-DPAT, was esterified with ß-alanine. Animal procedures were conducted in 
accordance with guidelines published in the NIH guide for the care and use of laboratory animals and 
all protocols were approved by the Institutional Animal Care and Use Committee of the University of 
Groningen. The surgical, experimental and analytical procedures were identical to the methods used 
for PK-PD studies performed with the parent drug (S)-5-OH-DPAT.9 A brief description is outlined 
below. 
5.2.7.1 Animals 
The pharmacokinetic-pharmacodynamic (PK-PD) studies were performed in albino male wistar rats 
(280-340 g) obtained from Harlan (Horst, the Netherlands). Prior to surgery the animals were housed 
at least 1 week in plexiglas cages, maximum 6 animals per cage with free access to water and 
standard laboratory chow. The cages were placed in a room with a controlled temperature at 21 °C 
and controlled humidity between 60-65% and a light-dark cycle of 12h. 
5.2.7.2 Surgical procedures 
Prior to surgery the rats were anaesthetized with Isofluran 2% in N2O/O2 (2/1). The permanent 
cannulations in the femoral vein and femoral artery were performed using silicone catheters (inner 
diameter (ID): 0.5 mm; outer diameter (OD): 0.9 mm) (UNO BV, Zevenaar, The Netherlands). After 
the cannulation the rats were kept under anaesthetized condition and mounted into a sterotaxic frame 
for the implementation of the microdialysis probes. A Y-shaped dialysis probe was used for the 
experiments, with an exposed tip length of 3 mm. The dialysis canulla (ID: 0.24 mm; OD: 0.34 mm) 
was prepared from polyacrylonitrile/sodium methallyl sulfonate copolymer (AN 69, Hospal, Bologna, 
Italy). The microdialysis canulla was implanted in the striatum. The following coordinates were used 
according to the atlas of Paxinos and Watson13: AP +0.9, LM ± 3.0 relative to bregma, and Vd – 6.0 
below dura. The dialysis probe, filled with Ringer solution (140 mM NaCl, 3.0 mM KCl, 1.2 mM 
CaCl2, 1.0 mM MgCl2), was positioned and fixed in the burr hole under stereotaxic guidance. 
Thereafter the rats were housed solitary. 
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5.2.7.3 Experimental procedures 
The PK-PD studies were performed 15-20 h after permanent cannulation and implementation of the 
probes. The rats were anaesthetized prior to and kept under anesthetized condition during the 
experiment with Hypnorm® and Dormicum® at a starting dose of 0.5 mL.kg-1 and subsequent 1h 
doses of 0.17 mL.kg-1.  
The donor solution consisted of ß-ala-(S)-5-OH-DPAT (3.9 mM), buffered in citric buffer 5 mM at 
pH 5. Before the start of the experiment, the hair of the back of the anesthetized rat was removed with 
an electrical clipper and scalpel. 15 minutes after attaching the patches to the skin surface, the 
cathodal patch was filled with PBS pH 7.4 and the anodal patch was filled with donor solution. The 
volume of the patches was 2.3 ml and the active area was 2.5 cm2. The protocol for the transdermal 
iontophoretic PK-PD studies was: 15 min passive diffusion + 90 min current application (250 μA.cm-
2). The patch was removed and the skin was wiped using tissue paper. Blood samples were taken at 
regular time intervals: 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 165, 195, 225, 255, 285 min. The 
blood samples (0.2 ml) were collected using lithium-heparin containing tubes (Microvette® 200 
Plasma/Lithium Heparin, Sarsted BV, Etten-Leur, the Netherlands) and subsequently the plasma 
samples were separated from the blood cells by centrifugation. The samples were kept at -20 °C prior 
to analysis with LC-MS/MS. The microdialysis probes in the striata were perfused with Ringer 
solution at a flow of 2 μL.min-1 (CMA/102 Microdialysis Pump, Sweden). The analysis of the 
microdialysate samples are described below. 
5.2.8 Analytical method 
5.2.8.1 in vitro samples 
Different HPLC methods were developed, in order to analyze simultaneously the respective prodrug, 
the parent drug 5-OH-DPAT and, if required, acetaminophen by RP-HPLC using a Superspher® 60 
RP-select B, 75 mm-4 mm column (Merck KGaA, Darmstadt, Germany). The prodrugs of 5-OH-
DPAT and acetaminophen were detected using a UV detector (Dual λ Absorbance Detector 2487, 
Waters, Milford, USA). The absorption wavelengths for the prodrugs and acetaminophen were 220 
nm and 243 nm respectively. 5-OH-DPAT was detected using a scanning fluorescence detector 
(Waters™ 474, Millipore, Milford, MA, USA) with excitation wavelength and emission wavelength 
of 276 nm and 302 nm, respectively. The composition of the mobile phase for analyzing the 
respective prodrug together with 5-OH-DPAT is presented in table 1. The flow rate was set to 1.5 
ml.min-1 and the volume of injection was 200 μl. Calibration curves showed a linear response when 
using concentrations of compounds between 0.1 and 40 μg.ml-1 (R2>0.999). The limit of detection 
(LOD) and limit of quantification (LOQ) for these HPLC methods can also be found in table 5.1. 
5.2.8.2 Blood samples of (S)-5-OH-DPAT 
Since the hydrolysis of ß-ala-(S)-5-OH-DPAT to (S)-5-OH-DPAT is occurring very rapidly in human 
blood plasma (t1/2=0.24 min in 80% human blood plasma), only (S)-5-OH-DPAT was analyzed in 
plasma.10 Blood samples of 5-OH-DPAT were analyzed with an on-line solid-phase-extraction-liquid-
chromatography-mass spectrometry/mass spectrometry (SPE-LC-MS/MS) method, described 




plasma, acetonitrile was added to precipitate the proteins. The mixture was vortexed, centrifuged, 
after which the supernatant was dried and redissolved in MilliQ and injected on the SPE cartridge 
(Hysphere Resin C8, endcapped, 10 x 4 mm (ID), 10μm SPE cartridge (Spark Holland B.V, The 
Netherland)). An external binary HPLC pump (Gynkotek, Germany) and an external Agilent 1200, 
2/6 switch valve (Agilent Technology, USA) were used for the SPE sample trapping.  
Table 5.1 Physicochemical properties of the different molecules investigated (Mw, charge/Mw ratio and cLogP) 




clogPa Mobile phase LOD LOQ 
  (x103)  Composition TEA    
 (g.mol-1) (mol.g-1)  (v/v) (mM) (µg.ml-1) (µg.ml-1) 
gly-5-OH-DPAT 304.4 6.6 3.6 Ace 50 mM/ACN 
85/15 
0 n.d n.d 
pro-5-OH-DPAT 344.5 5.8 4.1 Ace 50 mM /ACN 
74/26 
0 n.d n.d 
val-5-OH-DPAT 346.5 5.8 4.8 Ace 100 mM /THF 
95/5 
30 0.25 0.41 
β-ala-5-OHDPAT 318.4 6.3 3.8 Ace 100 mM/THF  
97.5/2.5 
30 1.6 2.7 
5-OH-DPAT 247.4 4.0 4.3 *  1.4.10-3 2.4.10-3 
acetaminophen 151.2 0.0 n.d *  0.9.10-3 1.4.10-3 
Ace: acetatebuffer pH 3.6; nd: not determined; * :mobile phase is dependent on the prodrug investigated 
acLogP was calculated using ACD/Chemsketch14-16; n.d.:not determined 
First the SPE cartridge was conditioned, then the injected sample was trapped, consequently the valve 
was switched to the analysis column after which the SPE cartridge was cleaned. Finally the cartridge 
was conditioned again. To analyze the extracted sample an Agilent 1200 HPLC system with 
autosampler (Agilent Technology, USA) was coupled online with an Agilent 6460 Triple Quadrupole 
mass spectrometer (Agilent Technology, USA). The samples were analyzed by μPLC-MS/MS using 
an Altima HP C18 column (150X 1.0 mm; 5 μm) (Grace Davison Discovery Sciences, Belgium). The 
detection was performed with a triple quadrupole mass spectrometer in the positive-ion electrospray 
mode and all analytes were monitored with Multiple Reaction Monitoring (MRM). System operation 
and handling the acquired data was performed using Agilent MassHunter data acquisition software 
(version, B.02.00; Agilent). Calibration curves showed a linear response when using concentrations of 
compounds between 0.2 and 50 ng.ml-1 (r2>0.999). The recovery, limit of detection (LOD) and limit 
of quantification (LOQ) were experimentally determined at 93.9 ± 2.9 %, 0.07 and 0.2 ng.ml-1, 
respectively. 
5.2.8.3 Microdialysate samples 
To analyze the striatal 5-OH-DPAT concentration the dialysate from the probe in the right striatum 
was collected every 15 min resulting a total volume of 30 μL per sample.  The solution was analyzed 
using LC-MS/MS method, described elsewhere.8 Briefly, d2-5-OH-DPAT.HBr was added as internal 
standard to a 100 μL mixture of water + 0.1% formic acid and Ringer (1:1). The HPLC system 
consisted of a Shimadzu LC 20 AD binary system with a Shimadzu SIL 20AC autosampler. The 
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samples were injected on a Grace Alltech Alltima HP C18 EPS reverse-phased column (150 x 2.1 
mm (ID), 3 μm). The compounds were detected on a SCIEX API3000 triple quadrupole mass 
spectrometer (Applied Biosystems/MDS SCIEX) equipped with a Turbo Ion Spray interface. The 
mass spectrometer was operated in the positive ion mode with MRM. The detection limit of 5-OH-
DPAT was 12.5 pg.ml-1.  
The dialysate contents of DA and its metabolites were quantified from the probe implanted at the 
right striatum by an on-line HPLC with electrochemical detection with the detection limit of 1 fMol 
per sample. An HPLC pump (LC-10AD vp, Shimadzu, Japan) was used in conjunction with an 
analytical cell (5011A, ESA, Chelmsford, MA, USA) and an electrochemical detector (Coulochem II, 
ESA) working at +300 mV for DOPAC and HIAA and -300 mV for DA. The analytical column was a 
Supelco Supelcosil™ LC-18-DB column (150 mm x 4.6 mm (ID), 3μm). Data were converted into 
percentage of basal levels. The basal levels were determined from four consecutive samples (less than 
20% variation), and set at 100%. After the experiments the rats were sacrificed and the brains were 
removed. After removal the brains were kept in 4% paraformaldehyde solution until they were 
sectioned to control the location of the dialysis probes. 
5.2.9 Data modeling 
The data of the in vitro transport of valine-, β-alanine-5-OH-DPAT and 5-OH-DPAT and the PK-PD 
data following transdermal iontophoresis of β-alanine-(S)-5-OH-DPAT was analyzed using non-
linear mixed effects modeling. 
in vitro model 
Previous studies suggested that two transport routes are involved in the iontophoretic delivery, linked 
in parallel.17 Therefore to describe the iontophoretic transport across the skin, one zero order mass 
input I0 from donor compartment into the skin during current application and two first order release 
constants KR1 and KR2 from skin to acceptor are used (Figure 5.2). The iontophoretic flux in vitro 
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where J(t) is the flux at time t and S is the diffusion area and tL is the kinetic lag time parameter, 
introduced to address the time required for drug molecules to enter the skin compartment and Jss as 
the flux at steady state. 
During the post iontophoresis period only one release constant is sufficient to describe the passive 
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where T is time of current application and PPI is the zero order drug input due to the passive driving 





Figure 5.2 Overview of the compartmental models, used to fit the in vitro iontophoretic flux profiles during the 
iontophoresis period (in vitro model) and the model, used to fit the plasma profile during the iontophoretic period 
(PK model). 
I0: the zero order input during the time of current application 
KR1 and KR2: first order release constants from the skin to the acceptor phase (in vitro) 
KR: the first order release constants from the skin to the plasma (in vivo)  
k: the elimination rate constant 
k14: the first order skin-hydrolysis compartment distribution rate constant 
k42: the first order hydrolysis compartment-plasma distribution rate constant 
k23: the first order plasma-peripheral distribution rate constant 
k32: the first order peripheral-plasma distribution rate constant 
PK model 
Since the hydrolysis of β-ala-(S)-5-OH-DPAT to (S)-5-OH-DPAT is occurring very rapidly in the 
blood, only the plasma concentration of the parent drug (S)-5-OH-DPAT was monitored. To account 
for the hydrolysis of β-ala-(S)-5-OH-DPAT to (S)-5-OH-DPAT during transport, an adaptation was 
made to the basic PK model, developed by Nugroho et al. to describe the plasma concentration 
following transdermal iontophoresis.18 It is believed that during transport of the prodrug into and 
through the skin 2 effects occur: hydrolysis and depot formation. The resulting effect of both 
mechanisms is described with the addition of a extra compartment, as illustrated in Figure 5.2. The 
differential equations to describe the plasma concentration of (S)-5-OH-DPAT following transdermal 
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)t(dX1  as the rate of change in the amount of the drug in compartment i, Xi as the amount of 
the drug in compartment i, which refers to the skin compartment (i=1), the plasma compartment (i=2), 
the peripheral compartment (i=3) and the hydrolysis compartment (i=4). I0 is defined as the zero order 
mass input, KR as the first order release rate constant from skin to plasma, k as the first order 
elimination rate constant, k23 and k32 as the first order distribution rate constants from plasma to tissue 
and tissue to plasma, respectively. k14 and k42 are the rate constants for the mass transfer from the skin 
to hydrolysis compartment and from the hydrolysis compartment to the systemic circulation. N is a 
flag in the model to indicate that the input rate I0 is only valid during the iontophoresis period. 
PD model 
An effect compartment model was used to describe the DA release following transdermal 
iontophoresis of β-ala-(S)-5-OH-DPAT. The rate of change of drug concentration 
dt
)t(dCe  in the 
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With ke0 as the rate constant from plasma to the effect compartment and the elimination rate constant 
from the effect compartment. The striatal DA release CDA, which is the pharmacodynamic end-point, 
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 Where Imax is the maximum inhibition of the DA production, IC50 is the plasma concentration of 5-
OH-DPAT to produce 50% of Imax, H is the Hill-slope coefficient, CDA(0) is the baseline values of DA 
(i.e., DA concentration prior to the inhibiting effect of 5-OH-DPAT).  
PK–PD data following IV infusion and transdermal delivery of (S)-5-OH-DPAT, obtained from 
literature, were included in the data set to obtain more reliable parameter estimates.8 In analogy to the 
PK–PD model of (S)-5-OH-DPAT a covariate of route of administration for IC50 was added.8 The 
fixed effect parameters (θ) included: I0, KR, clearance (CL), inter compartmental clearance (Q), 
volume of the central compartment (V2), volume of the peripheral compartment (V3), ke0, Imax and 
IC50. Variability in pharmacokinetic parameters was assumed to be log-normally distributed in the 
population. Inter-individual variability was modeled by an exponential error model as written in 
Equation 10: 
)exp(.P ii                                                                                                                                      (10) 
in which θ is the population value for the fixed effect parameter P, Pi is the individual estimate and ηi 
is the normally distributed interindividual random variable with mean zero and variance ω2. The 
coefficient of variation (CV%) of the structural model parameters is expressed as percentage of the 
root mean square of the interindividual variability term. The residual error was modeled by a 
proportional error model as written in Equation 11: 




where Cobs,ij is the jth observed concentration in the ith individual, Cpred,ij is the predicted 
concentration, and εij is the normally distributed residual random variable with mean zero and 
variance σ2. The estimation of the final population parameters was performed using the conventional 
first order estimation method (FOCE). The PK model parameters were estimated independently and 
subsequently used as input for the PD analysis. During model building, goodness-of-fit was based on 
statistical and graphical diagnostic criteria. Model selection and identification was based on 
likelihood ratio test, coefficient of variation of parameter estimates, parameter correlations and 
goodness-of-fit plots. For the likelihood ratio test, the significance level for the inclusion of one 
parameter was set at p<0.05, which corresponds with a decrease of 3.84 points, in the minimum valua 
of the objective function (MVOF) under the assumption that the difference in MVOF between two 
nested models is χ2 distributed. The following goodness-of-fit plots were subjected to visual 
inspection to detect systemic deviations from the model fits: individual observed versus population 
and individual predicted values. Finally, the performance of the population PK and PK-PD models 
were assessed by simulating 100 data sets with the final model parameter estimates. The evaluation of 
model performance also included visual predictive check (VPC), as implemented in Xpose 4 (R 
version 2.7.0, R-foundation).19 
5.2.10 Data analysis 
All data are presented as mean ± standard deviation (SD). When a statistical analysis was performed 
comparing only 2 groups, a Students t-test was used. When 3 or more groups were compared, a 1-way 
ANOVA statistical analysis was executed. Comparing effect of two factors simultaneously was 
performed using 2-way ANOVA. If the overall p-value was less than 0.05, a bonferonni post-test was 
applied to compare different groups. For all statistical analysis a significance level of p<0.05 was 
used. 
5.3 RESULTS 
5.3.1 Stability of prodrugs of 5-OH-DPAT in different conditions 
A series of prodrugs of 5-OH-DPAT were synthesized by esterification of 5-OH-DPAT 
with different amino acids.10 Because ester bounds are known to be susceptible to 
hydrolysis, the chemical stability of prodrugs was investigated. The various conditions were 
selected to mimic the conditions in the different compartments during iontophoretic 
transport. Apparent first order rate constants for hydrolysis were determined from the 
slopes of various plots of percent remaining prodrug vs time. The corresponding half lives 
are presented in Figure 5.3. Glycine-5-OH-DPAT and proline-5-OH-DPAT show a limited 
chemical stability in a citric buffer pH 5.0 at room temperature with a half life of 9.6 and 
7.5 h, respectively. Valine-5-OH-DPAT and β-alanine-5-OH-DPAT are stable under this 
condition with a half life of 318 and 692h, respectively. However increasing the pH from 
5.0 to 6.2 at room temperature (RT) decreases the half life of both valine- and β-alanine-5-
OH-DPAT to 7.6 h and to 64.2h, respectively. Further increasing the pH to 7.4 decreases 
the half life of the prodrugs to 0.7 and 4.5h for valine- and β-alanine-5-OH-DPAT, 
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respectively. Increasing the temperature from RT to 32 °C, the skin temperature, decreased 
the stability of glycine-, valine- and β-alanine-5-OH-DPAT. For instance the half life of 
valine-5-OH-DPAT at pH 6.2 decreases from 7.6 to 5.1h when increasing the temperature. 
Current application and the presence of HSC however do not affect the stability of the 
prodrugs. Since valine- and β-alanine-5-OH-DPAT are the most stable prodrugs, these 2 
compounds were selected for further investigations, concerning solubility and transdermal 
transport. 
 
Figure 5.3 The half life (t1/2) of the hydrolysis of the prodrugs glycine-5-OH-DPAT (striped bar), 
proline-5-OH-DPAT (blocked bar), valine-5-OH-DPAT (white bar) and β-alanine-5-OH-DPAT 
(black bar) under various conditions. The data are presented as estimate + the upper limit of the 
estimate. CB: citric buffer 5 mM; RT: room temperature; HSC: human stratum corneum; Cur: current 
320 µA. 
5.3.2 Solubility of valine- and β-alanine-5-OH-DPAT  
The maximum solubility was determined in citric buffer 5.0 mM pH 5 as this is the donor 
solution, used for transport studies. The maximum solubility of valine-5-OH-DPAT is 
232.2 mM. With respect to β-alanine-5-OH-DPAT the maximum solubility is expected to 
be higher than 832.2 mM. At this concentration the maximum solubility of β-alanine-5-OH-
DPAT is not yet reached. However, the study was discontinued due to the limited 





Figure 5.4 In vitro flux profiles of valine-5-OH-DPAT (closed triangle), β-ala-5-OH-DPAT (star) 
and 5-OH-DPAT (open circle). A: Iontophoresis of valine-5-OH-DPAT (only 3.9 mM (intermittent 
line)) and β-ala-5-OH-DPAT and 5-OH-DPAT at 3 different concentrations (1.5 (solid line), 3.9 
(intermittent line), 7.0 mM (thick solid line)) across stratum corneum. B: Iontophoresis of 3.9 mM 
valine-5-OH-DPAT, β-ala-5-OH-DPAT and 5-OH-DPAT across dermatomed human skin. PBS pH 
7.4 was used in all experiments as acceptor phase. 
5.3.3 In vitro iontophoresis of the two prodrugs in comparison to 5-OH-
DPAT  
Figure 5.4 illustrates the iontophoretic flux profiles of the prodrugs at different 
concentrations under various conditions. The flux profiles of the parent drug, adapted from 
literature, were added to the graphs for comparison.20 In case of the prodrugs the non-
hydrolyzed and the hydrolyzed fraction of the prodrug are added and the resulting total flux 
is displayed in figure 5.4. The iontophoretic transport of across HSC of the two prodrugs 
was evaluated in comparison to each other and their parent drug 5-OH-DPAT, using PBS 
pH 7.4 as acceptor phase (Figure 5.4A). The flux after 9h current application of β-alanine-
5-OH-DPAT (238.0±26.1 and 329.6±41.9 nmol.cm-2.h-1) across HSC is not significantly 
different from the flux of the parent drug 5-OH-DPAT (207.7±38.0 and 407.7±37.0 
nmol.cm-2.h-1) at 3.9 and 7.0 mM donor concentrations (p>0.05; 2-way ANOVA). Since the 
assay of iontophoretic delivery of 1.5 mM β-alanine-5-OH-DPAT was stopped after 7h of 
current application this time point was chosen to compare the flux of prodrug and parent 
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drug. A similar flux was observed for β-alanine-5-OH-DPAT (84.1±5.6 nmol.cm-2.h-1), 
compared to 1.5 mM 5-OH-DPAT (78.2±6.2 nmol.cm-2.h-1) (p<0.05; t-test).  
The results of the transport studies across DHS, with PBS pH 7.4 as acceptor phase, are 
depicted in Fig. 5.4B. 2-way ANOVA was performed to analyze the Flux after 9h of 
current application (Flux9h) across HSC and DHS for all the compounds at 3.9 mM. An 
overall significant difference could be observed between the Flux9h of the different 
compounds, which was due to compound variation and not due to the use of the different 
skin types (p<0.05). Bonferonni's post-test demonstrated that the Flux9h of the prodrug β-
alanine-5-OH-DPAT is significantly higher compared to the Flux9h of valine-5-OH-DPAT 
across DHS and HSC. In addition only across DHS the Flux9h of β-alanine-5-OH-DPAT is 
significantly higher than the Flux9h of the parent drug, 5-OH-DPAT. Furthermore the Flux9h 
of valine-5-OH-DPAT was significantly lower compared to the Flux9h of the parent drug 
across HSC and DHS. 
Acetaminophen (15 mM) as electroosmotic marker was added to the donor concentration to 
quantify the electroosmotic flux. 1-way ANOVA, with a bonferonni post test showed that 
the electroosmotic flux during transport of valine-5-OH-DPAT (7.8±1.9 nmol.cm-2.h-1) is 
significantly lower than the electroosmotic flux of 5-OH-DPAT (13.7±3.4 nmol.cm-2.h-1) 
(p<0.05), however not significantly different from β-alanine-5-OH-DPAT (11.7±4.2 
nmol.cm-2.h-1) (p>0.05). Also the electroosmotic flux of 5-OH-DPAT and β-alanine-5-OH-
DPAT are not significantly different (p>0.05). 
The iontophoretic transport profile across HSC and DHS of 3.9 mM β-alanine-5-OH-DPAT 
was modeled using Equations 1 and 3. The resulting parameters are displayed in Table 5.2. 
The estimated steady state flux, calculated with Equation 2, is higher for DHS, compared to 
HSC. The lag time (Tlag) and passive driving force post iontophoresis (Pass=PPI/S) are also 
higher for DHS, whereas the release constants KR1 and KR2 are lower compared to HSC. 
5.3.4 Hydrolysis during transport through HSC and DHS 
Approximately 19.8 ± 2.6% and 55.4 ± 15.1% of β-alanine-5-OH-DPAT is hydrolyzed in 
5-OH-DPAT when transported across HSC and DHS, respectively, using PBS pH 7.4 as 
acceptor phase. A similar observation is found for val-5-OH-DPAT, using PBS pH 6.2 as 
acceptor phase: 26.8±5.4% and 100% valine-5-OH-DPAT is converted into 5-OH-DPAT 
when transported through HSC and DHS, respectively. 
5.3.5 In vivo iontophoretic delivery of ß-ala-(S)-5-OH-DPAT 
The PK and PD of the active S-enantiomer of the most promising prodrug ß-ala-(S)-5-OH-
DPAT following transdermal delivery were investigated simultaneously. For comparison 




parent drug (S)-5-OH-DPAT, adapted from literature, are added to the resulting graphs 
(Figure 5.5B-D).8 
 
Figure 5.5 Resulting graphs of the PK-PD study with β-ala-(S)-5-OH-DPAT (open circle) together 
the results of (S)-5-OH-DPAT (closed triangle), adapted from literature. The observed plasma 
concentration (Cp) of (S)-5-OH-DPAT, following transdermal iontophoresis of β-ala-(S)-5-OH-DPAT 
(A) and (S)-5-OH-DPAT (B) are presented together with the population prediction (PRED)(full line). 
C: The striatal concentration of (S)-5-OH-DPAT (Cs), presented as mean ± SD, following 
iontophoretic delivery of β-ala-(S)-5-OH-DPAT and (S)-5-OH-DPAT. 
D: The DA release in the striatum, as % baseline, presented as mean ± SD, following iontophoretic 
delivery of β-ala-(S)-5-OH-DPAT and (S)-5-OH-DPAT. 
aadapted from literature8 
5.3.5.1 Plasma profile 
The prodrug is rapidly hydrolyzed to (S)-5-OH-DPAT in blood plasma, since the half life is 
0.24 min in 80% human blood plasma.10 Therefore the plasma concentration of the parent 
drug (S)-5-OH-DPAT was monitored during the PK-PD study. No detectible amount of 
(S)-5-OH-DPAT was observed after 15 min of passive diffusion (data not shown). Current 
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application starts at t=0 min, as depicted in Figure 5.5A. As can be observed current 
application results in immediate increase in plasma concentration. After 90 min of current 
application, the plasma profile tends towards a steady state situation. The resulting plasma 
concentration at time=90 min is 18.2±0.8 ng.ml-1. After current application is discontinued 
and the patch is removed, the profile shows a decline in plasma concentration, which is best 
described with a 2-compartmental model. 
5.3.5.2 Striatum profile 
The 5-OH-DPAT concentration of the microdialysate samples of the left striatum was 
analyzed following transdermal iontophoresis of ß-ala-(S)-5-OH-DPAT. With a delay of 
approximately 7.5 min, the striatal 5-OH-DPAT concentration (Cs) increased when starting 
iontophoresis to a maximum level of 0.88±0.18 ng.ml-1. This maximum was reached 22.5 
min after switching off the current (t=112.5 min). After this time point Cs declines again. 
5.3.5.3 Pharmacodynamic effect 
With on-line microdialysis the DA concentration (the pharmacodynamic end-point) in the 
right striatum was monitored. The resulting DA release profile (mean ± SD) is depicted in 
Figure 5.5D. Prior to iontophoresis the DA level was monitored and the average DA level 
from 4 consecutive points was set to 100%. As can be observed, when starting 
iontophoresis the DA level decreases with a lag time between 7.5 and 22.5 min. The DA 
level decreases to near steady state level of 48.6±8.2% baseline, 94.5 min after the start of 
iontophoresis. After removal of the patch, the DA level recovers again to its initial state 
(DA release=100%) at time=189.2±12.1 min following prodrug iontophoresis. 
5.3.6 Non-linear mixed effects modeling: model evaluation  
The in vitro transport flux profiles, the plasma profile and the pharmacodynamic effect are 
modeled with non linear mixed effects modeling, using compartmental models. The 
resulting parameter estimates are depicted in Table 5.2. A relatively low Residual Standard 
Error (RSE%) for the fixed in vitro (≤ 35%) and in vivo parameters estimates (≤ 23%) 
indicates a reliable prediction of the estimates. Moreover Figure 5.6A and B, displaying the 
visual predictive check (VPC), demonstrates that the in vivo observations are well 
distributed between the 2.5th and the 97.5th percentiles. This indicates that the variability, 
predicted by the PK/PD model, corresponds with the observed variability. In addition the 
diagnostic plots of the PK and PD profile, shown in figure 5.6C-F, indicate that the 






Table 5.2 The resulting population estimates of simultaneous modeling the plasma concentration and 
DA release following transdermal iontophoresis of β-ala-(S)-5-OH-DPAT (3.9 mM) in male wistar 
rats. The resulting parameters of fitting the in vitro transdermal iontophoretic transport of β-ala-5-OH-
DPAT (3.9 mM) across human stratum corneum (HSC) and dermatomed human skin (DHS) is 
depicted. PBS pH 7.4 was used as acceptor phase for the in vitro experiments. 
  Estimate Between 
animal 
variability 















PK-PD      HSC (in vitro)     
V2 L 0.46 18 0.13 97 Jss 500 * 272.5 4   
V3 L 0.78 16 0.07 52 KR1 h-1 0.278 28 0.516 82 
CL L.h-1 2 6 0.02 38 KR2 h-1 1.69 8 0.035 23 
Q L.h-1 1.96 21 0.16 73 Tlag h 0.005    
Jss 250 * 110.6 8   Pass * n.d.    
KR h-1 0.31 23         
k14 h-1 5.06 23   Sigma 1  0.019 17   
k42 h-1 4.79 21   Sigma 2  1.93 36   
keo h-1 3.79 12 0.19 48       
IC50 ng.ml-1 4.50 12 0.07 35       
N  3.12 9   DHS (in vitro)     
Imax  40.9 7 0.03 39 Jss 500 * 381.3 7   
      KR1 h-1 0.069 35 0.212 23 
      KR2 h-1 0.588 5 0.3 51 
      Tlag h 0.22 10   
      Pass * 29.1 14 0.045 33 
Sigma 1  PK 0.02 24   Sigma 1  0.002 67   
Sigma 1 PD 0.01 20   Sigma 2  18.4 59   
*: unit of Jss and Pass is: nmol.cm-².h-1 
Sigma 1: proportional error; Sigma 2: additive error 
n.d.: not determined because the parameter value was constrained to 0 
5.4 DISCUSSION  
The general aim of the present study is to evaluate different prodrugs and select the best 
candidate(s) for transdermal iontophoretic delivery. The presence of enzymes in the skin, 
such as esterases and amidases, makes the use of prodrugs an interesting approach for 
transdermal delivery. The prodrugs can be tailored to improve drug delivery and during 
transport across the skin, the enzymes hydrolyze the prodrugs to their active parent drug.7 
5.4.1 Chemical stability and solubility 
Ester prodrugs, as presented in this paper, are not only susceptible to enzymatic, but also to 
chemical hydrolysis. The stability of the prodrugs in different aqueous solutions is highly 
dependent on the side chain, esterified with 5-OH-DPAT (stability: glycine < proline < 
valine < β-alanine). Based on these results valine- and β-alanine-5-OH-DPAT were selected 
for further investigating the transdermal iontophoretic transport across human skin. 
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Esterification of 5-OH-DPAT with valine and β-alanine improved its solubility 
tremendously. The solubility of valine- and β-alanine-5-OH-DPAT was respectively 4 and 
more than 14 times higher, compared to its parent drug 5-OH-DPAT.20 A higher solubility 
enables reduction of the patch volume, while keeping sufficient amount of drug in the 
patch. Presumably addition of an extra chargeable amine group contributes substantially to 
the solubility of the prodrugs. 
5.4.2 Transdermal iontophoresis in vitro 
At pH 5.0 both prodrugs have an additional charge compared to 5-OH-DPAT. When 
increasing the charge from monovalent to bivalent, this affects in several ways the 
transport: (i)  bivalent ions have a larger hydrated volume, as suggested by Lai and Roberts, 
which can result in a reduced flux21, (ii) bivalent ions interact more with charged sites in 
SC, which according to Phipps et al. will result in a reduced flux22 and (iii) an increase in 
the charge/molecular weight ratio results in an equivalent higher electromigrative flux.23 It 
is suggested that the lipophilicity, indicated by the cLogP (Table 5.1), of the prodrugs 
influences the balance between these three factors and therefore affects the transport 
efficiency.14-16 Only for the more hydrophilic prodrug β-alanine-5-OH-DPAT with a 
charge/Mw ratio which is 1.5 times higher compared to 5-OH-DPAT, resulted in almost in 
an equivalent increase (1.4 times) in the total flux after 9h of current application across 
DHS. The flux of β-alanine-5-OH-DPAT is less affected by the increased hydrated volume 
and the skin interaction. In contrast valine-5-OH-DPAT with a hydrophobic prodrug moiety 
is retained more by the skin and shows a decreased flux compared to 5-OH-DPAT. This 
hypothesis is strengthened by the decreased electroosmotic flux during transport of valine-
5-OH-DPAT. Valine-5-OH-DPAT is retained more strongly and the two positive charges 
cause a neutralization of the skin negative charges, resulting in a reduced electroosmotic 
flux. Furthermore, the transport of valine-5-OH-DPAT is less affected by the 
charge/molecular weight ratio. These results are in agreement with the computational 
studies performed by Schuetz et al., who predicted with a 3D quantitative structure-
permeation relationship that iontophoresis was favored by peptide hydrophilicity and 
hindered by voluminous localized hydrophobicity.24 
Besides the transport efficiency it is also important to determine the rate of hydrolysis 
during iontophoretic transport across human skin in order to be able to predict the amount 
of prodrug and parent drug that will taken up by the blood stream. In analogy to the 
chemical stability, β-alanine-5-OH-DPAT is the more stable prodrug. For both prodrugs an 
increased hydrolysis is observed when transported across DHS. This increased hydrolysis 
rate is the result of 2 mechanisms. First, the presence of enzymes, such as esterases, is more 
abundant in the epidermis. Second, the increased migration time through DHS and the 
slower release from the DHS, reflected by KR1 and KR2 (Table 5.2), results in a possibly 
longer interaction of enzymes with the prodrugs augmenting the hydrolysis rate. The 




hydrolyzed rapidly when taken up by the blood stream, since the enzymatic half life of 
valine- and β-alanine-5-OH-DPAT in 80% human blood plasma was 0.22 and 0.24 min, 
respectively.10 
 
Figure 5.6. Diagnostic plots of simultaneous fitting the plasma concentration (A, C, D) and the DA 
release (B, E, F) following the transdermal iontophoresis of β-ala-(S)-5-OH-DPAT. Depicted are the 
observations (open circles) together with the interquantile concentration range (2.5%-97.5%, 
intermittent line) and the median (50%, solid line) of the plasma profile (A) and the DA release 
profile (B). A number of 100 samples were simulated based on the final parameter estimates. C,E: 
population predicted vs the observed data. D,F: individual prediction vs the observed data.  
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5.4.3 PK-PD properties 
The pharmacokinetic and pharmacodynamic properties of β-alanine-(S)-5-OH-DPAT, the 
more stable and soluble prodrug with improved in vitro transport efficiency, were 
investigated in an animal model. Under anesthetized conditions blood samples were taken 
and the DA level in the striatum (pharmacodynamic end-point) was monitored on-line with 
microdialysis. This animal model is identical to the animal model used to investigate the 
PK-PD properties of (S)-5-OH-DPAT, which enables us to compare the prodrug to its 
parent drug.8 The plasma concentration profile of (S)-5-OH-DPAT (Cp) following 
transdermal iontophoresis of the prodrug differs on 3 aspects from the profile following (S)-
5-OH-DPAT administration, as can be observed in Figure 5.5A-B. (i) The increase in 
plasma concentration during current application is slower for the prodrug than for the 
parent drug. This is reflected by a decreased skin release constant KR for the prodrug (Table 
5.2).8 (ii) After 90 min of current application the population predicted Cp is lower for β-ala-
(S)-5-OH-DPAT (19 ng.ml-1) than for (S)-5-OH-DPAT (23.5 ng.ml-1). (iii) During the 
elimination phase the Cp profile is different following administration of prodrug vs parent 
drug. It is hypothesized that these 3 differences can be partially attributed to the hydrolysis 
of the prodrug during transdermal transport, assuming the hydrolysis in blood plasma is 
occurring instantaneously. Furthermore it is believed that after penetration through the 
stratum corneum depot formation of the prodrug in the viable epidermis also delays the 
release to the systemic circulation. The resulting effect was included in the PK-model by 
adding an extra compartment between the skin and the central compartment (Figure 5.2). 
This model adequately described the plasma profile following transdermal administration 
of the prodrug (Figure 5.6).  
In addition the resulting parameter estimates corresponded very well with the parameters of 
(S)-5-OH-DPAT obtained for the PK-PD study.8 It can be observed in Figure 5.5C that in 
analogy to Cp the increase in Cs during the absorption phase is faster and that the striatal 
clearance is going more rapidly following iontophoresis of the parent drug (S)-5-OH-
DPAT. Finally the difference in Cp and Cs profile following prodrug vs parent drug 
administration resulted also in a different striatal DA release profile (Figure 5.5D). During 
the iontophoretic period no difference was observed in DA release with the same 
maximum. This suggests that despite a lower steady state plasma concentration the same 
maximum effect can be achieved. Post-iontophoresis however the time for the DA release 
to recover to baseline values post-iontophoresis was significantly longer for the prodrug 
(99.2±12.1 min) compared to (S)-5-OH-DPAT (79.4±1.3 min) (t-test; p<0.05). This can be 
attributed to higher Cp values after removal of the patch due to delayed skin release. On the 
one hand, this prolonged effect can be a drawback to initiate therapy to treat Parkinson’s 
disease, since rapid changes in delivery schemes may be required. On the other hand, the 
prolonged effect of the prodrug can be beneficial for patients who suffer from nocturnal 




in patients with Parkinson’s disease.25 It is believed that continuous stimulation of the DA 
receptor during the night can reduce the occurrence of nocturnal disturbances.26 
5.4.4 in vitro-in vivo correlation 
Fitting in vitro and in vivo transport using compartmental modeling allowed us to compare 
both iontophoretic transports. Different kinetic models were used to describe the in vitro 
and in vivo transport of the prodrug β-alanine-(S)-5-OH-DPAT. This suggests that different 
transport mechanisms can be involved in vitro and in vivo. These differences can at least 
partially be attributed to 3 factors. First, the structure of human skin differs from the 
structure of rats. Mainly the thickness of the different skin layers, the stratum corneum lipid 
composition and the density of hair follicles will contribute to the difference.27 But previous 
studies showed that iontophoresis under constant current conditions diminishes the 
interspecies variations28  and that rat skin has comparable permeation kinetic parameters 
with human skin.27 Second, the clearance of the penetrant by the acceptor flow may be 
different from the clearance in vivo by the microcirculation in the skin.27 Third, the activity 
of the esterase in vivo may be different from the esterase activity in freshly excised skin. 
Despite these differences a good correlation was observed between the steady state flux in 
vitro and in vivo. Assuming that there is a linear correlation in vivo between the flux and the 
current density8, applying a current density of 500 µA.cm-² would result in an in vivo steady 
state flux (Jss=I0/S) of 221.2 nmol.cm-2.h-1. This flux corresponded best with the in vitro Jss 
across HSC (272.5 nmol.cm-2.h-1) compared to the Jss across DHS (381.3 nmol.cm-2.h-1). 
This suggests that transport across HSC can provide valuable information for prediction 
towards the in vivo situation for this particular compound. Whether this is also the case for 
other drugs, remains to be established.   
In conclusion this study demonstrates the potential of improving solubility, iontophoretic 
transport and changing the plasma profile and the PD effect of the promising DA agonist 5-
OH-DPAT with the use of prodrugs. A good balance was found between an efficient 
transport rate and enzymatic conversion to the parent drug during transdermal transport. Of 
the synthesized prodrugs, presented in this research, β-alanine-5-OH-DPAT is the most 
promising prodrug and is a potential candidate for further investigation. This sufficiently 
stable prodrug shows a tremendous increase in solubility, which can be beneficial for 
manufacturing and practical use. The increased in vitro flux of β-alanine-5-OH-DPAT 
across human skin did not result in higher steady state plasma concentrations, but in a 
prolonged effect which reached the same maximum level as was observed with the parent 
drug.  
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Synthesis and chemical stability studies of 





Mono amino acid ester prodrugs of 5-OH-DPAT showed a good in vitro/in vivo stability 
ratio, but an improved chemical stability would be advantageous for several reasons. A 
higher chemical stability permits the conversion to alternative salt forms, it allows the 
incorporation of a wider variety of functional groups, and it gives prodrugs with a longer 
shelf-life. In addition, it may reduce hydrolysis during transport by iontophoresis across the 
human stratum corneum, the main barrier of the skin. A possible strategy to improve the 
chemical stability of prodrugs is the design of dipeptide esters. Therefore a series of 
dipeptide ester prodrugs of (S)-5-OH-DPAT based on glycine, L-valine and β-alanine were 
synthesized and the chemical stabilities were determined in citrate buffer pH 5 (donor 
phase) at 32 0C. All dipeptide ester prodrugs showed a higher chemical stability than their 
mono amino acid ester prodrug equivalents. These newly synthesized prodrugs are 
potential candidates for future studies on enzymatic stability and transdermal iontophoretic 
delivery. 
6.1 INTRODUCTION 
In vitro and in vivo studies show that the β-alanine ester of 5-OH-DPAT (2.39) is a 
promising prodrug, with a good balance between chemical stability, transport efficiency 
and enzymatic conversion (Chapter 3 and Chapter 5).1 Nevertheless, the hygroscopicity, the 
difficulty to introduce some other interesting amino acids, a relatively short shelf-life and 
the partial hydrolysis during skin transport by iontophoresis, are reasons that demand an 
improved stability. 
The mono amino acid ester prodrugs of 5-OH-DPAT were all highly hygroscopic which is 
probably caused by its dihydrochloride salt form (Chapter 2). Because the prodrugs were 
hydrolyzed very fast at higher pH, it was difficult to convert the prodrugs to the 
monohydrochloride salt or to other less hygroscopic salt forms. The hygroscopicity 
impeded easy handling and therefore it would be desirable to obtain chemically more stable 
prodrugs of 5-OH-DPAT which could be converted to the free amine without pronounced 
hydrolysis. 
Unfortunately, amino acid prodrugs of 5-OH-DPAT with weakly basic (L-arginine and L-
lysine) or alcoholic (L-serine) pro-moieties, showed insufficient chemical stability to be 
studied in iontophoretic experiments (Chapter 3). It would be eligible to incorporate these 
amino acids in a pro-moiety without losing chemical stability. Herewith, the influence of 
these weakly basic and alcoholic pro-moieties on transdermal iontophoretic delivery could 
be investigated. 
The chemical hydrolysis of the L-valine (2.31, half life 53 hours) and β-alanine (2.39, half 
life 117 hours) 5-OH-DPAT prodrugs at pH 5 and 32 ºC showed sufficient stability for 
SYNTHESIS AND STABILITY STUDIES OF DIPEPTIDE ESTER PRODRUGS OF (S)-5-OH-DPAT 
 
 169 
iontophoresic experiments.1 Nevertheless after 8 and 18 hours respectively, only 90% of the 
L-valine and β-alanine ester prodrugs would remain intact at this temperature and acidity. 
For practical use higher chemical stabilities are desired for a prolonged shelf-life. 
The hydrolysis of the L-valine and β-alanine 5-OH-DPAT prodrugs during transport 
through human stratum corneum was 27% and 20%, respectively.1 If the prodrug is 
prevented to hydrolyze during the transport across the human stratum corneum, the 
iontophoretic transport might be improved due to full availability of the additional charge 
on the pro-moiety and/or the lower lipophilicity of the prodrug. Therefore, an improved 
chemical and enzymatic stability would be advantageous. 
A possible strategy to increase the chemical stability of 5-OH-DPAT prodrugs would be the 
design of dipeptide esters. According to  Nashed and Mitra both geometrical isomerism and 
hydrogen bonding might enhance the stability of dipeptide ester prodrugs.2 Dipeptide 
prodrugs of the aliphatic alcohols acyclovir and ganciclovir showed higher chemical 
stabilities than their respective mono amino acid ester prodrugs.3-5 Dipeptide prodrugs of 
lopinavir did not show significant degradation in buffer solution.6 Also dipeptide prodrugs 
of the phenolic drug paracetamol led to highly soluble and chemically stable prodrugs.7 In 
contrast, dipeptide prodrugs of floxuridine generally showed lower chemical stabilities 
compared to the corresponding mono amino acid prodrugs.8 Thus, the ability of the 
dipeptide prodrug strategy to significantly increase the chemical stability depends on both 
the nature of the pro-moieties and the parent drug. 
In this chapter we describe the synthesis of a series of dipeptide prodrugs of 5-OH-DPAT. 
The hydrolysis rates of various combinations of glycine, L-valine and β-alanine were 
determined in order to gain insights in the influence of the position of amino acids in the 
dipeptide pro-moiety. These prodrugs could be used in further experiments for enzymatic 
stability and in vitro and in vivo transdermal iontophoretic delivery. 
6.2 CHEMISTRY 
From the glycine (2.28), L-valine (2.31) and β-alanine (2.39) esters of (S)-5-OH-DPAT a 
series of eight N-Boc-protected dipeptide (S)-5-OH-DPAT esters was synthesized. The 
coupling procedure was based on the carbodiimide method mentioned in Chapter 2, besides 
that N-methylmorpholine (NMM) was added to the reaction mixture in order to liberate the 
reacting amino group from its hydrochloride salt form. In this manner the Boc-protected 
dipeptide (S)-5-OH-DPAT esters 6.1-6.8 were prepared in yields between 28% and 82% 





Scheme 6.1 Synthesis of L-valine-glycine (S)-2-(di-n-propyl-amino)tetralin-5-yl ester 2HCl salt (6.9). 
Reagents and conditions: a) EDC, N-tert-Boc-amino acid, NMM, HOBt hydrate, 0°C-RT; b) 4N HCl 
in dioxane, RT. 
Although the N-Boc-L-valine-glycine (6.1) ester was obtained in a high yield, related 
compounds N-Boc-glycine-glycine and N-Boc-β-alanine-glycine (S)-5-OH-DPAT esters 
(not shown) were obtained in low yields and the synthesis of these compounds was 
abandoned. These low yields may be attributable to a very high aqueous solubility resulting 
in an increased uptake in the aqueous layer during extraction, and hydrolysis during column 
chromatography. 
Table 6.1 Overall yields and purities of dipeptide prodrugs of 5-OH-DPAT 6.9-6.16. 
Compound Prodrug Moiety Yield (%) HPLC Purity (%) 
6.9 L-Valine-Glycine 19 98 
6.10 Glycine-L-Valine 20 100 
6.11 L-Valine-L-Valine 16 100 
6.12 β-Alanine-L-Valine 13 100 
6.13 Glycine-β-Alanine 14 95 
6.14 L-Valine-β-Alanine 33 99 
6.15 β-Alanine-β-Alanine 16 99 
6.16 L-Lysine-β-Alanine 29 96 
The deprotection procedure of the N-Boc-dipeptide (S)-5-OH-DPAT esters 6.1-6.8 was 
completed in a hydrogen chloride solution in dioxane. The reaction products precipitated as 
oils and were separated from the dioxane. Next, the oils were dissolved in dry methanol and 
precipitated with dry ether to yield the dipeptide (S)-5-OH-DPAT esters 6.9-6.16 as the 
dihydrochloride salts with overall yields of 13%-33% and with purities of ≥ 95% (Scheme 
6.1 - Scheme 6.3 and Table 6.1). 




Scheme 6.2 Synthesis of glycine-L-valine (6.10), L-valine-L-valine (6.11) and β-alanine-L-valine 
(6.12) (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl esters as 2HCl salts. Reagents and conditions: a) 
EDC, N-tert-Boc-amino acid, NMM, HOBt hydrate, 0°C-RT; b) 4N HCl in dioxane, RT. 
 
Scheme 6.3 Synthesis of glycine-β-alanine (6.13), L-valine-β-alanine (6.14), β-alanine-β-alanine 
(6.15) and L-lysine-β-alanine (6.16) (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl esters as HCl salts. 
Reagents and conditions: a) EDC, N-tert-Boc-amino acid, NMM, HOBt hydrate, 0°C-RT; b) 4N HCl 
in dioxane, RT. 
6.3 RESULTS 
6.3.1 Chemical Stability 
The hydrolysis rate constants (kobs) and half-lives (t1/2) of compounds 2.28, 2.31, 2.39 and 
6.9-6.16 were obtained by measuring the initial rate of 5-OH-DPAT formation during 
hydrolysis experiments in 5 mM citrate buffer pH 5 at 32 ºC which is the temperature of the 





Figure 6.1 Pseudo first-order rate plots of 5-OH-DPAT formation during prodrug hydrolysis in citrate 
buffer pH 5 at 32°C, based on the estimated half-lives presented in Table 6.2. The prodrugs are listed 
per group in sequence of ascending half-life. The C-terminal is the carboxylic acid terminal end of the 
dipeptide. 
The formation of 5-OH-DPAT during prodrug hydrolysis followed pseudo-first-order 
kinetics and is described by: )e1(]DPAT-OH-5[]DPAT-OH-5[ ktmaxformed
 . The 
observed first-order hydrolysis rate constants of the 5-OH-DPAT formation from the 




formed  as 
a function of time. The linear regression slopes of these plots (r2 ≥ 0.95) are related to the 
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observed rate constant, kobs, and are given by:  time) vsC (log slope log
1 
e
kobs . The 
half-lives (t1/2) can be estimated by the equation: k
t 2ln2/1   and are presented in Table 
6.2.No mono amino acid ester prodrug degradation products were detected. 
Table 6.2 Estimated hydrolysis half-lives (t1/2) of 5-OH-DPAT prodrugs 2.28, 2.31, 2.39 and 6.9-6.16 
in 0.005 M citrate buffer (pH 5) at 32 ºC (n=3, exceptions are 2.28 (n=9), 2.31 (n=6) and 2.39 (n=6)). 
Compound 5-OH-DPAT ester t1/2 ± SEM (hours)  kobs x 103 (hours-1) ratio t1/2 
2.28 Glycine 20.7±0.3 33.5 1 
6.9 L-Valine-Glycine 46.8±3.2 14.9 2.3 
2.31 L-Valine 53.1±1.6 13.1 2.6 
6.10 Glycine-L-Valine 243±2.6 2.85 11.7 
6.11 L-Valine-L-Valine 2690±135 0.259 130 
6.12 β-Alanine-L-Valine 1399±54 0.497 68 
2.39 β-Alanine 117.0±5.3 5.99 5.7 
6.13 Glycine-β-Alanine 1824±52b 0.381 88 
6.14 L-Valine-β-Alanine 2407±49a 0.288 116 
6.15 β-Alanine-β-Alanine 2481±140a 0.281 120 
6.16 L-Lysine-β-Alanine 2033±228a, b 0.351 98 
a,b The mean t1/2 values were not significantly different (one-way ANOVA with post-hoc Tukey’s test 
for comparing means of 2.39 and 6.13-6.16 , p < 0.05). 
The chemical stability trend among the dipeptide prodrugs is as following: L-valine-L-
valine (6.11, 2690 hrs) ≥ β-alanine-β-alanine (6.15, 2481 hrs) ≈ L-valine-β-alanine (6.14, 
2407 hrs) ≥ L-lysine-β-alanine (6.16, 2033 hrs) ≥ glycine-β-alanine (6.13, 1824 hrs) > β-
alanine-L-valine (6.12, 1399 hrs) > glycine-L-valine (6.10, 243 hrs) > L-valine-glycine (6.9, 
46.8 hrs). The dipeptide prodrugs all show higher chemical stabilities compared to the 
glycine reference prodrug 2.28 with factors between 2 and 130 times of increased stability.  
A) Dipeptide prodrugs with a C-terminal glycine. From the comparison of the L-valine-
glycine dipeptide prodrug 6.9 with the glycine amino acid ester 2.28, an increased stability 
with a factor 2.3 was shown. The coupling of an L-valine amino acid to the amino group of 
an already esterified glycine, gave a higher chemical stability to the 5-OH-DPAT prodrug. 
Still, dipeptide prodrug 6.9 was the most labile prodrug to chemical hydrolysis of all 
investigated dipeptide prodrugs of 5-OH-DPAT. 
B) Dipeptide prodrugs with a C-terminal L-valine. The dipeptide prodrugs 6.10-6.12 
which were based on the L-valine ester of 5-OH-DPAT (2.31) all showed an increased 
chemical stability compared to 2.31. The glycine-L-valine prodrug 6.10 gave the smallest 
increase in stability, whereas the L-valine-L-valine prodrug 6.11 gave the highest increase, 
i.e. a half-life which was a factor of 50 and 130 times larger than the half-life of the L-
valine ester prodrug 2.31 and the glycine ester prodrug 2.28, respectively. In fact, prodrug 




The β-alanine-L-valine ester prodrug 6.12 showed an increase in stability of a factor 68 
compared to the reference glycine prodrug 2.28 and a factor 26 when compared to the 
reference L-valine prodrug 2.31. 
C) Dipeptide prodrugs with a C-terminal β-alanine. In general, the dipeptide prodrugs 
based on the β-alanine ester of 5-OH-DPAT, namely 6.13–6.16, all showed a greatly 
enhanced chemical stability compared to the reference glycine prodrug 2.28 with factors 
varying between 88 and 120 (Table 6.2). Compared to the β-alanine reference prodrug 2.39, 
dipeptides 6.13-6.16 showed chemical stability increased ratios between 16 and 21. All four 
dipeptides showed half-lives around 2000 hours. The half-lives were not significantly 
different from each other, with the exception of the glycine-β-alanine prodrug of which the 
half-live differed significantly from the L-valine-β-alanine (6.14) and β-alanine-β-alanine 
(6.15) dipeptide prodrugs. 
6.4 DISCUSSION 
Santos et al. investigated the chemical hydrolysis of dipeptide esters of paracetamol in 
buffer at pH 7.4. During the degradation studies paracetamol and diketopiperazines were 
quantitatively released, which indicated cyclization-activation (Figure 6.2).7, 9 Other 
hydrolysis pathways could be 1) stepwise removal of the amino acid residues and 2) direct 
cleavage of the dipeptide carrier. Since no mono amino acid ester prodrug degradation 
products were detected, it is expected that the dipeptide monoester prodrugs of 5-OH-
DPAT degrade via cyclization activation and/or direct dipeptide cleavage pathways which 
are similar to those suggested for glycine-phenylalanine dipeptide alkyl ester prodrugs by 
Larsen et al.10 Based on the previous results of the dipeptide prodrugs of the phenolic 
paracetamol, the release of 5-OH-DPAT from the dipeptide ester prodrugs could occur via 
cyclization-activation. However, the experiments were performed at pH 5 and it has been 
reported that the rate of intramolecular aminolysis is negligible at pH values below 6 
because the N-terminal amino group is protonated at low pH therefore not available for 
cyclization.10-12 Moreover, Tsume et al. reported that for dipeptide ester prodrugs of 
floxuridine no formation of diketopiperazine was observed in chemical stability studies at 
pH lower than 10.8 Therefore, the dipeptide ester prodrugs of 5-OH-DPAT probably 
followed direct cleavage of the dipeptide carrier as main degradation mechanism, and 
therefore we did not investigate the generation of diketopiperazines.  
In contrast to the influence of the amino acid pKa (data not shown) on the hydrolysis of 
several amino acid ester prodrugs of 5-OH-DPAT (Chapter 3), intramolecular catalysis 
appears to play the bigger role in the hydrolysis of dipeptide esters of 5-OH-DPAT (Figure 
6.3). 




Figure 6.2 Release of the parent drug by intramolecular cyclization forming diketopiperazines. 
A) Dipeptide prodrugs with a C-terminal glycine. Tsume et al showed that branched N-
terminal residues (the primary amino terminal end of the dipeptide) like L-leucine and L-
isoleucine next to a C-terminal residue (the carboxylic acid terminal end of the dipeptide) 
glycine, renders the prodrug of floxuridine more labile to chemical hydrolysis at 37 ºC in 
buffer pH 7.4. The degradation pathway was direct cleavage of the peptide.8 The L-valine-
glycine ester of paracetamol was relatively stable and showed a half-life similar to the 
glycine-L-valine ester prodrug of paracetamol at 37oC in pH 7.4 buffer. In these 
experiments the degradation pathway was through diketopiperazine formation.7 Peptide 
coupling of a branched L-valine amino acid to the glycine ester prodrug of 5-OH-DPAT at 
pH 5 increased the chemical stability, although not to the extent of the other dipeptide 
prodrugs of 5-OH-DPAT. As described in Chapter 3 differences in the hydrolysis rate are 
assumed to arise only from differences in pH, pKa and intramolecular catalysis of the amino 
group of the pro-moiety through several possible mechanisms (Figure 6.3). Apparently 
steric hindrance of the L-valine residue slightly hindered the intramolecular catalysis of the 
amino group. 
 
Figure 6.3 Possible mechanisms of intramolecular catalysis of dipeptide esters of 5-OH-DPAT: A A) 
nucleophilic catalysis; B) general-base catalysis; C) intramolecular general-acid specific base 
catalysis. 
B) Dipeptide prodrugs with a C-terminal L-valine. Both Anand et al. and Majumdar et 
al. found that a C terminal L-valine residue of  dipeptide esters stabilized the ester bond 
compared to prodrugs with only one L-valine moiety.3, 4 Dipeptide prodrugs 6.10-6.12 




stabilities than the mono L-valine ester prodrug 2.31. This stabilization could be explained 
by the steric hindrance introduced in the pro-moiety near the ester bond which could inhibit 
conformations which favour intramolecular catalysis. This is illustrated in Figure 6.3 where 
R1 is an isopropyl group. In contrast to an N-terminal L-valine residue as in prodrug 6.9, a 
C-terminal L-valine residue increased the chemical stability of dipeptide esters 
considerably. This was also found by Santos et al. for the degradation of dipeptide prodrugs 
of AZT, acyclovir and paracetamol, although the degradation of these prodrugs followed 
cyclization-activation.5, 7, 13 The L-valine-L-valine prodrug 6.11 showed one of the highest 
chemical stabilities of the dipeptide prodrugs of 5-OH-DPAT which could be explained by 
additional steric hindrance by the second L-valine residue. This high chemical stability 
induced by two L-valine residues was also found for dipeptide esters of acyclovir and 
AZT.3, 5, 13 The β-alanine residue at the N-terminal of compound 6.12 stabilized the ester 
bond more than the N-terminal glycine residue of compound 6.10 possibly because the 
incorporation of the β-alanine led to seven- and nine-membered rings during intramolecular 
catalysis which may be less favourable for catalysis (Figure 6.3). Talluri et al. synthesized 
dipeptide ester prodrugs with combinations of D- and L-valine which were all chemically 
stable. An advantage of the incorporation of D-valine at the terminal position or 
esterification with a peptide of two D-valine residues gave prodrugs which were less 
susceptible to enzymatic hydrolysis.14 This strategy could also be applied to dipeptide ester 
prodrugs of 5-OH-DPAT if higher enzymatic stability would be desired concerning 
hydrolysis during iontophoretic transport through the stratum corneum. 
C) Dipeptide prodrugs with a C-terminal β-alanine. All prodrugs 6.13-6.16 with β-
alanine at the C-terminal showed extremely high chemical stabilities. A reason for these 
high chemical stabilities might be the unfavourable seven- and nine membered ring 
conformations during intramolecular catalysis. Variations in the amino acids in the N-
terminal position did not influence the chemical stability much, although a glycine residue 
at the N-terminus gave the lowest chemical stability in this group. Both L-arginine and L-
lysine would be interesting amino acids to incorporate in a dipeptide prodrug to increase the 
number of protonatable groups. Schuetz et al. found that peptides with a lysine residue 
exhibited significantly higher iontophoretic fluxes than peptides with an arginine residue. 
Charge type appeared to play a significant role, with the primary amine in the lysine side-
chain functioning as a more favourable positive charge centre than the more delocalized 
guanidinium group present in arginine.15 Therefore, we synthesized prodrug 6.16, a 
dipeptide with an N-terminus L-lysine residue. 
First, more stable prodrugs could be converted to less hygroscopic salt forms. Second, these 
prodrugs allow the introduction of amino acids which may be advantageous for 
iontophoretic transdermal delivery, e.g. L-lysine for an additional chargeable group, while 
maintaining good chemical stability and aqueous solubility. The influence on iontophoretic 
flux of additional charges could be negative or positive, which depends on the interaction of 
the molecules with charged sites in the stratum corneum, hydrated molecular volume of the 
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ions and the charge/molecular weight ratio.16-18 Third, the high chemical stability of these 
dipeptide ester prodrugs give a prolonged shelf-life. Fourth, the possible higher stabilities 
of these 5-OH-DPAT prodrugs may lead to iontophoretic transfer through the human 
stratum corneum without or with less hydrolysis. Therefore the advantageous properties of 
the prodrug stay intact until arrival in the epidermis, dermis or blood stream. Fifth, the 
hydrolysis rates of various combinations of glycine, L-valine and β-alanine were 
determined in order to gain insights in the influence of the position of amino acids in the 
dipeptide pro-moiety. 
In conclusion, in this chapter the synthesis of a series of dipeptide ester prodrugs of 5-OH-
DPAT is presented. These prodrugs all show improved chemical stabilities compared to the 
mono amino acid ester 5-OH-DPAT prodrugs which are discussed in Chapter 2 and 
Chapter 3. Especially the L-valine-L-valine ester prodrug 6.11 and the C-terminal β-alanine 
dipepeptide ester prodrugs 6.13-6.16 are extremely stable and can be used in future studies 




The materials and analysis methods are described in section 2.4.1 
6.5.1.2 General procedure for preparation of protected dipeptide (S)-2-
(N,N-di-n-propyl-amino)tetralin-5-yl esters 6.1-6.8. 
The protected amino acid (0.33 mmol) and HOBt hydrate (0.33 mmol) were suspended in 1 mL 
anhydrous CH2Cl2 under nitrogen atmosphere and cooled to 0 oC. EDC (0.33 mmol) was added and 
the reaction mixture was stirred for 15 minutes. After all solid material dissolved, the appropriate 
amino acid (S)-5-OH-DPAT ester (0.30 mmol) in 1 mL anhydrous CH2Cl2 and NMM (0.90 mmol) 
were added to the solution. The yellow solution was allowed to attain room temperature and was 
shaken overnight at 32 oC in a closed vessel. CH2Cl2 (4 mL) was added and the reaction mixture was 
washed with aqueous 1 N HCl (0.5 mL) and 1 N NaOH (0.5 mL). The organic layer was dried over 
MgSO4 and evaporated in vacuo; the resultant yellow oil was purified by column chromatography 
(SiO2, CH2Cl2/MeOH = 30:1 to 15:1, gradient) to afford the pure compounds 6.1-6.8 as light yellow 
oils. 
N-tert-Boc-L-valine-glycine (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester (6.1). Prepared from 
compound 2.28 with N-tert-Boc-L-valine. Yield: 82%; IR (NaCl, cm-1) νmax 3325, 2960, 1774, 1662, 
1532, 1457, 1366, 1236, 1158; 1H NMR (400 MHz, CDCl3): δ 7.10 (t, J=7.7 Hz, 1H, ArH), 6.99 (d, 
J=7.7 Hz, 1H, ArH), 6.90-6.77 (m, 2H, NH, ArH), 5.14 (d, J=8.8 Hz, 1H, NH), 4.38-4.17 (m, 2H, α-
CH2), 4.09-3.97 (m, 1H, α'-CH), 2.99-2.72 (m, 4H, H1ax, H1eq, H2ax, H4eq), 2.54-2.40 (m, 1H, H4ax), 




5H, H3ax, N(CH2CH2CH3)2), 1.43 (s, 9H, OC(CH3)3), 0.98 (d, 
J=6.6 Hz, 3H, γ-CH3), 0.93 (d, J=7.0 Hz, 3H, γ-CH3), 0.87 (t, 
J=7.3 Hz, 6H, N(CH2CH2CH3)2); 13C NMR (50 MHz, 
CDCl3): δ 172.5, 168.6, 156.2, 148.6, 139.4, 129.0, 127.8, 
126.6, 119.0, 80.3, 60.0, 56.4, 52.8, 41.4, 32.2, 31.1, 28.5, 
25.3, 24.2, 22.2, 19.5, 17.9, 12.1; HR-MS m/z Calcd. for 
C28H45N3O5 504.3432 (M+H)+, found 504.3432 (M+H)+. 
N-tert-Boc-glycine-L-valine (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester (6.2). Prepared from 
compound 2.31 with N-tert-Boc-glycine. Yield: 65%; IR (NaCl, 
cm-1) νmax 3313 (br), 2956, 1757, 1711, 1679, 1536, 1457, 1164; 
1H NMR (400 MHz, CDCl3): δ 7.12 (t, J=7.7 Hz, 1H, ArH), 7.00 
(d, J=7.7 Hz, 1H, ArH), 6.82 (d, J=8.1 Hz, 1H, ArH), 6.77-6.68 
(m, 1H, NH), 5.18 (br s, 1H, NH), 4.87-4.77 (m, 1H, α-CH), 3.93-
3.74 (m, 2H, α-CH2), 3.05-2.74 (m, 4H, H1ax, H1eq, H2ax, H4eq), 
2.60-2.35 (m, 5H, H4ax, N(CH2CH2CH3)2), 2.13-2.03 (m, 1H, 
H3eq), 1.67-1.37 (m, 6H, H3ax, N(CH2CH2CH3)2, β-CH), 1.45 (s, 9H, OC(CH3)3), 1.08 (d, J=7.0 Hz, 
3H, γ-CH3), 1.03 (d, J=7.0 Hz, 3H, γ-CH3), 0.89 (t, J=7.3 Hz, 6H, N(CH2CH2CH3)2); 13C NMR (50 
MHz, CDCl3): δ 175.1, 170.5, 170.0, 148.7, 139.0, 128.8, 127.7, 126.6, 119.1, 80.8, 57.3, 56.6, 52.7, 
44.9, 32.2, 31.4, 28.5, 25.2, 24.3, 21.9, 19.6, 17.7, 12.1; HR-MS m/z Calcd. for C28H46N3O5 504.3432 
(M+H)+, found 504.34311 (M+H)+. 
N-tert-Boc-L-valine-L-valine (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester (6.3). Prepared 
from compound 2.31 with N-tert-Boc-L-valine. Yield: 65%; IR 
(NaCl, cm-1) νmax 3325 (br), 2960, 1761, 1687, 1655, 1524, 1175; 
1H NMR (400 MHz, CDCl3): δ 7.11 (t, J=7.7 Hz, 1H, ArH), 6.99 
(d, J=7.7 Hz, 1H, ArH), 6.80 (d, J=8.1 Hz, 1H, ArH), 6.49 (br d, 
J=8.4 Hz, 1H, NH), 5.11 (br d, J=8.1 Hz, 1H, NH), 4.83-4.75 (m, 
1H, α'-CH), 3.94 (t, J=6.3 Hz, 1H, α-CH), 3.00-2.70 (m, 4H, H1ax, 
H1eq, H2ax, H4eq), 2.57-2.35 (m, 6H, H4ax, β-CH, N(CH2CH2CH3)2), 
2.21-2.08 (m, 1H, β'-CH), 2.07-1.99 (m, 1H, H3eq), 1.82-1.37 (m, 5H, H3ax, N(CH2CH2CH3)2), 1.43 (s, 
9H, OC(CH3)3), 1.08 (d, J=7.0 Hz, 3H, γ-CH3), 1.04 (d, J=7.0 Hz, 3H, γ-CH3), 0.97 (d, J=7.0 Hz, 3H, 
γ-CH3), 0.95 (d, J=7.0 Hz, 3H, γ-CH3), 0.88 (t, J=7.3 Hz, 6H, N(CH2CH2CH3)2); 13C NMR (50 MHz, 
CDCl3): δ 172.1, 170.5, 156.1 148.8, 139.3, 128.9, 127.7, 126.6, 119.0, 60.5, 57.4, 56.4, 52.8, 32.3, 
31.4, 30.8, 28.5, 25.3, 24.4, 22.2, 19.6, 18.2, 17.8, 12.1; HR-MS m/z Calcd. for C31H52N3O5 
546.39015 (M+H)+, found 546.39001 (M+H)+. 
N-tert-Boc-β-alanine-L-valine (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester (6.4). Prepared 
from compound 2.31 with N-tert-Boc-β-alanine. Yield: 28%; IR (NaCl, cm-1) νmax 3330 (br), 2960, 
1757, 1712, 1694, 1660, 1516, 1459, 1174; 1H NMR (400 MHz, CDCl3): δ 7.11 (t, J=7.9 Hz, 1H, 
ArH), 6.99 (d, J=7.3 Hz, 1H, ArH), 6.81 (d, J=8.1 Hz, 1H, ArH), 6.24 (br d, J=8.1 Hz, 1H, NH), 5.19 
(br s, 1H, NH), 4.88-4.74 (m, 1H, α-CH), 3.51-3.33 (m, 2H, β'-CH2), 3.02-2.65 (m, 4H, H1ax, H1eq, 
H2ax, H4eq), 2.57-2.28 (m, 8H, H4ax, α-CH2, β'-CH, N(CH2CH2CH3)2), 2.11-1.98 (m, 1H, H3eq), 1.67-
1.52 (m, 1H, H3ax), 1.51-1.30 (m, 4H, N(CH2CH2CH3)2), 1.41 (s, 9H, OC(CH3)3), 1.07 (d, J=6.6 Hz, 
3H, γ-CH3), 1.03 (d, J=7.0 Hz, 3H, γ-CH3), 0.88 (t, J=7.3 Hz, 6H, N(CH2CH2CH3)2); 13C NMR (50 
MHz, CDCl3): δ 172.0, 170.8, 156.3, 148.7, 139.3, 128.8, 127.8, 126.6, 119.0, 67.1, 57.4, 56.5, 55.6, 
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52.8, 36.5, 32.3, 31.3, 28.6, 25.3, 24.4, 22.2, 19.6, 17.9, 12.1; HR-MS m/z Calcd. for C29H48N3O5 
518.35885 (M+H)+, found 518.35889 (M+H)+. 
N-tert-Boc-glycine-β-alanine (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester (6.5). Prepared 
from compound 2.39 with N-tert-Boc-glycine. Yield: 27%; 
IR (NaCl, cm-1) νmax 3309 (br), 2958, 1755, 1714, 1667, 
1535, 1367, 1246, 1162; 1H NMR (400 MHz, CDCl3): δ 
7.11 (t, J=7.7 Hz, 1H, ArH), 6.99 (d, J=7.3 Hz, 1H, ArH), 
6.82 (d, J=7.7 Hz, 1H, ArH), 6.75-6.67 (m, 1H, NH), 5.16 
(br s, 1H, NH), 3.77 (d, J=5.9 Hz, 2H, α'-CH2), 3.64 (q, 
J=6.2 Hz, 2H, β-CH2), 3.03-2.70 (m, 6H, H1ax, H1eq, H2ax, 
H4eq, α-CH2), 2.56-2.42 (m, 5H, H4ax, N(CH2CH2CH3)2), 2.10-1.99 (m, 1H, H3eq), 1.65-1.51 (m, 1H, 
H3ax), 1.50-1.35 (m, 4H, N(CH2CH2CH3)2), 1.42 (s, 9H, OC(CH3)3), 0.88 (t, J=7.7 Hz, 6H, 
N(CH2CH2CH3)2); 13C NMR (50 MHz, CDCl3): δ 171.1, 169.8, 156.2, 148.8, 139.1, 128.8, 127.7, 
126.6, 119.2, 80.6, 56.6, 52.8, 44.6, 35.1, 34.1, 32.1, 28.5, 25.3, 24.3, 22.1, 12.1; HR-MS m/z Calcd. 
for C26H42N3O5 476.3119 (M+H)+, found 476.31192 (M+H)+. 
N-tert-Boc-L-valine-β-alanine (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester (6.6). Prepared 
from compound 2.39 with N-tert-Boc-L-valine. Yield: 57%; 
IR (NaCl, cm-1) νmax 3308 (br), 2956, 1756, 1714, 1693, 1650, 
1536, 1365, 1161; 1H NMR (400 MHz, CDCl3): δ 7.12 (t, 
J=7.7 Hz, 1H, ArH), 7.00 (d, J=7.3 Hz, 1H, ArH), 6.81 (d, 
J=7.7 Hz, 1H, ArH), 6.58-6.50 (m, 1H, NH), 5.10-4.99 (m, 
1H, NH), 3.92-3.84 (m, 1H, α'-CH), 3.72-3.54 (m, 2H, β-
CH2), 3.04-2.70 (m, 6H, H1ax, H1eq, H2ax, H4eq, α-CH2), 2.59-2.42 (m, 5H, H4ax, N(CH2CH2CH3)2), 
2.19-2.08 (m, 1H, β'-CH), 2.07-1.98 (m, 1H, H3eq), 1.65-1.35 (m, 5H, H3ax, N(CH2CH2CH3)2), 1.42 (s, 
9H, OC(CH3)3), 0.95 (d, J=6.6 Hz, 3H, γ-CH3), 0.94-0.82 (m, 9H, γ-CH3, N(CH2CH2CH3)2); 13C 
NMR (50 MHz, CDCl3): δ 171.9, 171.1, 156.0, 148.8, 139.1, 128.8, 127.7, 126.6, 119.2, 80.2, 60.2, 
56.5, 52.8, 35.1, 34.1, 32.2, 31.1, 28.5, 25.3, 24.3, 22.1, 19.5, 17.9, 12.1; HR-MS m/z Calcd. for 
C29H47N3O5 518.35885 (M+H)+, found 518.35889 (M+H)+. 
N-tert-Boc-β-alanine-β-alanine (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester (6.7). Prepared 
from compound 2.39 with N-tert-Boc-β-alanine. Yield: 
33%; IR (NaCl, cm-1) νmax 3321, 2955, 1755, 1711, 1648, 
1535, 1458, 1365, 1247, 1162; 1H NMR (400 MHz, 
CDCl3): δ 7.12 (t, J=7.7 Hz, 1H, ArH), 6.99 (d, J=7.7 Hz, 
1H, ArH), 6.82 (d, J=8.1 Hz, 1H, ArH), 6.34 (br s, 1H, 
NH), 5.20 (br s, 1H, NH), 3.61 (q, J=6.2 Hz, 2H, β'-CH2), 
3.39 (q, J=5.9 Hz, 2H, β-CH2), 3.03-2.70 (m, 6H, H1ax, H1eq, H2ax, H4eq, α-CH2), 2.55-2.41 (m, 5H, 
H4ax, N(CH2CH2CH3)2), 2.40-2.30 (m, 2H, α'-CH2), 2.09-1.97 (m, 1H, H3eq), 1.65-1.51 (m, 1H, H3ax), 
1.50-1.30 (m, 4H, N(CH2CH2CH3)2), 1.42 (s, 9H, OC(CH3)3), 0.88 (t, J=7.3 Hz, 6H, 
N(CH2CH2CH3)2); 13C NMR (50 MHz, CDCl3): δ 171.8, 171.2, 156.3, 148.8, 139.2, 128.8, 127.7, 
126.6, 119.1, 79.6, 56.5, 55.6, 52.8, 36.5, 35.1, 34.2, 32.2, 28.6, 25.3, 24.3, 22.2, 12.1; HR-MS m/z 
Calcd. for C27H44N3O5 490.32755 (M+H)+, found 490.32761 (M+H)+. 
Nα,Nε-di-tert-Boc-L-lysine-β-alanine (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester (6.8). 




3352, 2955, 1755, 1711, 1689, 1667, 1518, 1365, 1248, 
1165; 1H NMR (400 MHz, CDCl3): δ 7.11 (t, J=7.7 Hz, 
1H, ArH), 6.99 (d, J=7.3 Hz, 1H, ArH), 6.83 (d, J=8.1 Hz, 
1H, ArH), 6.71 (br s, 1H, NH), 5.20 (br s, 1H, NH), 4.69-
4.58 (m, 1H, NH), 4.07-3.95 (m, 1H, α'-CH), 3.68-3.56 (m, 
2H, β-CH2), 3.16-3.02 (m, 2H, ε-CH2), 3.01-2.71 (m, 6H, 
H1ax, H1eq, H2ax, H4eq, α-CH2), 2.55-2.42 (m, 5H, H4ax, 
N(CH2CH2CH3)2), 2.10-2.00 (m, 1H, H3eq), 1.89-1.76 (m, 
1H, Hβ'), 1.67-1.54 (m, 2H, Hβ', H3ax), 1.53-1.26 (m, 8H, δ-CH2, γ-CH2, N(CH2CH2CH3)2), 1.42 (s, 
9H, OC(CH3)3), 1.41 (s, 9H, OC(CH3)3), 0.88 (t, J=7.3 Hz, 6H, N(CH2CH2CH3)2); 13C NMR (50 
MHz, CDCl3): δ 172.5, 171.0, 156.4, 156.0, 148.8, 139.0, 128.8, 127.6, 126.6, 119.2, 80.3, 79.4, 56.6, 
54.8, 52.8, 40.0, 35.2, 34.1, 32.2, 32.1, 29.9, 28.7, 28.5, 25.3,24.3, 22.0, 12.1; HR-MS m/z Calcd. for 
C35H59N4O7 647.43783 (M+H)+, found 647.43823 (M+H)+. 
6.5.1.3 General deprotection procedure for the preparation of the 
dipeptide (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester 
hydrochlorides 6.9-6.16. 
The N-tert-Boc-amino acid 2-(di-n-propyl-amino)tetralin-5-yl ester was dissolved in 4 N HCl in 
dioxane (0.5 mL) under nitrogen atmosphere. The solution was stirred for 2 hours at r.t. until. The 
product was precipitated with dry Et2O and the dioxane/ Et2O was removed. The vessel was cooled in 
ice and the remaining oil was dissolved in dry MeOH (0.5 mL) under nitrogen atmosphere. The 
product was reprecipitated with dry Et2O, the solvent was removed, the remaining oil was evaporated 
in vacuo and dried on the oil pump overnight to afford the hydrochloric acid salts of 6.9-6.16 as 
hygroscopic solid foams. 
L-valine-glycine (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester 2HCl salt (6.9). Yield: 46%; 
Purity: 98% (HPLC); IR (KBr, cm-1) νmax 3399 (br), 3215 (br), 
2967, 2649, 1772, 1686, 1561, 1461, 1154; 1H NMR (400 MHz, 
CD3OD): δ 7.22 (t, J=7.9 Hz, 1H, ArH), 7.14 (d, J=7.7 Hz, 1H, 
ArH), 6.96 (d, J=7.3 Hz, 1H, ArH), 4.42 (d, J=7.6 Hz, 1H, α-CH2), 
4.24 (d, J=8.0 Hz, 1H, α-CH2), 3.82 (d, 1H, α'-CH), 3.78-3.68 (m, 
1H, H2ax), 3.35-3.07 (m, 6H, H1ax, H1eq, N(CH2CH2CH3)2), 3.05-
2.95 (m, 1H, H4eq), 2.76-2.63 (m, 1H, H4ax), 2.44-2.33 (m, 1H, 
H3eq), 2.30-2.19 (m, 1H, β-CH), 2.00-1.88 (m, 1H, H3ax), 1.87-1.74 (m, 4H, N(CH2CH2CH3)2), 1.09 (t, 
J=6.8 Hz, 6H, γ-CH3), 1.05 (td, J=7.3 Hz; 1.10 Hz, 6H, N(CH2CH2CH3)2); 13C NMR (50 MHz, 
CD3OD): δ 169.1, 168.2, 148.8, 134.9, 127.7, 127.3, 127.1, 120.0, 59.9, 58.4, 52.9, 52.5, 40.8, 30.4, 
29.2, 23.3, 22.7, 18.6, 18.4, 17.5, 16.8, 10.2; HR-MS m/z Calcd. for C23H38N3O3 404.29077 (M+H)+, 
found 404.29053 (M+H)+. 
Glycine-L-valine (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester 2HCl salt (6.10). Yield: 51%; 
Purity: 100% (HPLC); IR (KBr, cm-1) νmax 3400 (br), 3205 (br), 2966, 
2622, 1760, 1687, 1461, 1119; 1H NMR (400 MHz, CD3OD): δ 7.22 (t, 
J=7.9 Hz, 1H, ArH), 7.14 (d, J=7.7 Hz, 1H, ArH), 6.93 (d, J=7.7 Hz, 
1H, ArH), 4.65 (d, J=5.5 Hz, 1H, α-CH), 3.82 (d, J=3.7 Hz, 2H, α'-
CH2), 3.85-3.70 (m, 1H, H2ax), 3.37-3.08 (m, 6H, H1ax, H1eq, 
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N(CH2CH2CH3)2), 3.04-2.96 (m, 1H, H4eq), 2.76-2.63 (m, 1H, H4ax), 2.48-2.33 (m, 2H, H3eq, β-CH), 
1.99-1.75 (m, 5H, H3ax, N(CH2CH2CH3)2), 1.12 (d, J=6.6 Hz, 3H, γ-CH3), 1.11 (d, J=6.6 Hz, 3H,  γ-
CH3), 1.05 (t, J=7.3 Hz, 6H, N(CH2CH2CH3)2); 13C NMR (50 MHz, CD3OD): δ 170.1, 166.7, 148.9, 
134.9, 127.5, 127.3, 127.1, 120.0, 59.9, 58.4, 52.5, 40.3, 30.4, 29.2, 23.3, 22.9, 18.6, 18.5, 17.1, 10.2, 
10.1; HR-MS m/z Calcd. for C23H38N3O3 404.29077 (M+H)+, found 404.29034 (M+H)+. 
L-valine-L-valine (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester 2HCl salt (6.11). Yield: 42%; 
Purity: 100% (HPLC); IR (KBr, cm-1) νmax 3420 (br), 3230 (br), 2968, 
2628, 1761, 1680, 1461, 1133; 1H NMR (400 MHz, CD3OD): δ 7.22 
(t, J=7.9 Hz, 1H, ArH), 7.14 (d, J=7.3 Hz, 1H, ArH), 6.92 (d, J=7.7 
Hz, 1H, ArH), 4.60 (d, J=5.5 Hz, 1H, α-CH), 3.87 (d, J=5.5 Hz, 1H, 
α'-CH), 3.82-3.70 (m, 1H, H2ax), 3.35-3.09 (m, 6H, H1ax, H1eq, 
N(CH2CH2CH3)2), 3.05-2.95 (m, 1H, H4eq), 2.77-2.64 (m, 1H, H4ax), 
2.58-2.30 (m, 2H, H3eq, β-CH), 2.27-2.19 (m, 1H, β'-CH), 1.99-1.76 
(m, 5H, H3ax, N(CH2CH2CH3)2), 1.16 (d, J=2.6 Hz, 3H, γ-CH3), 1.15 (d, J=2.6 Hz, 3H,  γ-CH3), 1.09 
(d, J=7.0 Hz, 3H, γ'-CH3), 1.05 (d, J=6.6 Hz, 3H, γ'-CH3), 1.05 (t, J=7.3 Hz, 6H, N(CH2CH2CH3)2); 
13C NMR (50 MHz, CD3OD): δ 170.0, 169.1, 148.9, 134.9, 127.5, 127.3, 127.1, 119.9, 59.9, 58.7, 
58.1, 52.8, 30.6, 30.2, 29.2, 23.2, 23.0, 18.6, 18.5, 17.7, 17.4, 16.6, 10.1; HR-MS m/z Calcd. for 
C26H44N3O3 446.33772 (M+H)+, found 446.33762 (M+H)+. 
β-alanine-L-valine (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester 2HCl salt (6.12). Yield: 76%; 
Purity: 100% (HPLC); IR (KBr, cm-1) νmax 3428 (br), 3256 (br), 
2967, 2641, 1759, 1656, 1461, 1135; 1H NMR (400 MHz, 
CD3OD): δ 7.22 (t, J=7.7 Hz, 1H, ArH), 7.13 (d, J=8.1 Hz, 1H, 
ArH), 6.93 (d, J=7.5 Hz, 1H, ArH), 4.58 (d, J=5.5 Hz, 1H, α-CH), 
3.82-3.68 (m, 1H, H2ax), 3.38-3.05 (m, 8H, β-CH2, H1ax, H1eq, 
N(CH2CH2CH3)2), 3.04-2.96 (m, 1H, H4eq), 2.81-2.63 (m, 3H, α'-
CH2, H4ax), 2.44-2.30 (m, 2H, H3eq, β-CH), 2.00-1.72 (m, 5H, H3ax, N(CH2CH2CH3)2), 1.12 (d, J=2.9 
Hz, 3H, γ-CH3), 1.11 (d, J=2.9 Hz, 3H, γ-CH3), 1.05 (t, J=7.3 Hz, 6H, N(CH2CH2CH3)2); 13C NMR 
(50 MHz, CD3OD): δ 171.6, 170.5, 148.9, 134.8, 127.5, 127.2, 127.1, 120.0, 59.9, 58.4, 52.5, 35.8, 
31.2, 30.3, 29.2, 23.3, 22.9, 18.5, 17.3, 10.1; HR-MS m/z Calcd. for C24H40N3O3 418.30642 (M+H)+, 
found 418.30634 (M+H)+. 
Glycine-β-alanine (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester 2HCl salt (6.13). Yield: 66%; 
Purity: 95% (HPLC); IR (KBr, cm-1) νmax 3391 (br), 3236 (br), 
2965, 2643, 1753, 1686, 1460, 1151; 1H NMR (400 MHz, 
CD3OD): δ 7.21 (t, J=7.9 Hz, 1H, ArH), 7.12 (d, J=7.3 Hz, 1H, 
ArH), 6.97 (d, J=7.7 Hz, 1H, ArH), 3.70 (s, 2H, α'-CH2),  3.62 (t, 
J=6.6 Hz, 2H, β-CH2), 3.81-3.09 (m, 7H, H2ax, H1ax, H1eq, 
N(CH2CH2CH3)2), 2.95 (dd, 1H, H4eq), 2.89 (t, J=6.6 Hz, 2H, α-
CH2), 2.75-2.59 (m, 1H, H4ax), 2.43-2.33 (m, 1H, H3eq), 1.99-1.87 (m, 1H, H3ax), 1.86-1.72 (m, 4H, 
N(CH2CH2CH3)2), 1.05 (t, J=7.0 Hz, 6H, N(CH2CH2CH3)2); 13C NMR (50 MHz, CD3OD): δ 170.3, 
166.9, 149.0, 134.7, 127.6, 127.1, 127.0, 120.2, 60.0, 52.9, 52.5, 40.3, 35.2, 33.4, 29.2, 23.3, 22.7, 
18.6, 18.4, 10.1; HR-MS m/z Calcd. for C21H34N3O3 376.25947 (M+H)+, found 376.25946 (M+H)+. 
L-valine-β-alanine (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester 2HCl salt (6.14). Yield: 76%; 




1H NMR (400 MHz, CD3OD): δ 7.21 (t, J=7.7 Hz, 1H, ArH), 
7.12 (d, J=7.3 Hz, 1H, ArH), 6.96 (d, J=7.7 Hz, 1H, ArH), 3.79-
3.61 (m, 3H, H2ax, β-CH2), 3.69 (d, J=5.9 Hz, 1H, α'-CH), 3.61-
3.08 (m, 6H, H1ax, H1eq, N(CH2CH2CH3)2), 3.00-2.86 (m, 3H, 
H4eq, α-CH2), 2.73-2.61 (m, 1H, H4ax), 2.44-2.33 (m, 1H, H3eq), 
2.22-2.12 (m, 1H, β'-CH), 1.98-1.75 (m, 5H, H3ax, 
N(CH2CH2CH3)2), 1.13-0.93 (m, 12H, γ-CH3, N(CH2CH2CH3)2); 
13C NMR (50 MHz, CD3OD): δ 170.2, 168.5, 149.0, 134.7, 127.6, 127.1, 127.0, 120.2, 59.9, 58.6, 
52.9, 52.5, 35.3, 33.4, 30.3, 29.2, 23.3, 22.8, 18.6, 18.5, 17.7, 16.9, 10.2; HR-MS m/z Calcd. for 
C24H40N3O3 418.30642 (M+H)+, found 418.30634 (M+H)+. 
β-alanine-β-alanine (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester 2HCl salt (6.15). Yield: 
65%; Purity: 99% (HPLC); IR (KBr, cm-1) νmax 3414 (br), 
3249 (br), 2961, 2636, 1752, 1656, 1460, 1149; 1H NMR (400 
MHz, CD3OD): δ 7.21 (t, J=7.7 Hz, 1H, ArH), 7.12 (d, J=7.7 
Hz, 1H, ArH), 6.96 (d, J=7.7 Hz, 1H, ArH), 3.84-3.73 (m, 
1H, H2ax), 3.58 (t, J=6.6 Hz, 2H, β-CH2), 3.38-3.02 (m, 8H, 
H1ax, H1eq, β'-CH2, N(CH2CH2CH3)2), 2.99-2.89 (m, 1H, 
H4eq), 2.86 (t, J=6.6 Hz, 2H, α-CH2), 2.63 (t, J=6.6 Hz, 2H, 
α'-CH2), 2.73-2.57 (m, 1H, H4ax), 2.46-2.30 (m, 1H, H3eq), 2.00-1.73 (m, 5H, H3ax, N(CH2CH2CH3)2), 
1.05 (t, J=7.2 Hz, 6H, N(CH2CH2CH3)2); 13C NMR (50 MHz, CD3OD): δ 171.1, 170.4, 149.0, 134.7, 
127.6, 127.1, 127.0, 120.2, 60.0, 52.9, 52.5, 35.9, 35.1, 33.5, 31.6, 29.2, 23.3, 22.8, 18.7, 18.5, 10.1; 
HR-MS m/z Calcd. for C22H36N3O3 390.27512 (M+H)+, found 390.2742 (M+H)+. 
L-lysine-β-alanine (S)-2-(N,N-di-n-propyl-amino)tetralin-5-yl ester 3HCl salt (6.16). Yield: 63%; 
Purity: 96% (HPLC); IR (KBr, cm-1) νmax 3417 (br), 3225 (br), 
2941, 2635, 1753, 1680, 1461, 1150; 1H NMR (400 MHz, 
CD3OD): δ 7.22 (t, J=7.7 Hz, 1H, ArH), 7.12 (d, J=7.7 Hz, 1H, 
ArH), 6.99 (d, J=7.7 Hz, 1H, ArH), 3.93 (t, J=6.6 Hz, 1H, α'-CH), 
3.82-3.07 (m, 9H, β-CH2, H1ax, H1eq, H2ax, N(CH2CH2CH3)2), 
3.00-2.83 (m, 5H, H4eq, α-CH2, ε-CH2), 2.76-2.63 (m, 1H, H4ax), 
2.45-2.35 (m, 1H, H3eq), 2.00-1.77 (m, 7H, H3ax, β'-CH2, 
N(CH2CH2CH3)2), 1.76-1.69 (m, 2H, δ-CH2), 1.56-1.44 (m, 2H, γ-CH2), 1.05 (td, J=7.3 Hz; 1.10 Hz, 
6H, N(CH2CH2CH3)2); 13C NMR (50 MHz, CD3OD): δ 170.3, 169.0, 149.0, 134.7, 127.6, 127.1, 
127.0, 120.2, 60.0, 53.0, 52.9, 52.5, 39.1, 35.4, 33.5, 30.9, 29.2, 26.9, 23.3, 22.8, 21.7, 18.6, 18.4, 
10.2; HR-MS m/z Calcd. for C25H43N4O3 447.33297 (M+H)+, found 447.33286 (M+H)+. 
6.5.2 Chemical hydrolysis experiments in 5 mM citrate buffer pH 5 
The methods for the chemical hydrolysis experiments of compounds 2.28, 2.31 and 2.39 were already 
described in Chapter 3. 
6.5.2.1 Procedure 
For the experiments with prodrugs 6.9-6.16 the chemical hydrolysis was initiated by adding 6 μl of a 
25 mM stock solution in 5 mM citrate buffer (pH 5) to 2.994 mL 5 mM citrate buffer (pH 5) 
preheated at 32 oC. The final concentration of the resulting solutions was about 50 μM. The test 
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solutions of the compounds were vortexed and maintained in a Lab-Line Orbit Shaker at a constant 
temperature of 32±0.2 °C. At appropriate intervals samples of 100 μL were withdrawn and diluted 
with 100 μL H2O/ACN/TFA (1.2/1/0.004) giving a concentration of 25 μM. The samples were stored 
in the freezer until they were analyzed by HPLC. The 5-OH-DPAT concentration was estimated by 
measuring the peak heights in relation to those of 5-OH-DPAT standards which were prepared by 
serial dilution of known concentrations (0.5, 5, 10 and 25 μM) and chromatographed under the same 
conditions. 
6.5.2.2 HPLC analysis 
Samples of prodrugs 6.9-6.16 were analyzed isocratically on a Hewlett Packard Series 1100 HPLC 
system connected to a Tray-Cooling Marathon Basic+ Autosampler and a Hewlett Packard HP3395 
Integrator. The samples were injected onto a Supelco Discovery C18 reversed-phase column (5 μm, 
250 x 4.6 mm I.D.). The mobile phase for the analysis of compounds 6.9 and 6.11-6.16 consisted of a 
mixture of 23% acetonitrile and 77% water with 0.1% trifluoroacetic acid added (eluent A). The 
mobile phase for the analysis of compounds 6.10 consisted of a mixture of 20% acetonitrile and 80% 
water with 0.1% trifluoroacetic acid added (eluent B). The flow was set at 1.0 mL/min and the 
analysis was performed at room temperature. The injection volume was 20 μL and the compounds 
were detected by UV at 217 nm. The runtime was 20 minutes. The retention times of 5-OH-DPAT 
and the amino acid 5-OH-DPAT esters were: 9.46 min (2.12, eluent A), 13.32 (2.12, eluent B), 6.94 
min (6.9), 17.82 min (6.10, eluent B), 16.19 min (6.11), 10.40 min (6.12), 5.06 min (6.13), 6.83 min 
(6.14), 5.59 min (6.15), 4.42 min (6.16). 
6.5.2.3 Data analysis 
All hydrolysis experiments were carried out in triplicate. The pseudo-first-order hydrolysis rate 
constants and the pseudo-first-order chemical hydrolysis rate constants were calculated from the 
linear slopes of plots of the logarithm of the formed 5-OH-DPAT concentration against time. The 
slopes of these plots are related to the rate constant, k, and given by k = 2.303 x slope (log C vs time). 
The formation of 5-OH-DPAT during prodrug hydrolysis follows pseudo-first-order kinetics and is 
described by the following formula: )1(]DPAT-OH-5[]DPAT-OH-5[ max
kte . The half-
lives (t1/2) can be estimated by the equation: k
2lnt 2/1  . 
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Structural analogs of 5-OH-DPAT: 
synthesis and their influence on in 






The transdermal iontophoretic flux of small molecules depends on the physicochemical 
properties of the transported molecule. In order to investigate the influence of the 
molecular structure of phenolic and catecholic dopamine (DA) agonists on the transdermal 
iontophoretic flux and solubility, we synthesized a series of analogs of 5-OH-DPAT with 
varying alkyl length, lipophilicity and molecular weight, i.e. 5-OH-EPAT, 5-OH-MPAT, 8-
OH-DPAC 5,6-(OH)2-MPAT and 5,6-(OH)2-DPAT. 8-OH-DPAC showed the highest 
solubility. 5-OH-MPAT and 5-OH-EPAT showed the highest increase in total transdermal 
iontophoretic flux in vitro. The synthesized DA receptor agonists are valuable compounds 
for studies to improve the understanding of molecular structure on transdermal 
iontophoretic delivery. 
7.1 INTRODUCTION 
The iontophoretic flux of small molecules depends on several physicochemical properties 
of the transported molecule. Important properties are the molecular volume or molecular 
weight1-3, the ratio of charge/molecular weight4, and the degree of lipophilicity.5, 6 In order 
to investigate the influence of the molecular structure of phenolic and catecholic DA 
agonists on the iontophoretic flux, we synthesized a series of analogs of 5-OH-DPAT with 
varying alkyl length, lipophilicity and molecular weight. Furthermore, the influence of the 
molecular structure and lipophilicity on aqueous solubility was investigated. 
Besides 5-OH-DPAT which is the parent drug of the compounds discussed in Chapter 2 to 
Chapter 6, the phenolic derivatives 5-hydroxy-2-(N-n-propyl-amino)-tetralin (5-OH-
MPAT) and 5-hydroxy-2-(N-ethyl-N-n-propyl-amino)tetralin (5-OH-EPAT) are found to be 
potent DA D2 agonists. The trend of increasing in vivo biochemical potencies was 5-OH-
MPAT < 5-OH-EPAT < 5-OH-DPAT.7 Moreover, van Vliet et al showed that the receptor 
affinity of (S)-5-OH-DPAT for cloned human DA receptor subtypes D2L, D3 and D4 was 
higher than the affinity of 5-OH-MPAT.8 Also the catecholic tetralin analogs 5,6-
dihydroxy-2-(N,N-di-n-propyl-amino)tetralin (5.6-(OH)2-DPAT) and 5,6-dihydroxy-2-(N-
n-propyl-amino)tetralin (5,6-(OH)2-MPAT) showed high DAergic activity, whereas the 
monopropyl analogue showed a lower potency in vivo.9-11 Additionally, 8-hydroxy-3,4-
dihydro-3-(N,N-di-n-propylamino)-2H-1-benzopyran (8-OH-DPAC) exhibited high 
DAergic activity in vivo and good DAergic receptor binding and affinity in vitro.12-16 The 
aminochroman was even found to displace the DAergic ligand [3H] 2-(N-propyl-N-2-
thienylethylamino)-5-hydroxytetralin with a higher potency than apomorphine and 5-OH-
DPAT.17 The structures of the DA agonists are depicted in Figure 7.1. 




Figure 7.1 Molecular structures of the DA agonists 5-OH-DPAT (2.12), 5-OH-EPAT (7.20), 5-OH-
MPAT (7.15), 8-OH-DPAC (7.22), 5,6-(OH)2-DPAT (7.8) and 5,6-(OH)2-MPAT (7.12). 
Iontophoretic studies could give insight in the structure-transport relationships of DA 
agonists with a tetrahydronaphthalene core. Also information on structure-solubility 
relationships may aid the optimization of drugs for transdermal delivery by iontophoresis. 
7.2 CHEMISTRY 
7.2.1 Synthesis of 5,6-dihydroxy-2-(N,N-di-n-propyl-amino)tetralin (7.8) 
and 5,6-dihydroxy-2-(N-n-propyl-amino)tetralin (7.12) 
In order to prepare compounds 7.8 (5,6-(OH)2-DPAT) and 7.12 (5,6-(OH)2-MPAT), first 
intermediate 5,6-dimethoxy-2-tetralone (7.6) was synthesized. The synthesis of 7.6 was 
described by Horn et al., Taber et al., McDermed et al. and Copinga et al.11, 18-20 We started 
with the route according to Taber et al. which is a modification of the routes described by 
Horn et al. and McDermed et al. First, 1,6-dibromo-2-naphthol was methylated by a 
nucleophilic substitution reaction with iodomethane to give 1,6-dibromo-2-methoxy-
naphthalene (7.9). Then, compound 7.9 was methoxylated using sodium methoxide in the 
presence of cuprous iodide and 2,4,6-collidine to form 1,2,6-trimethoxy-naphthalene (7.10) 
with a yield of 68%. This particular reaction only worked under very dry conditions and 
only with highly purified starting material. Via a Birch reduction the enol ether was 
prepared. Acid hydrolysis gave finally 5,6-dimethoxy-2-tetralone (7.6)(Scheme 7.1). 
Unfortunately, the reaction mixture solidified to a thick gel during the reduction and many 
side-products had been formed. For that reason, we decided to choose another route for the 





Scheme 7.1 Synthesis of 5,6-dimethoxy-2-tetralone (7.6) according to Taber et al. Reagents and 
conditions: a) iodomethane, K2CO3, DMF, beneath 30 °C, 3h; b) Na, MeOH, 2,4,6-collidine, 
copper(I)iodide, reflux, 5h; c) Na, EtOH, H2O, 36% HCl. 
The synthesis route according to Copinga et al. was chosen and the reactions are outlined in 
Scheme 7.2. Vanillin was methylated by a reaction with dimethylsulfate to afford 2,3-
dimethoxy-benzaldehyde (7.1).21 The methylated benzaldehyde was converted to (E)-3-
(2,3-dimethoxyphenyl)-2-propenoic acid (7.2) via the Doebner modification of the 
Knoevenagel condensation.22 Compound 7.2 was hydrogenated with palladium on carbon 
as catalyst into 2,3-dimethoxybenzenepropanoic acid (7.3) which was subsequently 
converted to the acid chloride 7.4 with thionyl chloride. The diazoketone 7.5 was prepared 
from the reaction of the acid chloride 7.4 with freshly prepared diazomethane. After a 
rhodium(II)-acetate-catalysed cyclization and a transformation under the influence of 
trifluoroacetic acid, crude 5,6-dimethoxy-2-tetralone (7.6) was synthesized.18 In contrast to 
literature, we were unable to purify 7.6 by vacuum distillation. Therefore the product was 
purified by sodium bisulfite adduct formation to give pure tetralone with an overall yield of 
11%.10, 19, 23 
 
Scheme 7.2 Synthesis of 5,6-dimethoxy-2-tetralone (7.6) according to Copinga et al. Reagents and 
conditions: a) K2CO3, (CH3)2SO4, MeOH, reflux, overnight; b) malonic acid, piperidine, pyridine, 
75°C, 2h, reflux, overnight; c) 3.5 bar H2, 10% Pd/C, 96% EtOH, RT; d) SOCl2, toluene, reflux, 1h; 
e) diazomethane, Et2O, 5°C, RT, overnight; f) [Rh(CH3COO)2]2, CH2Cl2, reflux for 20 min, 
CF3COOH, 15 min reflux. 
Then, 5,6-dimethoxy-2-(N,N-di-n-propyl-amino)tetralin (7.7) and 5,6-dimethoxy-2-(N-n-
propyl-amino)tetralin (7.11) were synthesized by condensation with dipropylamine and 
propylamine, respectively, followed by catalytic hydrogenation.11 The final catechols 7.8 
and 7.12 were obtained after refluxing in 48% aqueous hydrobromic acid. The two-step 
yields for 7.8 and 7.12 were 17% and 20%, respectively (Scheme 7.3). 




Scheme 7.3 Synthesis of 5,6-dihydroxy-2-(N,N-di-n-propyl-amino)tetralin HBr-salt (7.8) and 5,6-
dihydroxy-2-(N-n-propyl-amino)tetralin HBr/HCl-salt (7.12). Reagents and conditions: g) step 1: 
dipropylamine (7.7) / propylamine (7.11), p-toluenesulfonic acid, toluene; step 2: 3 bar H2, PtO2, 
100% EtOH, RT; h) 48% HBr, reflux. 
7.2.2 Synthesis of 5-hydroxy-2-(N-n-propyl-amino)-tetralin (7.15) and 5-
hydroxy-2-(N-ethyl-N-n-propyl-amino)tetralin (7.20) 
2-(Benzylamino)-5-methoxytetralin (2.9) was propylated with 1-iodopropane to give 5-
methoxy-2-(N-benzyl-N-n-propyl-amino)-tetralin (7.13). Subsequently, compound 7.13 was 
debenzylated by hydrogenolysis and demethylated by refluxing in 48% hydrobromic acid. 
Final compound 5-hydroxy-2-(N-n-propyl-amino)-tetralin (7.15) was obtained as the 
hydrobromide salt with a three-step yield of 14% (Scheme 7.4). 
 
Scheme 7.4 Synthesis of 5-hydroxy-2-(N-n-propyl-amino)-tetralin HBr-salt (7.15). Reagents and 
conditions: a) K2CO3, 2-butanone, 1-iodopropane, reflux, overnight; b) 3 bar H2, 10% Pd/C, 100% 
EtOH, 50°C; c) 48% HBr, reflux. 
Because of limited amounts of compound 7.14 the synthesis of compound 5-hydroxy-2-(N-
ethyl-N-propyl-amino)tetralin (7.20) was started from intermediate 2.9. The 
benzylaminotetraline was amidated with acetylchloride and then reduced by lithium 
aluminium hydride to give 5-methoxy-2-(N-benzyl-N-ethyl-amino)tetralin (7.17). 
Compound 7.17 was then successively debenzylated, amidated with propionylchloride and 
reduced with lithium aluminium hydride to 5-methoxy-2-(N-ethyl-N-propyl-amino)tetralin 
(7.19). After demethylation in 48% hydrobromic acid the final compound 5-hydroxy-2-(N-
ethyl-N-propyl-amino)tetralin (7.20) was obtained as the hydrobromide salt with a yield of 





Scheme 7.5 Synthesis of 5-hydroxy-2-(N-ethyl-N-n-propyl-amino)tetralin HBr-salt (7.20). Reagents 
and conditions: a) TEA, toluene, acetylchloride, RT, 1.5 h; b) THF, LiAlH4, RT, 40 min; c) 3.5 bar 
H2, 10% Pd/C, 100% EtOH, 50°C; d) step 1: TEA, toluene, propionylchloride, RT, 30 min; step 2: 
THF, LiAlH4, RT, 20 min; e) 48% HBr, reflux. 
7.2.3 Synthesis of 8-hydroxy-3,4-dihydro-3-(N,N-di-n-propylamino)-2H-
1-benzopyran (7.22) 
The route for the synthesis of 8-hydroxy-3,4-dihydro-3-(N,N-di-n-propylamino)-2H-1-
benzopyran (7.22) is outlined in Scheme 7.6. Benzopyranone 8.5 of which the synthesis 
was described in detail in Chapter 8, was condensated with dipropylamine in the presence 
of glacial acetic acid in pentan-1-ol, followed by catalytic hydrogenation to give 8-
methoxy-3,4-dihydro-3-(N,N-di-n-propylamino)-2H-1-benzopyran (7.21). After the 
demethylation in 48% hydrobromic acid the final compound 8-hydroxy-3,4-dihydro-3-
(N,N-di-n-propylamino)-2H-1-benzopyran (7.22) was obtained as the hydrobromide salt 
with a two-step yield of 4%.12 Both reactions gave very low yields because of difficulties 
during the purification steps. 
Boyé et al. observed an unexpected rearrangement after refluxing benzopyran 7.21 with 
boron tribromide in dichloromethane. Instead of the expected formation of compound 7.22 
another product was obtained, i.e. 7-hydroxy-2,3-dihydro-2-(N,N-di-n-
propylaminomethyl)-2H-1-benzofuran 7.23.14 In addition, we found that this rearrangement 
not only occurred after refluxing with boron tribromide, but also during the reaction when 
performed at -30 ºC. Wise et al. performed the reaction in chloroform at -30 ºC and did not 
observe any rearrangement.12 Hence, the solvent could have influence on a possible 
rearrangement of the benzopyran to the benzofuran. Further investigations were not 
performed. 




Scheme 7.6 Synthesis of 8-hydroxy-3,4-dihydro-3-(N,N-di-n-propylamino)-2H-1-benzopyran HBr-
salt (7.22) and 7-hydroxy-2,3-dihydro-2-(N,N-di-n-propylaminomethyl)-2H-1-benzofuran (7.23).  
Reagents and conditions: a) step 1: dipropylamine, CH3COOH, pentan-1-ol, reflux, 3 h; step 2: 3.5 
bar H2, PtO2, MeOH, RT, overnight; b) 48% HBr, reflux; c) BBr3, CH2Cl2, -30°C-RT, overnight. 
Table 7.1 Overall yields and purities of the HBr salts of compounds 7.8, 7.12, 7.15, 7.20, 7.22. 
Compound Name Yield (%) Purity (%) 
7.8 5,6-(OH)2-DPAT 1.8 >99a 
7.12 5,6-(OH)2-MPAT 2.3 >99a 
7.15 5-OH-MPAT 3.8 >95b 
7.20 5-OH-EPAT 5.8 99c 
7.22 8-OH-DPAC 2.5 >95b 
a Based on elemental analysis; b Based on HPLC; c Based on GCMS 
7.3 RESULTS 
The solubility data and in vitro iontophoretic transport results of the synthesized DA 
agonists that are presented in Section 7.3.1 and Section 7.3.2 were all adapted from studies 
by Ackaert et al.24 
7.3.1 Aqueous solubility 
The results of the solubilities of the HBr salts of compounds 7.8, 7.12, 7.15, 7.20, 7.22 in 
citric buffer 5mM pH 5.0, containing 4 g l-1 NaCl and 23.1 g l-1 D-mannitol can be found in 
Table 7.2. The solubility data of rotigotine.HCl and 5-OH-DPAT.HBr were added to the 
table for comparison. The DA agonists are ranked in order of increasing solubility as 
follows: rotigotine < 5,6-(OH)2-DPAT < 5-OH-DPAT < 5-OH-MPAT < 5-OH-EPAT < 8-




Table 7.2 The physicochemical properties and iontophoretic fluxes of compounds 7.8, 7.12, 7.15, 
7.20, 7.22.24 The molecular weight (MW), calculated log P (cLogP), aqueous solubility, and the 
observed flux after 9h iontophoresis across HSC and DHS are presented. The MW, cLogP, and 
solubility of 5-OH-DPAT and rotigotine, obtained from literature, are added to the table for 
comparison. 










263.38 3.74 44.2 175.0±15.9 175.2±25.9 
7.12 5,6-(OH)2-
MPAT 
221.30 2.50 n.d. 134.5±12.9 n.d. 
7.15 5-OH-MPAT 205.30 2.93 93.1 219.7±31.4 241.8±11.2 
7.20 5-OH-EPAT 233.36 3.71 111.7 247.7±12.1 199.8±8.0 
7.22 8-OH-DPAC 249.36 3.40 282.5 175.9±18.9 168.2±13.2 
2.12 5-OH-DPAT 247.38 4.15 56.7 a 207.7±38.0 193.0±19.9 
 Rotigotine 315.48 4.82 7.1 b - - 
a,b: value adapted from literature.1, 25;c: Calculated using ALOGPS 2.1.26-28; n.d.: not determined 
7.3.2 Iontophoretic transport across human stratum corneum and 
dermatomed human skin 
We have found that at pH 5.0 5,6-(OH)2-MPAT (7.12) and 5,6-(OH)2-DPAT (7.8) were 
more stable against oxidation than at pH 6.0. Increasing the pH to 7.4 resulted even in a 
more pronounced degradation of the mono N-propyl derivative 7.12.24 
The flux of the different compounds at a concentration of 3.9 mM was evaluated 
statistically after 9 hours of iontophoresis across human stratum corneum (HSC) and 
dermatomed human skin (DHS) (current density 500 μA.cm-2). Across HSC and DHS 1-
way ANOVA analysis showed an overall significant difference in the flux of the different 
compounds (p<0.0001 and p<0.05, respectively). The observed flux over HSC after 9 hours 
increased in the following order: 5,6-(OH)2-MPAT < 5,6-(OH)2-DPAT < 8-OH-DPAC < 5-
OH-DPAT < 5-OH-MPAT < 5-OH-EPAT. A similar trend was seen for iontophoretic 
transport studies across DHS: 8-OH-DPAC < 5,6-(OH)2-DPAT < 5-OH-DPAT < 5-OH-
EPAT < 5-OH-MPAT.24 
A significantly higher electro-osmotic contribution was observed when 5,6-(OH)2-DPAT 
(12.1 ± 3.4%) was transported through HSC, compared to the other compounds 5-OH-
EPAT (4.5 ± 0.9%), 5-OH-MPAT (4.6 ± 1.4%) and 8-OH-DPAT (6.1 ± 0.4%) (1-way 
ANOVA, Bonferroni post test; p<0.01).24 




7.4.1 Aqueous solubility 
The calculated lipophilicity expressed as the logP (clogP) of 5-OH-DPAT (2.12) is higher 
than the clogP of 5,6-(OH)2-DPAT (7.8). Nevertheless the aqueous solubility of both 
compounds are of the same order of magnitude. Apparently the catecholic structure 
abolishes the increased hydrophilicity which should have rendered the molecule more 
soluble. The reason of the absence of increased solubility may be intramolecular hydrogen 
bonding between the two alcohol groups which reduces the reactivity and solubility of 
catechols (Figure 7.2).29 The aqueous solubility of 5-OH-MPAT (7.15) and 5-OH-EPAT 
(7.20) are approximately two-fold the solubility of 5-OH-DPAT. Thus, decreasing the alkyl 
chain length on the amino group from propyl to ethyl or hydrogen led to a significant 
increase of aqueous solubility. Even though aminochroman 7.22 possibly also forms 
intramolecular hydrogen bonds (Figure 7.2), this compound showed the highest aqueous 
solubility. The impact on solubility of changing a methylene group in the 
tetrahydronaphthalene for an ether group as in the aminochroman is apparently large. 
Perhaps a significant decrease of intermolecular hydrogen bonding compared to that of the 
catechols gives the increased solubility. 
 
Figure 7.2 Possible intramolecular hydrogen bonding in the molecular structures of the DA agonists 
5,6-(OH)2-DPAT (7.8) 5-OH-DPA and 8-OH-DPAC (7.22). 
7.4.2 Transdermal iontophoretic delivery in vitro 
Although the catecholic compounds 7.8 and 7.12 have a lower calculated lipophilicity, 
these agonists showed lower iontophoretic fluxes than 5-OH-DAT, which may indicate that 
the additional ortho-subsituted phenol group interferes with the iontophoretic transport. A 
reason for this inhibition of iontophoretic delivery could be an increased molecular volume 
through intramolecular hydrogen bonds between the alcohol groups. It has been shown that 
an increased molecular volume leads to a decreased total iontophoretic flux.2, 3 Also the 
significantly increased electro-osmotic contribution observed with 5,6-(OH)2-DPAT 
compared to the mono-phenolic compounds may be explained by an increased molecular 




A similar explanation can be given for the low iontophoretic flux found for 8-OH-DPAC 
(7.22). Intramolecular hydrogen bond formation could lead to an enlarged molecular 
volume and consequently can be the reason for a lower iontophoretic flux (Figure 7.2). 
Also the electro-osmotic contribution of 7.22 is higher than this contribution of the tetralin 
monophenolic analogues 5-OH-MPAT and 5-OH-EPAT which is also an indication for a 
higher molecular volume.24 On the other hand, the high solubility found for aminochroman 
7.22 contradicts the occurrence of strong hydrogen bonding. This may be explained by a 
difference between intra- and intermolecular hydrogen bonding. The intramolecular 
hydrogen bonding being important for the iontophoretic flux, and the intermolecular 
hydrogen bonding being important for the solubility of this compound. 
The higher iontophoretic fluxes of 5-OH-MPAT as well as 5-OH-EPAT compared to 5-
OH-DPAT can be explained by the lower lipophilicity originating from the decreased alkyl 
chain length. Del Terzo et al. found that iontophoretic enhancement values decreased 
linearly with increasing alkyl chain length.6 
The influence of molecular structural features on transdermal iontophoretic delivery has 
been investigated in the literature, and molecular volume and molecular weight have been 
assigned as important physicochemical properties. Based on the results described in this 
chapter it is concluded that lipophilicity and molecular volume also play a significant role 
in the iontophoretic transdermal delivery of structurally related DA agonists. Possibly 
intramolecular hydrogen bonding within catecholic tetraline and alcoholic chroman 
structures leads to an increased molecular volume and decreased transdermal iontophoretic 
delivery. 
In conclusion, compared to 5-OH-DPAT, 8-OH-DPAC shows the highest solubility, which 
could allow a smaller patch size, higher concentrations in the donor phase of the 
iontophoretic device, and a higher iontophoretic flux. Also considering its strong DAergic 
activity, this agonist can be an interesting candidate for further investigation on transdermal 
iontophoretic delivery. The synthesized DA receptor agonists proved valuable compounds 




The materials and analysis methods are described in section 2.4.1 
7.5.2 Preparation of 5,6-dihydroxy-2-(N,N-di-n-propyl-amino)tetralin 
2,3-Dimethoxy-benzaldehyde (7.1).21 A mixture of o-vanillin (11 g, 1.19 mol), K2CO3 (269 g, 1.95 
mol), dimethylsulfate (200 mL, 2.1 mol) and MeOH (950 mL) was refluxed overnight. The yellow 
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suspension was cooled to room temperature, diluted with H2O (450 mL) and 
carefully acidified with 2.5 M H2SO4 (aq). Most of the MeOH was evaporated in 
vacuo and the remaining aqueous suspension was extracted with CH2Cl2 
(4x400mL). The combined organic layers were washed with 2N NaOH (3x200 mL), 
H2O (200 mL), brine (200 mL), dried on MgSO4 and evaporated in vacuo to yield 
7.1 as white solid material (178 g, 90%). Purity>98%; IR (KBr, cm-1) νmax 1688, 1584, 1481, 1263, 
1121; 1H NMR (200 MHz, CDCl3): δ 10.37 (s, 1H, CH=O), 7.41-7.30 (m, 1H, ArH), 7.17-7.02 (m, 
2H, ArH), 3.93 (s, 3H,  2-OCH3), 3.85 (s, 3H, 3-OCH3); 13C NMR (50 MHz, CDCl3): δ 190.3, 153.2, 
152.9, 129.9, 124.3, 119.3, 118.3, 62.5, 56.2; EI-MS m/z 166 (M)+. 
(E)-3-(2,3-Dimethoxyphenyl)-2-propenoic acid (7.2).22 A stirred mixture of 7.1 (178 g, 1.07 mol), 
malonic acid (263 g, 2.53 mol), piperidine (19.3 mL, 0.20 mol) and pyridine 
(600 mL, 7.42 mol) was heated at 75 °C for 2 hours and then refluxed 
overnight. The reaction mixture was cooled to room temperature and was 
slowly neutralized with 37% HCl (aq) while cooling in ice until no 
precipitation occurred anymore. The white precipitation was collected by filtration and was 
suspended and stirred in H2O for 1 hour. After filtration and drying in vacuo 7.2 was obtained as 
white solid material (192 g, 86%). Purity: 100%; EI-MS m/z 208 (M)+. 
2,3-Dimethoxybenzenepropanoic acid (7.3).18 To a solution of 7.2 (50 g, 0.24 mol) in 96% EtOH 
(240 mL) was added Pd/C 10% (3.5 g) under nitrogen atmosphere. The 
mixture was hydrogenated at room temperature under 3.5 bar H2 
atmosphere. After completion of the reaction the mixture was filtrated and 
evaporated in vacuo to yield 7.3 as a light yellow solid (39.4 g, 78%). 
Purity: 100%; IR (KBr, cm-1) νmax 2939, 1705, 1598,1480, 1433, 1289, 
1215, 1085, 1045, 1003; EI-MS m/z 210 (M)+. 
2,3-Dimethoxybenzenepropanoyl chloride (7.4).18 SOCl2 (8 mL, 0.11 mol) was added to a solution 
of 7.4 (16.5 g, 0.079 mol) in toluene (100 mL) under nitrogen atmosphere. The 
reaction mixture was refluxed for 1 hour and after cooling, the volatiles were 
removed in vacuo. The crude acid chloride was yielded as a dark yellow oil 
which was used without further purification in the next step. IR (NaCl, cm-1) 
νmax 2941, 1794, 1585, 1481, 1271, 1223, 1082. 
1-Diazo-4-(2,3-dimethoxyphenyl)-2-butanone (7.5).18 A solution of crude acid chloride 7.4 was 
dissolved in dry Et2O (100 mL) and slowly added to a cold dry yellow 
ethereal solution of diazomethane31 (approx. 8.5 g) at 5 °C under an 
atmosphere of nitrogen. When all acid chloride was added, the orange 
reaction mixture was stirred overnight at room temperature to allow excess 
diazomethane to evaporate in the fume hood. The solution was evaporated in vacuo to yield the crude 
product of 7.5 as a thick yellow-brown oil (23.4 g). IR (NaCl, cm-1) νmax 2911, 2102, 1643, 1480, 
1389, 1269, 1077. 
5,6-dimethoxy-2-tetralone (7.6).18 The crude diazoketone 7.5 (23.4 g) was dissolved in CH2Cl2 (200 
mL) and was slowly added to a stirring solution of rhodium diacetate dimer (200 mg) in CH2Cl2 (150 
mL) under nitrogen atmosphere. The reaction mixture was refluxed for 20 minutes, 3 drops of 
CF3COOH were added and refluxing was continued for 15 minutes. After cooling down, the reaction 




vacuo to yield a brown-orange oil (14.2 g). The oil was added to 50 mL of a 
solution of Na2S2O5 (80 g in 140 mL H2O and 70 mL EtOH) and the mixture 
was stirred vigorously until precipitation occurred. After filtration, the 
precipitated salt was washed with EtOH and Et2O. The white precipitation was 
dissolved in H2O, basified with Na2CO3, extracted with Et2O, dried on MgSO4 
and evaporated in vacuo to give 7.5 as white solid material (3.0 g, 18.3% over 3 steps). Purity: 100%; 
IR (NaCl cm-1) νmax 2935, 1715, 1493, 1273, 1088; 1H NMR (400 MHz, CDCl3): δ 6.82 (d, J=8.4 Hz, 
1H, ArH), 6.79 (d, J=8.4 Hz, 1H, ArH), 3.85 (s, 3H, OCH3), 3.81 (s, 3H, OCH3), 3.50 (s, 2H, H1), 
3.10 (t, J=6.6 Hz, 2H, H4), 2.48 (t, J=6.6 Hz, 2H, H3); EI-MS m/z 206 (M)+. 
5,6-dimethoxy-2-(N,N-di-n-propyl-amino)tetralin HCl-salt (7.7)11 Under nitrogen atmosphere a 
solution of 7.6 (2.0 g, 9.7 mmol), dipropylamine (5.5 mL, 39.7 mmol) and p-
toluenesulfonic acid monohydrate (0.19 g, 1 mmol) in toluene (55 mL) was 
refluxed with continuous removal of water. After completion of the reaction, 
100% EtOH (60 mL) and PtO2 (97 mg) were added and the reaction mixture 
was hydrogenated at room temperature under 3 bar H2 atmosphere. The 
reaction mixture was filtrated and the solvent was evaporated in vacuo to yield the crude product as a 
brown-red oil which was converted to the HCl-salt. The salt was decolourized with active charcoal 
and recrystallized from MeOH/Et2O to yield 7.7 as white solid material (2.0 g, 62%). IR (KBr, cm-1) 
νmax 2968, 2419, 1491, 1457, 1280, 1089, 1051; 1H NMR (200 MHz, CD3OD): δ 6.87 (s, 2H, ArH), 
3.81 (s, 3H, OCH3), 3.76 (s, 3H, OCH3), 3.72-3.58 (m, 1H, H2ax), 3.33-2.91 (m, 7H, H1ax, H1eq, 
N(CH2CH2CH3)2, H4eq), 2.84-2.60 (m, 1H, H4ax), 2.42-2.27 (m, 1H, H3eq), 1.99-1.71 (m, 5H, H3ax, 
N(CH2CH2CH3)2), 1.04 (t, J=7.3 Hz, 6H, N(CH2CH2CH3)2); 13C NMR (50 MHz, CD3OD): δ 151.2, 
146.4, 128.9, 124.6, 111.2, 60.5, 59.2, 55.2, 52.7, 28.9, 23.5, 22.7, 18.5, 10.2; EI-MS m/z 291 (M)+. 
5,6-dihydroxy-2-(N,N-di-n-propyl-amino)tetralin HBr-salt (7.8). A mixture of freshly distilled 
48% HBr (11 mL) and 7.7 (0.93 g, 2.9 mmol) was refluxed for 2 hours under 
nitrogen atmosphere. The hot solution was cooled down overnight while 
stirring slowly to allow the HBr salt to crystallize from the solution. The white 
crystals were filtrated, washed with EtOH 100% and recrystallized from 100% 
EtOH/Et2O to afford the HBr salt of 7.8 as white solid material (0.26 g, 27%). 
IR (KBr, cm-1) νmax 3233, 2930, 2727, 1498, 1293; 1H NMR (300 MHz, d6-DMSO): δ 9.25 (br s, 1h, 
NH), 9.04 (d, J=4.8 Hz, 1H, OH), 8.25 (d, J=3.3 Hz, 1H, OH), 6.60 (d, J=8.1 Hz, 1H, ArH), 6.40 (d, 
J=8.1 Hz, 1H, ArH), 3.63-3.45 (m, 1H, H2ax), 3.28-2.77 (m, 7H, H1ax, H1eq, N(CH2CH2CH3)2, H4eq), 
2.59-2.41 (m, 1H, H4ax), 2.33-2.18 (m, 1H, H3eq), 1.86-1.58 (m, 5H, H3ax, N(CH2CH2CH3)2), 0.90 (t, 
J=7.3 Hz, 6H, N(CH2CH2CH3)2); 13C NMR (50 MHz, d6-DMSO): δ 143.5, 143.0, 124.7, 123.2, 
129.8, 114.2, 60.2, 52.3, 39.8, 29.4, 23.5, 18.6, 11.7; HR-MS m/z Calcd. for C16H26NO2 264.19581 
(M+H)+, found 264.19540 (M+H)+; Anal. Calcd for C16H26NO2Br: C, 55.82; H, 7.61; N, 4.07. Found: 
C, 55.73; H, 7.64; N, 4.07. 
1,6-Dibromo-2-methoxy-naphthalene (7.9).20 Iodomethane (41 mL, 0.66 mol) was added dropwise 
to a stirring suspension of 1,6-dibromo-2-naphthol (101 g, 0.33 mol) and 
K2CO3 (114 g, 0.83 mol) in anhydrous DMF (100 mL) while the temperature 
was kept beneath 30 °C. After stirring for 3 hours, the reaction mixture was 
partitioned between CH2Cl2/H2O and extracted with CH2Cl2 (2x). The 
combined organic layers were dried on MgSO4, evaporated in vacuo and recrystallized from 
Et2O/Hexane to yield 7.9 as white crystals (93 g, 89%).  Purity:100% (GCMS); EI-MS m/z 316 (M)+.  
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1,2,6-Trimethoxy-naphthalene (7.10).19, 20 Under nitrogen atmosphere slowly sodium cut in small 
pieces (43.5 g, 1.95 mol) was added to cold dry MeOH (690 mL) while 
cooling in ice. When almost all sodium was added, the mixture was heated 
slightly to dissolve the remaining sodium. Vacuum-dried 7.9 (90 g, 0.28 mol) 
and dry 2,4,6-collidine (280 mL, 2.10 mol) were added and the grey cloudy 
grey solution turned into a clear brown solution. Then, vacuum-dried copper(I)iodide (65 g, 0.34 mol) 
was added and the solution turned into a yellow-green suspension. The nitrogen-flushed reaction 
mixture was refluxed for 5 hours , was filtrated over celite and evaporated in vacuo. The resultant 
orange slurry was diluted with H2O (1.4 L), neutralized with 37% HCl (aq, 240 mL) and extracted 
with EtOAc (3 x 1L). The combined organic layers were washed with 1N HCl (aq, 250 mL), H2O 
(250 mL), brine (100 mL), dried on MgSO4 and evaporated in vacuo. After purification by column 
chromatography (SiO2, Hexane/EtOAc=32:1 to 16:1, gradient) crude 7.10 was afforded as white-
green solid material (45.9 g, 68%). Purity: 90%; IR (KBr, cm-1) νmax 2960, 1602, 1448, 1358, 1271, 
1241, 1161, 1095, 1021; EI-MS m/z 218 (M)+. 
7.5.3 Preparation of 5,6-dihydroxy-2-(N-n-propyl-amino)tetralin 
5,6-dimethoxy-2-(N-n-propyl-amino)tetralin HCl-salt (7.11).11 Under nitrogen atmosphere a 
solution of 7.6 (0.98 g, 4.7 mmol), propylamine (0.48 mL, 5.8 mmol) and a 
catalytic amount of p-toluenesulfonic acid monohydrate in toluene (16 mL) 
was refluxed with continuous removal of water. After completion of the 
reaction, the solvent was evaporated in vacuo and 100% EtOH (25 mL) and 
PtO2 (19 mg) were added and the reaction mixture was hydrogenated at room 
temperature under 3 bar H2 atmosphere. The reaction mixture was filtrated and 
the solvent was evaporated in vacuo to yield the crude product as a dark 
purple oil which was converted to the HCl-salt. The salt was decolourized with active charcoal and 
recrystallized from 100% EtOH/Et2O to yield 7.11 as solid light-brown material (0.48 g, 36%). 
Purity: 93% (GCMS); 1H NMR (400 MHz, CDCl3): δ 6.79 (d, J=8.4 Hz, 1H, ArH), 6.72 (d, J=8.1 
Hz, 1H, ArH), 3.82 (s, 3H, OCH3), 3.79 (s, 3H, OCH3), 3.04-2.79 (m, 3H, H2, H4), 2.72-2.57 (m, 3H, 
N(CH2CH2CH3), H1), 2.51 (dd, J=15.4 Hz, J=9.5 Hz, 1H, H1), 2.10-1.97 (m, 1H, H3eq), 1.59-1.45 (m, 
3H, H3ax, N(CH2CH2CH3)), 1.38 (br s, NH, 1H), 0.93 (t, J=7.5 Hz, 3H, CH3); 13C NMR (50 MHz, 
CDCl3): δ 150.7, 146.7, 130.9, 129.0, 124.6, 110.5, 60.1, 56.1, 52.7, 49.3, 36.5, 29.5, 23.8, 22.7, 12.1; 
EI-MS m/z 249 (M)+. 
5,6-dihydroxy-2-(N-propyl-amino)tetralin HBr/HCl-salt (7.12). A mixture of freshly distilled 48% 
HBr (5 mL) and 7.11 (264 mg, 1.1 mmol) was refluxed for 3 hours under 
nitrogen atmosphere. The hot solution was allowed to attain room 
temperature and the HBr salt crystallized from the solution as white 
needles. The crystals were filtrated, washed with 100% EtOH and stirred 
in hot 2N HCl in MeOH for 2 hours to convert the HBr-salt to the HCl-
salt. After recrystallization from MeOH/Et2O compound 7.12 was afforded as the HBr/HCl (6:1) salt 
as white solid material (135 mg, 58%). IR (KBr cm-1) νmax 3486, 3096, 2972, 1498, 1464, 1299, 1015; 
1H NMR (400 MHz, CD3OD): δ 6.63 (t, J=8.4 Hz, 1H, ArH), 6.48 (d, J=8.4 Hz, 1H, ArH), 3.46-3.36 
(m, 1H, H2ax), 3.14 (ddd, J=5.9 Hz, J= 3.7 Hz, J=1.8 Hz, 1H, H1) 3.11-3.04 (m, 2H, NCH2CH2CH3, 
H4eq), 3.00 (ddd, J=17.6 Hz, J=5.9 Hz, J=3.3 Hz, 1H, H4eq), 2.79 (dd, J=15.2 Hz, J=10.4 Hz, 1H, H1), 




H3ax, N(CH2CH2CH3)2), 1.05 (t, J=7.5 Hz, 6H, N(CH2CH2CH3)2); 13C NMR (50 MHz, CD3OD): δ 
160.2, 147.0, 127.5, 126.2, 123.5, 117.3, 58.8, 50.6, 35.6, 29.6, 25.6, 23.7, 14.1; HR-MS m/z Calcd. 
for C13H20NO2 222.14886 (M+H)+, found 222.14888 (M+H)+; Anal. Calcd for 
C13H20NO2Br/C13H20NO2Cl (6:1): C, 52.78; H, 6.81; N, 4.73. Found: C, 52.75; H, 6.83; N, 4.72. 
7.5.4 Preparation of 5-hydroxy-2-(N-n-propyl-amino)-tetralin 
5-methoxy-2-(N-benzyl-N-n-propyl-amino)-tetralin (7.13). A mixture of 2.9 (which was recovered 
as free amine from the combined motherliquors of the resolution of (±)-2.9) (0.70 
g, 2.4 mmol), K2CO3 (0.99 g, 7.2 mmol) were suspended in 6 mL 2-butanone. 1-
Iodopropane (0.64 mL, 6.6 mmol) was added while the mixture was heated to 
reflux under nitrogen atmosphere. After refluxing overnight and evaporation of the 
solvent in vacuo, the reaction material was partitioned between CH2Cl2 and H2O. 
The organic layer was separated, dried on MgSO4 and evaporated in vacuo to give 
crude 7.13 as an oil (0.70 g, 63%). Purity: 67% (GCMS); IR (NaCl, cm-1) νmax 2930, 1585, 1467, 
1259, 1094; EI-MS m/z 309 (M)+. 
5-methoxy-2-(N-n-propyl-amino)-tetralin HCl salt (7.14). In a Parr flask, crude 7.13 (0.70 g, 2.3 
mmol) was dissolved in 100% EtOH (100 mL) and Pd/C 10% (200 mg) was 
added under nitrogen atmosphere. The dark suspension was hydrogenolyzed at 
50 °C under 3 bar H2 atmosphere. After completion of the reaction the mixture 
was filtrated, evaporated in vacuo, converted to the HCl-salt and recrystallized 
from 100% EtOH/Et2O to yield the HCl-salt of 7.14 as light pink crystals (0.27 
g, 55%). IR (KBr, cm-1) νmax 3435, 2958, 1589, 1471, 1261, 1094; 1H NMR (400 MHz, CDCl3): δ 
7.09 (t, J=7.9 Hz, 1H, ArH), 6.71 (d, J=7.7 Hz, 1H, ArH), 6.66 (d, J=8.1 Hz, 1H, ArH), 3.81 (s, 3H, 
OCH3), 3.07-2.81 (m, 3H, H1, H2), 2.69 (t, J=7.3 Hz, 2H, N(CH2CH2CH3)2), 2.65-2.48 (m, 2H, H4), 
2.12-2.01 (m, 1H, H3eq), 1.64-1.43 (m, 4H, NH, H3ax, N(CH2CH2CH3), 0.95 (t, J=7.3 Hz, 3H, CH3); 
13C NMR (50 MHz, CDCl3): δ 157.4, 137.0, 126.4, 125.4, 121.8, 107.2, 55.4, 53.4, 49.3, 37.1, 29.5, 
23.8, 22.4, 12.1; EI-MS m/z 219 (M)+. 
5-hydroxy-2-(N-n-propyl-amino)-tetralin HBr-salt (7.15). A mixture of freshly distilled 48% HBr 
(20 mL) and 7.14 (0.40 g, 1.6 mmol) was refluxed overnight under nitrogen 
atmosphere. After cooling down, the reaction mixture was evaporated in vacuo 
and the resultant orange-brown solid material was decolourized with active 
charcoal in MeOH. After recrystallization from MeOH/Et2O the HBr-salt of 
7.15 was obtained as light grey crystals (0.18 g, 40%); Purity>95% (HPLC); 
IR (KBr, cm-1) νmax 3305, 2938, 2457, 2166, 1591, 1468, 1283; 1H NMR (200 MHz, CD3OD): δ 6.96 
(t, J=7.8 Hz, 1H, ArH), 6.62 (d, J=7.6 Hz, 2H, ArH), 3.58-3.37 (m, 1H, H2ax), 3.22-2.77 (m, 5H, H1ax, 
H1eq, N(CH2CH2CH3), H4eq), 2.76-2.45 (m, 1H, H4ax), 2.44-2.21 (m, 1H, H3eq), 1.94-1.61 (m, 3H, 
H3ax, N(CH2CH2CH3)), 1.0 (t, J=7.3 Hz, 3H, N(CH2CH2CH3)); 13C NMR (50 MHz, CD3OD): δ 
155.0, 133.2, 126.8, 121.9, 120.0, 112.3, 54.7, 46.7, 32.0, 25.6, 21.5, 19.8, 10.2; EI-MS m/z 205 (M)+; 
Anal. Calcd for C13H19NO.HBr: C, 54.56; H, 7.04; N, 4.89; Found: C, 53.56; H, 7.03; N, 4.81.  
7.5.5 Preparation of 5-hydroxy-2-(N-ethyl-N-n-propyl-amino)tetralin 
5-methoxy-2-(N-benzylacetamido)-tetralin (7.16). TEA (1.8 mL, 12.9 mmol) was added to a cooled 
solution of 2.9 (which was recovered as free amine from the combined motherliquors of the resolution 
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of (±)-2.9) (3.7 g, 12.5 mmol) in dry toluene (30 mL) under nitrogen 
atmosphere. Acetylchloride (1.0 mL, 14.0 mmol) was added and the 
reaction mixture was stirred for 1.5 hours. The TEA-HCl salt was removed 
by filtration and the solvent was evaporated in vacuo. The resultant oil was 
purified on column chromatography (Al2O3, EtOAc/Hexane=1:8 to 1:4, 
gradient) to yield 7.16 as a clear yellow oil (2.6 g, 68%). Purity: 88% 
(GCMS); IR (NaCl, cm-1) νmax 2947, 1642, 1585, 1467, 1413, 1261; EI-MS m/z 309 (M)+. 
5-methoxy-2-(N-benzyl-N-ethyl-amino)tetralin (7.17). Under nitrogen atmosphere a solution of 
7.16 (2.2 g, 7.1 mmol) in dry THF (30 mL) was added to a suspension of 
LiAlH4 (0.41 g, 10.8 mmol) in dry THF (30 mL) and the mixture was 
stirred for 40 minutes. After addition of EtOAc, diluted H2SO4 (8 mL) was 
added until precipitation at pH 2. The mixture was filtrated, basified with 
2N NaOH (10 mL) and extracted with EtOAc (2x75 mL). The combined 
organic layers were washed with brine, dried on MgSO4, evaporated in 
vacuo and purified on column chromatography (Al2O3, Hexane/EtOAc=3:1 to 1:1, gradient) to yield 
7.17 as a colourless oil (1.19 g, 56%). Purity: 89% (GCMS); IR (NaCl, cm-1) νmax 2929, 1585, 1468, 
1260, 1094; EI-MS m/z 295 (M)+.  
5-methoxy-2-(N-ethyl-amino)tetralin (7.18). In a Parr flask, 7.17 (1.14 g, 3.9 mmol) was dissolved 
in 100% EtOH (100 mL) and Pd/C 10% (0.66 g) was added under nitrogen 
atmosphere. The dark suspension was hydrogenolyzed at 50 °C under 3.5 bar H2 
atmosphere. After completion of the reaction the mixture was filtrated, evaporated 
in vacuo to yield 7.18 as a colourless oil (0.58 g, 74%). Purity: 93% (GCMS); IR 
(NaCl, cm-1) νmax 2933, 1585, 1469, 1258, 1095; EI-MS m/z 205 (M)+. 
5-methoxy-2-(N-ethyl-N-propyl-amino)tetralin (7.19). TEA (0.4 mL, 2.9 mmol) was added to a 
cooled solution of 7.18 (0.58 g, 2.8 mmol) in dry toluene (15 mL) under nitrogen 
atmosphere. Propionylchloride (0.25 mL, 2.9 mmol) was added and the reaction 
mixture was stirred for 30 minutes. The TEA-HCl salt was removed by filtration 
and the solvent was evaporated in vacuo to give the intermediate crude amide as a 
light yellow oil which solidified on standing (0.78 g). Under nitrogen atmosphere a 
solution of the amide in dry THF (10 mL) was added dropwise to a suspension of LiAlH4 (0.16 g, 4.2 
mmol) in dry THF (10 mL) and the mixture was stirred for 20 minutes. After addition of EtOAc, 
diluted H2SO4 was added until precipitation at pH 2. The mixture was filtrated, basified with 2N 
NaOH (10 mL) and extracted with EtOAc. The combined organic layers were washed with brine, 
dried on MgSO4, evaporated in vacuo and purified by column chromatography (SiO2 (NH3), 
CH2Cl2/MeOH=20:1) to yield 7.19 as a clear yellow oil (0.43 g, 61%). Intermediate amide: EI-MS 
m/z 261 (M)+. Final compound: Purity: 68% (GCMS); IR (NaCl, cm-1) νmax 2959, 2933, 1585, 1468, 
1259, 1095; EI-MS m/z 247 (M)+. 
5-hydroxy-2-(N-ethyl-N-propyl-amino)tetralin HBr-salt (7.20). A mixture of freshly distilled 48% 
HBr (5 mL) and 7.19 (0.37 g, 1.5 mmol) was refluxed for 1 hour under nitrogen atmosphere. After 
cooling down, the reaction mixture was evaporated in vacuo and the resultant orange-brown solid 
material was recrystallized from 100% EtOH/Et2O to yield the HBr-salt of 7.20 as white crystals 
(0.18 g, 40%). Purity: 99% (GCMS); IR (KBr, cm-1) νmax 3186, 2940, 2646, 1591, 1466, 1271, 1015; 




1H, H2ax), 3.58-2.97 (m, 7H, H1ax, H1eq, N(CH2CH2CH3), N(CH2CH3), H4eq), 
2.76-253 (m, 1H, H4ax), 2.45-2.37 (m, 1H, H3eq), 2.01-1.71 (m, 3H, H3ax, 
N(CH2CH2CH3)), 1.40 (t, J=7.2 Hz, 3H, N(CH2CH2CH3)), 1.05 (t, J=7.4 Hz, 
3H, N(CH2CH3)); 13C NMR (50 MHz, CD3OD): δ 155.0, 133.7, 126.8, 121.9, 
120.0, 112.3, 60.0, 52.0, 46.6, 29.8, 23.7, 22.5, 18.7, 10.2, 9.4; EI-MS m/z 233 
(M)+; Anal. Calcd for C15H23NO.HBr: C, 57.33;H, 7.70; N, 4.46. Found: C, 57.50; H, 7.76; N, 4.50. 
7.5.6 Preparation of 8-hydroxy-3,4-dihydro-3-(N,N-di-n-propylamino)-
2H-1-benzopyran 
8-methoxy-3,4-dihydro-3-(N,N-di-n-propylamino)-2H-1-benzopyran (7.21).12 A mixture of 
benzopyranone 9.5 (1.2 g, 6.7 mmol), dipropylamine (1.3 mL, 9.5 mmol), and 
glacial acetic acid (0.06 mL, 1.0 mmol) in pentan-1-ol (10 mL) was refluxed for 3 
hours with continuous removal of water via a Dean-Stark water trap. The solvent 
was evaporated in vacuo, the residue was dissolved in EtOAc and filtered through 
a bed of silica gel. After evaporation of the solvent, the resultant dark oil was 
dissolved in MeOH (25 mL) and PtO2 (12 mg) was added under nitrogen 
atmosphere in a Parr flask. The mixture was hydrogenated overnight at room temperature under 3.5 
bar H2 atmosphere. The reaction mixture was filtrated, evaporated in vacuo and purified by column 
chromatography (SiO2, Hexane/EtOAc=2:1, 0.1% TEA) to yield 7.21 as a yellow oil (0.25 g, 14.4%). 
Purity: 94% (GCMS); IR (NaCl, cm-1) νmax 2958, 1585, 1485, 1262, 1212, 1083; 1H NMR (200 MHz, 
d6-DMSO): δ 6.77-6.57 (m, 3H, ArH), 4.26-4.13 (m, 1H, H2), 3.80-3.71 (m, 1H, H2), 3.68 (s, 3H, 
OCH3), 3.09-2.88 (m, 1H, H3), 2.74 (d, J=7.6 Hz, 2H, H4), 2.44 (t, J=7.2 Hz, 4H, N(CH2CH2CH3)2), 
1.45-1.24 (m, 4H, N(CH2CH2CH3)2), 0.81 (t, J=7.4 Hz, 6H, N(CH2CH2CH3)2); 13C NMR (50 MHz, 
d6-DMSO): δ 148.7, 123.2, 122.5, 120.5, 110.3, 67.9, 56.1, 53.4, 52.6, 28.4, 22.0, 12.3; EI-MS 
m/z263 (M)+. 
8-hydroxy-3,4-dihydro-3-(N,N-di-n-propylamino)-2H-1-benzopyran HBr-salt (7.22).12 A mixture 
of freshly distilled 48% HBr (1.5 mL) and 7.21 (0.20 g, 0.76 mmol) was refluxed 
for 45 minutes under nitrogen atmosphere. After cooling down, the reaction 
mixture was evaporated in vacuo and the resultant brown solid material was 
recrystallized from 100% EtOH to yield the HBr-salt of 7.22 as white crystals 
(0.08 g, 24%). Purity>95% (HPLC); IR (KBr, cm-1) νmax 3133 (br), 2937, 2647, 
2519, 1586, 1501, 1474, 1340, 1273, 1218, 1185, 1001; 1H NMR (300 MHz, 
CD3OD): δ 6.80 (t, J=7.9 Hz, 1H, ArH), 6.69 (d, J=7.0 Hz, 2H, ArH), 4.63-4.48 (m, 1H, H2), 4.47-
4.38 (m, 1H, H2), 4.08-3.95 (m, 1H, H3), 3.45-3.13 (m, 6H, H4, N(CH2CH2CH3)2), 1.95-1.70 (m, 4H, 
N(CH2CH2CH3)2), 1.02 (t, J=7.3 Hz, 6H, N(CH2CH2CH3)2); 13C NMR (50 MHz, CD3OD): δ 122.0, 
120.1, 114.2, 64.1, 56.4, 53.0, 25.4, 17.8, 10.1; HR-MS m/z Calcd. for C15H24N1O2 250.1802 (M+H)+, 
found 250.18001 (M+H)+; Anal. Calcd for C15H24NO2Br: C, 54.55; H, 7.32; N, 4.24. Found: C, 
54.42; H, 7.32; N, 4.22. 
7-Hydroxy-2,3-dihydro-2-(N,N-di-n-propylaminomethyl)-2H-1-benzofuran (7.23).14 Compound 
7.21 (0.56 g, 1.9 mmol) was dissolved in CH2Cl2 and cooled to -30 °C. 1M BBr3 in CH2Cl2 (2.5 mL, 
2.2 mmol) was added and the reaction mixture was allowed to slowly attain room temperature and 
stirred overnight. The reaction mixture was poured on ice (200 mL) and 25% NH3 (aq, 50 mL) was 
added. The basic water layer was extracted with CH2Cl2, filtrated and evaporated in vacuo. The crude 
brown oil was purified on column chromatography (SiO2, EtOAc) and 7.11 was obtained as a light 
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yellow oil (99 mg, 15%). Purity>98% (GCMS); IR (NaCl, cm-1) νmax 3145, 
2965, 2751, 1762, 1616, 1469, 1239, 1215; 1H NMR (300 MHz, CD3OD): δ 
6.78-6.62 (m, 3H, ArH), 5.35-5.15 (m, 1H, H2), 3.55=3.35 (m, 3H, 
CHCH2N), 3.34-3.12 (m, 4H, H3, N(CH2CH2CH3), 2.94 (dd, J=15.9 Hz; 6.2 
Hz, 1H, H3), 1.92-1.63 (m, 4H, N(CH2CH2CH3)2), 1.03 (t, J=7.4 Hz, 6H, 
N(CH2CH2CH3); 13C NMR (50 MHz, CD3OD): δ 122.2, 116.1, 116.0, 115.5, 
76.9, 56.2, 33.9, 17.0, 10.0; EI-MS m/z 249 (M)+.  
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studies of prodrugs of (-)-8-OH-






Skin depot formation can be a disadvantage in the treatment of Parkinson's disease when 
rapid changes in a transdermal iontophoresis delivery scheme are required. When drugs 
are delivered by iontophoresis, the compounds with lower lipophilicity show a decreased 
skin depot formation. Moreover, drugs with improved physico-chemical properties like low 
lipophilicity and high aqueous solubility can be advantageous for transdermal 
iontophoretic delivery. In comparison to 5-OH-DPAT, 8-OH-DPAC shows a higher 
aqueous solubility and a lower lipophilicity. In order to further improve the physico-
chemical properties we synthesized a series of less lipophilic, highly water-soluble mono 
amino acid prodrugs of (-)-8-OH-DPAC suitable for iontophoretic delivery. The chemical 
stability in citrate buffer pH 5 at 32 oC (donor phase) was determined. Especially, the 1-
aminocyclopropane-1-carboxylic acid (8.18) and the β-alanine (8.21) prodrugs of 8-OH-
DPAC showed suitable half-lives in combination with a decreased calculated lipophilicity 
compared to equivalent 5-OH-DPAT amino acid prodrugs. These candidates may be used 
for further in vitro and in vivo experiments on transdermal iontophoretic delivery. 
8.1 INTRODUCTION 
In Chapter 2 the synthesis of mono amino acid esters of 5-OH-DPAT is described. These 
compounds were designed to decrease lipophilicity and therewith increase aqueous 
solubility and iontophoretic flux of the parent drug 5-OH-DPAT. The 1-
aminocyclopropane-1-carboxylic acid (2.30), L-valine (2.31), L-isoleucine (2.33) and β-
alanine (2.39) esters of (S)-5-OH-DPAT, the pharmacologically active enantiomer, showed 
chemical stabilities which were considered sufficient for in vitro and in vivo iontophoretic 
experiments (Chapter 3). After iontophoretic in vitro experiments the highly soluble β-
alanine ester prodrug of (S)-5-OH-DPAT, which showed a lower calculated log P than the 
parent drug, was evaluated in vivo. Although this prodrug gave lower plasma 
concentrations than (S)-5-OH-DPAT, the prodrug showed post-iontophoretic higher plasma 
concentrations which could be explained by a delayed release due to skin depot formation. 
Nevertheless, despite a lower steady state plasma concentration the same maximum 
pharmacodynamic effect as iontophoretic administration of (S)-5-OH-DPAT was 
achieved.1 A prolonged effect due to depot formation can be a drawback to initiate therapy 
to treat Parkinson’s disease, since rapid changes in delivery schemes may be required. At 
the other hand, the prolonged effect of the prodrug can be beneficial for patients who suffer 
from nocturnal disturbances.2, 3 




Figure 8.1 Structures of rotigotine, 5-OH-DPAT (2.12) and 8-OH-DPAC (8.10). 
To study the effect of hydrophilicity on the iontophoresis and skin depot formation some 
less hydrophobic amino ester prodrugs of DA D2 receptor agonists were synthesized. 
Compared to rotigotine (calculated log P = 4.67) the absence of the thienyl group makes 5-
OH-DPAT (calculated log P = 3.99) (2.12)  less lipophilic (Figure 8.1).4-6 A lower 
lipophilicity could provide benefits for the delivery by iontophoresis, and accordingly the 
iontophoretic delivery of 5-OH-DPAT over human stratum corneum resulted in an increase 
of the transport rate relative to rotigotine.7 A small selection of chemicals was studied on 
dermal permeation by Moody et al., and the compounds with the higher lipophilicity 
showed higher skin depot formation.8   
The aim of this study was to decrease skin depot formation and at the same time achieve 
high aqueous solubility. A structural modification to decrease lipophilicity of the mono 
amino acid esters of 5-OH-DPAT is the bioisosteric replacement of a methylene group by 
an oxygen atom in the parent molecule structure as in 8-hydroxy-3,4-dihydro-3-(N,N-di-n-
propylamino)-2H-1-benzopyran (8-OH-DPAC, 8.10, calculated log P = 3.204-6) (Figure 
8.1). 8-OH-DPAC is a potent DA agonist comparable to 5-OH-DPAT with selectivity for 
presynaptic D2 DA receptors and only moderate affinity for 5-HT and NA receptors.9-11 
Although the aqueous solubility of 8-OH-DPAC was 5-fold higher than that of 5-OH-
DPAT (Chapter 7), the in vitro iontophoretic transport of 8-OH-DPAC was lower.12 
Nevertheless, conversion to an amino acid prodrug could improve the iontophoretic 
transport rate and this would be interesting to examine.  
In this chapter we describe the synthesis of mono amino acid prodrugs of (-)-8-OH-DPAC, 
the pharmacologically active enantiomer, and the evaluation of their chemical stability. The 
selection of coupled amino acid pro-moieties was based on the chemically most stable 5-
OH-DPAT prodrugs (Chapter 3). The influence of the bioisosteric replacement of the 
methylene group (5-OH-DPAT) by an oxygen atom (8-OH-DPAC) on chemical hydrolysis 
was also studied. The most stable prodrug might be used in further in vitro and in vivo 
experiments to study the influence of a less lipophilic dopaminergic amino acid prodrug on 





8.2.1 Synthesis of (-) and (+)-8-hydroxy-3,4-dihydro-3-(N,N-di-n-
propylamino)-2H-1-benzopyran ((-)-8.10 and (+)-8.10). 
Neirabeyeh et al. developed a route for the synthesis of the enantiomers of 8.10 including a 
resolution of an intermediate compound, i.e. (±)-8-methoxy-3,4-dihydro-3-diallyllamino-
2H-1-benzopyran (8.22) using binaphthylphosphoric acid as the chiral resolving agent.11 
Moreover, Holmberg et al. presented a resolution of another suitable intermediate 
compound, namely (±)-8-methoxy-3,4-dihydro-3-(N,N-dibenzylamino)-2H-1-benzopyran 
(8.23). This compound was recrystallized as the L-dibenzoyltartrate salt from a mixture of 
water and dichloromethane.13 Also Brisander et al. showed a resolution of an appropriate 
intermediate (±)-3,4-dihydro-3-(N,N-dibenzylamino)-2H-1-benzopyran (8.24) which was 
recrystallized from 95% ethanol as the mandelate salt (Figure 8.2).14  
 
Figure 8.2 Structures of resolvable intermediates (±)-8-methoxy-3,4-dihydro-3-diallyllamino-2H-1-
benzopyran (8.22), (±)-8-methoxy-3,4-dihydro-3-(N,N-dibenzylamino)-2H-1-benzopyran (8.23) and 
(±)-3,4-dihydro-3-(N,N-dibenzylamino)-2H-1-benzopyran (8.24). 
However, we preferred the synthesis of the benzylamino intermediate (±)-8.6 and the 
resolution thereof. Because of the successful resolution of 2-(benzylamino)-5-
methoxytetralin (2.9) described in Chapter 2, a synthetic route was chosen which includes 
the oxygen isostere of 2.9, i.e. (±)-8-methoxy-3,4-dihydro-3-(N-benzylamino)-2H-1-
benzopyran ((±)8.6).15 For that reason, the synthesis of (-) and (+)-8-hydroxy-3,4-dihydro-
3-(N,N-di-n-propylamino)-2H-1-benzopyran ((-)-8.10 and (+)-8.10) was performed based 
on the procedure described by Wise et al.16 The absolute stereochemistry of the 
enantiomers of 8.6 and 8.10 were not found in literature, therefore the enantiomers are 
denoted by their optical rotation. The nitrile 8.3 was synthesized by the treatment of 2-
hydroxy-3-methoxybenzaldehyde with acrylonitrile and 1,4-diazabicyclo[2.2.2]octane 
under reflux. Then, nitrile 8.3 was hydrolyzed to the carboxylic acid 8.4 under alkaline 
conditions, and was further converted to the ketone 8.5 by a Curtius rearrangement using 
diphenylphosphoryl azide followed by acidic hydrolysis. Subsequently, the racemic mixture 
of 8.6 was synthesized by reductive amination with sodium cyanoborohydride and 
benzylamine (Scheme 8.1).13 




Scheme 8.1 Synthesis and resolution of 8-methoxy-3,4-dihydro-3-(N-benzylamino)-2H-1-benzopyran 
(8.6). Reagents and conditions: a) acrylonitrile, 1,4-diazabicyclo[2.2.2]octane, reflux overnight, 
recrystallization from MeOH; b) 10% NaOH, 6h reflux, 37% HCl (aq); c) step 1: diphenyl phosphoryl 
azide, toluene, TEA, CH2Cl2, RT-60°C, 1.5 h at 85°C, step 2: 6N HCl (aq), 2h reflux; d) CH3COOH, 
benzylamine, THF, 30 min RT, NaCNBH3; e) (+)-chlocyphos, recrystallization from 96% EtOH; f) (-
)-chlocyphos, recrystallization from 96% EtOH. 
First, the diastereomeric D-(-)-mandelate and (+)-di-p-toluoyl-tartrate salts were 
recrystallized from 95% ethanol, but unfortunately no crystal formation or resolution was 
observed for the two salt forms. In order to continue the investigation to a successful 
resolution of (±)-8.6, the enantiomers of the resolving agent 4-(2-chlorophenyl)-5,5-
dimethyl-2-hydroxy-1,3,2-dioxaphosphorinane 2-oxide (8.2, chlocyphos) were synthesized 
by the method described by Ten Hoeve and Wynberg.17 An aldol-Cannizaro reaction of 2-
chloro-benzaldehyde with isobutyraldehyde in a solution of 6% potassium hydroxide in a 
mixture of water and ethanol gave 2,2-dimethyl-1-(2-chlorophenyl)-1,3-propanediol (8.1). 
Next, 8.1 was converted to the cyclic phosphoric acid chloride with phosphorus 
oxychloride, where after it was hydrolyzed with aqueous sodium hydroxide to form 4-(2-
chlorophenyl)-5,5-dimethyl-2-hydroxy-1,3,2-dioxaphosphorinane 2-oxide (8.2). The (-)-(p-
hydroxyphenyl)-glycinate salt of 8.2 was crystallized from a mixture of ethanol and water 
to yield after conversion to the free acid (S)-8.2. Ultimately, the motherliquor of the 
crystallization was collected, converted to the free acid and yielded pure (R)-8.2. The 





Scheme 8.2 Synthesis and resolution of 4-(2-chlorophenyl)-5,5-dimethyl-2-hydroxy-1,3,2-
dioxaphosphorinane 2-oxide (8.2, chlocyphos). Reagents and conditions: a) isobutyraldehyde, KOH 
in H2O/EtOH; b) step 1: POCl3, CH2Cl2, 45°C, 1.5 h at reflux; step 2: 2.4 M NaOH at 95°C, 15 min at 
60°C, 37% HCl; c) (-)-(p-hydroxyphenyl)-glycine, crystallization from 96% EtOH; d) conversion of 
mother liquor obtained from step c. 
The resolution of (±)-8.6 was achieved by recrystallization of the diastereomeric 
chlocyphos salts of 8.6 from 96% ethanol (Scheme 8.1).18 By parallel synthesis the (-)- and 
(+)-enantiomers of 8.6 were alkylated with 1-iodopropane to give the enantiomeric 8-
methoxy-3,4-dihydro-3-(N-benzyl-N-propyl-amino)-2H-1-benzopyrans (8.7) (Scheme 8.3). 
After deprotection by hydrogenolysis with palladium on carbon under hydrogen 
atmosphere, 8-methoxy-3,4-dihydro-3-(N-n-propylamino)-2H-1-benzopyran (8.8) was 
converted to the N-alkylated amide and immediately reduced to enantiomeric pure 8-
methoxy-3,4-dihydro-3-(N,N-di-n-propylamino)-2H-1-benzopyran (8.9). Finally, (-) and 
(+)-8-hydroxy-3,4-dihydro-3-(N,N-di-n-propylamino)-2H-1-benzopyran ((-)-8.10 and (+)-
8.10) were obtained as the hydrobromide salts after demethylation in 48% hydrobromic 
acid with e.e. values of 98% and 93%, respectively. The nine-step yield for (-)-8.10 was 3 
% and for (+)-8.10 this was 5 %. 
 
Scheme 8.3 Synthesis of (-)-8-hydroxy-3,4-dihydro-3-(N,N-di-n-propylamino)-2H-1-benzopyran ((-)-
8.10). The synthesis of (-)-8.10 followed the same reaction steps starting with (+)-8.10.  Reagents and 
conditions: g) K2CO3, 2-butanone, 1-iodopropane, reflux, 3 days; h) 3.5 bar H2, 10% Pd/C, RT; i) step 
1: TEA, toluene, propionylchloride, RT, 30 min; step 2: THF, LiAlH4, reflux, 1h. j) 48% HBr, reflux, 
4h. 
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8.2.2 Synthesis of (-)-3,4-dihydro-3-(N,N-di-n-propylamino)-2H-1-
benzopyran-8-yl esters (8.17-8.21) 
The prodrugs of (-)-8.10 were synthesized according to a procedure described in Chapter 2. 
The Boc-protected amino acid (-)-8-OH-DPAC esters 8.12-8.16 were synthesized from (-)-
8.10 by coupling the Boc-protected amino acid to (-)-8-OH-DPAC with EDC and HOBt in 
dichloromethane. The obtained yields of the coupling reaction varied between 62% and 
79%. Compounds 8.12-8.16 were deprotected by a reaction in hydrogen chloride in dioxane 
to give the amino acid (-)-8-OH-DPAC esters 8.17-8.21 as hygroscopic dihydrochloride 
salts (Scheme 8.4). The yields of these final compounds varied between 49% and 79%. The 
glycine (-)-8-OH-DPAC ester (8.17) was obtained with a purity of 86%, while the other 
esters had purities over 95%. Although compound 8.17 showed a lower purity, this prodrug 
would still be useful for investigations on chemical stability, because the hydrolysis rate is 
independent of prodrug concentration. Concluding, as the concentrations are still 
measurable, 86% purity is sufficient for this particular research. All overall yields and 
purities are presented in Table 8.1. 
 
Scheme 8.4 Synthesis of glycine (8.17), 1-aminocyclopropane-1-carboxylic acid (8.18), L-valine 
(8.19), L-isoleucine (8.20) and β-alanine (8.21) (-)-3,4-dihydro-3-(N,N-di-n-propylamino)-2H-1-
benzopyran-8-yl esters as 2HCl salts. Reagents and conditions: a) EDC, N-tert-Boc-amino acid, 




Table 8.1 Overall yields and purities (HPLC) of 8-OH-DPAC (8.10) and the prodrugs 8.17-8.21. The 
overall yields of the prodrugs were calculated with 8.10 as the starting material. 
Compound Prodrug Moiety Yield (%) Purity (%) 
(-)-8.10 - 3.5 100a 
(+)-8.10 - 4.4 100a 
8.17 Glycine 48 86 
8.18 1-Aminocyclopropane-1-carboxylic acid 38 98 
8.19 L-Valine 38 98 
8.20 L-Isoleucine 46 95 
8.21 β-Alanine 62 97 
a Purity determined on GCMS 
8.3 RESULTS 
8.3.1 Calculated log P and pKa values 
The calculated log P vales of 5-OH-DPAT and 8-OH-DPAC are 3.99 and 4.67, 
respectively. The calculated log P values of the mono amino acids prodrugs of 5-OH-DPAT 
are shown in Table 8.2. All 8-OH-DPAC prodrugs have calculated log P values which are 
±0.75 units lower than the log P values of the 5-OH-DPAT prodrugs. 
Table 8.2 Calculated log P and of mono amino acid esters of 5-OH-DPAT and 8-OH-DPAC 
prodrugs.4-6 
 5-OH-DPAT Prodrug 8-OH-DPAC Prodrug 
Prodrug Moiety Compound Cacluated Log Pa Compound Cacluated Log Pa 
Glycine 2.28 2.90 8.17 2.15 
1-Aminocyclopropane-1-
carboxylic acid 
2.30 3.37 8.18 2.66 
L-Valine 2.31 4.04 8.19 3.25 
L-Isoleucine 2.33 4.47 8.20 3.72 
β-Alanine 2.39 3.16 8.21 2.40 
8.3.2 Chemical Stability 
The hydrolysis rate constants (kobs) and half-lives (t1/2) of compounds 8.17-8.21 were 
obtained by measuring the remaining prodrug concentration in time during hydrolysis 
experiments in 5 mM citrate buffer pH 5 at 32 ºC which is the temperature of the skin in 
vivo. The hydrolysis rate plots of these experiments are presented in Figure 8.3. 




Figure 8.3 Pseudo first-order hydrolysis rate plots of 5-OH-DPAT prodrugs in citrate buffer pH 5 at 
32 ºC, based on the estimated half-lives presented in Table 8.3. The prodrugs are listed per group in 
sequence of descending half-life. 
Least-square equations, derived by correlating areas in HPLC chromatograms to known 
concentrations of prodrug were used for calculation of the residual prodrug concentration in 
the studied samples. The correlation coefficients of the standard curves were 0.99.  The 
observed first-order hydrolysis rate constants of the 5-OH-DPAT prodrugs were determined 
by plotting the logarithm of the remaining prodrug concentration as a function of time. The 
linear regression slopes of these plots (r2 ≥ 0.95) are related to the observed rate constant, 
kobs, and are given by:  time) vsC (log slope log
1 
e
kobs . The hydrolysis half-lives were 
then estimated by the equation: 
obsk
t 2ln2/1  . The half-lives of (-)-8-OH-DPAC prodrugs 
8.17-8.21 and reference (S)-5-OH-DPAT prodrugs 2.28, 2.30, 2.31, 2.33, 2.39 are 
presented in Table 8.3. 
Table 8.3 Estimated hydrolysis half-lives (t1/2) of prodrugs 2.28 (n=9), 2.30, 2.31, 2.33, 2.39 (n=6) 
and 8.17-8.21 (n=3).  
 0.005 M Citrate Buffer (pH 5)  
 (S)-5-OH-DPAT Prodrug (-)-8-OH-DPAC Prodrug  
Prodrug Moiety Compound Estimated 
t1/2 ± SEM 
(hours) 
Compound Estimated 






Glycine 2.28 20.7±0.3 8.17 6.3±0.05 3.3 
1-Aminocyclopropane-
1-carboxylic acid 
2.30 149.7±3.2 8.18 85.1±0.7 1.8 
L-Valine 2.31 53.1±1.6 8.19 23.5±2.3 2.3 
L-Isoleucine 2.33 72.7±2.8 8.20 65.1±2.6a 1.1 
β-Alanine 2.39 117.0±5.3 8.21 73.8±4.0a 1.6 
aThe mean t1/2 values of prodrugs 8.17-8.21 were significantly different, with exception of compound 




The half-lives of the 8-OH-DPAC prodrugs were all lower than the half-lives of their 
corresponding 5-OH-DPAT reference prodrugs. The hydrolysis rate of the 8-OH-DPAC 
prodrugs was a factor 1.1 to 3.3 times faster than the hydrolysis rate of the 5-OH-DPAT 
prodrugs (Table 8.3). The effect of 8-OH-DPAC as the leaving group during hydrolysis 
instead of 5-OH-DPAT was the most significant for the glycine ester prodrug 8.17 and the 
least significant for the L-isoleucine ester prodrug 8.20. The chemical stability trend for the 
5-OH-DPAT prodrugs was as follows: 1-aminocyclopropane-1-carboxylic acid (2.30, 150 
hrs) > β-alanine (2.39, 117 hrs) > L-isoleucine (2.33, 73 hrs) > L-valine (2.31, 53 hrs) > 
glycine (2.28, 21 hrs). The chemical stability trend for the 8-OH-DPAC prodrugs was as 
follows: 1-aminocyclopropane-1-carboxylic acid (8.18, 85 hrs) > β-alanine (8.21, 74 hrs) ≈ 
L-isoleucine (8.20, 65 hrs) > L-valine (8.19, 24 hrs) > glycine (8.17, 6 hrs). The difference 
between both trends was that the t1/2 found for the β-alanine 8-OH-DPAC prodrug was not 
significantly different than the t1/2 of the L-isoleucine 8-OH-DPAC prodrug. In contrast, the 
t1/2 of the β-alanine 5-OH-DPAT prodrug significantly differed from the t1/2 of the L-
isoleucine 5-OH-DPAT prodrug. 
8.4 DISCUSSION 
The calculated pKa values for the phenol group of 5-OH-DPAT and 8-OH-DPAC were 
11.29 and 10.68, respectively, which indicate that the alcohol group of 8-OH-DPAC is 
more acidic than the alcohol group of 5-OH-DPAT.19 Therefore 8-OH-DPAC may be the 
better leaving group in hydrolysis of ester prodrugs when compared to 5-OH-DPAT. Santos 
et al. showed for dipeptide ester prodrugs that a better leaving group led to faster hydrolysis 
of the ester bond.20 This property of 8-OH-DPAC could explain the shorter half-lives of the 
mono amino acid esters of 8-OH-DPAC compared to the prodrugs of 5-OH-DPAT. 
Generally the ascending half-life sequence of the 8-OH-DPAC prodrugs is equal to this 
sequence of the 5-OH-DPAT prodrugs. Apparently there is no significant difference in 
structural influence of the various amino acid residues in combination with this structural 
modification in the parent drug ring system on hydrolysis. The glycine prodrug was the 
most sensitive to the change in leaving group, while the L-isoleucine prodrug did not 
change much in half-life. Possibly steric hindrance of the s-butyl group of the L-isoleucine 
8-OH-DPAC prodrug makes the hydrolysis rate of the ester bond less susceptible to 
structural changes in the parent molecule. The glycine 8-OH-DPAC prodrug lacks a 
particular steric group, which may make the ester bond more liable to hydrolysis when 
varying to a better leaving group. 
In conclusion, the calculated lipophilicity of all 8-OH-DPAC prodrugs was lower than the 
calculated lipophilicity of the corresponding 5-OH-DPAT prodrugs. The improved physico-
chemical property of the prodrugs could be advantageous for the transdermal iontophoretic 
delivery. Especially, the 1-aminocyclopropane-1-carboxylic acid (8.18) and the β-alanine 
(8.21) prodrugs of 8-OH-DPAC showed suitable half-lives in combination with decreased 
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lipophilicity compared to the 5-OH-DPAT amino acid prodrugs. These candidates might be 
used for further in vitro and in vivo experiments to study the influence of the decreased 




The materials and analysis methods are described in section 2.4.1 
The e.e. of compounds (-)-8.6, (+)-8.6, (-)-8.10 and (+)-8.10 were determined on a HPLC system, 
which consisted of an ISCO Model 2360 Gradient Programmer, a Waters 510 HPLC Pump, a Waters 
486 Tunable Absorbance Detector and a HP 3396 Series II Integrator. The e.e. of compounds (-)-8.6 
and (+)-8.6 were determined at λ =254 nm on a Chiralcel OD column (250 x 4.6 mm) with an eluent 
mixture of 60% hexane and 40% ethanol with 0.1% triethylamine added and at a flow rate of 0.5 
ml/min. The e.e. of compounds (-)-8.10 and (+)-8.10 were determined at λ =275 nm on a Chiralcel 
OD column (250 x 10 mm) with an eluent mixture of 98.4% hexane and 1.6% ethanol with 0.1% 
triethylamine added and at a flow rate of 4.0 ml/min. 
8.5.1.2 Preparation of (-) -and (+)-4-(2-Chlorophenyl)-5,5-dimethyl-2-
hydroxy-1,3,2-dioxaphosphorinane 2-oxide (Chlocyphos). 
2,2-Dimethyl-1-(2-chlorophenyl)-1,3-propanediol (8.1).17 To a mixture of 2-chloro-benzaldehyde 
(40 mL, 0.36 mol) and isobutyraldehyde (65 mL, 0.72 mol) was added slowly 300 mL 
of a 6% solution of KOH (20 g, 0.36 mol in 30 mL H2O and 300 mL 95% ethanol). An 
exothermic reaction started and the solution turned yellow; when the temperature of 
the mixture had reached 50˚C, the flask was cooled by an ice bath. Usually the 
temperature rised to ca 70˚C and dropped again. When the temperature has fallen to 
ca. 55˚C, the remainer of the KOH solution was added rapidly (ca. 10 min). The reaction mixture was 
heated at 50-60˚C for 4 hours and then evaporated in vacuo. Water (500 mL) was added to the 
remaining residue, and this mixture was extracted with CH2Cl2 (3x100mL). The organic layer was 
washed with H2O (180 mL), dried over Na2SO4 and evaporated in vacuo to obtain the crude product 
as a yellow oil (52 g, 68%). IR (KBr cm-1) νmax 3366 (br), 2969, 1571, 1470, 1188, 1031; 1H NMR 
(200 MHz, CDCl3): δ 7.58-7.43 (m, 1H, ArH), 7.32-7.03 (m, 3H, ArH), 5.19 (s, 1H, CH), 3.52 and 
3.47 (AB-system, JAB= 10.9 Hz, 2H, CH2OH), 3.03 (br s, 2H, OH), 0.85 (s, 3H, CH3), 0.81 (s, 3H, 
CH3); 13C NMR (50 MHz, CDCl3): δ 139.4, 133.5, 129.8, 129.5, 128.8, 126.8, 77.0, 73.7, 72.6, 22.6, 
19.0. 
4-(2-Chlorophenyl)-5,5-dimethyl-2-hydroxy-1,3,2-dioxaphosphorinane 2-Oxide (8.2).17 A 
solution of POCl3 (24.6 mL, 0.27 mol) in 50 mL CH2Cl2 was added slowly to a warm (45 °C) 
solution of 8.1 (51.7 g, 0.24 mol) in 100 mL CH2Cl2 over 60 minutes. The yellow mixture was heated 
under reflux for 1.5 hours and then evaporated to give a brown residue. The residue was added in 15-




exothermic reaction is kept under control. After being stirred for 15 min the 
solution was cooled to ca. 60˚C and then acidified with 60 mL 37% HCl (aq) to 
precipitate the phosphoric acid. After the solution had cooled to room 
temperature, the product was sucked off, washed with water, washed with Et2O 
and dried in vacuo to obtain 8.2 as white solid material (47.7 g, 72%). A small 
amount was recrystallized from 96% EtOH for analytical purposes. IR (NaCl cm-1) νmax 2977, 1473, 
1441, 1313, 1037, 998; 1H NMR (200 MHz, CDCl3): δ 8.28 (br s, 1H, OH), 7.48-7.31 (m, 1H, ArH), 
7.23-7.03 (m, 3H, ArH), 5.65 (d, J=1.8 Hz, 1H, CH), 4.18 (d, J=11.2 Hz, 1H, CH2OPO3H), 3.69 (dd, 
J=19.4 Hz, 11.2 Hz, 1H, CH2OPO3H), 0.94 (s, 3H, CH3), 0.65 (s, 3H, CH3); 13C NMR (50 MHz, 
CDCl3): δ 134.2, 132.8, 130.3, 129.7, 129.4, 126.6, 82.1, 78.3, 37.5, 20.7, 17.9. 
(S)-(-)-4-(2-Chlorophenyl)-5,5-dimethyl-2-hydroxy-1,3,2-dioxaphosphorinane 2-Oxide ((S)-
8.2).17 A mixture of racemic 8.2 (47.7 g, 0.17 mol), (-)-(p-hydroxyphenyl)-glycine (28.9 g, 0.17 mol), 
290 ml of 96% EtOH, and 225 ml of H2O was heated to solution. The clear 
solution was allowed to cool to the room temperature while stirring. After the 
solution was stirred overnight, the salt was sucked off, washed with 100 ml of 
H2O and dried to give a white salt (48.6 g). This salt was stirred for 6 hours with 
50 ml of 37% HCl (aq) and 235 ml H2O, filtrated, washed with H2O and dried in 
vacuo to give (S)-(-)-8.2 as white solid material (17.7 g, 74%). m.p. 232 °C; 
    MeOH ,1.0 c 0.4621D  . 
(R)-(+)-4-(2-Chlorophenyl)-5,5-dimethyl-2-hydroxy-1,3,2-dioxaphosphorinane 2-Oxide ((R)-
8.2).17 The filtrate from the crystallization of (S)-8.2 (including the water used 
for washing) was stirred overnight with 75 ml of 37% HCl (aq). The crystals 
were filtrated, washed with H2O and dried in vacuo to give (R)-(+)-8.2 as white 
solid material (16.9 g, 71%). m.p. 220-231 °C;      ,1.0  0.4621 MeOHcD  . 
8.5.1.3 Synthesis of (-)-8-OH-DPAC 
3-Cyano-8-methoxy-2H-1-benzopyran (8.3).16 A mixture of 2-hydroxy-3-methoxybenzaldehyde (25 
g, 0.16 mol), acrylonitrile (54.5 mL, 0.82 mol) and 1,4-diazabicyclo[2.2.2]octane (5.2 
g, 0.046 mol) was refluxed overnight. The reaction mixture was diluted with Et2O, 
washed with 1N NaOH, 1N HCl (aq), brine and dried over Na2SO4. After evaporation 
in vacuo, the residue was recrystallized from MeOH to afford 8.3 as yellow crystals 
(30.6 g, 89%). Purity: 100% (GCMS); IR (KBr, cm-1) νmax 2204, 1624, 1576, 1482, 
1275, 1222, 1097; 1H NMR (200 MHz, CDCl3): δ 7.41 (s, 1H, H4), 6.97-6.87 (m, 2H, ArH),6.78-6.67 
(m, 1H, ArH), 4.85 (s, 2H, OCH2), 3.87 (s, 3H, OCH3); 13C NMR (50 MHz, CDCl3): δ 148.3, 139.1, 
122.5, 120.9, 120.5, 116.6, 115.5, 103.7, 64.8, 56.4; EI-MS m/z 187 (M)+. 
3-Carboxy-8-methoxy-2H-1-benzopyran (8.4).16 A suspension of 8.3 (28 g, 0.15 mol) in 10% 
NaOH (450 mL) was heated to solution and refluxed for 6 hours. The reaction 
mixture was acidified with 37% HCl (aq) and the precipitate was filtrated and 
dried in vacuo for 3 days to yield 8.4 as yellow solid material (30.9 g, 100%). 
Purity: 100% (GCMS); IR (KBr, cm-1) νmax 1671, 1483, 1342, 1271; 1H NMR 
(200 MHz, d6-DMSO): δ 7.41 (s, 1H, H4), 7.11-6.84 (m, 3H, ArH), 4.87 (s, 2H, 
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OCH2), 3.75 (s, 3H, OCH3); 13C NMR (50 MHz, d6-DMSO): δ 166.1, 148.2, 133.2, 124.2, 122.2, 
122.1, 121.5, 115.7, 102.9, 64.7, 56.4; EI-MS m/z 206 (M)+. 
8-Methoxy-3,4-dihydro-2H-1-benzopyran-3-one (8.5).16 A solution of diphenyl phosphoryl azide 
(25 g, 0.09 mol) in 100 mL toluene was added dropwise to a mixture of 8.4 (18.7 g, 
0.09 mol), TEA (14.5 mL, 0.10 mol) and CH2Cl (180 mL) while heating slowly to 
distill the CH2Cl2. At 60 °C an additional 100 mL toluene was added and subsequently 
the reaction mixture was heated for 1.5 hours at 85 °C. Then, 145 mL of 6N HCl (aq) 
was added dropwise and the mixture was refluxed for 2 hours. After attaining room temperature, the 
organic layer was separated, washed with NaHCO3 (sat), brine, dried over MgSO4, evaporated in 
vacuo to afford 8.5 as a brown-yellow oil (13 g, 81%). A small sample was purified on column 
chromatography (SiO2, Et2O:Hexane) for analytical purposes. For synthetic uses, the crude product 
was used without purification in the subsequent step. Purity>95% (GCMS); IR (NaCl, cm-1) νmax 3375 
(br), 2927, 1728, 1662, 1581, 1484, 1264, 1088; 1H NMR (200 MHz, CDCl3): δ 6.90 (t, J=7.8 Hz, 
1H, ArH), 6.73 (d,  J=7.1 Hz, 1H, ArH), 6.62 (d, J=7.6 Hz, 1H, ArH), 4.36 (s, 2H, 2-OCH2), 3.80 (s, 
3H, OCH3), 3.51 (s, 2H, 4-CH2); 13C NMR (50 MHz, CDCl3): δ 207.8, 149.5, 143.8, 123.6, 122.9, 
120.7, 111.0, 73.3, 56.2, 41.0; EI-MS m/z 178(M)+. 
8-methoxy-3,4-dihydro-3-(benzylamino)-2H-1-benzopyran (8.6).13 Glacial acetic acid (25.5 mL, 
0.42 mol) was added in portions to a mixture of 8.5 (13 g, 0.073 mol) and 
benzylamine (15.6 g, 0.15 mol) in 65 mL (THF). After stirring for 30 minutes 
at room temperature, NaBH3CN (5.0 g, 0.08 mol) was added portionwise and 
the reaction mixture was stirred overnight. The solvent was evaporated in 
vacuo and the residue was dissolved in CH2Cl2 (50 mL), washed with brine 
(3x50 mL), dried over MgSO4. After filtration, evaporation in vacuo and 
purification by column chromatography (SiO2 (NH3), Hexane/Et2O=1:2 to 
100% Et2O, gradient) compound 8.6 was obtained as an orange-yellow oil (8.3 g, 42%). Purity: 100% 
(GCMS); IR (KBr, cm-1) νmax 2930, 2833, 1584, 1485, 1265, 1212, 1083; 1H NMR (200 MHz, 
CDCl3): δ 7.37-7.21 (m, 5H, C6H5), 6.86-6.64 (m, 3H, ArH), 4.35-4.20 (m, 1H, H2), 4.10-3.96 (m, 
1H, H2), 3.92 (s, 2H, CH2C6H5), 3.86 (s, 3H, OCH3), 3.28-3.08 (m, 1H, H3), 3.07-2.91 (m, 1H, H4), 
2.81-2.62 (m, 1H, H4); 13C NMR (50 MHz, CDCl3): δ 148.4, 143.8, 140.3, 128.7, 128.3, 127.4, 122.3, 
121.4, 120.5, 109.5, 69.2, 56.0, 51.3, 49.4, 32.2; EI-MS m/z 269 (M)+. 
(+)-8-methoxy-3,4-dihydro-3-(benzylamino)-2H-1-benzopyran ((+)-8.6). (-)-Chlocyphos (13.3 g, 
0.048 mol) and racemic 8-methoxy-3,4-dihydro-3-(benzylamino)-2H-1-
benzopyran (13.0 g, 0.048 mol) were added together and were recrystallized 3 
times from 96% EtOH (150 mL, 90 mL, 68 mL) to give the chlocyphos-salt as 
white needles. The salt was converted to the free amine and (+)-8.6 was 
afforded as a colourless oil (2.0 g, 31%).     MeOH,3.0 c 47.827D  ; 
e.e.=96.8% (HPLC). 
(-)-8-methoxy-3,4-dihydro-3-(benzylamino)-2H-1-benzopyran ((-)-8.6). The motherliquors of the 
recrystallizations of compound (+)-8.6 were collected, evaporated in vacuo and converted to the free 
amine. (+)-Chlocyphos (9.1 g, 0.033 mol) was added to the resultant oil (8.9 g, 0.033 mol) and the 




salt was obtained as white needles. The salt was converted to the free amine and yielded (-)-8.6 as a 




(-)-8-methoxy-3,4-dihydro-3-(N-benzyl-N-propyl-amino)-2H-1-benzopyran ((-)-8.7). A mixture 
of (+)-8.6 (2.0 g, 7.4 mmol), K2CO3 (3.1 g, 22.3 mmol) were suspended in 25 mL 2-butanone. 1-
Iodopropane (2.0 mL, 20.8 mmol) was added while the mixture was heated to 
reflux under nitrogen atmosphere. After refluxing for 3 days, the solvent was 
evaporated in vacuo and purified on column chromatography (SiO2 (NH3), 
Hexane/Et2O=1:1) to yield (-)-8.7 as a light yellow oil (1.7 g, 73%). Purity: 
100% (GCMS);     MeOH,1.1 c 1.1826D  ; IR (NaCl, cm-1) νmax 2958, 2932, 
1584, 1485, 1262, 1213; 1H NMR (200 MHz, CDCl3): δ 7.42-7.15 (m, 5H, 
C6H5), 6.88-6.75 (m, 1H, ArH), 6.74-6.63 (m, 2H, ArH), 4.38-4.52 (m, 1H, H2), 4.01-3.89 (m, 1H, 
H2), 3.85 (s, 3H, OCH3), 3.76 (s, 2H, CH2C6H5), 3.35-3.15 (m, 1H, H3), 2.98-2.80 (m, 2H, H4), 2.65-
2.47 (m, 2H, N(CH2CH2CH3), 1.65-1.38 (m, 2H, N(CH2CH2CH3), 0.88 (t, J=7.4 Hz, 3H, 
N(CH2CH2CH3); 13C NMR (50 MHz, CDCl3): δ 148.5, 144.0, 140.7, 128.5, 127.1, 122.9, 122.2, 
120.3, 109.2, 68.2, 56.0, 55.1, 52.5, 52.4, 28.1, 21.6, 11.9; EI-MS m/z 311 (M)+. 
(+)-8-methoxy-3,4-dihydro-3-(N-benzyl-N-propyl-amino)-2H-1-benzopyran ((+)-8.7). Similar to 
the procedure described for the synthesis of (-)-8.7. Compound (+)-8.7 was 
obtained from (-)-8.6 as a light yellow oil (1.6 g, 81%). Purity: 100% (GCMS); 
IR (NaCl, cm-1) νmax 2957, 2933, 1584, 1485, 1262, 1212, 1083; 1H NMR (200 
MHz, CDCl3): δ 7.44-7.14 (m, 5H, C6H5), 6.89-6.75 (m, 1H, ArH), 6.89-6.63 (m, 
2H, ArH), 4.52-4.36 (m, 1H, H2), 4.01-3.89 (m, 1H, H2), 3.85 (s, 3H, OCH3), 
3.76 (s, 2H, CH2C6H5), 3.35-3.13 (m, 1H, H3), 2.99-2.76 (m, 2H, H4), 2.64-2.43 
(m, 2H, N(CH2CH2CH3), 1.60-1.38 (m, 2H, N(CH2CH2CH3), 0.88 (t, J=7.2 Hz, 3H, N(CH2CH2CH3); 
13C NMR (50 MHz, CDCl3): δ 148.5, 143.9, 140.7, 128.5, 127.1, 122.9, 122.2, 120.2, 109.2, 68.2, 
56.0, 55.1, 52.5, 52.4, 28.1, 21.6, 11.9; EI-MS m/z 311 (M)+. 
(-)-8-methoxy-3,4-dihydro-3-(N-n-propylamino)-2H-1-benzopyran ((-)-8.8). Compound (+)-8.7 
(1.6 g, 5.1 mmol) was dissolved in 100 mL EtOH 100% and Pd/C 10% (0.51 g) 
was added under nitrogen atmosphere. The solution was transferred to a Parr 
flask and hydrogenolyzed at room temperature under 3.5 bar H2 atmosphere. 
After completion of the reaction the mixture was filtrated, evaporated in vacuo 
and purified by column chromatography (SiO2, CH2Cl2/MeOH=10:1) to yield (-)-
8.8 as a light yellow oil (1.0 g, 90%). Purity: 100% (GCMS);     MeOH,0.1 c 3.2826D  ; IR (NaCl, 
cm-1) νmax 2956, 2931, 1584, 1484, 1264, 1212, 1097, 1079; 1H NMR (400 MHz, CDCl3): δ 6.80 (t, 
J=8.0 Hz, 1H, ArH), 6.71 (d, J=7.3 Hz, 1H, ArH), 6.66 (d, J=7.7 Hz, 1H, ArH), 4.35-4.23 (m, 1H, 
H2), 4.03-3.93 (m, 1H, H2), 3.85 (s, 3H, OCH3), 3.20-3.08 (m, 1H, H3), 3.07-2.93 (m, 1H, H4), 2.77-
2.58 (m, 3H, H4, N(CH2CH2CH3), 1.60-1.40 (m, 3H, NH, N(CH2CH2CH3), 0.92 (t, J=7.3 Hz, 3H, 
N(CH2CH2CH3); 13C NMR (50 MHz, CDCl3): δ 148.4, 143.8, 122.2, 121.5, 120.5, 109.3, 69.4, 56.0, 
50.3, 49.3, 32.3, 23.7, 12.0; EI-MS m/z 221 (M)+. 
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(+)-8-methoxy-3,4-dihydro-3-(N-n-propylamino)-2H-1-benzopyran ((+)-8.8). Similar to the 
procedure described for the synthesis of (-)-8.8. Compound (+)-8.8 was obtained 
from (-)-8.7 as a light yellow oil (1.1 g, 91%). Purity>98% (GCMS); 
    MeOH,1.1 c 0.2726D  ; IR (NaCl, cm-1) νmax 2957, 2930, 1584, 1485, 1264, 
1212, 1098, 1079; 1H NMR (400 MHz, CDCl3): δ 6.80 (t, J=7.9 Hz, 1H, ArH), 
6.70 (d, J=8.1 Hz, 1H, ArH), 6.66 (d, J=7.7 Hz, 1H, ArH), 4.32-4.23 (m, 1H, H2), 3.97 (dd, J=10.6 
Hz; 7.3 Hz, 1H, H2), 3.85 (s, 3H, OCH3), 3.18-3.09 (m, 1H, H3), 3.05-2.95 (m, 1H, H4), 2.76-2.60 (m, 
3H, H4, N(CH2CH2CH3), 1.58-1.44 (m, 3H, NH, N(CH2CH2CH3), 0.92 (t, J=7.3 Hz, 3H, 
N(CH2CH2CH3); 13C NMR (50 MHz, CDCl3): δ 148.4, 143.8, 122.2, 121.5, 120.5, 109.3, 69.4, 56.0, 
50.3, 49.3, 32.3, 23.7, 12.0; EI-MS m/z 221 (M)+. 
(-)-8-methoxy-3,4-dihydro-3-(N,N-di-n-propylamino)-2H-1-benzopyran ((-)-8.9). TEA (0.75 mL, 
5.3 mmol) was added to a cooled solution of (+)-8.8 (1.06 g, 4.8 mmol) in dry 
toluene (10 mL) under nitrogen atmosphere. Propionylchloride (0.5 mL, 5.3 
mmol) was added and the reaction mixture was stirred for 30 minutes. The TEA-
HCl salt was removed by filtration and the solvent was evaporated in vacuo. The 
resultant oil was dissolved in dry THF (8 mL) under nitrogen atmosphere and a 
suspension of LiAlH4 (0.33 g, 7.2 mmol) in dry THF (8 mL) was added and the 
mixture was refluxed for 1 hour. After addition of EtOAc (5 mL), diluted H2SO4 was added until 
precipitation at pH 4. The mixture was filtrated, basified with 1N NaOH (20 mL) and extracted with 
EtOAc (3x50 mL). The combined organic layers were washed with brine, dried on MgSO4, 
evaporated in vacuo and purified on column chromatography (SiO2, CH2Cl2/MeOH=40:1, 1% TEA) 
to yield (-)-8.9 as a colourless oil (1.09 g, 80%). Intermediate amide: EI-MS m/z 277 (M)+. Final 
compound: Purity: 100% (GCMS);     MeOH,0.1 c 8.526D  ; IR (NaCl, cm-1) νmax 2957, 1585, 
1485, 1263, 1213, 1084; 1H NMR (200 MHz, CDCl3): δ 6.85-6.74 (m, 1H, ArH), 6.73-6.62 (m, 2H, 
ArH), 4.50-4.35 (m, 1H, H2), 3.85 (s, 3H, OCH3), 3.92-3.76 (m, 1H, H2), 3.27-3.08 (m, 1H, H3), 2.85 
(d, J=8.5 Hz, 2H, H4), 2.59-2.42 (m, 4H, N(CH2CH2CH3)2), 1.58-1.33 (m, 4H, N(CH2CH2CH3)2), 
0.87 (t, J=7.4 Hz, 6H, N(CH2CH2CH3)2); 13C NMR (50 MHz, CDCl3): δ 148.5, 144.0, 122.9, 122.2, 
120.3, 109.2, 68.5, 56.0, 53.4, 52.9, 28.6, 21.9, 12.0; EI-MS m/z263 (M)+. 
(+)-8-methoxy-3,4-dihydro-3-(N,N-di-n-propylamino)-2H-1-benzopyran ((+)-8.9). Similar to the 
procedure described for the synthesis of (-)-8.9. Compound (+)-8.9 was obtained 
from (-)-8.8 as a very light yellow oil (0.89 g, 76%). %). Intermediate amide: EI-
MS m/z 277 (M)+. Final compound: Purity: 100% (GCMS); 
    MeOH,0.1 c 6.526D  ; IR (NaCl, cm-1) νmax 2955, 1585, 1485, 1263, 1213, 
1084; 1H NMR (200 MHz, CDCl3): δ 6.87-6.75 (m, 1H, ArH), 6.74-6.62 (m, 2H, 
ArH), 4.43 (dd, J=10.3 Hz; 3.2 Hz, 1H, H2), 3.85 (s, 3H, OCH3), 3.92-3.75 (m, 
1H, H2), 3.28-3.08 (m, 1H, H3), 2.85 (d, J=8.2 Hz, 2H, H4), 2.59-2.43 (m, 4H, N(CH2CH2CH3)2), 1.46 
(sextet, J=7.3 Hz, 4H, N(CH2CH2CH3)2), 0.87 (t, J=7.4 Hz, 6H, N(CH2CH2CH3)2); 13C NMR (50 
MHz, CDCl3): δ 148.5, 144.0, 122.9, 122.2, 120.3, 109.2, 68.5, 56.0, 53.4, 52.9, 28.6, 21.9, 12.0; EI-
MS m/z 263 (M)+. 
(-)-8-hydroxy-3,4-dihydro-3-(N,N-di-n-propylamino)-2H-1-benzopyran HBr salt ((-)-8.10). A 
mixture of freshly distilled 48% HBr (5 mL) and (+)-8.9 (1.0 g, 3.8 mmol) was refluxed for 4 hours 




resultant orange solid material was recrystallized from 100% EtOH to afford the 
HBr salt of (-)-8.10 as white crystals (1.0 g, 81%). Purity: 100% (GCMS). 
   327D CHCl ,6.0 c 5.74  ; e.e.>98% (HPLC); IR (KBr, cm-1) νmax 3133 (br), 
2934, 2647, 2525, 1586, 1502, 1474, 1338, 1274, 1217, 1187, 1000; 1H NMR 
(400 MHz, CD3OD): δ 6.80 (t, J=7.9 Hz, 1H, ArH), 6.68 (d, J=8.1 Hz, 2H, ArH), 
4.55 (ddd, J=11.0 Hz; 5.5 Hz; 1.5 Hz, 1H, H2), 4.48-4.37 (m, 1H, H2), 4.05-3.94 
(m, 1H, H3), 3.36 (dd, J=7.6 Hz; 6.2 Hz, 1H, H4), 3.32-3.08 (m, 5H, H4, N(CH2CH2CH3)2), 1.91-1.69 
(m, 4H, N(CH2CH2CH3)2), 1.02 (t, J=7.3 Hz, 6H, N(CH2CH2CH3)2); 13C NMR (50 MHz, CD3OD): δ 
145.8, 142.2, 122.0, 120.1, 119.2, 114.2, 64.1, 56.4, 53.1, 25.4, 17.9, 10.1; EI-MS m/z249 (M)+; Anal. 
Calcd for C15H24NO2Br: C, 54.55; H, 7.32; N, 4.24. Found: C, 54.54; H, 7.35; N, 4.27. 
(+)-8-hydroxy-3,4-dihydro-3-(N,N-di-n-propylamino)-2H-1-benzopyran HBr salt ((+)-8.10). 
Similar to the procedure described for the synthesis of (-)-8.10. The HBr salt of 
compound (+)-8.10 was obtained from (-)-8.9 as white crystals (0.98 g, 89%). 
Purity: 100% (GCMS).    327D CHCl ,6.0 c 6.74  ; e.e.=93.0% (HPLC); IR 
(KBr, cm-1) νmax 3131 (br), 2934, 2648, 2525, 1586, 1502, 1474, 1338, 1274, 
1217, 1187, 1000; 1H NMR (400 MHz, CD3OD): δ 6.79 (t, J=7.9 Hz, 1H, ArH), 
6.68 (d, J=8.3 Hz, 2H, ArH), 4.55 (ddd, J=10.8 Hz; 5.3 Hz; 1.3 Hz, 1H, H2), 4.43 (dd, J=12.1 Hz; 
1.83 Hz, 1H, H2), 4.05-3.95 (m, 1H, H3), 3.36 (dd, J=7.6 Hz; 6.2 Hz, 1H, H4), 3.32-3.09 (m, 5H, H4, 
N(CH2CH2CH3)2), 1.91-1.66 (m, 4H, N(CH2CH2CH3)2), 1.02 (t, J=7.3 Hz, 6H, N(CH2CH2CH3)2); 
13C NMR (50 MHz, CD3OD): δ 145.8, 142.2, 122.0, 120.1, 119.2, 114.2, 64.1, 56.4, 53.1, 25.4, 17.9, 
10.1; EI-MS m/z249 (M)+; Anal. Calcd for C15H24NO2Br: C, 54.55; H, 7.32; N, 4.24. Found: C, 
54.52; H, 7.34; N, 4.28. 
8.5.1.4 General procedure for preparation of protected amino acid (-)-
3,4-dihydro-3-(N,N-di-n-propylamino)-2H-1-benzopyran-8-yl esters 
8.12-8.16 
The preparation of the protected amino acid (-)-3,4-dihydro-3-(di-n-propylamino)-2H-1-benzopyran-
8-yl esters from (-)-8.10 was similar to the preparation of the protected amino acid (S)-2-(di-n-propyl-
amino)tetralin-5-yl esters from (-)-2.12 described in section 2.5.5. 
N-tert-Boc-glycine (-)-3,4-dihydro-3-(N,N-di-n-propylamino)-2H-1-benzopyran-8-yl ester (8.12). 
Yield: 71%; IR (NaCl, cm-1) νmax 3408 (br), 2957, 1778, 1719, 
1481, 1366, 1254, 1152; 1H NMR (400 MHz, CDCl3): δ 6.97 (d, 
J=7.3 Hz, 1H, ArH), 6.90-6.78 (m, 2H, ArH), 5.13 (br s, 1H, NH), 
4.31 (dd, J=10.3 Hz; 2.9 Hz, 1H, H2), 4.20 (d, J=5.1 Hz, 2H, α-
CH2), 3.78 (t, J=10.3 Hz, 1H, H2), 3.23-3.12 (m, 1H, H3), 2.86 (d, 
J=8.1 Hz, 2H, H4), 2.57-2.41 (m, 4H, N(CH2CH2CH3)2), 1.53-1.34 
(m, 4H, N(CH2CH2CH3)2), 1.46 (s, 9H, OC(CH3)3), 0.87 (t, J=7.3 
Hz, 6H, N(CH2CH2CH3)2); 13C NMR (50 MHz, CDCl3): δ 168.9, 155.8, 146.1, 138.7, 128.1, 124.2, 
120.5, 120.3, 80.3, 68.4, 53.2, 52.9, 42.5, 28.5, 28.3, 22.0, 11.9; HR-MS m/z Calcd. for C22H35N2O5 
407.25405 (M+H)+, found 407.25397 (M+H)+. 
N-tert-Boc-1-aminocyclopropane-1-carboxylic acid (-)-3,4-dihydro-3-(N,N-di-n-propylamino)-
2H-1-benzopyran-8-yl ester (8.13). Yield: 62%; IR (NaCl, cm-1) νmax 3358 (br), 2964, 1757, 1723, 
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1481, 1253, 1133; 1H NMR (400 MHz, CDCl3): δ 6.97-6.88 (m, 1H, 
ArH), 6.87-6.74 (m, 2H, ArH), 5.31 (br s, 1H, NH), 4.34-4.25 (m, 1H, 
H2), 3.76 (t, J=10.3 Hz, 1H, H2), 3.23-3.10 (m, 1H, H3), 2.84 (d, J=8.4 
Hz, 2H, H4), 2.57-2.37 (m, 4H, N(CH2CH2CH3)2), 1.80-1.65 (m, 2H, β-
CH2), 1.56-1.33 (m, 4H, N(CH2CH2CH3)2), 1.45 (s, 9H, OC(CH3)3), 
1.32-1.18 (m, 2H, β-CH2), 0.86 (t, J=7.3 Hz, 6H, N(CH2CH2CH3)2); 
13C NMR (50 MHz, CDCl3): δ 171.6, 156.2, 146.3, 139.1, 127.8, 124.0, 120.7, 120.3, 80.3, 68.4, 
53.2, 52.9, 34.7, 28.5, 28.2, 22.0, 18.3, 11.9; HR-MS m/z Calcd. for C24H37N2O5 433.2697 (M+H)+, 
found 433.26929 (M+H)+. 
N-tert-Boc-L-valine (-)-3,4-dihydro-3-(N,N-di-n-propylamino)-2H-1-benzopyran-8-yl ester 
(8.14). Yield: 78%; IR (NaCl, cm-1) νmax 3442 (br), 2965, 1765, 1713, 1483, 1367, 1254, 1174, 1027; 
1H NMR (400 MHz, CDCl3): δ 6.99-6.91 (m, 1H, ArH), 6.87-6.77 
(m, 2H, ArH), 5.10 (d, J=9.2 Hz, 1H, NH), 4.50 (dd, J=9.2 Hz; 4.4 
Hz, 1H, α-CH), 4.26 (dd, J=10.5 Hz; 3.5 Hz, 1H, H2), 3.85-3.73 (m, 
1H, H2), 3.24-3.12 (m, 1H, H3), 2.85 (d, J=7.3 Hz, 2H, H4), 2.56-
2.43 (m, 4H, N(CH2CH2CH3)2), 2.42-2.28 (m, 1H, β-CH), 1.54-1.32 
(m, 4H, N(CH2CH2CH3)2), 1.46 (s, 9H, OC(CH3)3), 1.05 (d, J=3.9 
Hz, 3H, γ-CH3), 0.96 (d, J=6.6 Hz, 3H, γ-CH3), 0.87 (t, J=7.3 Hz, 
6H, N(CH2CH2CH3)2); 13C NMR (50 MHz, CDCl3): δ 170.7, 155.9, 146.2, 138.8, 128.0, 124.1, 
120.3, 80.0, 68.2, 58.8, 53.2, 52.9, 31.7, 28.6, 28.1, 22.0, 19.3, 17.5, 11.9; HR-MS m/z Calcd. for 
C25H41N2O5 449.301 (M+H)+, found 449.30093 (M+H)+. 
N-tert-Boc-L-isoleucine (-)-3,4-dihydro-3-(N,N-di-n-propylamino)-2H-1-benzopyran-8-yl ester 
(8.15). Yield: 72%; IR (NaCl, cm-1) νmax 3445 (br), 2967, 1765, 1714, 1482, 1254, 1159; 1H NMR 
(400 MHz, CDCl3): δ 6.98-6.90 (m, 1H, ArH), 6.87-6.77 (m, 2H, 
ArH), 5.11 (d, J=9.2 Hz, 1H, NH), 4.54 (dd, J=9.2 Hz; 4.4 Hz, 1H, 
α-CH), 4.25 (dd, J=10.3 Hz; 3.3 Hz, 1H, H2), 3.86-3.74 (m, 1H, H2), 
3.24-3.12 (m, 1H, H3), 2.86 (d, J=7.7 Hz, 2H, H4), 2.58-2.40 (m, 4H, 
N(CH2CH2CH3)2), 2.13-1.98 (m, 1H, β-CH), 1.70-1.56 (m, 1H, γ-
CH2), 1.52-1.34 (m, 4H, N(CH2CH2CH3)2), 1.33-1.18 (m, 1H, γ-
CH2), 1.46 (s, 9H, OC(CH3)3), 1.06 (d, J=7.0 Hz, 3H, γ'-CH3), 0.98 
(t, J=7.5 Hz, 3H, δ-CH3), 0.87 (t, J=7.3 Hz, 6H, N(CH2CH2CH3)2); 13C NMR (50 MHz, CDCl3): δ 
170.6, 155.8, 146.2, 138.7, 128.0, 124.1, 120.6, 120.3, 80.0, 68.2, 58.3, 53.2, 52.9, 38.4, 28.6, 28.1, 
25.0, 22.0, 15.7, 12.1, 11.9; HR-MS m/z Calcd. for C26H43N2O5 463.31665 (M+H)+, found 463.31616 
(M+H)+. 
N-tert-Boc-β-alanine (-)-3,4-dihydro-3-(N,N-di-n-propylamino)-2H-1-benzopyran-8-yl ester 
(8.16). Yield: 79%; IR (NaCl, cm-1) νmax 3384 (br), 2960, 1762, 1716, 1481, 1252, 1164; 1H NMR 
(400 MHz, CDCl3): δ 6.98-6.93 (m, 1H, ArH), 6.89-6.80 (m, 2H, ArH), 
5.41 (br s, 1H, NH), 4.36 (dd, J=10.3 Hz; 3.3 Hz, 1H, H2), 3.82 (t, 
J=10.3 Hz, 1H, H2), 3.58-3.47 (m, 2H, β-CH2), 3.25-3.13 (m, 1H, H3), 
2.86 (d, J=8.1 Hz, 2H, H4), 2.76 (t, J=5.9 Hz, 2H, α-CH2), 2.57-2.40 
(m, 4H, N(CH2CH2CH3)2), 1.54-1.35 (m, 4H, N(CH2CH2CH3)2), 1.45 




(50 MHz, CDCl3): δ 170.6, 156.1, 145.9, 138.9, 128.0, 124.2, 120.7, 120.5, 79.5, 68.5, 53.1, 52.9, 
36.6, 35.2, 28.7, 28.1, 22.1, 11.9; HR-MS m/z Calcd. for C23H37N2O5 421.2697 (M+H)+, found 
421.26953 (M+H)+. 
8.5.1.5 General deprotection procedure for the preparation of the 
amino acid (-)-3,4-dihydro-3-(N,N-di-n-propylamino)-2H-1-
benzopyran-8-yl ester hydrochlorides 8.17-8.21 
The preparation of the amino acid (-)-3,4-dihydro-3-(di-n-propylamino)-2H-1-benzopyran-8-yl ester 
hydrochlorides was similar to the preparation of the amino acid (S)-2-(di-n-propyl-amino)tetralin-5-yl 
ester hydrochlorides described in section 2.5.6. 
Glycine (-)-3,4-dihydro-3-(N,N-di-n-propylamino)-2H-1-benzopyran-8-yl ester 2HCl salt (8.17). 
Yield: 68%; Purity: 86% (HPLC); IR (KBr, cm-1) νmax 3431 (br), 2970, 
2883, 2631, 2520, 1778, 1484, 1257, 1188; 1H NMR (400 MHz, CD3OD): δ 
7.19 (dd, J=7.3 Hz; 1.1 Hz, 1H, ArH), 7.10-6.97 (m, 2H, ArH), 4.61 (dd, 
J=12.1 Hz; 4.8 Hz, 1H, H2), 4.45 (dd, J=12.2 Hz; 2.3 Hz, 1H, H2), 4.18 (s, 
2H, α-CH2), 4.10-4.00 (m, 1H, H3), 3.44 (dd, J=17.8 Hz; 6.8 Hz, 1H, H4), 
3.37-3.08 (m, 5H, H4, N(CH2CH2CH3)2), 1.89-1.70 (m, 4H, 
N(CH2CH2CH3)2), 1.00 (t, J=7.3 Hz, 6H, N(CH2CH2CH3)2); 13C NMR (50 
MHz, CD3OD): δ 165.7, 145.4, 138.5, 127.9, 121.7, 121.0, 120.9, 64.3, 55.6, 53.2, 52.9, 39.8, 24.6, 
18.1, 18.0, 10.1; HR-MS m/z Calcd. for C18H29N2O3 307.20162 (M+H)+, found 307.20515 (M+H)+. 
1-Aminocyclopropane-1-carboxylic acid (-)-3,4-dihydro-3-(N,N-di-n-propylamino)-2H-1-
benzopyran-8-yl ester 2HCl salt (8.18). Yield: 62%; Purity (HPLC): 98%; IR (KBr, cm-1) νmax 3424 
(br), 2970, 2880, 2649, 1762, 1484, 1165; 1H NMR (400 MHz, CD3OD): δ 
7.19 (dd, J=7.0 Hz; 2.2 Hz, 1H, ArH), 7.07-6.95 (m, 2H, ArH), 4.59 (dd, 
J=12.1 Hz; 4.4 Hz, 1H, H2), 4.46 (dd, J=12.1 Hz; 2.2 Hz, 1H, H2), 4.10-
3.99 (m, 1H, H3), 3.47-3.36 (m, 1H, H4), 3.35-3.10 (m, 5H, H4, 
N(CH2CH2CH3)2), 1.92-1.70 (m, 6H, β-CH2, N(CH2CH2CH3)2), 1.64-1.54 
(m, 2H, β-CH2), 1.01 (t, J=7.2 Hz, 6H, N(CH2CH2CH3)2); 13C NMR (50 
MHz, CD3OD): δ 167.9, 145.4, 138.4, 127.9, 121.7, 121.0, 120.9, 64.4, 55.6, 53.3, 34.2, 24.6, 18.1, 
13.8, 10.1; HR-MS m/z Calcd. for C19H29N2O3 333.21727 (M+H)+, found 333.21725 (M+H)+. 
L-Valine (-)-3,4-dihydro-3-(N,N-di-n-propylamino)-2H-1-benzopyran-8-yl ester 2HCl salt 
(8.19). Yield: 49%; Purity: 98% (HPLC); IR (KBr, cm-1) νmax 3412 (br), 2971, 2880, 2631, 1768, 
1484, 1257, 1189, 1162; 1H NMR (400 MHz, CD3OD): δ 7.21 (dd, J=7.0 Hz; 
2.2 Hz, 1H, ArH), 7.10-6.97 (m, 2H, ArH), 4.60 (dd, J=11.9 Hz; 5.0 Hz, 1H, 
H2), 4.47 (dd, J=12.1 Hz; 2.2 Hz, 1H, H2), 4.27 (d, J=4.8 Hz, 1H, α-CH), 
4.13-4.02 (m, 1H, H3), 3.45 (dd, J=17.6 Hz; 6.6 Hz, 1H, H4), 3.38-3.10 (m, 
5H, H4, N(CH2CH2CH3)2), 2.57-2.43 (m, 1H, β-CH), 1.93-1.72 (m, 4H, 
N(CH2CH2CH3)2), 1.23 (d, J=4.8 Hz, 3H, γ-CH3), 1.22 (d, J=4.8 Hz, 3H, γ-
CH3), 1.01 (td, J=7.3 Hz; 2.9 Hz, 6H, N(CH2CH2CH3)2); 13C NMR (50 MHz, CD3OD): δ 166.9, 
145.3, 138.3, 128.1, 121.8, 121.1, 120.9, 64.3, 58.2, 55.6, 53.4, 52.9, 30.1, 24.6, 18.1, 17.2, 17.1, 
10.1; HR-MS m/z Calcd. for C20H33N2O3 349.24857 (M+H)+, found 349.24854 (M+H)+. 
L-Isoleucine (-)-3,4-dihydro-3-(N,N-di-n-propylamino)-2H-1-benzopyran-8-yl ester 2HCl salt 
(8.20). Yield: 64%; Purity: 95% (HPLC); IR (KBr, cm-1) νmax 3403 (br), 2970, 2877, 2629, 1769, 
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1484, 1258, 1184, 1164; 1H NMR (400 MHz, CD3OD): δ 7.21 (dd, J=6.6 
Hz; 2.2 Hz, 1H, ArH), 7.10-6.99 (m, 2H, ArH), 4.61 (dd, J=12.3 Hz; 5.0 
Hz, 1H, H2), 4.46 (dd, J=12.3 Hz; 2.4 Hz, 1H, H2), 4.35 (d, J=3.7 Hz, 1H, 
α-CH), 4.14-4.00 (m, 1H, H3), 3.45 (dd, J=17.6 Hz; 6.2 Hz, 1H, H4), 3.38-
3.10 (m, 5H, H4, N(CH2CH2CH3)2), 2.27-2.11 (m, 1H, γ-CH2), 1.90-1.68 
(m, 5H, N(CH2CH2CH3)2, γ-CH2), 1.57-1.45 (m, 1H, β-CH), 1.20 (d, J=7.0 
Hz, 3H, γ'-CH3), 1.08 (t, J=7.3 Hz, 3H, δ-CH3), 1.01 (t, J=7.3 Hz, 6H, 
N(CH2CH2CH3)2); 13C NMR (50 MHz, CD3OD): δ 166.8, 145.3, 138.3, 128.1, 121.8, 121.2, 120.9, 
64.3, 57.2, 55.7, 53.5, 52.9, 36.9, 25.5, 24.6, 18.1, 13.7, 11.0, 10.1; HR-MS m/z Calcd. for 
C21H35N2O3 363.26422 (M+H)+, found 363.26416 (M+H)+. 
β-Alanine (-)-3,4-dihydro-3-(N,N-di-n-propylamino)-2H-1-benzopyran-8-yl ester 2HCl salt 
(8.21). Yield: 79%; Purity: 97% (HPLC); IR (KBr, cm-1) νmax 3433 (br), 2968, 2888, 2632, 2522, 
1761, 1483, 1257, 1178; 1H NMR (400 MHz, CD3OD): δ 7.15 (dd, J=7.2 
Hz; 2.0 Hz, 1H, ArH), 7.07-6.96 (m, 2H, ArH), 4.58 (dd, J=12.1 Hz; 5.1 
Hz, 1H, H2), 4.45 (dd, J=12.1 Hz; 2.2 Hz, 1H, H2), 4.09-3.99 (m, 1H, H3), 
3.43 (dd, J=16.7 Hz; 5.7 Hz, 1H, H4), 3.37-3.05 (m, 5H, H4, 
N(CH2CH2CH3)2), 3.32 (t, J=6.8 Hz, 2H, β-CH2), 3.07 (t, J=6.8 Hz, 2H, 
α-CH2), 1.91-1.72 (m, 4H, N(CH2CH2CH3)2), 1.00 (t, J=7.3 Hz, 6H, 
N(CH2CH2CH3)2); 13C NMR (50 MHz, CD3OD): δ 168.9, 145.5, 139.0, 
127.5, 121.6, 121.1, 120.8, 64.3, 55.7, 53.3, 52.8, 35.2, 30.9, 24.8, 18.1, 10.1; HR-MS m/z Calcd. for 
C18H29N2O3 321.21727 (M+H)+, found 321.21725 (M+H)+. 
8.5.2 Chemical hydrolysis experiments in 5 mM citrate buffer pH 5 
The methods for the chemical hydrolysis experiments of compounds 2.28, 2.30, 2.31, 2.33 and 2.39 
were already described in Chapter 3. 
8.5.2.1 Procedure 
For the experiments with prodrugs 8.17-8.21 the chemical hydrolysis was initiated by adding 6 μl of a 
25 mM stock solution in 5 mM citrate buffer (pH 5) to 2.994 mL 5 mM citrate buffer (pH 5) 
preheated at 32 oC. The final concentration of the resulting solutions was about 50 μM. The test 
solutions of the compounds were vortexed and maintained in a Lab-Line Orbit Shaker at a constant 
temperature of 32±0.2 °C. At appropriate intervals samples of 100 μL were withdrawn and diluted 
with 100 μL H2O/ACN/TFA (1.2/1/0.004) giving a concentration of 25 μM. The samples were stored 
in the freezer until they were analyzed by HPLC. The prodrug concentration was estimated by 
measuring the peak heights in relation to those of prodrug standards which were prepared by serial 
dilution of known concentrations (0.5, 5, 10 and 25 μM) and chromatographed under the same 
conditions. 
8.5.2.2 HPLC analysis 
Samples of prodrugs 8.17-8.21 were analyzed isocratically on a Hewlett Packard Series 1100 HPLC 
system connected to a Tray-Cooling Marathon Basic+ Autosampler and a Hewlett Packard HP3395 




250 x 4.6 mm I.D.). The mobile phase for compound 8.17 and 8.20 consisted of a mixture of 22% 
acetonitrile and 78% water with 0.1% trifluoroacetic acid added (eluent A). The mobile phase for 
compound 8.18 and 8.21 consisted of a mixture of 20% acetonitrile and 80% water with 0.1% 
trifluoroacetic acid added (eluent B). The mobile phase for compound 8.19 consisted of a mixture of 
23% acetonitrile and 77% water with 0.1% trifluoroacetic acid added (eluent C). The flow was set at 
1.0 mL/min and the analysis was performed at room temperature. The injection volume was 20 μL 
and the compounds were detected by UV at 217 nm. The runtime was 12 minutes. The retention times 
of 8-OH-DPAC and the amino acid 8-OH-DPAC esters were: 6.95 min (8.10, eluent A), 8.15 min 
(8.10, eluent B), 6.46 min (8.10, eluent C), 4.12 min (8.17, eluent A), 5.25 min (8.18, eluent B), 5.41 
min (8.19, eluent C), 8.31 min (8.20, eluent A), 4.85 min (8.21, eluent B)  
8.5.2.3 Data analysis 
All hydrolysis experiments were carried out in triplicate. The pseudo-first-order chemical hydrolysis 
rate constants (k) from the experiments were calculated from the linear slopes of plots of the 
logarithm of the remaining prodrug concentration against time (t). The slopes of these plots are 
related to the rate constant, k, and given by k = 2.303 x slope (log C vs time). The hydrolysis of the 
prodrug follows pseudo-first-order kinetics described by the formula: kt0e]odrug[Pr]Prodrug[
 . 
The half-lives (t1/2) can be estimated by the equation: k
2lnt 2/1  . 
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The neurotransmitter dopamine (DA) plays an important role in the central nervous system 
and is related to symptoms of Parkinson's disease. Parkinson's disease is a 
neurodegenerative disorder with the gradual loss of nigrostriatal DAergic neurons as its 
main feature. The best therapeutic strategy for treatment of Parkinson's disease is based on 
restoring the DA deficiency by increasing DA concentrations with L-DOPA, MAO-B 
inhibitors or COMT inhibitors. Another approach for treatment of Parkinson's disease is the 
replacement of the decreased DA levels with potent DA receptor agonists. Although not as 
efficacious as L-DOPA, their effect is significant and DA agonists are frequently given as 
monotherapy or as adjunctive therapy in combination with L-DOPA. 
Unfortunately, in many cases disabling motor complications appear after a few years of L-
DOPA treatment, i.e. motor fluctuations and dyskinesia. Continuous DAergic stimulation 
(CDS) might delay or prevent these motor complications and this strategy should be taken 
into consideration when designing new therapies for Parkinson's disease. An interesting 
development in the field of CDS is the application of Duodopa® which continuously 
delivers L-DOPA directly into the duodenum. Another promising method of CDS is the 
transdermal delivery of DA receptor agonists by iontophoresis. Transdermal iontophoresis 
is a non-invasive technique which transports molecules across the human skin under 
influence of an electrical current. Iontophoresis enables constant, programmed, and 
controlled delivery by manipulating the current to the needs of the patient. Moreover, the 
circumvention of the first-pass metabolism is advantageous for drugs which are sensitive to 
this.  
Apomorphine, rotigotine and 5-OH-DPAT (2.12) are DA receptor agonists which have 
been evaluated for transdermal iontophoretic delivery. Iontophoresis is ideal for these drugs 
because they are sensitive to first-pass metabolism. Furthermore, they have a narrow 
therapeutic window and thus should be titrated accurately. In addition they represent 
relatively small molecules that are positively charged at low pH which enables electro-
repulsion from the electrode. Drugs which lack a positive ionic group are unlikely to be 
transported by iontophoresis, but conversion to a prodrug and introduction of a cationic 
moiety can make them suitable for iontophoresis. 
The transdermal iontophoretic delivery of 5-OH-DPAT has been investigated in vitro and 
in vivo. Important factors which influence the transdermal iontophoretic flux of 5-OH-
DPAT are the drug concentration and electrical current density. Although a sufficient 
amount of drug was delivered in vivo to achieve a strong DAergic effect, the moderate 
lipophilicity and the relatively low aqueous solubility can cause a limitation for further 
development of its iontophoretic delivery into a clinical application. By increasing the 
aqueous solubility two major improvements can be accomplished, i.e. both the 
iontophoretic patch size as well as the necessary electrical current can be decreased. A 
possible strategy is conversion of 5-OH-DPAT into a prodrug with improved 
physicochemical properties for iontophoretic transport. By preparation of prodrugs with 
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naturally occurring amino acids, an additional positive charge is introduced in the molecule 
making the prodrugs more water soluble. It would also be of interest to determine the 
influence of these bivalent cationic prodrugs on iontophoresis. Overall, our aim was the 
development of highly soluble prodrugs which can be delivered efficiently by transdermal 
iontopheretic delivery. 
In Chapter 2 we describe the synthesis of a series of amino acid ester prodrugs of 5-OH-
DPAT (2.12) with various amino acids in order to primarily obtain a chemically stable 
prodrug, and in addition to investigate the influence of the side chain groups on the 
hydrolysis rate. The prodrugs were obtained as the hydrochloride salts which were highly 
water soluble, but also hygroscopic. Hygroscopicity impedes easy handling and therefore 
investigation of other salt forms would be desired, e.g. dicarboxylic acids. However, the 
low chemical stability of the prodrugs under basic aqueous conditions interfered with 
conversion of the hydrochloride salt to the free amines to form alternative salt forms. It 
would thus be attractive to synthesize prodrugs with higher chemical stability. Besides the 
utilization of dipeptides described in Chapter 6, rigid promoieties as piperidine carboxylic 
acids or unsaturated derivatives of β-alanine or GABA may prevent hydrolysis by 
intramolecular catalysis. A disadvantage is the likely toxicity of these promoieties. 
The determination of the chemical stabilities of the amino acid ester prodrugs of 5-OH-
DPAT is presented in Chapter 3. Especially the 1-aminocyclopropane-1-carboxylic acid 
(2.30), L-valine (2.31), D-valine (2.32), L-isoleucine (2.33) and  β-alanine (2.39) ester 
prodrugs of (S)-5-OH-DPAT (S-2.12), the active enantiomer of 5-OH-DPAT (2.12), show 
relatively high chemical stabilities. Steric hindrance by aliphatic side chains probably 
stabilizes the ester function against hydrolysis. The number of carbon atoms between the 
promoiety's amino group and the carbonyl group are crucial for chemical stability, with 
ethyl being the optimum in this series. A higher pKa of the amino group in the promoiety 
can cause faster chemical hydrolysis, e.g. by increased intramolecular catalysis. The 
chemically stable prodrugs 2.30, 2.31, 2.32, 2.33 and 2.39 were selected for enzymatic 
hydrolysis studies. Fortunately, all were shown to hydrolyze instantaneously in human 
blood plasma at 37 ºC which indicates the immediate release of the drug from its prodrug 
form after uptake in the blood stream. 
First, in Chapter 4 the relationship between the current density, the in vivo iontophoretic 
transport and the (S)-5-OH-DPAT ((S)-2.12) plasma profile has been described. The results 
show that the passage of the drug into the skin can be controlled accurately by modifying 
the current density. Second, the effect of transdermal iontophoresis on the striatal DA 
release was investigated in anesthetized rats. With this study a rat model was established 
which displayed stable DA release levels during anesthesia, which enabled us to investigate 
the DAergic effect of (S)-5-OH-DPAT following intravenous infusion and transdermal 
iontophoresis. Finally, the pharmacokinetic (PK) and pharmacodynamic (PD) relationship 




demonstrated that the applied DA agonist induced a clear long lasting and reversible 
decrease in the release of DA. These results are crucial for designing a self-controlled 
delivery device, guided by a feedback system based on PK-PD modeling. 
 
Scheme 9.1 Overview of analogs and prodrugs of 5-OH-DPAT. 
Chapter 5 covers the in vitro and in vivo studies of a selection of the amino acid ester 
prodrugs of (S)-5-OH-DPAT for iontophoresis. The feasibility of the transdermal 
iontophoretic delivery of the highly aqueous soluble glycine (2.28), L-proline (2.37), L-
valine (2.31) and β-alanine (2.39) prodrugs of (S)-5-OH-DPAT ((S)-2.12) was investigated 
in vitro. Subsequently, the PK and PD effect of the β-alanine prodrug, which showed the 
highest in vitro transport efficiency, was investigated in vivo. Despite a higher in vitro 
transport, lower plasma concentrations were observed following 1.5 h current application 
(250 µA/cm2) of the β-alanine (S)-5-OH-DPAT ester in comparison to (S)-5-OH-DPAT. 
This resulted in a pharmacological effect with the same maximum as 5-OH-DPAT, but the 
effect lasted for a longer time. In conclusion, this study demonstrates the potential of 
improving solubility, iontophoretic transport and changing the plasma profile and the PD 
effect of the promising DA agonist 5-OH-DPAT by using a prodrug approach. 
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In Chapter 6 the synthesis and evaluation of the chemical stability of a series of novel 
dipeptide esters of (S)-5-OH-DPAT ((S)-2.12) is described. The dipeptide promoiety 
esterified with (S)-5-OH-DPAT consisted of glycine, L-valine, β-alanine and L-lysine 
combinations. All dipeptide esters showed a higher chemical stability than their mono 
amino acid ester prodrug equivalents. In particular, the L-valine-L-valine (S)-5-OH-DPAT 
ester (6.11) and the dipeptide ester prodrugs with β-alanine at the C-terminal of the 
dipeptide (6.13 to 6.16) gave excellent chemical stabilities. The high chemical stability may 
be explained by the steric hindrance in the case of 6.11 and conformers which are 
unfavourable to hydrolysis in the case of 6.13 to 6.16. These factors may diminish 
intramolecular catalysis during hydrolysis. The newly synthesized dipeptide prodrugs could 
be valuable candidates to improve iontophoretic transport by maintaining an intact prodrug 
structure during transport across the human stratum corneum. Moreover, extremely stable 
dipeptide prodrugs with multiple charges can be synthesized in order to further investigate 
the influence of drug valency on iontophoretic transport. 
The synthesis of a series of 5-OH-DPAT analogs is described in Chapter 7. These 
compounds were used to study the influence of the molecular structure of phenolic and 
catecholic DA receptor agonists on their aqueous solubility and iontophoretic flux in vitro. 
The aminochroman 8-OH-DPAC (7.22) showed the highest solubility, and the 
aminotetralins 5-OH-MPAT (7.15) and 5-OH-EPAT (7.20) were delivered with higher 
fluxes than 5-OH-DPAT. Intra -and intermolecular hydrogen bonding may explain the 
different aqueous solubilities. The found iontophoretic fluxes are possibly dependent on 
molecular weight, molecular volume and lipophilicity. 
Improved aqueous solubility and decreased lipophilicity are molecular properties which can 
benefit transdermal iontophoresis. Therefore in Chapter 8 the synthesis of a series of 
amino acid ester prodrugs of the water-soluble potent DA agonist (-)-8-OH-DPAC is given. 
Chemical stability studies show that 1-aminocyclopropane-1-carboxylic acid (8.18) and β-
alanine (8.21) (-)-8-OH-DPAC esters are suitable candidates for further in vitro and in vivo 
iontophoretic studies. 
In conclusion, highly water-soluble prodrugs and several analogs of 5-OH-DPAT have 
been synthesized and developed specifically for transdermal iontophoresis. By investigation 
of these novel compounds we have gained more understanding of the influence of 
molecular structure on chemical stability, enzymatic stability, solubility and iontophoretic 
flux in vitro and in vivo. The extremely soluble β-alanine ester prodrug of (S)-5-OH-DPAT 
(2.39) is the most promising candidate for further research on transdermal iontophoretic 
delivery of DAergic prodrugs for the treatment of Parkinson's disease. 
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LIST OF ABBREVIATIONS 
3-MT 3-Methoxytyramine 
5-OH-DPAT 5-Hydroxy-2-(N,N-di-n-propylamino)tetralin  
(S)-5-OH-DPAT  (S)-5-Hydroxy-2-(N,N-di-n-propylamino)tetralin  
5,6-(OH)2-DPAT 5,6-Dihydroxy-2-(N,N-di-n-propylamino)tetralin 
5,6-(OH)2-MPAT 5,6-Dihydroxy-2-(N-n-propylamino)tetralin 
6-OH-DA 6-Hydroxydopamine  
6-OH-DPAT 6-Hydroxy-2-(N,N-di-n-propylamino)tetralin  
(R)-7-OH-DPAT (R)-7-Hydroxy-2-(N,N-di-n-propylamino)tetralin 
8-OH-DPAC 8-hydroxy-3,4-dihydro-3-(N,N-di-n-propylamino)-2H-1-benzopyran 
AAAD Aromatic-L-amino-acid decarboxylase 
AC Adenylate cyclase  
ADEPT Antibody-directed enzyme prodrug therapy  
AIC Aikaike Information Criterion 
AZT Zidovudine 
BBB Blood-brain barrier  
BCSFB Blood-cerebrospinal fluid barrier  
BDCRB 2-Bromo-5,6-dichloro-1-(β-D-ribofuranosyl)benzimidazole 
Boc N-tert-butoxycarbonyl 
cAMP Cyclic adenosine monophosphate 
Cbz Carbobenzyloxy 
CDA Baseline values of DA  
CDS Continuous dopaminergic stimulation 
CL Clearance 
cLogP Calculated log P  
CNS Central nervous system  
COMT Catechol-O-methyltransferase  
Cp Plasma concentration  
Cs Striatal concentration  
CSF Cerebrospinal fluid  
D1 Dopamine D1 receptor 
D2 Dopamine D2 receptor 
d2-5-OH-DPAT 5-Hydroxy-2-(N-n-propyl-N-α,α-dideutero-propylamino)-tetralin  
DA Dopamine 
DAergic Dopaminergic 
DBS Deep brain stimulation  
DCC N,N'-Dicyclohexylcarbodiimide 
DHEA Dehydroepiandrosteron 
DHS Dermatomed human skin  
DOPAC 3,4-Dihydroxyphenylacetic acid  
ECF Extracellular fluid  
EDC N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide 
EI Electron ionization  
Enk Enkephalin 
ESI Electrospray ionization  
FOCE First order estimation method 
GABA γ-Aminobutyric acid 
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GCMS Gas chromatography–mass spectrometry  
Glu Glutamate 
GLUT1 Glucose transporter 1 
GPCR G protein-coupled receptor  
GPe External segment of globus pallidus 
GPi Internal segment of globus pallidus 
GTP Guanosine triphosphate 
H Hill-slope coefficient 
HBP Human blood plasma 
HOBt 1-Hydroxybenzotriazole  
HPLC High-performance liquid chromatography  
HPLC-MS/LC-MS Liquid chromatography–mass spectrometry 
HRMS High-resolution mass spectrometry  
HSA Human serum albumin  
HSC Human stratum corneum  
HVA Homovanillic acid  
IC50 Half maximal inhibitory concentration 
Imax Maximum inhibition of the DA production 
ITS Iontophoresis transdermal system  
IV Intravenous 
k Hydrolysis rate constant 
kobs Observed rate constant 
LAT1 L Amino acid transporter 1  
L-DOPA  3,4-Dihydroxy-L-phenylalanine 
LOD Limit of detection  
LOQ Limit of quantification  
MAO-B Monoamine oxidase B  
MPP+ 1-Methyl-4-phenylpyridinium 
MPTP 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine  
MRM Multiple Reaction Monitoring  
mRNA Messenger ribonucleic acid 
MS Mass spectrometry 
MVOF The minimum value of the objective function 
N-0437 5-Hydroxy-2-(N-propyl-N-2-thienylethylamino)tetralin  
NMDA N-Methyl-D-aspartate  
NMR Nuclear magnetic resonance 
PBS Phosphate buffered saline 
PD Pharmacodynamic 
PEPT1 Peptide transporter 1  
PK Pharmacokinetic 
PK-PD Pharmacokinetic-pharmacodynamic 
PMEA 9-[2-(Phosphonomethoxy)-ethyl] adenine 
Q Inter compartmental clearance  
SC Stratum corneum  
SN Substantia nigra  
SNc Substantia nigra pars compacta  
SNr Substantia nigra pars reticulata 
STN Subthalamic nucleus 






TLC Thin-layer chromatography  
V2 Volume of central compartment  
V3 Volume of peripheral compartment 
VPC Visual predictive check 
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SAMENVATTING EN ALGEMENE DISCUSSIE 
De neurotransmitter dopamine (DA) speelt een belangrijke rol in het centrale zenuwstelsel 
en is gerelateerd aan symptomen van de ziekte van Parkinson. De ziekte van Parkinson is 
een neurodegeneratieve ziekte waarbij het geleidelijke verlies van striatonigrale DAerge 
neurons het hoofdkenmerk is. De beste therapeutische strategie voor de behandeling van de 
ziekte van Parkinson is gebaseerd op het herstellen van het DA tekort door een verhoging 
van de DA concentraties met L-DOPA, MAO-B remmers en COMT remmers. Een andere 
benadering voor de behandeling van de ziekte van Parkinson is de vervanging van de 
verlaagde DA niveaus met potente DA receptor agonisten. Ook al zijn DA agonisten niet zo 
effectief als L-DOPA, toch is hun effect significant en worden DA agonisten gegeven als 
monotherapie of als adjunctieve therapie in combinatie met L-DOPA. 
Helaas verschijnen er in veel gevallen invaliderende motor complicaties na een aantal jaar 
behandeling met L-DOPA, bijvoorbeeld motor fluctuaties en dyskinesie. Continue DAerge 
stimulatie (CDS) zou deze motor complicaties kunnen vertragen of voorkomen, en hier zou 
rekening mee moeten worden gehouden tijdens het ontwerpen van nieuwe therapieën voor 
de ziekte van Parkinson. Een interessante ontwikkeling op het gebied van CDS is de 
toepassing van Duodopa® welke L-DOPA op een continue wijze rechtstreeks in het 
duodenum afgeeft. Een andere veelbelovende methode van CDS is de transdermale afgifte 
van DA receptor agonisten met iontoforese. Transdermale iontoforese is een niet-invasieve 
techniek die moleculen over de menselijke huid transporteert onder invloed van een 
elektrische stroom. Iontoforese maakt constante, geprogrammeerde en gecontroleerde 
afgifte mogelijk door het instellen van de stroom naar de behoefte van de patient. 
Bovendien is de omzeiling van het first-pass metabolisme voordelig voor geneesmiddelen 
die hiervoor gevoelig zijn. 
Apomorphine, rotigotine en 5-OH-DPAT (2.12) zijn DA receptor agonisten welke zijn 
geëvalueerd voor transdermale iontoforetische afgifte. Iontoforese is ideaal voor deze 
geneesmiddelen omdat ze gevoelig zijn voor het first-pass metabolisme, ze hebben een 
smal therapeutisch venster en moeten dus nauwkeurig worden getitreerd, en hun kleine 
moleculaire structuur is positief geladen bij lage pH wat elektro-repulsie vanaf de elektrode 
mogelijk maakt. Het is onwaarschijnlijk dat geneesmiddelen die een ionische groep missen, 
kunnen worden getransporteerd met iontoforese, maar de omzetting naar een prodrug en 
daarbij de introductie van een geïoniseerde deel zou ze geschikt kunnen maken voor 
iontoforese. 
De transdermale iontoforetische afgifte van 5-OH-DPAT is in vitro en in vivo onderzocht. 
Belangrijke factoren die de transdermale iontoforetische flux van 5-OH-DPAT beïnvloeden 
zijn de geneesmiddel concentratie en de elektrische stroomdichtheid. Hoewel een 
voldoende hoeveelheid van het geneesmiddel in vivo was afgegeven om een sterk DAerg 
effect te bewerkstelligen, kunnen de matige lipofiliciteit en de relatief lage water 
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oplosbaarheid de verdere ontwikkeling van deze iontoforetische afgifte tot een klinische 
toepassing beperken. Door het verhogen van de water oplosbaarheid kan de grootte van de 
iontoforetische pleister worden verkleind en de benodigde elektrische stroom worden 
verlaagd. Een mogelijke strategie is de omzetting van 5-OH-DPAT in een prodrug met 
verbeterde fysisch-chemische eigenschappen voor het iontoforetische transport. Door de 
bereiding van prodrugs met natuurlijk voorkomende aminozuren, wordt een additionele 
positieve lading in het molecuul geïntroduceerd. Ook zou het interessant zijn om de invloed 
van bivalente kationische prodrugs op transdermale iontoforetische afgifte te onderzoeken. 
In Hoofdstuk 2 beschrijven we de synthese van een serie aminozuur ester prodrugs van 5-
OH-DPAT (2.12) met verscheidene aminozuren vooral om een chemisch stabiele prodrug 
te verkrijgen, en daarbovenop te onderzoeken wat de invloed is van de zijketen groepen op 
de hydrolyse snelheid. De prodrugs werden verkregen als het hydrochloride zout welke 
bijzonder water oplobaar, maar tevens hygroscoop waren. Hygroscopiciteit verhindert 
gemakkelijke handelbaarheid, en daarom zou onderzoek naar andere zoutvormen zoals 
dicarbonzuren gewenst zijn.  Alhoewel, de lage chemische stabiliteit van de prodrugs onder 
basische condities verhinderde de conversie van het zout naar de vrije amines om zodoende 
andere zoutvormen te vormen. Het zou daarom interessant zijn om prodrugs te 
synthesizeren met een hogere chemische stabiliteit. Mogelijke rigide prodrug deeltjes zoals 
piperidine carbonzuren of onverzadigde afgeleiden van β-alanine or GABA zouden de 
hydrolyse door intramoleculaire katalyse kunnen verhinderen. Echter een nadeel is de 
mogelijke toxiciteit van deze moleculen. 
De bepaling van de chemische stabiliteit van de aminozuur ester prodrugs van 5-OH-DPAT 
wordt gepresenteerd in Hoofdstuk 3. Vooral de 1-aminocyclopropaan-1-carbonzurur 
(2.30),  L-valine (2.31), D-valine (2.32), L-isoleucine (2.33) en  β-alanine (2.39) ester 
prodrugs van (S)-5-OH-DPAT (S-2.12), de actieve enantiomeer van 5-OH-DPAT (2.12), 
vertonen een relatief hoge chemische stabiliteit. Sterische hinder door alifatische zijketens 
stabiliseren waarschijnlijk de ester functionele groep tegen hydrolyse. Het aantal koolstof 
atomen tussen de amino groep en de het carbonzuur op het prodrug gedeelte, zijn cruciaal 
voor de chemische stabiliteit, waarbij ethyleen de optimale lengte is in deze serie. Een 
hogere pKa van de amino groep in het prodrug gedeelte kan zorgen voor een snellere 
chemische hydrolyse, bijvoorbeeld door een verhoogde intramoleculaire katalyse. De 
chemisch stabiele prodrugs 2.30, 2.31, 2.32, 2.33 and 2.39 werden geselecteerd voor 
enzymatische hydrolyse studies en elke prodrug vertoonde  hydrolyse in menselijk 
bloedplasma bij 37 ºC. 




Schema Overzicht van analoga en prodrugs van 5-OH-DPAT. 
Ten eerste is in Hoofdstuk 4 de relatie tussen de stroomdichtheid, het in vivo 
iontoforetische transport en het (S)-5-OH-DPAT ((S)-2.12) plasma profiel beschreven. De 
resultaten laten zien dat de drug input in de huid nauwkeurig kan worden gecontroleerd 
door het veranderen van de stroomdichtheid. Ten tweede werd het effect van het 
anaesthesie mengsel, de transdermale iontoforese en het nemen van bloedmonsters op de 
striatale DA afgifte onderzocht. Met deze studie werd een proefdiermodel van de rat 
ontwikkeld met stabiele DA afgifte levels tijdens anesthesie. Dit maakte het voor ons 
mogelijk om het DAerge effect van (S)-5-OH-DPAT na intraveneuze infusie en 
transdermale iontoforese te volgen. Tot slot werd de pharmacokinetische (PK) en 
pharmacodynamische (PD) relatie na transdermale iontoforese onderzocht tijdens een 
gecontroleerde en reversibele farmacologische respons. Deze studie laat zien dat niet alleen 
een gecontroleerde DAerge reversibel effect kan worden behaald, maar ook dat een 
continue stimulatie van de DA receptoren mogelijk is. Samen met PK-PD modeling zullen 
deze resultaten cruciaal zijn voor de ontwerpen van een zelf-gecontroleerd afgifte apparaat, 
geleid door een feedback systeem. 
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Hoofdstuk 5 behandelt de in vitro en in vivo studie met een selectie van de aminozuur ester 
prodrugs van (S)-5-OH-DPAT voor iontoforese. De uitvoerbaarheid van de transdermale 
iontoforetische afgifte van de zeer water oplosbare glycine (2.28), L-proline (2.37), L-valine 
(2.31) en β-alanine (2.39) prodrugs van (S)-5-OH-DPAT ((S)-2.12) werden onderzocht in 
vitro. Vervolgens werd het PK en PD effect van de prodrug met de hoogste in vitro 
transport efficientie in vivo onderzocht. Ondanks het hogere in vitro transport, werden 
lagere plasma concentraties waargenomen na 1.5 uur stroom toepassing (250 µA/cm2) van 
de β-alanine (S)-5-OH-DPAT ester in vergelijking met (S)-5-OH-DPAT. Dit resulteerde in 
een farmacologisch effect met hetzelfde maximum als 5-OH-DPAT, maar het effect duurde 
langer. In conclusie toonde deze studie de kracht van het gebruik van prodrugs aan voor het 
verbeteren van de oplosbaarheid, het iontoforetische transport en het veranderen van het 
plasma profiel en het PD effect van de veelbelovende DA agonist 5-OH-DPAT. 
In Hoofdstuk 6 wordt de synthese en evaluatie van de chemische stabiliteit van een serie 
dipeptide esters van (S)-5-OH-DPAT ((S)-2.12) behandeld. Het dipeptide deeltje dat werd 
veresterd met (S)-5-OH-DPAT bestond uit glycine, L-valine, β-alanine en L-lysine 
combinaties om de invloed van de aminozuur volgorde op chemische hydrolyse te 
onderzoeken. Alle dipeptide esters vertoonden een hogere chemische stabiliteit van hun 
mono aminozuur ester prodrug equivalenten. Met name, de L-valine-L-valine (S)-5-OH-
DPAT ester (6.11) en de dipeptide ester prodrugs met β-alanine aan het C-uiteinde van de 
dipeptide (6.13 tot en met  6.16) vertoonden de hoogste chemische stabiliteit. De hoge 
chemische stabiliteit kan worden uitgelegd door de sterische hinder in het geval van 6.11 en 
door conformeren die nadelig zijn voor hydrolyse in het geval van 6.13 tot en met 6.16. 
Deze factoren kunnen de intramoleculaire katalyse tijdens hydrolyse verminderen. De 
dipeptide prodrugs kunnen waardevolle kandidaten zijn die het iontoforetische transport 
kunnen verbeteren door het behouden van de intacte prodrug structuur tijdens het transport 
over het humane stratum corneum. Bovendien kunnen dipeptide prodrugs worden 
gesynthetiseerd met meerdere ladingen om de invloed van de valentie van een 
geneesmiddel op iontoforetisch transport te kunnen onderzoeken.  
De synthese van een serie van 5-OH-DPAT analoga is beschreven in Hoofdstuk 7. Deze 
verbindingen werden gebruikt om de invloed van de molecuulstructuur van fenolische en 
catecholische DA receptor agonisten op hun wateroplosbaarheid en in vitro iontoforetische 
flux te bestuderen. De aminochromaan 8-OH-DPAC (7.22) vertoonde de hoogste 
oplosbaarheid, en de aminotetralines 5-OH-MPAT (7.15) en 5-OH-EPAT (7.20) werden 
afgegeven met een hogere flux dan 5-OH-DPAT. Intra- en intermoleculaire 
waterstofbruggen zouden de verschillende wateroplosbaarheden kunnen verklaren. De 
gevonden iontoforetische flux waarden zijn mogelijk afhankelijk van molecuul gewicht, 
moleculair volume en lipofiliteit. 
Een verbeterde wateroplosbaarheid en verminderde lipofiliteit zijn moleculaire 
eigenschappen waar transdermale iontoforese van kan profiteren. Daarom wordt in 
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Hoofdstuk 8 de synthese van een serie aminozuur ester prodrugs van de wateroplosbare 
potente DA agonist (-)-8-OH-DPAC beschreven. Studies met betrekking tot de chemische 
stabiliteit laten zien dat 1-aminocyclopropaan-1-carbonzuur (8.18) en β-alanine (8.21) (-)-8-
OH-DPAC esters geschikte kandidaten zijn voor verdere iontoforetische studies in vitro en 
in vivo. 
Samenvattend, zeer wateroplosbare prodrugs en verscheidene analoga van 5-OH-DPAT 
werden gesynthetiseerd en specifiek ontwikkeld voor transdermale iontoforese. Door het 
onderzoeken van deze nieuwe verbindingen hebben we meer inzicht gekregen in de invloed 
van de molecuulstructuur op chemische stabiliteit, enzymatische stabiliteit, oplosbaarheid 
en iontoforetische flux in vitro en in vivo. De extreem wateroplosbare β-alanine ester 
prodrug van (S)-5-OH-DPAT (2.39) is de meest veelbelovende kandidaat voor verder 
onderzoek naar transdermale iontoforetische afgifte van DAerge prodrugs voor de 





SAMENVATTING VOOR NIET INGEWIJDEN 
De substantia nigra en het striatum zijn twee hersengebieden die belangrijk zijn voor 
coördinatie en beweging. De zenuwcellen tussen deze twee gebieden communiceren via 
een signaalstof genaamd dopamine. Bij de ziekte van Parkinson zijn deze zenuwcellen sterk 
verminderd waardoor er minder dopamine wordt afgegeven en het bewegingsapparaat 
verstoord raakt. De meest voorkomende symptomen zijn trillen, spierstijfheid, 
bewegingsarmoede en een verstoorde houding. De geneesmiddelen die doorgaans worden 
gebruikt in de farmacotherapie hebben als doel de verlaagde dopamine afgifte in de 
hersenen te herstellen (levodopa), te verhogen (MAO-B remmers en COMT remmers) of na 
te bootsen (dopamine agonisten). In de loop van de tijd treden er echter vooral bij 
toediening van levodopa, het meest effectieve geneesmiddel tot nu toe, zeer ernstige 
bijwerkingen op. Deze bijwerkingen zijn dyskinesieën (onwillekeurige bewegingen) en 
motorfluctuaties. Motorfluctuaties kunnen worden samengevat als de (on)voorspelbare, 
afnemende of wisselende werking van levodopa op het bewegingsapparaat van de patiënt. 
Uit onderzoek blijkt dat een meer constante dopaminespiegel deze bijwerkingen zou 
kunnen beperken, iets wat bij orale toediening van levodopa niet gerealiseerd wordt. Een 
bekende methode om een geneesmiddel constant af te geven is via infusie, echter hierbij is 
kans op ontsteking. Een alternatief is het toedienen van een geneesmiddel vanuit een 
pleister met behulp van een lage elektrische stroom vanuit een batterij. Deze techniek heet 
transdermale iontoforese. Transdermale iontoforese geeft een constante afgifte van het 
geneesmiddel en maakt het mogelijk om de juiste dosis in te stellen door de stroomsterkte 
te variëren. Bovendien is de kans op ontsteking klein door de niet invasieve aard van deze 
techniek.  
De chemische structuur van sommige dopamine agonisten maakt dat deze geneesmiddelen 
gevoelig zijn voor de grootschalige afbraak in de lever na orale inname, dit heet het first-
pass-effect. Transdermale iontoforese zou deze afbraak in de lever kunnen omzeilen, omdat 
het geneesmiddel via de huid direct in de bloedbaan terechtkomt. Verscheidene dopamine 
agonisten werden al onderzocht op de mogelijkheid om deze via iontoforese toe te dienen. 
Het blijkt mogelijk te zijn, echter een hogere oplosbaarheid van de geneesmiddelen zou een 
tweetal voordelen kunnen bieden. Ten eerste zou een hogere oplosbaarheid de grootte van 
de pleister tot handbare proporties kunnen verkleinen, omdat dezelfde hoeveelheid 
geneesmiddel dan kan worden opgelost in een kleiner volume vloeistof. Ten tweede, de 
mate van afgifte met transdermale iontoforese kan afhankelijk zijn van de concentratie van 
het geneesmiddel. Een hogere oplosbaarheid geeft een hogere concentratie en wellicht dus 
ook een snellere afgifte. Hierdoor kan de benodigde stroomsterkte verkleind worden en 
wordt de kans op irritaties van de huid verminderd.  
In dit proefschrift beschrijven we het chemisch bereiden en de evaluatie van zeer 
wateroplosbare varianten van de dopamine agonist 5-OH-DPAT. Deze varianten zijn 
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chemisch aan elkaar gekoppelde stoffen van de dopamine agonist 5-OH-DPAT met andere 
moleculen. In dit geval zijn dat aminozuren. In de farmacie noemt men deze stoffen 
prodrugs. Een prodrug is een niet werkzame stof die na omzetting in het lichaam het actieve 
geneesmiddel vrijgeeft. Ons onderzoek heeft geleid tot een aantal bevindingen. Ten eerste 
blijkt het mogelijk te zijn zeer wateroplosbare prodrugs te maken die voldoende stabiel zijn 
in de iontoforese pleister (voldoende houdbaarheid), maar eenmaal in de bloedbaan het 
geneesmiddel direct vrijgeven. Ten tweede, door het koppelen van 5-OH-DPAT aan 
dipeptiden (twee gecombineerde aminozuren), is het mogelijk de stabiliteit van de prodrug 
in de pleister nog groter te maken. Ten derde is het mogelijk om 5-OH-DPAT 
gecontroleerd toe te dienen aan het lichaam wat de ontwikkeling van een feedback systeem 
in principe mogelijk zou maken. En als laatste vonden we dat de iontoforetische toediening 
van een zeer wateroplosbare prodrug van 5-OH-DPAT een verlenging van het effect van 
het geneesmiddel geeft in vergelijking met 5-OH-DPAT zelf.  
Al deze resultaten laten zien dat de toepassing van prodrugs voordelig kan zijn bij de 
toediening van dopamine agonisten of andere geneesmiddelen met behulp van transdermale 
iontoforese. Verder onderzoek naar deze farmaceutische toedieningsvorm zou uiteindelijk 
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"If music be the food of love, play on" 
William Shakespeare, from "Twelfth Night" 
